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The present research has investigated the molecular characterization of oral yeasts in 
healthy individuals from different dental clinical settings in the United Kingdom, and 
patients  from  the  UK  and  Italy  who  were  affected  by  diabetes  mellitus  (DM)  to 
determine the impact of DM upon candidal infection of the mouth.
In the present study of patients with DM from the UK and Italy a lower than expected 
incidence  of oral  candidal  infections  (7/249,  2.8%)  was  observed.  The  presence  of 
oral  yeasts and  genotypic  diversity  of C.  albicans was also  not  influenced  by  DM. 
There was no significant difference between the presence of oral yeasts in Italian and 
UK  DM  patients.  However,  more  (p=0.04)  C.  dubliniensis  isolates  were  found  in 
non-DM individuals.
Higher  levels  of Candida  adhesion  to  fibronectin-coated  paramagnetic  beads  were 
observed  in  isolates  from  DM  patients.  Isolates  from  patients  with  low  oral  yeast 
loads  adhered  significantly  (p=0.01)  more  than  those  from  patients  with  high  oral 
yeast loads. In general, there was no difference in proteolytic activity of isolates from 
DM or control patients.
Candida isolates from UK DM patients had significantly greater in vitro resistance to 
azole  antifungal  agents  (miconazole  pO.OOOl;  fluconazole  p=0.02;  ketoconazole 
p=0.01) than those from Italian DM patients. In addition, C. albicans isolates from all 
examined patients were more susceptible to fluconazole (p=0.0008) and miconazole 
(p=0.01) than non-C. albicans strains.
PCR  fingerprinting  and  subsequent  phylogenetic  analysis  revealed  that  C.  albicans 
isolates  from  UK  DM  patients  were  the  most diverse  (p<0.0001)  in  comparison to 
those from Italian DM patients or from healthy subjects.
Finally,  it  was  observed  that  the  activity  of a  rat  IgM  monoclonal  anti-idiotypic 
antibody  (mAbKlO)  and  a  synthetic  decapeptide  (KP)  had  a  significant  dose-
2dependant  fungicidal  activity  upon  a  wide  spectrum  of  C.  albicans  and  non-C. 
albicans isolates from patients with and without DM.
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single-chain fragment variable format
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LB: Lennox L broth base
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MF: major facilitator genes
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OD: optical density
PaKT: Pichia anomala killer toxin
PAS: periodic acid Shiff
PAUP: phylogenetic analysis using parsimony
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activity in vitro
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REA: restriction enzyme analysis
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21CHAPTER 1 
Introduction  ✓
1.1  Candida epidemiological aspects
The genus Candida is a collection of approximately  150 asporogenus yeast species. It 
is  well  established  that  only  a  small  number  of these  are  human  pathogens,  since 
approximately 65% of Candida species are unable to grow at a temperature of 37°C 
(Schauer & Hanschke, 1999).
Although  a  sexual  stage  (teleomorph)  for  C.  albicans  has  historically  not  been 
detected  (thus  this  species  has  been  classified  in  the  class  of Fungi  imperfecti)
(Kwon-Chung &  Bennet,  1992),  a mating-type-like (MTL)  locus  has recently  been 
identified in C. albicans, which is involved in meiotic differentiation in S. cerevisiae, 
suggesting the existence of a sexual cycle for this diploid fungus (Hull  et al,  2000;
Magee  &  Magee,  2000;  Tzung  et al,  2001).  For  some  of the  Candida  species  for 
which a teleomorph stage has been described, such as C. krusei, C. guilliermondii, C.
S   S'
lusitaniae, the  sexual  stages are ascomycetous (Kurtzman &  Fell,  1998;  Calderone, 
2002).  Furthermore,  comparative  sequence  data  from  different  studies  supports  the 
idea that both sexual and non-sexual Candida spp. are related phlyogenetically to the
Ascomycete class of fungi (Calderone, 2002).
The presence of Candida by  itself is not  indicative of disease.  Candida  species are 
ubiquitous  organisms  and  most  of  them  are  commensals,  or  at  least  transient
s
commensals in the gastrointestinal tract (Samaranayake,  1990). Candida albicans, the 
most common human commensal of the genus Candida, is generally regarded as the 
most virulent of the Candida species being recovered from 70 to 80% of individuals. 
However, more recently (during the 1980s and  1990s), epidemiological data reveals a
22mycological shift from C. albicans to non-C. albicans species, such as C. glabrata, C. 
tropicalis, C. parapsilosis,  C. krusei and C. lusitaniae (Fidel et al,  1999; Moran et al, 
2002). In  1995, a novel Candida species, C.  dubliniensis, was identified for the first 
time (Sullivan et al,  1995)  in  Dublin,  Ireland.  Oral  carriage and  infection with this 
species was  prevalent  in  HIV  (human  immunodeficiency  virus)-infected  and  AIDS 
(acquired immune deficiency  syndrome) patients. This changing pattern of Candida 
carriage  and  the  increased  incidence  of Candida  infections  is  a  result  of several 
different  factors,  such  as  the  emergence  of  HIV-diseases,  the  increased  use  of 
immunosuppressive  therapies and the widespread  use  of broad-spectrum  antibiotics 
(Calderone, 2002).
In addition, the transfer of Candida between individuals often occurs via the hands of 
health care workers (Strausbaugh et al,  1994) and nosocomial transmission can also 
occur  (Schmid  et  al,  1995;  Cannon  &  Chaffin,  1999).  Furthermore,  it  has  been 
reported that treatment with azole antifungals for protracted periods may lead to the 
selection  of non-C.  albicans  species,  some  of which  have  been  shown  to  be  less 
susceptible  to  these  agents  than  C.  albicans  (Bodey,  1986;  Chavanet  et  al,  1994; 
Ruhnke et al,  1994; Tumbarello et al,  1996;  Schoofs et al,  1998;  Fidel et al,  1999; 
Moran et al, 2002).
It  can  be  difficult  to  determine  the  precise  frequency  of oral  carriage  of Candida 
species (Odds,  1988b; MacFarlane,  1990; Cannon & Chaffin, 1999; Ruhnke, 2002) as 
this is influenced by population age, the health of the sample population, the presence 
or  absence  of  oral  prostheses  and  the  techniques  used  for  oral  sampling,  yeast 
isolation  and  identification.  It  is  estimated  that  about  40%  of healthy  individuals, 
without  signs  of oral  candidosis,  harbour  Candida  in  their mouth  as  a commensal. 
The rate of carriage of Candida in saliva increases with pregnancy, tobacco smoking 
and when dentures are worn (Ellepola & Samaranayake, 2000a). Several studies have
23reported that oral Candida carriage is higher in hospitalised patients (54.7%), but high 
counts  of Candida  species  do  not  necessarily  mean  that patients will  have  clinical 
signs and symptoms of oral candidosis (Scully et al, 1994; Al Karaawi et al, 2002). 
Although C.  albicans is still the most frequently recovered yeast (70-75%) from the 
oral  cavity,  several  studies have  indicated higher incidences of the  non-C.  albicans 
species  (7%)  such  as  C.  glabra  ta,  C.  tropicalis,  C.  krusei,  C. parapsilosis  and  C. 
dubliniensis.  These species are often recovered from a mixed population and usually 
in combination with C. albicans (Odds, 1988b; Sullivan & Coleman,  1998; Cannon & 
Chaffin,  1999).
It  has  become  possible  to  understand  the  epidemiology  of Candida  infection  and 
colonisation more clearly due to the introduction of reliable identification and typing 
systems to evaluate strain homology. Such techniques are able to make a distinction 
between  different  Candida  species  and  strains that  share phenotypical  traits.  In the 
past,  this  inability  to  differentiate  between  species  and  strains  may  have  led  to  an 
underestimation  of the  prevalence  of colonisation  and  infection  of non-C.  albicans 
spp.
1.1.1  Candida albicans
As  previously  reported,  C.  albicans  is the  most  common  Candida  species  isolated 
from the oral cavity of healthy subjects or from patients affected by different diseases 
(Cannon  &  Chaffin,  1999;  Leung  et  al,  2000).  Candida  albicans  is  usually 
characterised by the production in vitro of true hyphae as detected by the germ tube 
test  (Section  1.6.2.2)  although  this  is  a  feature  also  evident  with  C.  dubliniensis 
(Section  1.1.2). Over the years, a variety of studies have investigated the pathogenic 
attributes  of  C.  albicans  and  these  have  recently  been  reviewed  by  a  variety  of 
authors (Cannon & Chaffin,  1999; Hoyer, 2001; Calderone & Gow, 2002; Chauhan et
24al, 2002; Douglas, 2003; Naglik et al, 2003). In comparison with C.  glabrata or C. 
krusei  (Sections  1.1.3-1.1.4),  C.  albicans  is  usually  more  sensitive  to  conventional 
antifungal  agents  (Section  1.4,  Table  1.3),  but  some  resistance  has  been  reported, 
particularly to azole therapy in severely immunodepressed patients (Yoon et al,  1999; 
Rex et al, 2000).
1.1.2  Candida dubliniensis
Candida dubliniensis was first isolated in  1995 from the oral cavities of HIV-infected 
individuals, with and without acquired  immune deficiency  syndrome (AIDS).  Since 
this time, the species has been widely detected from a variety of sources including the 
oral cavities of DM patients (Willis et al,  1999; Willis et al, 2000b; Manfredi et al, 
2002).  Candida dubliniensis  is rarely isolated from healthy individuals (Coleman et 
al, 1997; Sullivan & Coleman,  1997; Sullivan & Coleman, 1998). It is usually present 
in  a  mixed  culture  with  other  Candida  species,  particularly  C.  albicans.  However, 
pure cultures of C.  dubliniensis have been  isolated from HIV-infected patients with 
clinical  signs of oral  candidosis  (Coleman et al,  1997).  The  most common  clinical 
manifestation  of  oral  candidosis  in  this  group  of  patients  and  caused  by  C. 
dubliniensis  is  erythematous  candidosis  (Table  1.2)  (Sullivan  &  Coleman,  1998). 
Candida dubliniensis has also been isolated from faecal, sputum, vaginal and blood 
cultures  (Odds  et al,  1998;  Meis  et al,  2000;  Polacheck  et al,  2000;  Moran  et al, 
2002). Numerous studies have reported the mis-identification of C. dubliniensis as C. 
albicans  but  it  is  now  considered  that this  species  can  emerge  as  an  opportunistic 
pathogen in severe immunodeficiency from the commensal microbial flora (Moran et 
al,  2002).  Although  C.  dubliniensis  is  not  inherently  less  susceptible  to  antifungal 
drugs  (Pfaller  et  al,  1999b;  Moran  et  al,  2002),  susceptible  isolates  can  readily
25develop resistance to fluconazole in vitro when exposed to this agent (Moran et al, 
1998).
1.1.3 Candida glabrata
As with  C.  dubliniensis,  it is now evident that C.  glabrata can cause oral  infection 
(Fidel  et  al,  1999).  There  are  now  reports  of  increased  C.  glabrata  infection  in 
immunocompromised  and  hospitalised  patients,  indeed  C.  glabrata  is  the  most 
commonly  recovered  non-C.  albicans  species  from the  oral  cavity  of HIV-infected 
patients (Occhipinti et al,  1994;  Pfaller et al,  1999b). Nosocomial  acquisition  of C. 
glabrata  is  not uncommon.  Furthermore, two  major risk factors associated  with  C. 
glabrata  colonisation  are  prolonged  duration  of  hospitalisation  and  prior 
antimicrobial use (Fidel et al,  1999). Of clinical concern, several studies have noted 
that a significant proportion of C. glabrata isolates are resistant to fluconazole (9%) 
and  itraconazole (37-40%) (Price et al,  1994;  Rex et al,  1997;  Pfaller et al,  1998a; 
Barchiesi  et al,  1999;  Moran  et al,  2002).  Fluconazole  resistance  can  also  develop 
rapidly in a clinical environment (Moran et al, 2002).
1.1.4 Candida krusei
Candida krusei can replace C.  albicans in the oral cavities of HIV-infected patients, 
particularly  after  azole  therapy  (Chavanet  et  al,  1994;  Lischewski  et  al,  1995; 
Coleman et al,  1997; Ruhnke et al, 2000). It is now generally accepted that C. krusei 
is inherently resistant to fluconazole, and that fluconazole prophylaxis may promote 
the proliferation of this organism (Rex et al, 2000; Moran et al, 2002).
261.1.5  Other important Candida species
Other pathogenic  species  of Candida  such  as  C. parapsilosis  and  C.  tropicalis  are 
generally  recovered  from  blood  cultures  and  the  skin  of  immunocompromised 
patients,  particularly  in  hospital  environments,  but these  species  are  rarely  isolated 
from the oral cavity (Levin et al, 1998; De Bemardis et al,  1999b; Moran et al, 2002). 
Candida  lusitaniae  is  a  rare  pathogen,  mainly  isolated  from  immunocompromised 
patients  where  it  is  often  responsible  for  candidemia  (Pfaller,  1996).  Candida 
lusitaniae can easily develop resistance to amphotericin B (Moran et al, 2002). Like 
all pathogenic microorganisms,  Candida  species have developed different virulence 
mechanisms that confer the ability to colonize a host surface, to penetrate into deeper 
host tissue, and to evade host defences (Hube & Naglik, 2002) that are described in 
Section 1.2.
1.2  Virulence attributes of Candida spp.
In order to promote successful colonization or invasion of host tissues, Candida spp. 
have  developed  different  virulence  attributes.  The  most  investigated  factors  are 
related to the Candida cell wall, adherence to tissues and surfaces and production of 
proteinases, which are all discussed in the following sections.
1.2.1  Candida cell wall
Of all the Candida spp., the composition of the cell wall has been mostly studied in 
C.  albicans  through  different  approaches,  mainly  based  on  biochemical  analysis. 
Candida  albicans  has  a  cell  wall  that  is  primarily  composed  of glucans  (40-60%), 
chitin  (25-6%)  and  mannan  (23%);  however,  lipids  and  proteins  are  also  present 
(Calderone  &  Braun,  1991).  The  cell  wall  is  considered  essential  for  C.  albicans 
pathogenicity, not only because it provides sites for adhesion to host surfaces, but it
27acts as a barrier against osmotic pressure and environmental insult (McCullough et al,
1996). There is comprehensive  literature on this subject, which focuses on the most 
important  properties  of this  essential  fungal  structure  (Calderone  &  Braun,  1991; 
Chaffin et al, 1998; Cannon & Chaffin, 1999; Chauhan et al, 2002).
1.2.2  Adhesion
Adhesion  is  a necessary  step  for  Candida  spp.  to  colonize  and  invade  a  host  eco­
system. The oral cavity presents many niches for Candida colonisation, and yeasts are 
able to adhere to many ligands such as epithelial and bacterial cell surface molecules, 
extracellular  matrix  (ECM)  proteins  and  dental  acrylics.  Salivary  molecules, 
including  basic proline-rich proteins, adsorbed to  many  oral  surfaces,  also  promote 
Candida adherence (Cannon & Chaffin,  1999; Cotter & Kavanagh, 2000). Adherence 
to host tissue  is the first step  in the pathogenic process of Candida  infections:  once 
first contact with  the  host  surface  has  been  made,  enzymes  facilitate  adherence  by 
damaging  or  degrading  host  cell  membranes  and  extracellular  proteins  (Cotter  & 
Kavanagh, 2000).
The mechanisms of adherence of Candida species to many cell types or surfaces are 
complex and aspects of adhesion are unclear, although it is known that adherence is 
achieved  through  a  combination  of specific  (ligand  receptor  interaction)  and  non­
specific  mechanisms  (electrostatic  forces,  aggregation,  cell  surface  hydrophobicity) 
(Cotter &  Kavanagh,  2000).  Specific  adherence  is  mediated  by  a  number of target 
proteins located on the endothelial cell or within the ECM. With respect to the latter, 
fibronectins are adhesive glycoproteins located in the ECM interstitium, which have a 
high  molecular  weight  and  are  involved  in  cell  adhesion  and  cell  migration 
(Castellani et al,  1986; Cotter & Kavanagh, 2000). Other microorganisms apart from 
Candida, such as Staphylococcus aureus and Streptococcus pyogenes, have also been
28shown in vitro to adhere to the ECM protein, fibronectin (Skerl et al,  1984). Trans­
membrane  integrins  present  on  the  surface  of C.  albicans  are  thought  to  mediate 
adherence to ECM (Hostetter,  1994) by recognising ligands that contain amino acid 
sequences  such  as  the  Arginine-Glycine-Aspartic  acid  (RGD)  sequence  (Varner  & 
Cheresh,  1996).  Candida albicans also binds to RGD  sequence-containing proteins, 
such  as  fibronectin,  laminin  and  collagen  types  I  and  IV,  through  integrin-related 
structures  (Klotz  et  al,  1994).  Adherence  of  Candida  to  epithelial  cells  is  also 
mediated  by  cell-wall  mannoproteins,  particularly  the  protein  portion  (Cotter  & 
Kavanagh,  2000),  as  pre-treatment  with  a  variety  of proteolytic  enzymes  inhibits 
adherence significantly (Douglas, 1986).
Interestingly, most of the genes that encode proteins whose expression correlates with 
hyphal  formation,  also  encode  cell-wall  mannoproteins  (Calderone  &  Gow,  2002). 
Whilst  nine  ALS  (agglutinin-like  sequence)  genes  that  encode  cell-surface 
glycoproteins  had  been  originally  detected  in  C.  albicans  (Hoyer  &  Hecht,  2000; 
Hoyer, 2001; Hoyer & Hecht, 2001), the homologous nature of two of these (ALS3- 
ALS8) has been recently shown (Zhao et al, 2004): these proteins are thought to play 
roles in adhesion with the host.
A  novel  mechanism  that  C.  albicans  hyphae  use  to  adhere  specifically  to  buccal 
epithelial cells (BECs) has been shown (Staab et al,  1999) by the isolation of a Hwpl 
protein  encoded  by  a  HWP1  gene  expressed  in  germ-tube  and  hyphal  forms  of C. 
albicans. It has been demonstrated that the NH2-terminus of this protein is a substrate 
for mammalian transglutaminase,  a cross-linking enzyme found  in human epithelial 
and endothelial tissue (Staab et al, 1999).
It  has  also  been  shown  that  the  C.  albicans  integrin-like  Inti  gene/protein  is 
implicated  in adhesion. The Inti  protein  is a transmembrane protein encoded by the 
INTI  gene, the deletion of which causes a partial reduction in adhesion to epithelia,
29loss of virulence and inhibition of hyphal formation (Gale et al,  1998; Calderone & 
Gow, 2002).
Finally,  the  ability  of Candida  spp.  to  form  biofilms  on  the  surfaces  of medical 
devices,  such  as  catheters  and  oral  prostheses,  has  been  studied  by  several 
investigators  (Chaffin  et al,  1998;  Cannon  &  Chaffin,  1999;  Chandra  et al,  2001; 
Ramage et al, 2001; Calderone & Gow, 2002; Garcia-Sanchez et al, 2004). Biofilms 
seem to confer drug resistance to their inhabitants as the drugs have poor penetration 
to cells within the biofilms (Kuhn et al, 2002a; Kuhn et al, 2002b). Microscopy has 
been used to determine cellular composition  during the development of the biofilm 
(Baillie & Douglas, 1999; Douglas, 2003).
1.2.3  Extracellular hydrolases
Candida  spp.  produce  a  range  of  extracellular  enzymes  that  facilitate  adherence 
and/or tissue penetration. The three most significant hydrolytic enzymes produced by 
Candida species (and most notably by C.  albicans) are secreted aspartic proteinases 
(Saps,  which  hydrolyse  peptide  bonds),  phospholipases  (which  hydrolyse 
phospholipids) and  lipases  (which  hydrolyse  ester bonds of tryglycerides)  (Hube & 
Naglik, 2002; Naglik et al, 2004).
£
1.2.3.1  Secreted aspartyl proteinases (Sap)
To  date, ten members of the  SAP gene family,  encoding different secreted aspartyl 
proteinases  (Sap  1-10)  have  been  isolated.  Many  Candida  species  are  known  to 
possess  SAP  genes  and  produce  active  extracellular proteinases  in  vitro;  and  these 
include C. albicans, C. dubliniensis (Gilfillan et al,  1998), C.  tropicalis (Togni et al, 
1991;  Monod et al,  1994;  Zaugg et al,  2001) and  C. parapsilosis (de  Viragh  et al, 
1993; Monod et al,  1994). The pathogenicity of different Candida species may reflectthe  ability  to  produce  Saps,  and  it  has  been  reported  that  less  pathogenic  or  non- 
pathogenic  Candida  species produce no  Saps or do  so  in  limited amounts  (Ruchel, 
1992).  Furthermore,  it has been reported that the  success of the fungal  pathogen  in 
different types of infection depends partly upon the expression of distinct virulence 
factors, such as members of the  SAP gene family (Hube et al,  1997;  Sanglard et al, 
1997; De Bemardis et al,  1999b).  Whereas SAPs 4-6 have been shown to facilitate 
systemic infections, the expression of SAPs 1-3 appears important for the virulence of 
Candida  in  superficial  candidosis  (Schaller et al,  2001).  All  the  secreted  Candida 
proteinases belong to the same class of aspartic proteinase (Hube & Naglik, 2002). 
Extracellular  matrices  and  host  surface  proteins  such  as  laminin,  fibronectin,  and 
mucin  are  efficiently  degraded  by  Saps,  in  particular  by  Sap2,  thus  aiding  yeast 
adhesion to buccal epithelial cells (BECs).  Sap 2 has also been shown to hydrolyse 
secretory IgA (normally resistant to bacterial proteinases) (Ghannoum & Abu Elteen, 
1986; Douglas,  1988) and the action of Sap 2 is greatest at low pH levels (pH 2-5). It 
has however also been reported that Sap 2 remains stable, and has some activity, at 
neutral pH  levels (Capobianco et al,  1992;  Wagner et al,  1995).  It is further known 
that Sap4 and Sap6 are particularly active at physiological pH levels (pH 5-7) (Hube 
& Naglik, 2002; Naglik et al, 2003). This stability of Saps at different pH levels may 
assist Candida species, in particular C.  albicans, to colonize and/or infect hosts in a 
neutral  pH  environment,  such  as  the  oral  cavity  (Naglik  et al,  2003;  Naglik  et al, 
2004).
1.2.3.2  Phospholipases
Phospholipases  are  thought  to  contribute  to  the  pathogenicity  of  C.  albicans  via 
hydrolysis of lipids in  host cell  membranes, particularly during invasion (Mayser et 
al,  1996; Fu et al,  1997) and dissemination in the host. It has been proposed that 30-
3170%  of  C.  albicans  isolates  exhibit  phospholipase  activity  to  varying  degrees 
(Kothavade & Panthaki,  1998). A number of different classes of phospholipase (PL) 
are known and are classified based on their mode of action (Hube & Naglik, 2002). 
Phospholipases A,  B,  C  and  D  (PLA,  PLB,  PLC,  PLD)  have  been  identified  in  C. 
albicans, but it has been shown that only PLB1  is required for virulence in an animal 
model  of candidosis  (Ghannoum  &  Abu  Elteen,  1986;  Calderone  &  Fonzi,  2001). 
Phospholipases  and  lysophospholipases  may  damage  host-cell  membranes  and 
facilitate Candida invasion. Interestingly enough, it has also recently been discovered 
that  non-C.  albicans  species  secrete  phospholipases,  although  in  smaller  quantities 
compared to C. albicans (Ghannoum, 2000).
A  correlation  between  phospholipase  activity  in  vitro  and  virulence  has  been 
demonstrated.  A  study comparing phospholipase activity of C.  albicans commensal 
isolates with those from blood revealed that extracellular phospholipase activity was 
higher in the  latter group of isolates,  inferring that phospholipases played a role  in 
haematological  (and  presumably  systemic)  infection  (Ibrahim  et  al,  1995).  In 
addition,  the  blood  isolates  had  significantly  higher rates  of germination  and  their 
germ tubes were  longer than those produced by commensal  strains.  This study also 
compared  isolates  that  exhibited  high  and  low  phospholipase  activity  in  a  murine 
model  of disseminated  candidosis.  Phospholipase-deficient  strains  demonstrated  a 
reduced  ability  to  invade  and  isolates  exhibiting  increased  phospholipase  activity 
caused greater mortality (Ibrahim et al,  1995). It would therefore appear that candidal 
phospholipases  may  enhance  the  dissemination  of C.  albicans  contributing  to  the 
pathogenesis of Candida infections (Hube & Naglik, 2002).
321.2.3.3  Lipases
Lipases secreted by Candida spp. are able to catalyse the hydrolysis of esters bonds 
of triglycerides  (Hube  &  Naglik,  2002).  Up  to  now,  a  family  containing  10  lipase 
genes  (LIP1-10)  has  been  identified  (Hube  et  al,  2000;  Stehr  et  al,  2004)  in  C. 
albicans.  Furthermore,  sequences  similar  to  LIP1-10  were  also  detected  in  other 
pathogenic Candida spp., such as C. tropicalis, C. parapsilosis and C. krusei, but not 
in  C.  glabrata (Fu et al,  1997;  Hube  et al,  2000;  Hube & Naglik,  2002).  Different 
experiments on LIP genes have shown that the transcription of at least some of these 
genes  is  lipid-independent  and  suggest  that  lipases  may  have  functions  other  than 
solely  providing  nutrients  for  the  cells,  i.e.  contributing  to  the  persistence  and 
virulence of C. albicans in human tissue (Hube & Naglik, 2002). It has recently been 
demonstrated  by  reverse  transcriptase  polymerase  chain  reaction  (RT-PCR),  that 
some  LIPs  of C.  albicans  are  expressed  constitutively,  whilst  others  are  induced 
under  different  environmental  conditions  (Hube  et  al,  2000;  Stehr  et  al,  2004). 
Furthermore, the expression profile of the lipase gene family appears to be dependent 
on the stage of infection (Stehr et al, 2004).
1.2.4  Phenotypic switching
Phenotypic  switching,  first  observed  in  C.  albicans  as  differences  in  colony 
morphology (Pomes et al,  1985; Slutsky et al,  1985; Slutsky et al,  1987; Soil,  1992), 
has also been noted with other Candida species,  such as  C.  glabrata (Lachke et al,
2000),  C.  tropicalis  (Soli  et al,  1988) and  C. parapsilosis (Enger et al,  2001;  Soil,
2002).  In  the  1980s,  research  demonstrated  that  low  doses  of UV  light  induced  a 
frequent,  but reversible transition  in  Candida colony  morphology to produce  rough 
colonies (Pomes et al,  1985).  Correspondingly, another study revealed other colony 
types,  described as “fuzzy”,  “hat”,  “stippled”  and “wrinkled”  (Slutsky et al,  1985).
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opaque  (WO-1)  system  in  C.  albicans,  where  transition  between  a  hemispherical 
smooth  white  colony  morphology  (white  phase)  and  a  flat  smooth  grey  colony 
morphology (opaque phase) occurs (Slutsky et al,  1987; Soil et al,  1994; Soil, 2002). 
Switching regulates a number of phase-specific genes and a high proportion of these 
genes directly or indirectly  influence a variety  of virulence traits,  such as  adhesion 
(Kennedy  et al,  1988),  yeast-hyphal  transition  (Anderson  et al,  1989),  secretion  of 
proteinases  (Morrow  et  al,  1992;  White  et  al,  1993;  Monod  et  al,  1994),  drug 
susceptibility  (Soil  et al,  1989)  and  antigenicity  (Anderson  et al,  1990).  Switching 
occurs both at sites of commensalism and infection, although more frequently in the 
latter,  providing  a  variety  of minor  phenotypes  for  rapid  adaptation  to  immediate 
environmental challenges (Soil, 2002).
1.2.5  Morphogenesis
Candida albicans is a dimorphic organism that exists in the form of unicellular yeasts 
(budding cells or blastospores) and filamentous hyphae. Phase transition from yeast to 
hyphae is termed morphogenesis and is regarded as important in the pathogenesis of
infections  by  C.  albicans  (and  C.  dubliniensis).  A  recent study  established that the ^
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ability of C. albicans to invade a model of oesophageal candidosis depended upon the  ■  
ability  of the  strain  to  convert  from  the  yeast to  the  hyphal  form  (Bernhardt  et al,
2001).  A  hyphal-forming  strain  was  able  to  invade  in  two  days,  whereas  a  strain 
unable  to  form  hyphae  showed  no  evidence  of  invasion.  The  dependence  upon 
filamentation for invasion may be attributed to differences in surface characteristics 
and  antigenicity  (Bouchara  et  al,  1990),  and  morphogenesis  may  be  an  important 
immune evasion  mechanism.  Yeast cells, as previously reported, are able to  invade 
the pancreas of mice,  indicating that yeast cells also possess some invasive potential(Young,  1958).  Hence, morphogenesis can  influence pathogenicity of Candida,  but 
yeast forms can even cause disease.
1.2.6  Immune evasion
Candida albicans can avoid aspects of the host immune defences using a variety of 
mechanisms.  As  mentioned  above,  C.  albicans  produces  proteases  that  cleave 
immunoglobulins  and  can  avoid  immune  elimination  via  antigenic  variation  using 
phenotypic switching and morphogenesis (Naglik et al, 2003). However, C. albicans 
can also mask surface antigens by binding to platelets via fibrinogen-binding ligands 
(Odds,  1994),  and  has  been  shown  to  possess  complement  binding  receptors, 
considered important in preventing phagocytosis (Heidenreich & Dierich, 1985).
1.3  Clinical aspects of Candida infections 
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Candida spp. produce a broad range of infections, ranging from non-life-threatening 
mucocutaneous  illnesses to  invasive processes  involving any organ.  In this  section, 
particular attention is focused on predisposing factors implicated in the development 
of oral candidal infections, and on the principal forms of oral candidosis that may be 
observed in healthy subjects or in patients affected by systemic disease, such as DM.
1.3.1  Host predisposing factors for oral candidosis
Candida  spp.  are  opportunistic  oral  commensals  that  can  switch  to  a  pathogenic 
existence  resulting  in  oral  candidosis.  This  commensal-pathogen  transition  is 
associated with  a number of virulence attributes  of Candida  spp.  (Section  1.2),  but 
host factors are also of critical importance in the development of candidal infections. 
Only  when  host  defences  are  inadequate  can  the  organism  induce  infection 
(Samaranayake,  1990).  A  wide  range  of local  and  systemic  host  factors  has  beenimplicated in the pathogenesis of oral candidosis (Table  1.1) (Odds,  1988a; Ellepola 
& Samaranayake, 2000a) and these are discussed in the following sections.
1.3.1.1  Local factors
The  integrity  of  the  oral  mucosa  is  essential  in  preventing  the  adhesion  and 
penetration of Candida spp. into deeper tissue. Although various factors could lead to 
a  breach  of oral  tissue,  trauma  caused  by  natural  and  artificial  teeth  is  relatively 
common  (Samaranayake,  1990;  Scully  et al,  1994).  Dental  prostheses,  particularly 
maxillary  dentures,  can  lead to  a continuous  maceration  of the  oral  fitting  mucosa 
resulting  in  microscopic  breaches  of  the  epithelium  (Samaranayake,  1990).  In 
addition, the ability of Candida spp. to adhere to the acrylic resins of the dentures, in 
combination  with  reduced  salivary  flow  under the  prostheses  and/or poor  hygiene, 
creates  a  potential  reservoir  of yeasts,  in  contrast  to  a  prosthesis-free  oral  cavity 
(Budtz-Jorgensen, 1990b; Radford et al, 1999).
Epithelial  changes  to  the  oral  mucosa,  such  as  atrophy,  hyperplasia  and  dysplasia, 
may compromise the structure of the mucosal barrier and facilitate candidal invasion, 
although there are no studies that have compared the thickness of the epithelium  in 
relation  to  candidal  invasion  (Samaranayake,  1990;  Sitheeque  &  Samaranayake,
2003).
Adequate  salivary  flow  is  essential  in preventing  oral  colonisation  and  invasion  of 
Candida  spp.  because  it  removes  unattached  or poorly  adherent  Candida  from  the 
mucosa  and  inhibits  candidal  adhesion  to  host  surfaces  by  the  inhibitory  action  of 
salivary  IgA (Samaranayake,  1990).  Furthermore, the presence of lysozyme,  a  low- 
molecular  weight  protein  present  in  high  concentrations  of saliva  and  in  gingival 
crevicular  fluid,  increases  Candida  permeability  and  stimulates  phagocytosis  in 
combination with  IgA.  Finally,  salivary  lactoferrin  has an antifungal  effect through
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surprising  that  several  authors  (MacFarlane  &  Mason,  1974;  Martin  et  al,  1981; 
Samaranayake et al,  1984a; Samaranayake et al,  1988) have reported that a reduced 
salivary flow resulting from pathological conditions,  such as Sjogren’s syndrome or 
head and neck radiation therapy,  may  determine an  increase  in the carriage of oral 
Candida  and  predisposition  to  oral  candidosis.  Furthermore,  qualitative  changes  of 
saliva,  such  as  high  glucose  concentration  and  low  pH  ranges  (pH  <5),  may  also 
enhance  oral  candidal  carriage,  thus  promoting  subsequent  oral  infections 
(Samaranayake, 1990).
There is still controversy regarding the relationship between tobacco smoking and the 
development  of oral  candidosis.  Some  studies  (Gergely  &  Uri,  1966;  Bastiaan  & 
Reade,  1982) have suggested that smoking habits do not affect oral Candida carriage 
and  predisposition  to  oral  candidosis.  However,  other  authors  have  reported  that 
smoking may lead to localised epithelial alterations, such as epithelial keratinisation, 
reduction  in  salivary  IgA  and  possible  depression  of  the  polymorphonuclear 
leukocyte  function,  favouring  oral  candidal  colonisation  (Zimmermann  & 
Zimmermann,  1965; Kenney et al,  1977; Mosadomi et al,  1978).  In addition,  it has 
been hypothesised that cigarette smoking provides nutrition for Candida spp., which 
are able to enzymically convert some polycyclic aromatic  hydrocarbons to produce 
carcinogens (Hsia et al,  1981; Clark et al,  1984; Samaranayake,  1990). Furthermore, 
it  has  been  reported  that  certain  C.  albicans  biotypes  are  capable  of  producing 
carcinogenic nitrosamine N-nitrosobenzylmethylamine from its precursors (Krogh et 
al,  1987). These observations may partly explain the potential role of Candida spp. in 
oral epithelial dysplasia and neoplasia (Scully et al, 1994; McCullough et al, 2002).
371.3.1.2  Systemic factors
Different systemic conditions have been evaluated as predisposing to oral candidosis. 
Systemic  diseases  characterised  by  quantitative  and  qualitative  immune  deficiency 
(cell-mediated  and/or humoral  immunity)  have  been  investigated  and  proved  to  be 
involved in the pathogenesis of systemic and mucosal candidosis.
Chronic Mucocutaneous Candidosis (CMC) is a primary immune deficiency in which 
patients  are  predisposed  to  candidal  infection  which  has  a  characteristic  clinical 
presentation  -   recurrent  and/or  recalcitrant  candidal  infection  of  mucocutaneous 
surfaces,  as  well  as  a  range  of  haematological,  endocrine  and  neurological 
complications.  It  is  classified  as  a  distinct  primary  immunodeficiency,  the  exact 
mechanism  that  predisposes  to  the  candidal  infection  remain  to  be  determined 
(Lehner et al, 1972; Porter & Scully, 1990; Porter & Scully,  1994b; Lilic & Gravenor, 
2001; Lilic et al, 2003).
In addition, altered physiological states, such as infancy and old age, in combination 
with co-factors, such as therapeutic procedures (antibiotic and corticosteroid therapy), 
congenital  defects  or  local  factors,  may  lead  to  oral  candidal  infections 
(Samaranayake, 1990; Scully et al, 1994).
Diabetes  mellitusis  one  of the  systemic  diseases  most  frequently  implicated  with 
enhanced carriage of oral Candida and a higher risk of developing oral candidosis. As 
this  is the  principal  subject  of this thesis,  an  extensive  revision  of the  relationship 
between DM and oral candidosis is presented in Section 1.8.9.1.1.
Systemic  and/or  superficial  candidal  infection  can  arise  with  both  solid  (e.g. 
lymphoma)  and  non-solid  (e.g.  leukaemia)  malignancies.  These  candidal  infection^ 
occur as  a result of tumour-related  immunosuppresion  (e.g.  neutropenia) as well  as 
therapy that ablates the bone  marrow (e.g.  cytotoxic  drug regimes) (Sandford et al, 
1980; Scully et al, 1994; Powderly et al, 1995; Feld, 1997; Ruhnke, 2002).Due  to  their  efficacious  anti-inflammatory  and  immunosuppressive  properties, 
corticosteroids, used systemically or topically, may also result in a lower resistance to 
infections.  Inhaled steroids  in particular appear to play a primary role  in  increasing 
the  risk  of oral  and  oropharyngeal  candidosis.  Other  immunosuppressive  regimes 
(e.g. post-allograft receipt) may also predispose to candidal infection -  particularly of 
the mouth (Samaranayake,  1990;  Scully et al,  1994;  Budtz-Jorgensen &  Lombardi, 
2000).
Broad-spectrum antibiotic therapy is one of the most common iatrogenic factors that 
is implicated in the development of oral candidosis, altering the local oral microflora 
and  creating  a  suitable  environment  for  the  proliferation  of  Candida  spp.  It  is 
important to emphasise that local mucosal  immunity and normal oral  microflora are 
restored  once  these  therapies  are  suspended  (Budtz-Jorgensen,  1990a;  Budtz- 
Jorgensen, 1990b; Samaranayake, 1990; Ellepola & Samaranayake, 2000a).
Studies  show  that  several  nutritional  deficiencies  are  also  implicated  in  the 
pathogenesis of oral candidal infections. Of these, iron deficiency can cause a series 
of alterations  that  may  increase  the  susceptibility  of oral  mucosa  to  yeasts.  Iron 
deficiency results in depression of cell-mediated immunity both in vitro and in vivo, 
and  may  determine  defects  in  phagocytosis  and  inadequate  antibody  production 
(Samaranayake, 1986; Samaranayake, 1990; Sitheeque & Samaranayake, 2003).
Other nutritional deficiencies, such as those involving folic acid, vitamins A and B12 
are also involved in the causation of oral candidosis often in combination with other 
systemic and local co-factors (Samaranayake,  1986).
1.3.2  Classification of oral candidosis
Different classifications for oral  candidosis have been proposed over the years.  The 
currently  accepted  classification  of  oral  Candida  infections  is  based  on  two
39categories:  primary  and  secondary  oral  candidosis  (Table  1.2).  In  primary  oral 
candidosis,  the  oral  candidal  infection  is  confined  to  the  oral  and  perioral  tissues 
whilst oral lesions that are a manifestation of generalized systemic or mucocutaneous 
candidal  infections are classified as secondary oral candidosis (Holmstrup & Axell, 
1990;  Scully  et  al,  1994).  Recently,  a  proposal  for  a  new  classification  of  oral 
candidosis  has  been  suggested  (Axell  et  al,  1997).  The  suggestion  is  that  some 
keratinised primary  lesions that are super-infected by  Candida,  such as leukoplakia, 
lichen planus and lupus erythematosus, may be classified as primary oral candidosis. 
Examples of clinical presentations of oral  candidal  infections are  shown  in  Figures 
1.3-1.10.
1.3.3  Systemic forms of candidosis
Although less common than oral candidosis, systemic types of candidal infection may 
manifest  themselves  in  the  form  of localised  primary  disease  of deep  organs  or 
haematogenously disseminated infections (Odds, 1988b). Candida spp. are frequently 
isolated from blood culture  in severely  immunocompromised patients; the mortality 
rates from systemic candidosis can be as high as 50% (Romani, 2002). Common risk 
factors for bloodstream candidosis include extremes of age (low-birth-weight infants 
and  the  elderly),  immunosuppression,  malignancy  with  leucopenia,  central  venous 
catheterisation  and  prolonged  hospitalisation,  recently  reviewed  (Kullberg  &  Filler, 
2002).
Although  DM  is reported as one of the potential  risk factors  in the development of 
candidemia (Kao et al,  1999), DM patients are usually not affected by systemic forms 
of candidosis and for this reason systemic candidal infections are not reviewed in the 
thesis.
401.4  Treatment of oral candidosis
A variety of antifungal agents with different action mechanisms are available for the 
treatment of oral Candida infections (Table  1.4). The most common antifungal drugs 
in  current  clinical  use  are  polyenes  (amphotericin  B  and  nystatin),  azoles 
(fluconazole,  clotrimazole,  miconazole,  ketoconazole,  itraconazole,)  and  less 
frequently,  5-fluorocytosine  (5-FC).  Recently,  a  new  second-generation  triazole 
(voriconazole)  and  an  echinocandin  antifungal  agent  (capsofungin)  have  been 
approved  for  clinical  use  by  the  Food  and  Drug  Association  (FDA)  (Johnson  & 
Kauffman, 2003). Furthermore, other new triazoles (posaconazole, ravuconazole) are 
in  development for clinical  use  (Espinel-Ingroff,  1998;  Espinel-Ingroff et al,  2001; 
Sanglard & Odds, 2002). In addition, chlorhexidine gluconate has also been proposed 
(Budtz-Jorgensen  &  Loe,  1972)  as  an  adjunctive  therapeutic  supplement  for  the 
prevention  and  treatment  of some  types  of oral  candidosis,  particularly  Candida- 
associated denture stomatitis (Budtz-Jorgensen & Lombardi, 2000).
Ergosterol  biosynthesis  is  specific to  fungi  and  is  necessary  for their growth.  As  a 
result, this feature has been used as the main target in the design of antifungal agents. 
Among  currently  used  antifungals,  only  a  few  (5-FC  and  echinocandins)  do  not 
directly interfere with the ergosterol biosynthetic pathway. The modes of action and 
resistance  mechanisms  for  each  antifungal  agent  used  for  the  treatment  of  oral 
candidal  infections  are  summarised  in  Table  1.3.  Several  researchers  have,  in 
particular,  evaluated  the  mechanisms  responsible  for  the  development  of  drug 
resistance  in  some  Candida  spp.  isolates  at  the  molecular  level.  For  azoles,  four 
distinct  resistance  mechanisms  have  been  reported  (Table  1.3).  Up  regulation  of 
multidrug  efflux  transporter  genes  has  been  linked  with  decreased  azole 
susceptibility:  these  transporters  include  ATP-binding  cassette  (ABC)  transporter 
genes  (e.g.  CDR1,  CDR2,  CDR3,  CDR4  from  C.  albicans)  (Sanglard  et al,  1995;
41Franz  et  al,  1999;  Balkis  et  al,  2002);  CgCDRl  and  PDH1  from  C.  glabrata; 
CdCDRl  for C. dubliniensis) and major facilitator (MF) genes (MDR1) (Moran et al, 
1997;  Miyazaki  et al,  1998;  Sanglard  et al,  1999).  The  most  important  difference 
between the two efflux pump systems is that ABC transporters accept almost all the 
azole  agents  as  substrates,  while  MF  transporters  only  accept  fluconazole  as  a 
substrate. In addition, up regulation of ERG 11 (a gene encoding for Ergl lp, the target 
of azole  derivatives)  has  been  reported  as the  possible  cause  of azole  resistance  in 
some C. albicans and C. glabrata isolates. Amino acid substitutions in Egrl lp could 
also affect optimal binding of this target to azole derivatives (Sanglard & Bille, 2002; 
Sanglard & Odds, 2002).
Recently, the cloning of the gene encoding for a subunit of the p-1,3 glucan synthase 
in  C.  albicans  (CaFKSl)  has  provided  genetic  evidence  that  alterations  of  this 
enzyme are implicated in echinocandin resistance, although this is a rare occurrence 
in comparison with azole resistance (Douglas et al, 1997; Frost et al,  1997; Mio et al,
1997).
1.5  Analysis of Candida virulence attributes and associated host responses
1.5.1  Phenotypic methods
1.5.1.1 Adhesion assays
Various methods have been used to examine the adherence of yeast cells to host cells, 
immobilised  protein  ligands  and  plastic  surfaces.  Typically,  the  cell-cell  adherence 
assays, using Candida spp. and host cells, are either performed in suspension or host 
cells  are  grown  (or  attached)  in  monolayers  to  which  Candida  spp.  are  added 
(Calderone & Gow,  2002).  After rinsing  or filtration to  remove  non-adherent yeast 
cells, the number of adherent or non-adherent organisms is determined.
42Candida adherence to exfoliated BECs as well as vaginal, urogenital and corneal cells 
(Cannon & Chaffin,  1999; Cotter & Kavanagh, 2000) has been examined in this way. 
Human  embryonic  kidney  epithelial  cells,  HeLa  (Henrietta  Lacks  cells  -  human 
epithelial cells from a fatal  cervical  carcinoma  infected by  Human Papilloma Virus 
18-  HPV18),  fibroblasts,  vascular  endothelial  cells  and  human  umbilical  vein 
endothelial  cells  have  been  studied  to  determine  Candida  adherence  (Cotter  & 
Kavanagh, 2000). However, a number of different factors can influence the result of 
adhesion assays. These factors include the type of fungal strain used and source of the 
epithelial cells, the number of viable or non-viable BECs and the environment of the 
yeast culture (e.g. temperature and carbon source) (Sandin et al,  1987a; Sandin et al, 
1987b; Polacheck et al,  1995). It is also possible to determine the inhibitory action of 
an  agent  by  first  incubating  the  yeast  or  host  cell/material  with  the  inhibitor  in 
question before the assay.
Candida adherence may be also evaluated microscopically  after initial  fixation  and 
staining (ruthenium red,  crystal  violet,  Gram  stain) of cells  (Bernhardt et al,  2001; 
Vitkov et al, 2002), or growth (colony forming units - cfu) may act as a measure of 
adherence by plating cells on agar.
Co-aggregation assays of Candida spp., particularly C. albicans, with several species 
of oral bacteria,  such as S.  gordoni, S.  sanguis, S.  mutans and Actinomyces  species 
have been developed, although the growth conditions for the bacteria can affect co­
adherence  (Cannon  &  Chaffin,  1999).  Co-aggregation  of  C.  albicans  and  C. 
dubliniensis with  oral  bacteria,  such  as Fusobacterium  nucleatum  (one  of the  most 
frequent  isolate  microbes  from  the  subgingival  plaque  of periodontitis  lesions),  has 
recently  been  described  (Jabra-Rizk  et al,  1999;  Calderone  &  Gow,  2002).  These
studies are able to identify microorganisms with which Candida spp. may interact in
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the oral cavity. Finally, in vitro assays that isdWte adhesion by blocking the adherenceof extracted proteins from cells of Candida, have also been developed (Edwards et al, 
1992; Calderone & Gow, 2002).
1.5.1.2  Proteinase assays
Proteinase  activity  has  been  primarily  investigated  using  an  assay  (Macdonald  & 
Odds,  1980) in which C.  albicans is grown in media to  induce proteinase secretion. 
The  culture  supernatant  is  then  assayed  for  its  ability  to  degrade  bovine  serum 
albumin  (BSA) over a specific  period  of time (usually  30  min),  where  cleavage  of 
BSA  acts  as  a  measure  of enzyme  activity.  Undigested  BSA  is  removed  from  the 
reaction,  either by  precipitation  or filtration,  and the  amount of digested  protein  is 
determined by measuring the optical density at 280nm. Usually, the number of yeast 
cells  per  reaction  is  known,  so  that  enzyme  activity  is  recorded  as  a  change  in 
absorbance  per  number  of yeast  cells  over  a  30  min  period.  There  are  different 
variations  of this  assay  involving  the  use  of proteinase-activity  inhibitors  such  as 
pepstatin A (Macdonald & Odds, 1980; Kwon-Chung et al, 1985; Korting et al, 1999) 
and others (Macdonald & Odds, 1980).
It  is  well  known  that  Saps  are  expressed  and  secreted  during  different  stages  and 
types of Candida infections by different Candida spp. (Hube & Naglik, 2002; Naglik 
et al,  2003).  For this  reason,  researchers  have  investigated  the  in  vitro  SAP  gene 
expression in culture media (Ruchel,  1992; Stewart et al,  1999; Monod & Borg-von 
Zepelin, 2002) and the role of Saps in virulence, using proteinase inhibitors (pepstatin 
A)  and  C.  albicans  strains  lacking  distinct  proteinase  genes  (Fallon  et  al,  1997; 
Schaller et al,  1998).
441.5.1.3 Phospholipase assays
The  traditional  method  of assessing  phospholipase  activity  involves  the  growth  of 
isolates on  Sabouraud’s Dextrose Agar supplemented with egg yolk.  Phospholipase 
activity (expressed as a Pz value) appears as a white area of precipitation around each 
colony, the agar having a turbid appearance (Ibrahim et al,  1995; Mayser et al,  1996; 
Fu et al,  1997; Kothavade & Panthaki,  1998; Ghannoum, 2000) probably due to the 
formation  of calcium  complexes  with  the  fatty  acids  released  by  phospholipases 
acting upon phospholipids in the egg yolk. However, this assay is not specific, as the 
egg  yolk  contains  substrates  from  both  phospholipases  (phospholipids)  and  lipases 
(triglycerides), and is not suitable for examining yeast species that produce low levels 
of phospholipases.  Methods  for analysing phospholipase  activity  directly  in  culture 
supernatant  have  also  been  developed  utilizing  radiolabelled  substrates.  Following 
phospholipase cleavage,  radiolabelled products are  extracted and  initially  identified 
using  thin  layer  chromatography.  Liquid  scintillation  analysis  of  the  separated 
products then  provides  an  estimate  of phospholipase  activity.  This  is  expressed  as 
nanomoles of product formed per ml per min or as percentage total  of radioactivity 
per lane (Kothavade & Panthaki, 1998).
1.5.1.4 Organotypic cultures
An organotypic or ‘histotypic’  culture  is the reconstitution of cells to form a three- 
dimensional tissue structure that mimics the tissue architecture from which the cells 
originated. For mucosa, the culture comprises fibroblasts dispersed in a collagen gel 
as  a  dermal  equivalent  onto  which  the  epithelial  cells  are  seeded.  A  variety  of 
epithelial cells may be used,  such as keratinocytes or enterocytes, depending on the 
type of organotypic culture required. Once established, cultures may be infected with 
microorganisms  to  produce  a  model  of  infection  that  facilitates  examination  of
45microbial  pathogenesis  and  thereby  allows  investigation  of  host-microbial 
interactions. Methods of analysis involve histopathology and immunohistochemistry, 
but  the  cellular  response  to  infection,  such  as  cytokine  production,  can  also  be 
investigated  using  Enzyme  Linked  Immunosorbent  Assays  (ELISAs)  or  RT-PCR. 
Organotypic cultures have been used as models of cutaneous candidosis (Korting et 
al,  1998; Dieterich et al, 2002) and oral candidosis (Korting et al,  1999;  Schaller et 
al,  1999a;  Schaller  et al,  1999b)  to  investigate  C.  albicans  adhesion  and  invasion 
(Dieterich et al, 2002). Organotypic cultures may be an effective alternative to animal 
models  for  the  investigation  of  microbial  pathogenicity  and  host  microbial 
interactions.  In  particular,  the  model  of  oral  candidosis  was  considered  to 
morphologically resemble normal oral mucosal epithelium, and,  in infection with C. 
albicans, the observed pathology was similar to that observed during natural infection 
(Schaller  et  al,  1998).  However,  although  organotypic  cultures  provide  a 
representative  model  for the  investigation  of host-microbial  interactions,  they  lack 
systemic components important in homeostasis, as well as humoral and cell-mediated 
immune responses, which play pivotal roles in infection control.
1.5.1.5  Animal models
A  number  of  different  animal  models  of  candidosis  have  been  employed  to 
investigate  host-microbial  interactions.  Murine  and  rat  models  have  primarily  been 
utilised  for  the  investigation  of  systemic,  vaginal,  cutaneous  and  oral  candidosis 
(Samaranayake  &  Samaranayake,  2001).  Candida  production  of  Saps  and  SAP 
expression have been  investigated  using animal  models,  particularly regarding their 
roles  in  adhesion,  invasion  and  dissemination  (Naglik  et  al,  2003).  The  effects  of 
pepstatin A (Fallon et al,  1997) and gene expression during infection (De Bemardis et
46al,  1995;  Staib et al, 2000; Naglik et al, 2003;  Schaller ef al, 2003) have also been 
examined.
The virulence and pathogenesis of Candida in an animal model may be calculated as 
a percentage survival rate of animals tested, although conventional histopathological 
(Fallon et al,  1997) or microbiological methods (Calderone & Fonzi, 2001) are also 
employed.  The  examination  of organs  (e.g.  kidneys,  spleen,  liver,  lungs  and  heart) 
can  be  important  in  determining  tissue  tropism  and  microbial  clearance.  Although 
animal  models  allow  the  investigation  of  host  microbial  interactions,  including 
systemic  influences,  most  of  the  studies  have  been  performed  under  different 
experimental conditions, making them particularly difficult to compare.  In addition, 
C.  albicans  infection  of mice  has  not  been  reported  to  occur  naturally  (Ekenna  & 
Sherertz,  1987). Therefore, extrapolation of findings in animal models to C. albicans 
infection in humans may be limited, as the model does not fully represent the human 
situation (Schaller et al, 1998; Naglik et al, 2003).
1.5.1.6  Host immune responses in Candida infections
Multiple  arms  of  the  immune  response  act  in  concert  to  eliminate  infecting 
organisms. More specifically, phagocytosis, complement and inflammatory mediators 
have  been  investigated  for  their  role  in  C.  albicans  clearance.  The  ability  of 
polymorphonuclear leukocytes and macrophages to both  ingest and kill  C.  albicans 
blastoconidia  has  been  studied.  Previously,  a  radiometric  assay,  which  measured 
3H’uridine incorporation, was used to investigate phagocytosis (Bridges et al,  1980). 
Since  a  linear  relationship  exists  between  uridine  incorporation  and  yeast  cell 
numbers,  phagocytosis  can  be  determined  by  comparing  uridine  incorporation  in  a 
fixed  number  of  C.  albicans  cells  with  the  presence  or  absence  of phagocytes.
47Similarly, phagocytic killing can be determined by comparing uridine  incorporation 
after disruption of the phagocyte membrane.
The  ability  of  C.  albicans  to  activate  complemen^ and  its  susceptibility  to  X  
complement-mediated killing have also been investigated (Willcox et al,  1998). The 
susceptibility  of  C.  albicans  blastoconidia  to  complement  can  be  evaluated  by 
determining  the  number  of colony  forming  units  (cfu)  following  incubation  of a 
blastoconidia suspension with human serum. Western blotting can be used to examine 
complement activation, where the supernatant from a blastoconidia/serum suspension 
is separated using gel  electrophoresis, transferred to a nitrocellulose membrane  and 
probed using anti-human C3 antibodies. This permits identification of C3 fragments, 
and therefore indicates complement activation.
The ability of C. albicans to stimulate production of inflammatory mediators has been 
examined  using  ELISAs  (Willcox  et  al,  1998).  This  not  only  allows  cytokine 
detection,  but titration  of the  culture  supernatant  allows  quantification  of cytokine 
production.
1.5.1.7 Immune evasion
As mentioned previously, Candida has a variety of methods for evading host immune 
responses;  these  include  the  binding  of  platelets  to  hide  surface  antigens  and 
phenotypic  switching.  The  ability  of  Candida  spp.  to  bind  to  platelets  has  been 
investigated,  as  has  the  effect  of  inhibitors,  using  platelet  rich  and  platelet  poor 
plasma (Willcox et al,  1998). Platelets and Candida cells are mixed in varying ratios, 
and aggregation is defined as a decrease in optical density. Phenotypic switching can 
be  detected  using  conventional  mycological  techniques  (Soil  et  al,  1994).  Genetic 
analysis of differential gene expression during transition has been the primary focus
48of investigation,  particularly  on  strain  WO-1,  which  switches  between  a white  and 
opaque phase (Soil et al, 1994).
1.5.2  Genetic methods
Phenotypic  methods  provide  an  insight  into  morphological  alterations  involved  in 
host-microbial  interactions,  whereas  genetic  methods  elucidate  the  molecular 
mechanism behind these interactions.
1.5.2.1 Transcription
The  investigation  of gene  transcription  by  Candida  under  different  conditions  has 
been  investigated  in  an  attempt  to  identify  specific  genes  important  for  microbial 
pathogenesis  and  survival  in  the  host.  This  can  be  undertaken  by  investigating 
changes  that  occur  in  specific  known  genes,  or  gene  families,  or  genome-wide 
variations.
1.5.2.2 Genome-wide transcriptional analysis
Various techniques have been  used to assess differential  gene expression,  including 
hybridisation  screening  of  cDNA  libraries,  prepared  from  extracted  RNA  of  C. 
albicans  cells  grown  under  different  conditions.  Conditions  that  have  been 
investigated  include  altered  growth temperature,  carbon  dioxide concentration, type 
of culture media and pH  level.  Furthermore, differential hybridisation has been used 
to study C. albicans infection in animal models, yeast budding and hyphal formation 
(Hoyer et al,  1995), as well as phenotypic switching for WO-1  (Morrow et al,  1993). 
A  variation  of  this  method  using  subtractive  hybridisation  was  employed  to 
investigate white opaque switching (Srikantha & Soil, 1993).
49More  recently,  DNA  arrays  have  been  constructed  and  used  to  examine  microbial 
gene  transcription.  The  DNA  microarray  is  a  hybridization-based  genotyping 
technique that offers simultaneous analysis of many polymorphisms. A partial array 
for C.  albicans containing approximately 7000 genes was constructed in 2001. This 
was used to compare gene expression during yeast to hyphal transition of wild types 
and mutants with changes in pathways important in this transition (Lane et al, 2001). 
Several  subsequent  studies  have  used  the  DNA  microarray  technique  to  study 
different  gene  expressions  associated  with  Candida  resistance  to  antifungal  agents 
(Rogers &  Barker, 2002),  implicated  in Candida cel 1-wall  biosynthesis (Sohn et al, 
2003; Lotz et al, 2004) or in adaptation to oxidative stress (Chauhan et al, 2003).
1.5.2.3  Gene-specific transcription analysis
The primary method for analysing specific genes or gene families in recent years has 
been  RT-PCR.  This  involves  the  extraction  of RNA  from  C.  albicans  grown  in 
different environments,  and  performing  PCR on  cDNA  synthesised  from the  RNA 
using primers specific for the gene or gene family in question. Internal controls may 
be  included,  such as actin genes, which allow the evaluation of RT-PCR sensitivity 
and efficiency  (Schaller et al,  1998).  This  method  has  been  applied to  examine  C. 
albicans SAP gene expression during infection of reconstituted human epithelium and 
oral  biopsy  specimens  (Schaller  et  al,  1998;  Schaller  et  al,  1999a).  However,  an 
alternate method for examination of gene expression  is the use of promoter-reporter 
gene  constructs.  Here,  the  abundance  of  reporter  product  acts  as  a  measure  of 
transcription.  This  method  has  again  been  used  predominantly  to  assess  SAP  gene 
expression (Cormack et al, 1997; Staib et al, 2000).
501.5.2.4  Mutants
An  alternative  genetic  method  that  assists  elucidation  of molecular mechanisms  of 
host-microbial  interactions  is the  investigation  of specific  mutants and their role  in 
pathogenesis. Unlike many other microorganisms,  C.  albicans is diploid. Hence, the 
construction  of mutants  requires  disruption  of both  alleles  in  a  gene.  The  method 
commonly  used  for  gene  disruption  in  C.  albicans  is  the  ‘URA-blaster’  method 
(Alani et al,  1987; Fonzi & Irwin,  1993; Calderone & Fonzi, 2001) that involves the 
use  of  a  selectable  marker  (URA3)  flanked  by  direct  repeats  (bacterial  hisG 
sequences), whose presence and absence can be selected.  SAP mutants have been a 
particular focus of research using this method. The ability of SAP mutants to adhere 
and  invade reconstructed human epithelium (Schaller et al,  1999a), as well  as their 
role in inhibiting phagocytosis and killing in murine macrophages (Borg-Von Zepelin 
et  al,  1998)  have  been  studied.  However,  other  C.  albicans  mutants  such  as  the 
proteinase deficient mutant M l2  and transcription  factor mutants  EFG1  and  CPH1 
have been investigated (Macdonald & Odds, 1983; Dieterich et al, 2002).
Overall  C.  albicans  is an  exceedingly  versatile  eukaryotic  organism  that  inhabits  a 
wide variety of niches within the host. Each of these niches exerts different selective 
pressures upon the organism. Due to this variation and the local or systemic changes 
in the host’s ability to resist infection, the Candida-host relationship may be of either 
a  commensal  or  parasitic  nature.  The  application  of both  phenotypic  and  genetic 
methods to investigate this relationship enhances our understanding of host-microbial 
interactions. Elucidation of such interactions will ultimately facilitate identification of 
putative targets for intervention.
511.6  Isolation  and  identification  of  Candida  species  from  the  oral  cavity 
(phenotypic-genotypic methods)
A number of different techniques are proposed for the isolation of Candida spp. from
the oral cavity (Table  1.6). The choice of method often depends on the type of lesion
being investigated (Williams & Lewis, 2000). The oral rinse technique (Section 2.2)
involves collecting a 30 s mouthrinse of 10 ml of sterile distilled water (or phosphate-
buffered saline). Prostheses should be removed prior to sampling. The solution is then
vibrated  for 30s  for optimal  disaggregation;  a known  volume  (lOOpl)  is  inoculated
onto  an  agar medium  and  then  incubated  for 24-48  h  at  37°C.  Candida  growth  is
r\OS^
expressed in cfu per ml of sajj^ra. This method is rapid, easy to perform and provides 
quantification  of  Candida  and  other  microorganisms  through  samples  grown  in 
specific culture medium (Samaranayake et al, 1986).
1.6.1  Primary culture media
The  most  frequently  used  primary  isolation  medium  for  Candida  species  is  SDA 
(Odds,  1991), which although permitting growth of Candida species,  suppresses the 
growth of many commensal oral bacteria due to its low pH (< pH 6). Bacterial growth 
can  be  further  suppressed  by  adding  antibiotics  (chloramphenicol,  penicillin, 
streptomycin, ciprofloxacin) to the culture medium (Silverman et al, 1990). Plates can 
either be  incubated aerobically  at  37°C  for 24-48  h or at room temperature  for 2-3 
days; Candida develop in the form of cream-coloured, convex colonies and may have 
a  fringe  of submerged  hyphae.  It  should  be  noted,  however,  that  coliforms  which 
sometimes grow on  SDA, may mimic yeasts in appearance (Silverman et al,  1990). 
SDA rarely permits differentiation between Candida species within the same sample. 
It  is  in  fact estimated that more than one  Candida  species occurs  in  approximately 
10% of oral samples and consequently, it is recommended that SDA should be used 
in combination with other culture media (MacFarlane, 1990).Examples of other culture media used for the isolation and identification of Candida 
spp. are reported in Section 1.6.2.1.
1.6.2  Identification of Candida species from the mouth - Phenotypic Methods 
As  described previously,  there  is  increasing  diversity  of Candida  isolates  from the 
mouth and  so consequently, there  is a need  not only detect to  Candida, but also to 
identify  the  isolated  yeast.  Different  systems  of identification  based  on  phenotypic 
properties of Candida have been proposed. Although they are simple and have been 
applied  in epidemiological studies,  it is not always possible to accurately repeat the 
techniques.
1.6.2.1  Direct identification on primary culture media
The  incorporation of fluorogenic  or chromogenic  substrate  directly  into the growth 
agar  media  to  reveal  species-specific  enzyme  activities  allows  discrimination  of 
particular  Candida  species  colonies  in  a  mixed  yeast  population,  and  thus  allows 
rapid identification of Candida species on the primary isolation medium (Freydiere et 
al, 2001). Chromogenic substrates are now preferred to fluorogenic substrates due to 
their  stability  and  ease  of  interpretation.  Chromogenic  substrates  are  also 
commercially  available.  Of  note,  CHROMagar®  Candida  (CHROMagar,  Paris, 
France) can detect and differentiate between C. albicans,  C.  tropicalis,  C. krusei and 
C.  dubliniensis,  based  on  colony  colour and  appearance,  while  other  chromogenic 
media identify only C. albicans (Freydiere et al, 2001).
CHROMagar Candida can differentiate C. albicans from C. dubliniensis (Sullivan et 
al,  1995), as the latter appear as darker green colonies. However, this differentiation 
appears to decline after isolate and subsequent subculture. Failure of C.  dubliniensis 
to grow on agar media at the elevated  incubation temperature of 45°C  has recently
53been suggested as an alternative test (Odds & Bernaerts,  1994;  Schoofs et al,  1997; 
Pinjon et al,  1998;  Williams &  Lewis, 2000).  Recently,  it has been shown that the 
speed of assimilation of some sugars achieved with rapid commercial systems allows 
differentiation  between  C.  albicans and  C.  dubliniensis (Freydiere et al,  2001).  An 
anti-C. albicans cell wall surface-specific monoclonal antibody has been described as 
useful for differentiating between the two species (Marot-Leblond et al, 2000).
In contrast to the findings of others (Pfaller,  1996; Willinger & Manafi,  1999), some 
authors (San Millan et al, 1996; Powell et al, 1998; Hoppe & Frey,  1999; Freydiere et 
al,  2001)  report that CHROMagar  Candida  does  not allow the  identification  of C. 
glabrata  and  other  emerging  pathogens  that  have  different  susceptibility  levels  to 
antifungal  agents.  To  avoid  misidentification,  it  is  thus  important  to  establish  the 
limitations of the methods and reagents used for fungal identification.
Pagano  Levin  agar  (Pagano  et  al,  1957),  which  is  not  commercially  produced, 
distinguishes yeast species on the basis of differences in colour, which are attributed 
to  a  reduction  in  triphenyltetrazolium  chloride  incorporated  in  SDA.  This  medium 
produces  pale  coloured  colonies  of C.  albicans,  while  colonies  of other  Candida 
species produce colonies in varying degrees of pink (Samaranayake et al, 1987).
1.6.2.2  Germ-tube test
This  is  the  standard  laboratory  method  for  differentiating  C.  albicans  from  other 
Candida species; however, C. dubliniensis is now also known to produce germ-tubes 
(Sullivan & Coleman,  1997; Sullivan & Coleman,  1998). The test involves the rapid 
induction  of hyphal  outgrowths (germ-tubes)  from yeasts cultured  in  serum  (rabbit, 
bovine,  horse  or  pooled  human  sera)  for  2-4  h  at  37°C.  Following  incubation, 
suspensions  are  placed  on  a  glass  slide  and  examined  microscopically  for  the 
presence of germ-tubes. A germ-tube is a filamentous, cylindrical hyphal outgrowth
54from the yeast cell with no constriction present at the base (Odds,  1988c; Silverman 
et  al,  1990;  Williams  &  Lewis,  2000)  (Fig. 1.1).  The  formation  of germ-tubes  is 
influenced by different factors,  e.g.  temperature,  inoculum  size,  composition of the 
medium and C. albicans strain (Mackenzie et al, 1962).
1.6.2.3 Chlamydospore formation
Similar  to  germ-tube  production,  chlamydospore  formation  is  a  peculiar  ability 
observed  in  C.  albicans,  C.  dubliniensis  (Sullivan  &  Coleman,  1998)  and 
occasionally  in  isolates of C.  tropicalis (Hasenclever,  1971;  Silverman  et al,  1990; 
Williams & Lewis, 2000). The chlamydospore has been defined as a large, refractile, 
thick-walled  cell  induced  in  vitro  by  culture  on  agar  supplemented  with  commeal 
Tween  80  (Fig.  1.2).  Following  incubation  for  1-2  days  at  room  temperature, 
chlamydospore  growth  can  be  observed  by  direct  microscopy  (Odds,  1988c; 
Silverman et al, 1990; Williams & Lewis, 2000).
1.6.2.4 Physiological tests
The  physiological  properties  of  Candida  species  often  need  to  be  related  to  the 
morphological criteria.  The main tests used  in the  identification of different species 
involve the examination of their ability to assimilate and ferment individual  carbon 
and nitrogen sources (Silverman et al,  1990) by inspecting zones of Candida growth 
around  disks  or wells  impregnated  with  various  sugars  in  basal  agars  (Di  Menna, 
1955).  It  is also possible to evaluate  Candida growth  in  tubes  containing  synthetic 
basal medium (yeast nitrogen base) to which different carbon sources are added.
551.6.2.5 Rapid commercial identification systems
The introduction of rapid commercial identification systems increases the accuracy of 
Candida species’  identification. These systems are based on growth (relatively slow, 
72  h  of incubation)  and  enzyme  production  profiles  (results  within  a  few  h).  The 
analysis can be performed manually or using automated systems (Table 1.7).
1.6.2.6 Histopathological appearance of Candida species in tissue
Periodic  Acid  Shiff,  PAS)  tissue  specimens  from  superficial  or  systemic  sites,  as 
yeasts and pseudohyphae, or yeast cell alone. Candida albicans may be distinguished 
from  other yeasts  by the  presence  of yeast cells plus  hyphae  and/or pseudohyphae 
(Richardson & Carlson, 2002).
1.6.2.7  Yeast killer toxin typing
A  Candida  strain  differentiation  system  based  on  the  susceptibility  of  Candida 
isolates to yeast killer toxins, has been reported (Polonelli et al,  1983; Caprilli et al, 
1985).  Candida  isolates  are  grown  with  killer toxin-producing  yeast  strains  (direct 
technique) (Section  1.7) in modified agar containing glucose and peptone. Following 
incubation,  toxins  released  in  the  agar medium  inhibit the  growth  of Candida  test 
strains (Polonelli et al,  1983;  Silverman et al,  1990). A method using purified yeast 
killer toxins (particularly ones produced by the genera Pichia) in place of killer yeast 
cells  can  also  be  used  for  differentiating  strains  of  Candida  isolates  (indirect 
technique). A computer-aided system can be used to evaluate, record and compare the 
halo of inhibition displayed by each killer toxin on each susceptible strain (Polonelli 
& Morace,  1986a; Polonelli & Morace, 1986b; Magliani et al, 1997b).
Candida  species  can  be  identified  histopathologically  in  appropriate  stained
561.6.3  Identification of Candida species - Genotypic Methods
Recent reports indicate an increasing number of pathogenic non-C.  albicans species 
such as C. dubliniensis, C. glabrata and C. krusei, possibly selected for as a result of 
widespread introduction of antifungal drugs (Nguyen et al,  1996; Pfaller et al,  1998a;
Pfaller  et  al,  1999a;  Sullivan  &  Coleman,  2002).  Routine  standard  methods  of 
identification,  including  commercial  automated  systems,  are  not  always  able  to 
analyse and  identify these  species,  and  subsequent treatment may  be  inappropriate. 
Correct identification is important to establish whether recurrent infections are due to 
a  novel  organism  or the  persistence/re-infection  of the  original  strain  and  whether 
specific clones or clusters of related strains develop a resistance to drugs (Sullivan & 
Coleman,  2002).  The  accurate  differentiation  of  species  and  strains  requires  the 
implementation of molecular biological  methods that are mainly based on  different 
PCR techniques. It is generally accepted that genetic methods of strain delineation are 
sensitive, reproducible and have relatively high discriminatory powers (Wilson et al,
2001)  and  thus  are  proposed  to  be  more  advantageous  than  phenotypic  methods. 
However, genetic methods can be time-consuming, laborious, costly and may require 
specialized  equipment  (Lehmann  et  al,  1992).  Table  1.7  summarises  the  most 
important molecular biology techniques jrfsecbin, literature for Candida identification.  /  
Details  of these  techniques  can  be  found  elsewhere  (Soil,  2000;  Dassanayake  & 
Samaranayake, 2003b; Gil-Lamaignere et al, 2003). The following discussion details 
the  molecular  biological  techniques  directly  employed  or  strictly  related  to  those 
adopted  in  this  study  for the  identification  of Candida  spp.  or analysis  of genetic 
differences within a Candida spp.
571.6.3.1  Polymerase Chain Reaction-based typing
Different  PCR  techniques  have  been  used  to  identify  Candida  species,  based  on
specific candidal genes. Ribosomal DNA (rDNA-genes encoding for ribosomal RNA)
is  a  frequent  target  in  PCR  systems  as  multiple  copies  of rDNA  sequences  exist
*
sensitiv^/ One of the most frequently used methods 
is based on the analysis of repeated sequences (PCR amplicons) of rDNA of Candida 
species achieved by restriction fragment length polymorphisms (RFLPs).
To  differentiate  between  all  medically  important species  of Candida,  PCR  primers 
have been directed against the V3 region of the 25S rDNA and against specific sites 
of the Intergenic Transcribed Spacer^region ^Jts)| of Candida species. Amplicons of 
V3-25S and ITS PCR are then digested with specific restriction endonucleases, e.g. 
Hae III and Dde I, respectively. The resulting restriction fragments are then analysed 
by  agarose  gel  electrophoresis.  This  technique  has  been  used  by  several  authors 
(Williams et al,  1995; McCullough et al,  1999a) to  identify a number of medically 
relevant important Candida species,  such as C.  glabrata,  C.  krusei,  C. parapsilosis, 
C.  guilliermondii,  C.  tropicalis,  C.  lusitaniae,  C.  pseudotropicalis  and  C. 
dubliniensis,  based on  size and primary  structural  differences  in the rDNA  regions. 
This  method  has  shown  that  one  of  the  Candida  species,  C.  stellatoidea,  is 
synonymous with C. albicans (genotype B) (McCullough et al, 1999b).
There are a number of PCR-based methods that have been used for C. albicans strain 
differentiation,  including random amplified polymorphic DNA (RAPD),  inter repeat 
PCR  (IR-PCR)  and  microsatellite  analysis,  often  collectively  referred  to  as  PCR 
fingerprinting.  Random  amplified  polymorphic  DNA  (RAPD),  or  arbitrary  primer 
PCR (AP-PCR) analyse short regions of DNA sequence for variation based on PCR 
priming  regions.  These  PCR  methods  are  based  on  the  use  of  one  short  PCR 
oligonucleotide  primer  (about  10-15  bp)  of  arbitrary  sequence  and  with  low
within the genome and it islmorestringency amplification reaction conditions. Due to the low annealing temperatures 
used,  primers  can  bind  to  many  sites  throughout  the  genome,  thus  allowing  the 
amplification  of  products  that  vary  in  size.  When  separated  by  agarose  gel 
electrophoresis  and  subsequently  stained  with  ethidium  bromide,  the  fragments 
obtained from PCR can yield strain-specific fingerprint patterns comprising 3-6 bands 
(Sullivan & Coleman, 2002). If a comparison of several isolate amplifications shows 
a band (locus) that varies, alleles are assigned to the presence (1) or absence (0) of the 
band (Taylor et al, 1999).
Although  these  techniques  are  methodologically  simpler,  less  time-consuming  and 
more  cost-effective  than  other  genomic  typing  methods,  they  are  limited  in  their 
ability to identify significant problems regarding the reproducibility of typing results 
(Taylor et al, 1999).
1.6.3.2  PCR fingerprinting with repetitive DNA sequences
In this  PCR technique, the  primers recognise a repeat DNA  sequence,  producing a 
large number of fragments with each reaction. The primers are longer (16 to 28 bp) 
than  those  used  in  RAPD  and  the  annealing  temperature  used  is  higher  to  avoid 
reproducibility  problems.  In  comparison  with  other  strain-typing  methods,  PCR- 
fingerprinting techniques are usually the most differentiating, simple and reproducible 
(Diaz-Guerra et al,  1997;  Taylor et al,  1999)  but due  to  the possible  homology  of 
bands, estimating a genetic relationship between groups of strains is problematic and 
it  is  difficult with  PCR-fingerprinting techniques to  establish  the  precise  degree to 
which strains differ.
591.7  Yeast killer phenomenon
Yeast killer toxins (KTs) are exotoxins (generally proteins or glycoproteins) that are 
secreted naturally by many different yeasts and are capable of killing susceptible cells 
belonging  to  the  same  or  congeneric  species  (Somers  &  Bevan,  1969;  Young  & 
Yagiu,  1978;  Wickner,  1985;  Polonelli  et al,  1991b;  Magliani  et  al,  1997b).  This 
phenomenon, first reported in Saccharomyces cerevisiae (Bevan & Makower,  1963) 
has been described in different yeasts and genera, such as Kluyveromyces,  Ustilago, 
Candida,  Cryptococcus, Debaryomyces, Pichia,  Torulopsis,  and  Williopsis amongst 
others  (Philliskirk  &  Young,  1975;  Wickner,  1985;  Young,  1989).  The  killer 
phenotype  is  genetically  encoded  by  cytoplasmatic  viral  double  stranded  RNA 
(dsRNA) or linear DNA plasmids as well as chromosomal genes and is mediated by 
specific  cell-wall  receptors  in  sensitive  yeasts  (Stumm  et al,  1977;  Bussey,  1981; 
Hutchins & Bussey,  1983; Tipper & Bostian,  1984; Schmitt & Radler,  1987; Starmer 
et al,  1987; Sawant & Aheam,  1990; Kimura et al,  1993; Kasahara et al,  1994). The 
Pichia and  Williopsis killer systems, produce different killer toxins,  some of which 
interfere  with  the  synthesis  of p-l,3-D-glucan,  the  major  cell-wall  polysaccharide 
polymer involved in determining cell morphology and maintaining osmotic integrity 
(Magliani et al,  1997b). In particular, HM-1  (or HMK), one of the most studied killer 
toxins  produced  by  Williopsis  mrakii,  a  basic  unglycosylated  polypeptide  of 
10.721kDa,  shows  high  thermostability  (100°C  for  10  min)  and  a  pH  stability 
between pH 2 and  11  (Yamamoto et al,  1986). It has been reported that HM-1  is able 
to kill susceptible strains of S.  cerevisiae and other yeasts, by firstly interfering with 
the synthesis of p-l,3-D-glucan, thus rendering the cell wall osmotically fragile and 
subsequently resulting in lytic cell death (Magliani et al,  1997b). This mechanism is 
similar  to  that  of antifungal  antibiotics  such  as  aculeacin  A,  echinocandin  B  and 
papulocandin B (Yamamoto et al, 1986).
60Killer cells are immune to their own toxins, and the exact mechanisms of killing and 
immunity still remain unknown for some killer systems (Magliani et al, 1997b). 
Interest  in  the  yeast  killer  phenomenon  has  increased  particularly  because  of the 
surprising susceptibility of microorganisms of clinical  interest,  such as  C.  albicans, 
Pneumocystis carinii and Mycobacterium  tuberculosis, to killer toxins from species 
of the genera Pichia and Williopsis (Polonelli & Morace,  1986a; Morace et al,  1989; 
Aliouat  et  al,  1993;  Magliani  et  al,  1997b).  The  biological  activity  of  a  toxin 
produced by the killer strain P.  anomala ATCC 96603  (PaKT), a large glycoprotein 
encoded by nuclear genes, has been studied against susceptible microorganisms, such 
as Candida.  Susceptible organisms to this toxin are characterized by the presence of 
specific  cell  wall  receptors,  most  likely  0-glucans  (Polonelli  &  Morace,  1986b; 
Polonelli et al,  1990). The wide spectrum of activity has led to the consideration of 
PaKT as a potential therapeutic agent in the treatment of fungal infections (Polonelli 
et al, 1986). Regretfully, PaKT has proven to be toxic and very labile at physiological 
pH and temperatures necessary for systemic antifungal therapy (Pettoello-Mantovani 
et al,  1995; Conti et al,  1996).  It has been also reported that yeast killer toxins will 
not  be  as  effective  as  antibiotics  because  of their  toxicity  and  strong  antigenicity, 
features  that  are  not  unsurprising  considering  that  these  molecules  represent  large 
foreign glycoproteins.
In  order  to  exploit  the  antimicrobial  activity  of PaKT  without  inducing  undesired 
effects, KT-neutralizing monoclonal antibody (mAbKT4) was produced according to 
idiotypic network theory (Jeme,  1974). To obtain the  large amounts of standardized 
reagents  required  for  therapeutic  purposes  and  still  exploit  PaKT’s  antimicrobial 
activity  without  undesired  effects,  anti-idiotypic  antibodies  (KT-IdAbs)  have  been 
produced.  These molecules represent the internal image of PaKT and are produced in 
the  monoclonal  (mAbKT)  and  recombinant  format  (KTscFv)  using  a  PaKT-
61neutralizing  monoclonal  antibody  (mAbKT4)  as  an  immunogen  (idiotypic 
vaccination) (Polonelli & Morace,  1987; Magliani et al,  1997a; Polonelli et al,  1997). 
^Killer  toxin  monoclonal  antibodies  (mAbKlO)  and  KTscFv  (scFvH6)^displayed  a 
microbicidal  activity  in  vitro  and  a  therapeutic  effect  in  vivo  against  killer  toxin 
receptor  (KTR)-bearing  eukaryotic  and  prokaryotic  pathogenic  microorganisms 
(Magliani et al,  1997a; Seguy et al,  1997; Conti et al,  1998; Conti et al, 2000; Cenci 
et al, 2002; Conti et al, 2002; Savoia et al, 2002).
1.8 Diabetes Mellitus and its association with oral candidosis
Diabetes mellitus is a complex multisystemic disorder characterized by a relative or 
absolute  deficiency  of  insulin  secretion  and/or  concomitant  resistance  to  the 
metabolic  action of insulin  on target tissues  (Garber,  1998).  Hyperglycaemia  is the 
immediate  metabolic  consequence  of DM  but  ultimately,  widespread  multisystem 
damage  can  occur,  e.g.  microvascular  disease  (microangiopathy)  with  capillary 
basement  membrane  thickening,  macrovascular  disease  (macroangiopathy)  with 
accelerated  arteriosclerosis,  neuropathy  involving  both  the  somatic  and  autonomic 
nervous systems, neuromuscular dysfunction, embryopathy, and decreased resistance 
to infection (Garber, 1998).
Diabetes  mellitus  can  have  a  variable,  and  sometimes,  profound  effect  upon  oral 
tissues.  This  is  typified  by  patients  with  poor glycaemic  control  being particularly 
prone to severe and/or recurrent bacterial or fungal infections.
1.8.1  Classification and pathogenesis of DM
A number of different classification  systems have been proposed for DM  (National
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Diabetes  Data  Group,  1979;  World  Health  Organization,  1985).  The  American 
Diabetes  Association  has  recently  described  a  classification  system  based  upon
62disease  etiology  (The  Expert  Committee  on  the  Diagnosis  and  Classification  of 
Diabetes  Mellitus,  1998;  American  Academy  of  Periodontology,  1999).  The 
classification  scheme  includes  two  major  forms  of DM,  termed type  1   (previously 
insulin-dependent DM or IDDM), and type 2 (previously non-insulin-dependent DM 
or  NIDDM)  DM  (The  Expert  Committee  on  the  Diagnosis  and  Classification  of 
Diabetes Mellitus, 1998).
1.8.2 General signs and symptoms of DM
The  initial  clinical  features  of type  1   DM  include  the  typical  triad  of polyuria, 
polydypsia and polyphagia. Irritability, malaise, apathy and pruritus can also be early 
features of type  1   DM (Teuscher ei al,  1989; Rees & Otomo-Corgel,  1992; Nathan, 
1993; Rees,  1994; Bell & Hockaday,  1996; Garber,  1998; The Expert Committee on 
the  Diagnosis  and  Classification  of  Diabetes  Mellitus,  1998).  Patients  with 
undiagnosed  type  1   DM  are  prone  to  ketoacidosis  (Bell  &  Hockaday,  1996;  The 
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus,  1998). 
The features of type  1   DM are reversible with effective insulin therapy. The features 
of type  2  DM  are  of slower  onset  and  less  specific  than  those  of type  1   and  are 
sometimes only detected when patients are examined for diseases unrelated to  DM. 
Patients  with  type  1   and  type  2  DM  have  an  equal  risk  of developing  vascular 
complications.
1.8.3 Complications of DM
While  good  glycaemic  control  can  prevent  or  reduce  the  likelihood  of  possible 
complications  linked  to  DM,  approximately  50%  of  patients  with  DM  develop
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chronic vascular complications following years of DM  (Rees,  1994).  These chronic
63complications of DM are summarised in Table  1.8 (Teuscher et al,  1989; The Expert 
Committee on the Diagnosis and Classification of Diabetes Mellitus, 1998).
1.8.4  Type 1  DM
Type  1   DM immune-mediated (A) (previously termed juvenile-type onset diabetes or 
insulin dependent) constitutes 5% to  15% of all cases of DM. Although this condition 
is prevalent on a global scale, North Americans and Europeans are more affected than 
other ethnic groups (Atkinson & Maclaren,  1994; Winter,  1996). This type of DM is 
caused  by  cell-mediated  autoimmune  destruction  of  the  (3-cells  on  the  islet  of 
Langerhans  in  the  pancreas  (Atkinson  &  Maclaren,  1994),  leading  to  a  complete 
inability of the cells to secrete insulin. Type  1   DM usually develops before 30 years 
of age,  although  can  occur  at  any  age.  It  is  suggested  that  pancreatic  destruction 
occurs when genetically predisposed  individuals are subjected to a triggering event, 
such  as  a  viral  infection  that  induces  a  destructive  autoimmune  response  (Smith, 
1987;  Rees,  1994).  The  rate  of p-cell  destruction  is  variable,  being  rapid  in  some 
individuals  (usually  infants  and  children)  and  slow  in  others  (typically  adults) 
(Zimmet  et  al,  1994).  There  are  two  age-associated  peaks  of  incidence,  most 
commonly halfway through the first ten years of age, and during adolescence. It has 
recently  been  suggested  that  p-cell  damage  is  caused  by  islet  cell  autoantibodies 
(ICAs),  autoantibodies  to  insulin  (IAAs),  autoantibodies  to  glutamic  acid 
decarboxylase (GADA65) and autoantibodies to the tyrosine phosphatases IA-2 and 
IA-2p.  Eight-five to  ninety  percent of individuals  with  initial  hyperglycaemia have 
one or more of these autoantibodies, which can be considered as markers for this type 
of DM j(Cantor et al, 1995; Atkinson & Eisenbarth, 2001; Bingley et al, 2001).
The  idiopathic  form  of type  1   DM  (B)  is  of  unknown  aetiology.  Most  affected 
patients  have  permanent  insulinopenia and  are  prone  to  ketoacidosis.  This  form  of
64DM is strongly inherited, but lacks immunological evidence for p-cell autoimmunity 
and is not HLA associated (Banerji & Lebovitz,  1989; The Expert Committee on the 
Diagnosis and Classification of Diabetes Mellitus, 1998).
1.8.5  Type 2 DM
Type 2 DM, previously termed non-insulin-dependent DM, often occurs in middle to
late life and is the more common form of DM, accounting for 80% to 93% of all DM
patients  (National  Diabetes  Data  Group,  1985;  American  Academy  of
Periodontology,  1999). Type 2 DM is characterized by p-cell dysfunction in secreting
adequate  amounts  of  insulin,  particularly  after  meals,  and/or  peripherical  insulin
resistance.  Patients  with  type  2  DM  have  some  endogenous  insulin  secretory
capability,  but  have  overt  abnormalities  of glucose  homeostasis,  including  fasting
hyperglycaemia  (Reaven  et al,  1976;  Turner et al,  1979;  Bell  &  Hockaday,  1996;
Garber,  1998). Depending on the degree of accompanying hyperglycaemia, patients
with  type  2  DM  are  managed  by  dietary  control  of  sugars  and/or  with  oral
hypoglycaemic agents, although sometimes insulin therapy becomes necessary if their
disease cannot be managed adequately with oral agents and diet.
Type 2 DM frequently remains undiagnosed for many years and in the early stages of
disease,  hyperglycaemia develops gradually  and  is often not severe enough to give
rise  to  polyuria,  polydypsia  or  weight  loss  (Fujimoto  et  al,  1987;  Harris,  1989).
Unlike patients with the type  1   disease, those with type 2 DM are relatively resistant
to  the  development  of  ketoacidosis  as  a  direct  consequence  of the  retention  of
endogenous  insulin secretion.  Type 2  DM  often has a familial  basis,  although does
not clinically manifest until middle to late life. As a consequence of an accompanying 
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resistance  to  insulin,  obesity  is  a  major  risk  factor  in  DM,  indeed  up  to  80%  of 
patients with type 2  DM  have mild to marked obesity  (Zimmet,  1992;  Harris et al,
651995). Women with prior gestational DM (GDM) may also be prone to type 2 DM as 
are individuals with hypertension or hyperlipidemia (Barnett et al,  1981; Newman et 
al, 1987).
1.8.6 Diagnostic criteria for DM
The diagnostic criteria for DM as recommended by the National Diabetes Data Group 
(National  Diabetes  Data  Group,  1979)  and  the  World  Health  Organisation  (World 
Health  Organization,  1985)  have  been  modified  recently  by  an  Expert  Committee 
(The  Expert  Committee  on  the  Diagnosis  and  Classification  of Diabetes  Mellitus,
1998)  and are reported in Appendix 1.
1.8.7 Assessment of glycaemic control in patients affected by DM
Different methodologies for assessing glycaemic control are available, depending on 
the severity of the disease and the clinical setting (Table 1.9). Of these, the estimation 
of the  blood  level  of glycosylated  haemoglobin  (HbAlc)  provides  an  accurate  and 
objective  measure  of glycaemic  control  over  past  weeks  to  months.  The  rate  of 
formation  of  this  HbAlc  is  directly  proportional  to  the  ambient  blood  glucose 
concentration. Glycosylated haemoglobin is expressed as a percentage of the normal 
haemoglobin. Non-DM subjects have HbAlc values of less than 6%, while levels in 
poorly  controlled  patients  may  reach  10  to  12%,  and  can  be  as  high  as  20%.  In 
clinical  practice,  HbAlc  is  usually  measured  periodically  (at  least  biannually)  to 
assess glycaemic control, to permit appropriate changes to treatment and to determine 
the  degree  of  inconsistency  with  a  patient’s  records  of  home  blood  glucose 
monitoring (The Expert Committee on the Diagnosis and Classification of Diabetes
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Mellitus, 1998; Goldstein et al, 2003).
661.8.8  Management of DM
The aims of DM management are to maintain normal blood glucose  levels without 
episodes of hypoglycaemia, and to prevent or reduce complications caused by  long­
standing disease. These aims cannot be achieved without good patient cooperation.
1.8.8.1  Oral hypoglycaemic agents and insulin
Drugs  commonly  used  to  manage  type  2  DM  are  oral  hypoglycaemic  agents, 
particularly sulphonylureas and biguanides. Sulphonylureas stimulate the secretion of 
insulin  and  increase  the  number  of insulin  receptors  if there  is  some  endogenous 
insulin  production.  Examples  of currently  employed  sulphonylureas  are  shown  in 
Table  1.10.  Metformin  is  the  only  biguanide  available.  This  drug  acts  mainly  by 
decreasing hepatic gluconeogenesis and increasing peripheral utilisation of glucose. A 
number of other available agents for managing DM appear in Table 1.11. Newer anti­
diabetic  drugs  are  usually  prescribed  in  combination  with  sulphonylureas  and 
biguanides  when  older  agents  prove  inadequate  in  reducing  high  blood-glucose 
levels.
Insulin therapy is required for type  1   DM, and for patients with long-standing type 2 
DM  when  other  therapies  prove  unsuccessful.  Insulin  is  administered  by 
subcutaneous  injection and  is  available  in  short-acting (for 2  to  6  h),  intermediate- 
acting (1  to 20 h) and long-acting (over 40 h) forms (Mealey,  1998). Mixed  insulin 
preparations  are  also  available.  Management  typically  involves  a  combination  of 
short-acting  and  intermediate-acting  insulin  (Table  1.11).  Continuous  subcutaneous 
insulin infusions or “insulin pumps” are now available. These deliver a basal dosage 
of  insulin  to  maintain  glucose  control  without  hypoglycaemia  (Varon  &  Mack-
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Shipman, 2000).
67Insulin  is  available  in  three  different  forms:  human  (produced  synthetically  or  by 
DNA recombinant technology using Escherichia coli),  porcine  and bovine.  Human 
insulin has a more rapid onset and shorter duration than porcine insulin, while bovine 
insulin has the longest duration of activity (Mealey,  1998), although the non-human 
forms are now rarely employed.
The absorption of insulin from subcutaneous sites is variable both within and between 
individuals and therapy needs to be tailored to suit the life-style of the patient (Bell & 
Hockaday,  1996).  The main aim of insulin therapy  is to reproduce the natural peak 
levels of insulin during and after meals post-prandially using a basal concentration. 
The pharmacokinetics of insulin make this difficult and hypoglycaemia is the  most 
common complication of inadequate management (Bell & Hockaday,  1996). Detailed 
descriptions of insulin therapy can be found elsewhere (Garber, 1998).
1.8.9  Oral disease manifestations associated with DM
A wide spectrum of oral manifestations of DM is discussed in the following sections.
1.8.9.1 Fungal infections
1.8.9.1.1  Oral candidosis and other candidosis
Several  authors  have  reported  that  DM,  especially  when  poorly  controlled,  may 
predispose  to  a  variety  of superficial  and  systemic  fungal  infections  (Fisher  et al, 
1987; Hill et al,  1989; Lamey et al,  1992; Finney et al,  1997;  Guggenheimer et al, 
2000b;  Lalla  &  D'Ambrosio,  2001),  particularly  oral  candidal  infections,  whose 
clinical  course can  be more  severe (i.e.  recurrent and chronic) than that of patients 
without DM.  However, although the majority of reports show a correlation between 
Candida  and  DM  (Ueta  et  al,  1993;  Guggenheimer  et al,  2000b),  the  notion  that
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candidal  infection  is  more  severe  or  frequent  in  DM  sufferers  than  in  healthy 
individuals remains unresolved (Samaranayake, 1990; Vazquez & Sobel, 1995).
68It  also  remains  unclear  as  to  whether the  candidal  load  is  a true  reflection  of the
likelihood of a clinical manifestation of fungal disease and if an increased  Candida 
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oraljpromotes  systemic  infection.  A  number of specific  studies  have  attempted  to  ^
establish cut-off limits  for cfu  in order to  distinguish between carriers and  patients 
with  oral  candidosis  (Samaranayake  et  al,  1986)  but  it  is  evident  from  literature 
(Bartie et al, 2004) that checks can reveal higher levels of Candida (> 9 X 103  cfu/ml) 
in healthy individuals than in patients affected by oral candidal infection.
Candida albicans is the most prevalent Candida species isolated from the oral cavity 
of both DM and healthy individuals (Dorocka-Bobkowska et al,  1996;  Willis et al,
1999).  Candida  dubliniensis,  a  recently  discovered  species  of  Candida  that  was 
mostly  isolated from the oral  cavities of HIV-infected patients, was detected  in  58 
out of 318 insulin-treated DM patients (Willis et al,  1999). Candida dubliniensis has 
also been isolated from the oral cavity of patients with both type  1   and type 2 DM 
(Manfredi  et al,  2002)  and  seems  to  have  a predilection  for dentate  patients.  The 
pathogenic  significance of this new  species  in the  oral  cavity of patients with  DM 
remains unknown.  It has been established that C.  dubliniensis usually co-colonizes 
the  oral  cavity  with  C.  albicans  or with  other Candida  spp.  (Willis  et al,  2000b). 
Whether  this  co-colonisation  has  any  influence  on  clinical  outcomes  is  yet  to  be 
determined.
The  frequency  and  density  of Candida  colonisation  and  the  development  of oral 
candidosis  in  DM  patients  appear to  result  more  from  a  combination  of host  and 
fungal risk factors (e.g.  degree of glycaemic control, presence of dentures, smoking 
habits,  age,  medication,  adherence  of Candida  spp.),  rather  than  any  other  single 
factor (Darwazeh et al, 1990; Darwazeh et al, 1991b).
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As  with  healthy  individuals,  there  is  great  variation  in  the  isolation  rates  of oral 
Candida in patients affected by DM (Table  1.12). These differences are often due to
69the  diversity  of  sampling  techniques  used  by  the  authors  to  quantify  oral  yeast 
carriage.  However,  a  number  of studies  have  shown  that  the  oral  rinse  sampling 
method (Samaranayake et al,  1986) is the most appropriate and sensitive technique 
for evaluating overall oral Candida carriage. A recent study (Manfredi et al, 2002), 
using this methodology found that patients with DM are no more  likely to harbour 
yeast  in their oral  cavity than  healthy  individuals, thus  DM  itself may  not place  a 
person  at  increased  risk  of  fungal  carriage  or  clinical  infection,  although  poor 
diabetic  control  and  a high  level  of glycosylated  haemoglobin  (>12%)  (Hill  et al, 
1989;  Vazquez  &  Sobel,  1995)  may  increase  susceptibility  to  fungal  infection 
(Gibson et al, 1990; Ueta et al, 1993; Willis et al, 2000b).
Furthermore, it must be noted that different DM populations (in terms of type of DM 
or diabetic  treatment)  have  been  examined  in  different  studies  over the  years  and 
different variables evaluated (e.g.  glycaemic control), thus rendering the comparison 
between these studies quite difficult.
There is no clear mechanism by which DM may predispose to higher oral candidal 
carriage rates than in healthy subjects. However, it is well known that high salivary 
glucose levels in patients affected by DM favour yeast growth (Knight &  Fletcher, 
1971).  The hyperglycaemia of poorly controlled DM may  influence the pathogenic 
colonisation  of Candida  (Samaranayake  &  MacFarlane,  1982).  Yeast  growth  and 
adhesion  may  be  enhanced  by  high  glucose  concentration  (Samaranayake  et  al, 
1984b) in blood (Odds et al,  1978) and in saliva (Knight & Fletcher,  1971), which 
can serve as a nutrient for Candida.
The reduced capacity for killing Candida by neutrophilis (Hostetter,  1990; Ueta et al, 
1993;  Vazquez &  Sobel,  1995)  in the presence of high glucose concentrations may
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also  account  for  any  increased  colonisation  by  Candida.  Reports  show  that 
polymorphonuclear leukocyte activity  in DM patients (with high salivary and blood
70glucose levels was reduced) with oral candidosis (Ueta et al,  1993). There was also a 
concurrent  reduction  in  phagocytosis  and  intracellular  killing  of  Candida  cells 
compared with non-DM subjects or DM patients with good metabolic control.
In vitro studies have demonstrated that in type 1   DM, the adhesion of Candida seems 
to  be  higher to  palatal  cells  than  buccal  mucosal  epithelial  cells.  The  adhesion  of 
Candida strains to oral mucosa seems to be  influenced by the type of sugars in the 
culture  medium  and  by  the  Candida  strain,  which  could  modify  its  surface 
composition in response to high salivary glucose concentration (Willis et al, 2000a). 
It  has  also  been  reported  that  the  adhesion  of  Candida  to  BECs  collected  from 
patients affected by DM  is  significantly greater than  adhesion obtained  from  BECs 
from non-DM controls (Darwazeh et al,  1990). These results have also been reported 
by others (Dorocka-Bobkowska et al,  1996) who stated that type 1   DM patients had a 
greater  mean  candidal  load  than  non-DM  subjects.  Thus  in  DM  patients,  intrinsic 
qualitative  changes  on  cell  surface  receptors  may  modulate  yeast  adhesion 
(Samaranayake,  1990).  Salivary  glucose,  in  particular,  may  form  chemically 
reversible  glycosylation  products  with  proteins  in  tissues  during  hyperglycaemic 
episodes (Brownlee et al,  1988). It has been postulated that the accumulation of these 
glycosylation products on BECs may  increase the number of available receptors for 
Candida cells.
In addition, it has been reported that DM patients are prone to developing xerostomia 
(Section  1.8.9.3)  for  a  number  of  different  reasons, such  as decreased  salivary
function  and  reduced  salivary  flow  rate  caused  by  microvascular  disease  and
neuropathy  dysfunction affecting the  minor/major salivary glands.  It is well  known 
that a reduction in salivary flow and associated salivary components (slgA, lysozyme,
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lactoferrin)  inhibitory  to  Candida  adhesion  to  BECs,  could  promote  candidal
colonisation (Clowes et al, 1978).
71It has been suggested that oral carriage loads of Candida species may be influenced 
by the DM type. However, there is no confirmed association between oral candidal 
carriage  and  DM  type  or  severity.  The  different reported  rates  of oral  carriage  of 
Candida  obtained  (Barlow  &  Chattaway,  1969;  Aly  et  al,  1992;  Bai  et  al,  1995; 
Manfredi  et al,  2002)  may  reflect the  different  sample  sizes  or differences  in  the
influence from DM.
Indeed, denture wearing may influence yeast colonisation in patients with DM more 
than any systemic aspect of DM. Several studies have reported a high prevalence of 
Candida  carriage  in  DM  patients  using  removable  dentures  (Tapper-Jones  et  al, 
1981;  Fisher  et  al,  1987;  Lamey  et  al,  1988;  Hill  et  al,  1989;  Aly  et  al,  1992; 
Dorocka-Bobkowska  et  al,  1996;  Willis  et  al,  1999).  It  is  well  recognised  that 
Candida spp. are able to adhere not only to host mucosa but also to acrylic surfaces, 
which could act as a reservoir for microorganisms, especially when the dentures are 
ill-fitting  and  not  routinely  cleansed  (Samaranayake  &  MacFarlane,  1980; 
Samaranayake et al,  1980; Ellepola et al,  1990; Ellepola & Samaranayake, 2000a). 
Furthermore, in full-denture wearers, the palatal mucosa is more exposed to denture- 
induced  trauma  and  this  could  increase  the  permeability  of  the  epithelium  to 
Candida,  exposing epithelial  ligands (e.g.  fibronectin,  laminin,  collagen type I  and 
IV) which specifically bind candidal molecules (Budtz-Jorgensen,  1990b;  Cotter & 
Kavanagh, 2000). A correlation between  Candida-associated denture stomatitis and 
type 2 DM (Odds,  1988a; Budtz-Jorgensen,  1990a) has been suggested, particularly 
in  patients  with  DM-associated  peripheral  neuropathy.  Hyperglycaemia  and  high 
salivary glucose  levels can  lead to a nutritionally derived enhancement of candidal
4
growth,  but  they  are  probably  not  the  only  factors  that  enhance  the  growth  of 
Candida species in the oral cavity of DM patients (Darwazeh et al,  1991b; Vitkov et
sample  populations (^•g^ age,  diabetic therapies,  denture  status)  rather  than  any  ^
72al,  1999). It is probable that the association of type 2 DM with Candida-associated 
denture stomatitis reflects some reduced immunosurveillance to Candida.
1.8.9.1.2 Rhinocerebral Zygomycosis (Mucormycosis)
Diabetic ketoacidosis is a major predisposing factor in rare infections caused by fungi 
of the  family  Mucoraceae  and  the  class  Zygomycetes  (Sugar,  1992;  Nussbaum  & 
Hall,  1994;  Eliopulos,  1995),  indeed  approximately  50%  of  patients  with 
rhinocerebral  murcomycosis  have  DM  (Joshi  et  al,  1999).  Usually,  this  infection 
initially arises in the nose or palate and manifests itself as a bloody ulceration of the 
nose  or  as  a  pseudomembranae  with  ulceration  of the  palate.  Treatment  requires 
prompt control for DM, correction of any acidosis, aggressive surgical debridement 
of infected tissue and systemic antifungal therapy (Scully & de Almeida, 1992).
1.8.9.1.3 Aspergillosis
Aspergillus  species  are  filamentous  saprophytes  that  live  in  soil  and  decaying 
vegetation.  Aspergillosis  particularly  affects patients with prolonged  and  profound 
neutropenia  and  less  frequently,  invasive  aspergillosis  may  occur  in  patients  with 
DM  (Rinaldi,  1983).  Infections  can  develop  in  any  part  of the  respiratory  tract, 
including  the  paranasal  sinuses,  larynx  and  lungs.  Primary  lesions  can  also  be 
localized to the eyes, ears and oral cavity (Benson-Mitchell et al,  1994; Myoken et 
al,  1995)  and  underlying  structures,  as  well  as  facial  skin.  Oral  lesions  can  be 
predominant  in  immunocompromised  patients  and  are  described  as  grey  necrotic 
ulcers affecting the gingiva,  alveolar bone,  palate and occasionally the posterior of 
the tongue  (Dreizen  et al,  1985; Napoli  &  Donegan,  1991;  Chambers et al,  1995;
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Myoken  et  al,  1996).  Infections  may  spread  to  the  brain,  bones  or  endocardium 
through  the  bloodstream  (Scully  &  de  Almeida,  1992).  Therapy  for  invasive
73aspergillosis often requires systemic amphotericin, and systemic azoles (Vazquez & 
Sobel,  1995).  Surgical  therapy,  either  alone  or  in  combination  with  antifungal 
therapy,  may  be  required  in  selected  patients  with  localised  disease  (Scully  &  de 
Almeida,  1992; Vazquez & Sobel,  1995).
1.8.9.2 Xerostomia
Dryness of the  mouth  as  a feature of uncontrolled  DM  was  first recorded  in  1942 
(Sheppard,  1942;  Lamey  et  al,  1992).  Xerostomia  may  be  a  consequence  of 
dehydration,  although  long-standing  oral  dryness  may  be  due  to  microvascular 
disease and neuropathy affecting the major salivary glands (Newrick et al,  1991). In 
addition,  xerostomia  may  be  result  from  concomitant  drug  therapy 
(antihypertensives,  diuretics,  anxiolytics  or  antidepressants)  (Sharon  et  al,  1985; 
Albrecht  et  al,  1987;  Harrison  &  Bowen,  1987;  Finney  et  al,  1997).  Prolonged 
xerostomia  predisposes  to  local  accumulation  of  plaque  and  debris  and  may 
contribute  to  the  development  of opportunistic  oral  infections  (liability  to  dental 
caries,  periodontal  disease),  altered  taste  (Rees,  1994;  Finney  et  al,  1997),  oral 
malodour and oral mucosal soreness.
Xerostomia in type  1   DM seems to be dependent on glucose control  (Conner et al, 
1970; Tenovuo et al,  1986; Sreebny et al,  1992;  Swanljung et al,  1992) whereas in 
type  2  DM,  salivary  secretion  seems  to  be  influenced  in  particular  by  xerogenic 
drugs and autonomic neuropathy (Meurman et al, 1998).
1.8.9.3 Taste impairment
Diabetes mellitus can cause a loss of sweet taste sensation (Lawson et al,  1979;  Le
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Floch et al,  1989), indeed this may be already present at time of diagnosis. Although 
taste impairment is usually not severe, and is generally tolerated without complaint,
74the undiagnosed DM patient may favour sweet, sugary food hence exacerbating any 
hyperglycaemia.  Many  patients  with  polydypsia  with  hyperglycaemia  have  a 
predilection  for  sweet  drinks  which  have  a  high  content  of refined  carbohydrate 
(Lamey  et  al,  1992).  Altered  taste  sensation  of  DM  may  reflect  taste  receptor 
anomalies (Hardy et al, 1981). In addition, sulphonylureas may cause an alteration of 
the taste sensation (Rollin,  1978).
1.8.9.4 Sialosis
Histologically,  the  enlargement  of  salivary  glands,  sometimes  termed  sialosis, 
comprises fatty infiltration of the interstitium (Davidson et al, 1969) and enlargement 
of acinar cells (Donath & Seifert,  1975). It has been previously reported that between 
10%  and  25%  of  patients  with  long-standing  type  1   and  2  DM  can  develop 
asymptomatic,  non-neoplastic  enlargement  of the  salivary  glands  (Russotto,  1981; 
Murrah,  1985;  Lamey  et  al,  1992;  Greenspan,  1996),  although  a  low  correlation 
between  DM  and  parotid  enlargement  has  been  recently  reported:  only  3%  of 405 
patients with DM type 1  were found to have salivary gland enlargement of this nature 
(Guggenheimer et al, 2000a).  Both parotid glands are usually affected, although the 
submandibulary glands may be also involved (Russotto,  1981; Greenspan,  1996). It is 
suggested  that  patients  may  be  predisposed  to  calculus  formation  and  obstruction, 
nevertheless salivary function is largely preserved and sialosis does not influence the 
duration nor the severity of DM.
1.8.9.5 Dental caries
It remains  unclear whether patients with  DM  are at  increased  risk of dental  caries
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(Karjalainen et al,  1997;  Ponte et al,  2001).  Cross-sectional  and controlled  studies 
(Kirk  &  Kinirons,  1991;  Jones  et al,  1992;  Swanljung  et al,  1992)  have  reported
75conflicting results (Reuterving et al, 1986; Harrison & Bowen, 1987). Several studies 
have  suggested  that  poor  glycaemic  control  could  be  a  risk  factor  for  caries  in 
children and adolescents with type  1   DM (Karjalainen et al,  1997), while type 2 DM 
seemed^have  no  effect  on  the  prevalence  of caries  (Collin  et al,  1998).  Although 
dietary  intake  of  carbohydrates  by  DM  patients  is  lower  than  that  of  non-DM 
subjects, a higher number of meals per day could promote the development of caries 
(Lamey et al,  1992; Karjalainen et al,  1997). Any  increased proneness to caries  in 
DM may of course reflect elevated concentrations of glucose in saliva and gingival 
crevicular fluid of DM patients (Kjellman,  1970)  but more  likely,  individuals with 
DM develop caries as a consequence of poor oral hygiene (Karjalainen et al,  1997).
1.8.9.6  Periodontal disease
Although  not  universally  agreed,  an  increase  in  the  risk  of  periodontal  disease 
-association with both type  1   and type 2 DM nag bean reported](Albrecht et al,  1987; 
Bacic  et al,  1989;  Emrich  et al,  1991;  Moore  et al,  1999;  American  Academy  of 
Periodontology,  2000).  Uncontrolled  or  poorly  controlled  DM  may  give  rise  to 
increased  susceptibility  to  oral  infection,  including  periodontitis  (Bartolucci  & 
Parkes,  1981;  Ureles,  1983)  and  interestingly,  DM patients with  severe periodontal 
disease  are  at a  much  greater risk  of developing  microvascular and  macrovascular 
diabetic  complications  (Thorstensson  et  al,  1995;  American  Academy  of 
Periodontology,  1999;  Lalla  &  D'Ambrosio,  2001).  The  incidence  of periodontitis 
increases among DM patients after puberty and as the adult population ages (Cohen et 
al,  1970;  Cianciola  et  al,  1982;  Galea  et  al,  1986;  Albrecht  et  al,  1987;  de 
Pommereau  et al,  1992;  Seppala  et al,  1993).  It  has  also  been  suggested  that  the
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disease  is  associated  with  poor  glycaemic  control  and  hyperglycaemia  (American 
Academy of Periodontology, 2000). Epidemiological studies of Pima Indians, a groupwith an extremely high prevalence of type 2 DM (Shlossman et al, 1990), have found 
that  affected  patients  have  a  higher  prevalence  of periodontal  disease  than  other 
ethnic groups, irrespective of age. Other studies (Emrich et al,  1991) have also found 
that patients with type 2 DM were more likely to have periodontal disease than non- 
DM control  subjects, this risk not being  influenced by age,  gender or oral  hygiene. 
Some  studies  however,  have  found that periodontal  attachment  loss,  probing  depth 
and gingivitis occur more frequently and more extensively in moderately and poorly 
controlled  DM  patients  of  either  type  than  in  those  with  good  glucose  control 
(Shlossman et al, 1990; Katz et al, 1991; Tervonen & Oliver, 1993).
However, while the  facts  stated above would  seem  to  describe the  most consistent 
trends, there is considerable conflicting data on any possible increased occurrence of 
periodontal  disease  in  DM  (Porter  &  Scully,  1994a).  A  number  of factors  could 
potentially contribute to any enhancement of periodontal disease in patients with DM 
(American  Academy  of  Periodontology,  2000).  Oral  microflora,  phagocytic  and 
connective-tissue defects are the most investigated aspects in individuals affected by 
DM.
The  function  of  polymorphonuclear  leukocytes  (PMNL)  (chemotaxis,  adherence, 
phagocytosis and killing) can be reduced in DM, leading to impaired host resistance 
to infection (Hill et al, 1974; Molenaar et al,  1976; Bagdade et al,  1978; Repine et al, 
1980; Manouchehr-Pour et al, 1981; Iacono et al,  1985; Leeper et al,  1985; Wilson & 
Reeves,  1986;  Kjersem  et  al,  1988;  Marhoffer  et  al,  1992).  The  severity  of 
periodontitis has been  connected to  defective chemotaxis;  DM  patients with  severe 
periodontitis  had  depressed  PMN  chemotaxis  compared  to  those  with  mild 
periodontitis or non-DM subjects with severe or mild periodontitis (Manouchehr-Pour 
et al,  1981;  McMullen  et al,  1981).  Furthermore,  decreased  PMN  chemotaxis  has 
been reported in a family with a history of DM and severe periodontitis, suggesting
77that the PMN defect was of genetic origin (McMullen et al, 1981). However, most of 
these PMN anomalies can usually be corrected by good glucose control.
Any  increased  risk  of  periodontal  diseases  in  DM  may  be  influenced  by  a 
hyperglycaemia-associated reduction in cell proliferation and growth and synthesis of 
collagen  and  glycosaminoglycans  (Golub  et al,  1978;  Weringer  &  Arquilla,  1981; 
Lien et al, 1984; Seibold et al, 1985).
78Table 1.1: Predisposing (local and systemic) factors of oral candidosis
(Samaranayake, 1990; Budtz-Jorgensen & Lombardi, 2000; Ruhnke, 2002)
L o c a l  p r e d is p o s in g   f a c t o r s S y s t e m ic   p r e d is p o s in g   f a c t o r s
P r o s t h e s e s  ( c h a n g e s   in   e n v ir o n m e n t a l 
c o n d it io n s ,  tr a u m a ,  d e n tu r e   u s a g e ,  c le a n lin e s s )
P h y s io lo g ic a l  ( e ld e r ly ,  p r e g n a n c y ,  in f a n c y )
E n d o g e n o u s   e p it h e lia l  c h a n g e s  (a tr o p h y , 
h y p e r p la s ia ,  d y s p la s ia )
E n d o c r in e   d is o r d e r s   ( D M ,  h y p o t h y r o id is m , 
h y p o p a r a t h y r o id is m )
S a liv a - q u a n t it a t iv e   c h a n g e s   ( x e r o s t o m ia , 
S jO g r e n ’s   s y n d r o m e ,  r a d io th e r a p y ,  d r u g - 
th e r a p y )
N u tr itio n a l  d e f ic ie n c y   ( ir o n ,  f o la t e ,  v it a m in   B 1 2 )
Q u a lit a t iv e   s a liv a  c h a n g e s  ( p H ,  g lu c o s e  
c o n c e n t r a t io n )
M a lig n a n c ie s   ( a c u t e   le u k a e m ia ,  a g r a n u lo c y t o s is , 
o th e r s )
C o m m e n s a l  flo r a
P r im a r y   im m u n o d e f ic ie n c y   D iG e o r g e ’s  
s y n d r o m e )
H ig h   c a r b o h y d r a te   d ie t
S e c o n d a r y   im m u n o d e f ic ie n c y   ( £ g )   H I V   d is e a s e , 
c o r t ic o s t e r o id s ,  a n t ic a n c e r  th e r a p y )
S m o k in g  ( ? )
4
79Table 1.2: Classification of oral candidosis
(Holmstrup  &  Axell,  1990;  Scully  et  al,  1994;  Ellepola  &  Samaranayake,  2000a; 
Sitheeque & Samaranayake, 2003)
P r im a r y   o r a l  c a n d id o s is  
( G r o u p   I )
C lin ic a l  f e a t u r e s S it e   in v o lv e d
1 .  A c u t e
P s e u d o m e m b r a n o u s  c a n d id o s is
S e m i-a d h e r e n t,  w h itis h , s o ft a n d  c r e a m y .
d r o p -lik e  o r  c o n flu e n t p a tc h e s.  T h e  
p s e u d o m e m b r a n e s c a n   b e  r e m o v e d   fr o m  
m u c o s a   le a d in g  a  r e d  a n d  s lig h tly  
b le e d in g  su rfa cjv " "
P a la te ,  d o r su m   o f  th e  to n g u e , 
b u c c a l  m u c o s a  .
E r y th e m a to u s
C a n d id o s is
S m a ll  o r  la r g e  e r y th e m a to u s a r e a s 
fo llo w in g  to p ic a l  o r  s y s te m ic  
c o r tic o s te r o id  u se ,  b ro a d   sp e c tr u m  
a n tib io tic  th e r a p y  o r  in  H IV   d is e a y '
D o r su m   o f  th e  to n g u e  
(d e p a p i H a ted  a r e a ),  r a r e ly  
p a la te  o r  b u c c a l  m u c o sa .*
2 . C h r o n ic
P s e u d o m e m b r a n o u s  c a n d id o s is
P s e u d o m e m b r a n o u s   le s io n s  m a y   r e c u r  in  
p a tie n ts u s in g  c o r tic o s te r o id s  to p ic a lly  o r  
b y   a e r o s o l,  in   H I V -in fe c te d  p a tie n ts o r  in  
o th e r  im m u n o c o m p r o m ise d  p a tie n ts.
P a la te ,  o r a l  p h a r y n x ,  d o r su m  
o f  th e  to n g u < y
E r y th e m a to u s  c a n d id o s is  
(Candida-a s s o c ia te d   d e n tu r e  
s to m a titis )
C h r o n ic  e r y th e m a  a n d  o e d e m a  o f  th e  o ra l 
m u c o s a  in  c o n ta c t w ith  a  d e n tu r e .  T h e  
le s io n s  a r e  u su a lly  p a in le ss.
P a la ta l  m u c o s a ,  th e   m u c o s a  
b e lo w   th e   lo w e r   d e n tu r e   b e in g  
r a r e ly  a f f e c t e d ./
C h r o n ic   h y p e r p la s tic  
c a n d id o s is -C H C  
(Candida  le u k o p la k ia )
C h r o n ic   le u k o p la k ia  le s io n s  in fe c te d  b y  
Candida.  T h e  le s io n s  c o u ld   b e  
h o m o g e n e o u s  o r  n o n -h o m o g e n e o u s  
(n o d u la r ,  sp e c k le d ).  M a le s a r e  m o r e  
c o m m o n ly  a ffe c te d   a n d  th e   le s io n s  
ty p ic a lly  a p p e a r  in   lo n g -te r m  to b a c c o  
sm o k e r s.  H is to lo g ic a l  e x a m in a tio n  o f  
le s io n s   is e s se n tia l  a s s o m e  n o d u la r  C H C  
m a y  e x h ib it e p ith e lia l  d y sp la sia .
T h e   le s io n s   a r ise   ty p ic a lly   o n  
th e   c o m m is s u r e s  o f  th e   m o u th , 
le s s   c o m m o n ly   o n   th e   b u c c a l 
m u c o s a ,  p a la te  o r  to n g u ^ /*
C h r o n ic   m u ltifo c a l  o r a l 
c a n d id o s is
R a r e  d iso r d e r s c h a r a c te r ise d  b y  c h r o n ic  
c a n d id a l  le s io n s  in   m u ltip le  o r a l  s ite s  a t 
th e   sa m e  tim e .  M o s t a ffe c te d  p a tie n ts a re 
e ld e r ly   a n d  to b a c c o  s m o k e r y '
M u ltip le   o r a l  s ite s   a t  th e   s a m e  
tim e /'
3 .  Candida-a s s o c ia te d   le s io n s
A n g u la r  c h e ilitis
L e s io n s  a r e  c h a r a c te r ise d  b y   o e d e m a , 
s o r e n e s s ,  b u r n in g  a n d  fis s u r in g  w ith  a  
te n d e n c y  to  lo c a l  b le e d in g .  T h e  a e tio lo g y  
o f  th is  in fe c tio n  is  m a in ly   d u e  to  th e  
in fe c tio n  o f  Staphylococcus aureus a n d  
Candida s p p V
T h e   le s io n s   a ffe c t  th e   c o m e r s  
(a n g le s ) o f  th e  m o u t h y
M e d ia n   r h o m b o id   g lo s s itis A r e a  o f  p a p illa ry ' a tr o p h y  ,  e llip tic a l  o r 
r h o m b o id   in   s h a p e ^
T h e   le s io n   is  p la c e d   ty p ic a lly  
c e n tr a lly   in   th e   m id lin e   o f  th e  
to n g u e .
S e c o n d a r y   o r a l  c a n d id o s is  
(G r o u p   II)
4
O ra l  m a n ife s ta tio n s  o f  s y s te m ic  
m u c o c u ta n e o u s  c a n d id o s is  (th y m ic  
a p la sia  a n d  c a n d id o s is  e n d o c r in o p a th y  
s y n d r o m e -C E S ) /
80Table 1.3: Mode of action and resistance mechanism of current antifungal agents 
active against Candida spp.
(Sanglard & Bille, 2002)
A n t if u n g a l  a g e n t s M lo d e (s )  o f  a c t io n M e c h a n is m s   o f  r e s is t a n c e
P o ly e n e s
- A m p h o t e r ic in   B  
- N y s t a t in
B in d in g   to   e r g o s t e r o l  in   th e   m e m b r a n e  
b ila y e r  o f  y e a s t s :   lo s s   o f  m e m b r a n e  
p e r m e a b ilit y   w ith   le a k a g e  o f  v ita l 
c y t o p la s m a t ic   c o m p o n e n t s   a n d   c e ll  d e a th
- A b s e n c e   o f  e r g o s t e r o l  o r  
d e c r e a s e   o f  e r g o s t e r o l  c o n t e n t  
in   c e lls  
-I n c r e a s e d   c a t a la s e   a c t iv it y
A z o le s
a .  I m id a z o le s
- K e t o c o n a z o le
- M ic o n a z o le
- C lo t r im a z o le
b .  T r ia z o le s  
- F lu c o n a z o le  
- I t r a c o n a z o le
c .  N e w   t r ia z o le s  
- V o r ic o n a z o le  
- P o s a c o n a z o le *  
- R a v u c o n a z o le *
I n h ib itio n   o f   1 4 a - la n o s t e r o l  d e m e t h y la s e  
( E R G 1 1 ):  b lo c k   o f  1 4 a - d e m e t h y la t io n  
s t e p   in   th e   s y n t h e s is   o f  e r g o s t e r o l
- E n h a n c e d   e f f lu x   m e d ia t e d   b y  
m u ltid r u g  tr a n s p o r te r s  
- D e c r e a s e   a f f in it y   in   E r g   1  lp  
b y   m u t a t io n s  
- U p   r e g u la t io n   o f  E R G  11 
- A lt e r a t io n   in   e r g o s t e r o l 
b io s y n t h e t ic   p a t h w a y
5 - F C
I n h ib itio n   o f  D N A /R N A   s y n t h e s is :   5 - F C  
c o n v e r t e d   ( c y t o s in e   d e a m in a s e )   in   5 -  
f lu r o r a c il  ( 5 - F U )
5 - F U   m a y   b e   c o n v e r t e d  t o   a  n u c le o s id e  
tr ip h o s p h a te  w h e n   in c o r p o r a te d   in   R N A  
5 - F U   m a y   b e   c o n v e r t e d  t o  a  
d e o x y n u c le o s id e  w h ic h   in h ib its   D N A  
s y n t h e s is
- D e f e c t   in   c y t o s in e   p e r m e a s e  
- D e f ic ie n c y   o r   la c k   o f  
e n z y m e s   im p lic a t e d   in   th e  
m e t a b o lis m   o f  5 - F C
A lly la m in e s
I n h ib itio n   o f  s q u a le n e   e p o x id a s e :   th e   fir s t 
p o s t s q u a le n e   e n z y m e   o f  th e   e r g o s t e r o l 
b io s y n t h e t ic   p a t h w a y ,  e n c o d e d   b y   E R G  1
N .R .
E c h in o c a n d in s
-C a p s o f u n g in
I n h ib itio n   o f  P -1 ,3   g lu c a n   s y n t h a s e - L o s s   o f  p - 1 ,3   g lu c a n   s y n t h a s e  
f u n c t io n
* N o t  y e t   a v a ila b le   in   c o m m e r c e  
N .R .:  N o t  r e p o r te d
81Table 1.4: Typical antifungal regimens used in the treatment of oral candidosis
(Ellepola & Samaranayake, 2000a)
Drug Form Dosage
Amphotericin  B
L o z e n g e ,  1 0   m g
S lo w ly   d is s o lv e d   in   m o u th   3 - 4   X   d a y   a fte r  
m e a ls   fo r  2   v y K  m in im u m
O r a l  s u s p e n s io n , 
1 0 0   m g /m l
P la c e d   in   m o u th   a fte r  m e a l  a n d   r e ta in e d  
n e a r   le s io n s  4   t im e s   d a ily   f o r  2   w e e k s
C r e a m A p p ly   t o   a f f e c t e d   a r e a   3 - 4   t im e s   d a ily
Nystatin
P a s t ille ,  1 0 0 ,0 0 0   u n its
D is s o lv e   1  p a s t ille   s lo w ly   a fte r  m e a ls  4  
t im e s   d a ily ,  u s u a lly   7   d a y s  
C a u s e   p r e s e n c e   o f  s u c r o s e ,  D M   p a tie n ts  
s h o u ld   a v o id   u s in g  th is   f o r m u la t io n   o f  th e  
d r u g
O r a l  s u s p e n s io n s , 
1 0 0 ,0 0 0   u n its
A p p ly   a fte r  m e a ls   4   t im e s   d a ily ,  u s u a lly   7  
d a y s   a n d   c o n t in u e   u s e   fo r  s e v e r a l  d a y s   a fte r  
p o s t - c lin ic a l  h e a lin g  
C a u s e   p r e s e n c e   o f  s u c r o s e ,  D M   p a t ie n t s  
s h o u ld   a v o id   u s in g  th is   fo r m u la t io n   o f  th e  
d r u g
Clotrimazole
C r e a m
A p p ly  t o  a f f e c t e d   a r e a  2 - 3   t im e s   d a ily   f o r  3 -  
4   w e e k s
S o lu t io n 5   m l  3 - 4   t im e s   d a ily   fo r  2   w e e k s   m in im u m
O r a l  g e l A p p ly   t o   a f f e c t e d   a r e a   3 - 4  t im e s   d a ily
Miconazole
C r e a m
A p p ly   t w ic e   p e r  d a y   a n d   c o n t in u e   f o r   1 0 - 1 4  
d a y s   a fte r  th e   le s io n   h e a ls
Ketoconazole T a b le t s
2 0 0 - 4 0 0   m g   t a b le t s  ta k e n   o n c e   o r  t w ic e  
d a ily   w ith   f o o d   fo r  2   w e e k s
Fluconazole C a p s u le s 5 0 - 1 0 0   m g  c a p s u le   o n c e   d a ily   f o r  2 - 3   w e e k s
Itraconazole C a p s u le s
1 0 0   m g   c a p s u le s   d a ily   ta k e n   im m e d ia t e ly  
a fte r   m e a ls   fo r  2   w e e k s
82Table 1.5:  Methods of sampling the oral cavity for the isolation of Candida spp.
(Williams & Lewis, 2000)
Method Procedure Quantitative Advantages Disadvantages
Imprint
culture
S te r ile   p la s t ic   f o a m   p a d s   o f  
k n o w n   s iz e   ( t y p ic a lly   2 .5  
c m 2) p la c e d   o n   s u r f a c e   o f  
t h e   le s io n   fo r  3 0 -6 0 < (n ^ m d  
th e n   p la c e d   o n   S D A
Y e s
T a r g e ts   in f e c t e d   s it e *  
D if f e r e n t ia t e s  
in f e c t e d   a n d   c a r r ie r  
s ta te
D if f ic u lt   i f  
le s io n s   a r e   n o t 
e v id e n t
Oral
rinse
C o lle c t io n   o f  a  m o u t h r in s e  
w it h   1 0   m l  o f  s t e r ile  
d is t ille d   w a te r .  A f t e r  
v ib r a tio n ,  1  m l  o f  
s u s p e n s io n   is   in o c u la t e d  
o n t o   S D A
Y e s
P o s s ib le   d e t e c t io n   o f  
o t h e r  
m ic r o o r g a n is m s
D o e s   n o t  lo c a lis e  
t h e   in f e c t io n
Swab
G e n t le   r u b b in g  o f  a   s t e r ile  
c o tto n   s w a b  o v e r  th e  
le s io n a l  t is s u e ( s )   a n d  
s u b s e q u e n t   in o c u la t io n   o n  
S D A
N o E a s y   t o   u s e
C a n   r e m o v e  
s u r f a c e   e p it h e lia l 
la y e r s
Whole
saliva
C o lle c t io n   o f  2   m l  o f  s a liv a ; 
s o lu t io n   is   v ib r a te d   a n d   1 
m l  is   in o c u la t e d  o n t o   S D A .
P r o s t h e s is   s h o u ld   b e  
r e m o v e d   b e f o r e   s a m p lin g
Y e s
G o o d   fo r  a s s e s s in g  
c a n d id a l  c a r r ia g e
M a y   ta k e   s o m e  
t im e
Biopsy
B io p s y   s p e c im e n  
( e x c is io n a l  o r  in c is io n a l)   is  
s e n t   fo r  h is t o p a t h o lo g ic a l 
e x a m in a t io n
N o
I m p o r ta n t  fo r  
d ia g n o s is   o f  C H C
I n v a s iv e   a n d  
in a p p r o p r ia te   fo r  
m a j o r it y   o f  
Candida 
in f e c t io n s
Smear
S m e a r  ta k e n   fr o m   le s io n a l 
s it e ( s ) ,  f ix e d   o n t o  
m ic r o s c o p e   s lid e   a n d  
s t a in e d   b y   G r a m -s ta in   o r  
P A S
N o
W id e ly   a p p lic a b le  
D if f e r e n t ia t e s  
b e t w e e n   y e a s t   a n d  
h y p h a l  fo r m
L e s s   s e n s it iv e
4
83Table 1.6: Commercial test systems for the identification of Candida spp.
(Williams & Lewis, 2000)
System Basis of test Manufacturer
CHROMagar®
Candida
C h r o m o g e n ic   s u b s t r a t e - b a s e d   a g a r  m e d iu m
C h r o m a g a r  L td
Albicans ID C h r o m o g e n ic   s u b s tr a te -b a s e d   a g a r   m e d iu m b io M e r ie u x
Candichrom C h r o m o g e n ic   s u b s t r a t e - b a s e d   a g a r  m e d iu m I n te r n a tio n a l  M ic r o b io s
Fluroplate F lu o r o g e n ic   s u b s t r a t e - b a s e d   a g a r  m e d iu m M e r c k
API-20C AUX C a r b o h y d r a te   a s s im ila t io n b io M e r ie u x
MiniTek C a r b o h y d r a te   a s s im ila t io n B B L   L a b o r a to r ie s
Microring YT C h e m ic a l  s e n s it iv it y
M e d ic a l  W ir e  &  
E q u ip m e n t  C o   L td
Candifast B io c h e m ic a l  p r o f ilin g I n te r n a tio n a l  M ic r o b io s
RapidID yeast plus B io c h e m ic a l  p r o f ilin g I n n o v a t iv e   D ia g n o s t ic s
latron Candida  Check S e r o lo g y la tr o n   L a b o r a to r ie s
AMS-YBC B io c h e m ic a l  p r o f ilin g b io M e r ie u x
Abbott MS-2 B io c h e m ic a l  p r o f ilin g A b b o t t   L a b o r a to r ie s
Abbott Quantum  II B io c h e m ic a l  p r o f ilin g A b b o tt  L a b o r a to r ie s
84Table 1.7: Most common methods used to DNA fingerprint Candida isolates
(Soli, 2000; Dassanayake & Samaranayake, 2003b; Gil-Lamaignere et al, 2003)
Molecular techniques How they work
Advantages and 
disadvantages
Restriction fragment 
length  polymorphism 
without hybridisation 
(RFLP) or restriction 
enzyme analysis (REA)
It  is   b a s e d   u p o n   r e s tr ic tio n  
e n d o n u c le a s e   ( R E )   d ig e s t io n   o f  D N A  
a t s p e c if ic   s it e s   t o   g e n e r a t e   s h o r t e n e d  
f r a g m e n t s   o f  D N A   s e q u e n c e s   th a t a r e  
th e n   s e p a r a te d   in   a g a r o s e   g e l.  B a n d in g  
p a tte r n s   a r e  b a s e d   o n   d iffe r e n t  
fr a g m e n t  le n g t h s   d e t e r m in e d   b y   th e  
R E   u s e < ^ /
E a s y  t o   p e r fo r m   a n d   r a p id . 
L o w   d is c r im in a t o r y   p o w e r /
Restriction fragment 
length  polymorphism 
with hybridisation 
probes
T h e   fr a g m e n t s   g e n e r a t e d   b y   R F L P   c a n  
b e   tr a n s fe r r e d   t o  a   m e m b r a n e   a n d  
h y b r id iz e d   b y   S o u th e r n   b lo t  w ith   a  
p r o b e  th a t  c a n   r e c o g n is e   o n e   o r  m o r e  
fr a g m e n ts   o f  th e   r e s tr ic te d   D N A . 
D if f e r e n t   k in d s  o f  p r o b e  c a n   b e   u s e d  
fo r  t h is   p u r p o s e ^
I f  th e   p r o b e   is   c a r e f u lly  
s e le c t e d ,  th e   t e c h n iq u e   c a n  
h a v e   h ig h e r  d is c r im in a t o r y  
p o w e r  th a n   c o n v e n t io n a l 
R F L P .
N o t   s u it a b le   fo r   la r g e  
e p id e m io lo g ic a l  s t u d i e s /
Electrophoretic 
karyoty ping and 
pulsed field gel 
electrophoresis (PFGE)
C h r o m o s o m e - le n g t h   p o ly m o r p h is m   is  
e v a lu a t e d   b y   e le c t r o p h o r e t ic  
k a r y o t y p e   ( E K )  a n a ly s is ,  w h ic h   u s e s  
e le c t r ic   f ie ld s   o f  a lte r n a tin g  
o r ie n ta tio n   t o  m o v e   in ta c t 
c h r o m o s o m e s   th r o u g h   a n   a g a r o s e  g e l 
m a t r ix ./
L a r g e r   D N A   m o le c u le s   ( > 4 0 k b )   c a n  
b e   s e p a r a te d   b y   P F G E   in   w h ic h  
e le c t r ic   f ie ld   is   s w it c h e d   p e r io d ic a lly  
b e t w e e n   t w o   d if f e r e n t  d ir e c t io n s ,  '
A c c u r a t e   t e c h n iq u e s   b u t 
e x p e n s iv e   e q u ip m e n t   is 
n e c e s s a r y . 
T im e - c o n s u m in g . 
K a r y o t y p e s   c a n   v a r y   a s   a   r e s u lt 
o f  p h e n o t y p ic   s w i t c h i n g /
Random amplified 
polymorphic DNA 
(RAPD) or arbitrarily 
primed  PCR
A n a ly s e   s h o r t r e g io n s  o f  D N A  
s e q u e n c e   fo r  v a r ia tio n   b a s e d  o n   th e  
P C R   p r im in g   r e g io n s .  S h o r t  s in g le  
p r im e r  ( 1 0 - 1 5 b p )  o f  a r b itr a r y  
s e q u e n c e  a n d   lo w   s tr in g e n c y  
a m p lif ic a t io n   r e a c tio n   c o n d it io n s   a r e  
u s e d /
E a s y   t o  p e r fo r m .
D u e  t o  t h e   u s e  o f  a n   a r b itr a r y  
p r im e r  a n d   a   lo w   a n n e a lin g  
t e m p e r a tu r e ,  it  is   p o s s ib le   t o  
e n c o u n t e r  r e p r o d u c ib ilit y  
p r o b le m s ,  n o t  o n ly   a m o n g  
la b o r a to r ie s   b u t w it h in   a  
la b o r a to r y   f o r  th e   d u r a tio n . 
C h a n g e s   in   te m p e r a tu r e , 
p r im e r - t o - t e m p la t e - 
c o n c e n t r a t io n   r a tio ,  c o u ld  
in f lu e n c e   th e   p r e s e n c e   o f  lo w -  
in t e n s it y   b a n d s /
Inter-repeat PCR 
(IR-PCR)
B a s e d   o n   d e t e c t io n   o f  g e n o m ic  
r e g io n s   k n o w n   to   b e   v a r ia b le  a m o n g  
e u k a r y o t e s ,  s u c h   a s   t e lo m e r ic   o r  
r e p e a te d   D N A .  S h o r t  p r im e r s   th a t  w ill 
a m p lif y   g e n o m ic   fr a g m e n ts   f la n k e d  
b y   in v e r s e ly   o r ie n t e d   ta r g e te d   m o t i f s /
H ig h e r  r e p r o d u c ib ilit y   th a n  
R A P D   b e c a u s e  th e   a n n e a lin g  
te m p e r a tu r e   is   h i g h e r /
85Table 1.8: Chronic systemic complications of DM
(Bell & Hockaday,  1996)
Chronic systemic complications of DM
Macroangiopathies
- a r t h e r o s c le r o s is  
- m y o c a r d ia l  d is e a s e  
- is c h a e m ic   h e a r t  d is e a s e  
- c e r e b r o v a s c u la r  d is e a s e  
-in te r m itte n t  c la u d ic a t io n  
- g a n g r e n e   o f  f e e t
Macroangiopathies
- r e tin o p a th y  
-n e p h r o p a th y  
- c a p illa r y   b a s e m e n t   m e m b r a n e   t h ic k e n in g
Neuropathies
-p e r ip h e r a l  s e n s o r y   n e u r o p a th y  
- f e m o r a l  n e u r o p a th y  
- m o n o n e u r o p a t h y  
-a u t o n o m ic   n e u r o p a th y  
a .  p o s tu r a l  h y p o t e n s io n  
b .  im p o t e n c e
c .  d ia b e t ic   d ia r r h o e a
d .  u r in a r y   r e te n tio n  
e .  g u s ta to r y   s w e a t in g
f.  a b n o r m a l  p u p illa r y   r e f le x e s  
g .  c a r d ia c   a u t o n o m ic   d is t u r b a n c e
86Table  1.9:  Principal  techniques  used  to  assess  the  glycaemic  control  in  patients
affected by DM
(Viberti  et al,  1979;  Parving  et  al,  1982;  Viberti  et  al,  1982;  Pickup  et  al,  1984; 
Lugari  et  al,  1988;  Bell  &  Hockaday,  1996;  Goldstein  et  al,  2003)
Principal techniques used to 
assess glycaemic control in 
DM
Advantages Disadvantages
Blood glucose monitoring
S e lf - m o n it o r in g  
R e s u lt s   a v a ila b le   im m e d ia t e ly  
A v o id s   k e t o a c id o s is   a n d  
e n c o u r a g e s   g o o d   p a tie n t 
c o o p e r a t io n
N o t   p r e c is e   m e a s u r e   o f  
g ly c a e m ic   c o n tr o l 
N o t  d ia g n o s t ic
Glycosylated haemoglobin 
(HbA)c)
A c c u r a t e   a n d   o b j e c t iv e  
m e a s u r e  o f  g ly c a e m ic   c o n tr o l 
o v e r  p a s t  w e e k s   2 - 3   m o n t h s
H b A lc m a y   b e   in c o r r e c t ly  
r e d u c e d   in   a n a e m ia  o r  d u r in g  
p r e g n a n c y
Plasma fructosamine
G o o d   i f  H b A k-  c a n n o t  b e  
m e a s u r e d   (j€ ? g )h a e m o ly tic  
a n a 5 m ia s )
It  p r o v id e s   a n   in d e x   o f  
g ly c a e m ic   s ta tu s   o v e r  th e  
p r e c e d in g   1 -2   w e e k s   o n ly
Urine testing
U s e f u l  fo r  m o n it o r in g  th e  
le v e ls   o f  u r in a r y   p r o te in s   a n d  
k e t o n e s   o f  r e n a l  in s u f f ic ie n c y  
in   D M   p a tie n ts
U s u a lly   n o t g o o d   e n o u g h   a s   a  
d ia g n o s t ic   a n d   c o n t r o l  te s t
ihcJs  C
87Table 1.10:  Major hypoglvcaemic agents used to control DM ty pe 2
Drug class
Daily dose 
Range (mg)
N° of daily 
doses
Site of metabolism
Mechanism of 
action
Sulphonylureas
Stimulate insulin 
secretion
G lib e n c la m id e 5 - 1 5 1 -3
O x id is e d   in   liv e r - e x c r e t e d  
u r in e s ;  5 0 %  e x c r e t e d  
u n c h a n g e d   in   f a e c e s
G lic la z id e 4 0 - 3 2 0 1 -3 9 5 %   liv e r
G lim e p ir id e 1 - 4 /6 1
G lip iz id e 2 .5 - 2 0 2 - 3
9 0 - 9 5 %   liv e r - e x c r e t e d  
u n c h a n g e d   in   u r in e ;  1 2 %  
e x c r e t e d   in   f a e c e s
G liq u id o n e 1 5 - 1 8 0 2 - 3
9 0 - 9 5 %   liv e r  m e t a b o lit e s  
e x c r e t e d   in   b ile
Biguanides
Increase hepatic 
glucose output
M e tfo r m in 5 0 0 - 1 7 0 0 1 -3
L iv e r ,  n o t  m e t a b o liz e d . 
E x c r e te d   u n c h a n g e d   in  
u r in e
Alpha-
Glucosidase
inhibitors
Decrease gastro­
intestinal 
absorption of 
carbohydrates
A c a r b o s e 2 5 - 1 0 0 1 -3 L iv e r
M ig lit o l L iv e r
Meglitinides
Stimulate insulin 
release
R e p a g lin id e 0 .5 - 1 /1 6 1 -3 M o s t ly   e x c r e t e d   in   u r in e
Thiazolidine-
diones
Reduce peripheral 
insulin  resistance
P io g lit a z o n e 1 5 -3 0 1 L iv e r
R o s ig lit a z o n e 4 - 8 1 -2 L iv e r
T r o g lit a z o n e 4 0 0 - 6 0 0 1 L iv e r  ( liv e r  t o x ic it y ) W I T H D R A W N
88Table  1.11:  Principal insulin preparations used to control DM
Insulin preparation
types
Onset of 
duration (h-min)
Peak of 
action (h)
Maximal 
duration of 
action (h)
Commonly used 
regimens
Short-acting insulin 0 .5 - 1   h 1 -3 6 - 8
G iv e n  2 0 - 3 0   m in  
b e f o r e   m e a ls
I n s u lin   S o lu b le 3 0   m in 1 -3 8
Rapid-acting insulin 
analogue
1 0 - 3 0   m in 1 -3 3 - 5
G iv e n   im m e d ia t e ly  
b e f o r e   m e a ls
I n s u lin   L is p r o 3 0   m in 1 -2 8
I n s u lin   A s p a r t 3 0   m in 1 -2 8
Intermediate-acting
insulin
1 .5 - 2   h 4 - 1 2 1 8 - 2 4
1 .  G iv e n   b e f o r e   b e d  
2 .  G iv e n   b e f o r e   b e d ,  in  
c o m b in a t io n   w ith  
t a b le t s   fo r  o v e r w e ig h t  
p a t ie n t s  
3 .  G iv e n   o n c e  d a ily  
b e f o r e   b r e a k fa s t,  fo r  
e ld e r ly  
4 .  G iv e n   t w ic e   a  d a y , 
fo r  t y p e  2   D M
Long-acting insulin 1 -2   h 4 - 1 2 2 0 - 4 0
O n c e   d a ily ,  o r  t w ic e  
d a ily   w it h   a   s h o r t- 
a c t in g   ( s o lu b le )   in s u lin
Biphasic action 
(combination of 
rapid or short and 
intermediate action)
0 .5 - 1   h 1 - 1 0 1 8 - 2 4
1 0 /9 0   ( 1 0 %   s o lu b le -  
9 0 %   is o p h a n e   in s u lin )
3 0   m in 2 - 8 2 4
G iv e n  2 0 - 3 0   m in  
b e f o r e   b r e a k fa s t  a n d  
e v e n in g   m e a l,  a s   a  
t w ic e   d a ily   r e g im e n
2 0 /8 0  ( 2 0 %   s o lu b le -  
8 0 %   is o p h a n e   in s u lin ) 3 0   m in 2 - 8 2 4
G iv e n   2 0 - 3 0   m in  
b e f o r e   b r e a k fa s t  a n d  
e v e n in g   m e a l,  a s   a  
t w ic e   d a ily   r e g im e n
3 0 /7 0  ( 3 0 %   s o lu b le -  
7 0 %   is o p h a n e   in s u lin )
3 0   m in 2 - 8 2 4
G iv e n  2 0 - 3 0   m in  
b e f o r e   b r e a k fa s t  a n d  
e v e n in g   m e a l,  a s   a  
t w ic e   d a ily   r e g im e n
4 0 /6 0  ( 4 0 %   s o lu b le -  
6 0 %   is o p h a n e   in s u lin )
3 0   m in 2 - 8 2 4
G iv e n   2 0 - 3 0   m in  
b e f o r e   b r e a k fa s t  a n d  
e v e n in g  m e a l,  a s   a  
t w ic e   d a ily   r e g im e n
5 0 /5 0  ( 5 0 %   s o lu b le -  
5 0 %   is o p h a n e   in s u lin )
4
3 0   m in 2 - 8 2 4
G iv e n   2 0 - 3 0   m in  
b e f o r e   b r e a k fa s t  a n d  
e v e n in g   m e a l,  a s   a  
t w ic e   d a ily   r e g im e n
2 5 %   in s u lin   L is p r o   -  
7 5 %   in s u lin   L is p r o  
P r o ta m id e
3 0   m in 2 2 4
G iv e n   im m e d ia t e ly  
b e f o r e   b r e a k f a s t   a n d  
e v e n in g   m e a l,  a s   a  
t w ic e   d a ily   r e g im e n
89Table 1.12: Oral Candida carriage in patients with  DM investigated by different authors
1. Authors
*
2. Oral Candida 
carriage in DM 
patients( %)
3. Sampling 
methods
4. Total 
number of 
DM patients 
investigated
5. Number 
of patients 
with DM 
type 1
6. Number 
of patients 
with DM 
ty pe 2
7. Oral 
Candida 
carriage in 
controls (%)
8. Increased oral 
Candida carriage 
in DM patients 
denture wearers
9. Oral Candida 
carriage related 
to type of DM
10. Increased oral 
Candida carriage 
with poor 
metabolic control
Barlow et al, 1969 62.5% Swab 24 __** __** 35% Not investigated Not investigated No
Tapper-Jones et al, 
1981
60%
Imprint
culture
50 __** 42% Yes Not investigated Not investigated
Fisher et al, 1987 51% Oral rinse 412 232 180 - Yes Not investigated No
Lamey et al, 1988 57% Oral rinse 106 57 52 27% Yes No difference No
Hill et al, 1989 49% Swab 51 __** - Yes Not investigated Yes
Da rw a/eh et al, 1990 54%
Swab and 
smear
50 19 31 40% No No difference No
Aly etal, 1992 66% Swab and oral 
rinse 436 231 205 ■ No
Yes: more 
Candida carriers in 
DM type 1
No (oral rinse), yes 
(palatal carriage in 
dentures)
Dorocka-Bobkow ska 
etal, 1996
54%
Swab and 
imprint 
culture
70 0 70 41% Yes Not investigated No
Willis et al, 2000b 77% Oral rinse 414 414 0 - Not investigated Not investigated No
Guggenheimer et al, 
2000a 23%
Cytologic
smear 405 405 0 5.7% Yes Not investigated Yes
Manfredi et al, 2002 60% Oral rinse 137 56 83 57% Yes No difference No
1   Studies that have investigated the oral Candida carriage in patients affected by DM
2  Oral Candida carriage (cfu/ml) in DM patients is expressed in percentage
3  Methods of sampling that have been used to evaluate the oral Candida carnage in the studies
4  Number of DM patients investigated in the studies
5. Number of patients affected by DM type  1   investigated in the studies
6. Number of patients affected by DM type 2 investigated in the studies
**: In these studies, the researchers did not differentiate between type I  DM and type 2 DM
7. Oral Candida carriage (cfu/ml) in controls is expressed in percentage
8. Difference of oral Candida carriage (increased levels of cfu/ml) in DM patients 
wearing a denture in comparison to non denture wearers.
9  Difference of oral Candida carriage (cfu/ml) in patients affected by type  1   DM in 
comparison to patients affected by type 2 DM
10. Difference of oral Candida carriage (cfu/ml) in DM patients with poor metabolic control in comparison to 
DM patients with good metabolic control.
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Figure 1.1: In vitro C. albicans germ-tube
Figure 1.2: In vitro C. albicans clamvdospore
'
•
 
vFigure 1.3: Pseudomembranous candidosis of the palate
Figure 1.4: Acute erythematous candidosis
92Figure 1.5: Chronic hyperplastic candidosis (candidal leukoplakia)
Figure 1.6: Denture stomatitis associated with Candida
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93Figure 1.7: Unilateral angular cheilitis associated with C. albicans
Figure  1.8:  Bilateral  angular  cheilitis  associated  with  Candida  in  an  elderly 
woman affected by DM ty pe 2
94Figure 1.9-1.10: Median rhomboid glossitis
The lesion is associated with the presence of C.  albicans (left) and kissing lesion of 
the plate in the same patient (right)1.9 Summary
The range  of human  infections caused by  Candida  spp.  is considerable.  They vary 
from local conditions, such as oral and general thrush, to fatal  infections in patients 
who are already seriously ill with other diseases.
Candida spp. have been frequently isolated from the oral cavity of patients affected 
by DM (Darwazeh et al,  1990; Aly et al,  1995;  Willis et al,  1999).  Much has been 
written  about  the  incidence  of  the  oral  carriage  of  Candida  spp.  and  candidal 
infections in the mouth of patients with DM compared with non-DM control subjects 
(Dorocka-Bobkowska  et  al,  1996;  Abu-Elteen  &  Abu-Alteen,  1998;  Willis  et  al, 
1999; Willis et al, 2000b; Willis et al, 2001). However, controversy still exists as to 
whether  the  carriage  of  Candida  spp.  and  the  oral  manifestations  of  candidal 
infections  are  more  common  in  the  oral  cavity  of DM  patients  than  in  non-DM 
individuals and whether this is related to oral and/or systemic factors.
Furthermore, the epidemiology of Candida spp. has changed over recent years, with 
selective  pressure  from  increased  use  of  antifungals.  Differences  in  geographic 
distribution and patient populations of Candida spp.  and C.  albicans genotype have 
also been reported in several studies (McCullough et al, 1999b).
1.10 Aims of the thesis
The aims of this study were:
1.  To  assess  the  prevalence  of Candida  carriage  in  the  oral  cavities  of two 
groups of patients with DM and of a group of healthy non-DM subjects;
2.  To genotype the Candida isolates from the studied populations;
3.  To  evaluate  extracellular  proteinase  production  in  vitro  and  the  ability  to
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adhere  in  vitro to  fibronectin  of the  oral  Candida  isolates  from  the  studied 
groups;
964.  To  assess the  in  vitro antifungal  susceptibility of the  Candida  isolates  from 
the oral cavities of the patients affected by DM and from the control group;
5.  To  assess the  phylogenetic  relatedness  between  C.  albicans  strains  isolated 
from two groups of patients with DM and from the non-DM control subjects;
6.  To evaluate the in vitro activity of a monoclonal antibody (mAbKlO) and of a 
synthetic decapeptide (KP) on the Candida isolates of the oral cavities of DM 
patients and non-DM subjects.
1.11  Hypotheses of the thesis
Due to the altered oral  environment of DM patients compared with healthy control 
subjects, it is hypothesised that there is an associated variation in the prevalence and 
type of Candida spp. that colonise the oral cavity of patients with DM. The following 
phenotypic  and  genotypic  features  of  Candida  were  characterised  to  test  this 
hypothesis:
1.  Variation in the frequency of Candida spp. isolation, degree of oral colonisation, 
Candida  species and  C.  albicans genotypic distribution of oral  yeasts  isolated from 
patients with DM and a non-DM control group;
2.  Differences  in  the  in  vitro  ability  to  produce  extracellular  proteinases  and  to 
adhere  to  fibronectin  of  Candida  isolates  from  patients  with  DM  and  non-DM 
individuals;
3.  Differences  in  the  in  vitro  antifungal  susceptibility  to  six  different  antifungal 
agents of Candida isolates from the oral cavity of patients with DM and from healthy 
subjects;
4.  Variation  in the genetic relatedness of C.  albicans  isolates of patients with  DM 
from two different geographic locales and from a group of non-DM subjects;
975.  Differences  in the  in  vitro  candidacidal  activity  of mAbKlO  and of KP  against 
isolates of different Candida spp. and with a different susceptibility to conventional 
antifungal agents isolated from patients with DM and from healthy individuals.
98CHAPTER 2 
Patients and General Methods
2.1 Patient samples
2.1.1 UK patients with DM
Ethical  approval  for the  project was  granted  by  the  Joint  Ethics  Committee  of the 
University  College  of  London,  University  College  London  Hospitals  (UK).  All 
patients gave written informed consent prior to being enrolled in the present study.
One  hundred  and  forty-two  patients  attending  an  outpatient  Diabetology  Clinic  at 
Middlesex  Hospital,  UCLH,  London,  were  enrolled  during  their  routine  diabetic 
review appointment. The medical history of each patient was recorded at the time of 
examination.  This  included tobacco  smoking habits, type of DM  (type  1   or type  2) 
and duration of the disease (time since diagnosis <10 years; >10 years). The type of 
DM was diagnosed by a specialist diabetologist using the guidelines of the American 
and British Association of Diabetes (British Diabetic Association,  1997; The Expert 
Committee on the Diagnosis and Classification of Diabetes Mellitus,  1998; American 
Academy  of Periodontology,  2000).  The  presence  of the  most  common  long-term 
complications  of  DM  (retinopathy,  nephropathy  and  peripheral  neuropathy)  was 
similarly  recorded.  The  diagnosis of these  conditions was based on  clinical  reports 
provided by ophthalmologists, nephrologists and neurologists attending each patient.
Glycaemic  control,  assessed  by  HbAjc (glycosylated  haemoglobin),  was  used  as  a 
measure  of  recent  diabetic  control.  Patients  were  classified  into  three  mutually
99exclusive groups, depending on the level of haemoglobin glycosylation at the time of 
oral examination (group 1: <7.5%; group 2: >7.5%, <8.5%; group 3: >8.5%).
All patients received a detailed oral  examination and oral rinses (Section 2.2) were 
used  to  assess  the  growth  and  the  degree  of yeast  colonisation  for  each  patient. 
Patients were asked to rinse their mouth with 10 ml of sterile distilled water for 1  min 
and expectorate back into a 50 ml sterile container.
2.1.2 Italian patients with DM
Ethical  approval  for  the  project  was  granted  by  the  Parma  Hospital  Medical 
Committee  on  the  Ethics  of Human  Research.  All  patients  gave  written  informed 
consent prior to being enrolled in the present study. A medical history, detailed oral 
examination and estimation of yeast carriage by oral rinse was obtained as was the 
case  for the  UK  DM  patients  above.  In  total  107  patients  attending  an  outpatient 
Diabetology  Clinic  at the  Parma  Hospital,  Parma,  Italy,  were  enrolled  during their 
routine review appointments for their DM.
2.1.3 Patients without DM
A total of 130 healthy, non-DM subjects were enrolled in London, UK. Patients were 
attending either a General Dental Clinic (n = 41), a Special Needs Clinic (n = 42), a 
Prosthodontic  Clinic  (n  =  31)  or  an  Oral  Medicine  Clinic  (n  =  16).  The  medical 
history  of  each  patient  was  recorded,  including  current  medication  and  tobacco 
smoking  habits.  All  patients  received  a  detailed  oral  examination,  which  also 
recorded the presence or absence of dentures (either partial or full) and the presence 
of any mucosal abnormalities. As with the DM patients oral rinses were obtained to
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determine the presence of yeast in the oral cavity.
1002.2 Concentrated oral rinse
Oral  rinse  samples  were  assessed  for  qualitative/quantitative  estimation  of yeast
colonisation. Mouth swills (30 s) using 10 ml of sterile distilled water, were collected
from each patient in a 50 ml sterile tube. Each mouth rinse was vortexed for 30 s and 
V\j(X2>
lOOpl were  spread evenly on a  SDA (Sigma-Aldrich,  Dorset,  UK) plate containing  )< 
chloramphenicol  (1 mg/1,  Sigma-Aldrich).  Furthermore,  two  10-fold  dilutions  (in 
sterile  distilled  water)  of  the  vortexed  mouth  rinse  were  plated  onto 
SDA/chloramphenicol  plates  for  enumeration  of the  degree  of colonisation.  Each 
plate was incubated for 48 h at 37°C.
2.3 Cfu/ml determination
Growth  of Candida  was  quantitatively  assessed  by  enumeration  of cfu  per  ml  of 
mouth rinse. Non-identical,  single colonies were isolated and cultured (re-incubated 
for 48 h at 37°C) to confirm their identity.
2.4 Species determination
2.4.1  Phenotypic methods for identifying Candida species
Each representative colony type from the oral sample was incubated in  1   ml of horse 
serum (Sigma-Aldrich) for 2 to 4 h at 37°C. Approximately 20  pi was placed on a 
glass  slide  and  microscopically  examined  to  identify  whether  germ-tubes  were 
present. The presence of germ-tubes gave a positive identification for C. albicans and 
C. dubliniensis.  Each strain was subsequently stored in Lennox L Broth Base (2g of 
Lennox L  Broth Base-Sigma Aldrich,  50 ml of sterile water and 50 ml of glycerol, 
Sigma-Aldrich) in a 2 ml Eppendorf tube and kept at -20°C for subsequent analysis.
1012.4.2. Genetic identification of isolates at species level
Genomic DNA was extracted by spheroplast formation and precipitation in ethanol as 
detailed elsewhere (Scherer & Stevens,  1987) over a three day time period.
Each strain was cultured on a SDA plate for 24 h at 37°C, inoculated in  1   ml of 1   M 
sorbitol pH 7.5 (Sigma-Aldrich) and then vortexed. After centrifugation at 5000 rpm 
(2700  g)  (Centrifuge  5417C,  Eppendorf,  Hamburg,  Germany)  for  10  min,  the 
supernatant  was  removed  and  re-suspended  in  1   ml  of  spheroplast  buffer.  This 
spheroplast buffer consisted of 42 pi 2-mercaptoethanol (0.1% v/v) (Sigma-Aldrich), 
0.2 pg zymolase (Sigma-Aldrich), 2 ml of phosphate buffer 50 mM (Sigma-Aldrich) 
and 40 ml 1M sorbitol pH 7.5 (Sigma-Aldrich). The cells were incubated overnight at 
room temperature to allow the  spheroplasts to  form.  The  supernatant was  removed 
after centrifugation at 5000 rpm (Centrifuge 5417C) for 10 min and re-suspended in 1  
ml  of lysis  buffer  consisting  of 50  mM  EDTA  (Sigma-Aldrich)  and  2%  sodium 
dodecyl sulphate (SDS) (Sigma-Aldrich), pH 8.5. Spheroplasts were incubated for 1  h 
between 65°C and 70°C.  The lysed cells were allowed to cool to room temperature 
and 50 pi of 5M potassium acetate (Sigma-Aldrich) were added. Subsequently, each 
sample was incubated for  1   h on grounded ice to allow for complete precipitation of 
the  SDS  and  protein.  A  0.5^ml  volume  of supernatant  was  carefully  removed  and 
added  to  1ml  of  100%  ethanol  (Sigma-Aldrich)  to  allow  the  nucleic  acid  to 
precipitate. Precipitated nucleic acids were collected by centrifugation at  11000 rpm 
(Centrifuge 5417C) for  10 min and the resultant pellet allowed to air dry. The dried 
pellet was re-suspended in 0.5 ml of a Tris-EDTA buffer (lOmM Tris and  1M EDTA, 
pH  7.5  supplied  in  ready-mix  pellets  by  Bio-Rad,  Mames  La  Coquette,  France) 
containing  lpg of ribonuclease A (1.4 x  10 to 4 w/v) (Sigma-Aldrich) and incubated
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overnight at room temperature.
102DNA was precipitated by the addition of 100% isopropanol (Sigma-Aldrich) in a 1:1 
ratio and centrifuged at  11000 rpm (Centrifuge 5417C) for  10 min. The supernatant 
was  discarded,  the  resultant  pellet  was  re-suspended  in  1   ml  of  75%  ethanol  to 
remove cations and the  DNA was  finally  collected by  centrifugation  at  11000 rpm 
(Centrifuge 5417C) for 2 min. The DNA pellet was air dried and suspended in 200 pi 
of TE (Sigma-Aldrich). Each sample was stored at 4°C and diluted 1:10 for use in the 
PCR.
2.4.2.1  PCR for species identification
PCR amplifications were performed on DNA preparations from all yeast isolates to 
identify the Candida species. PCR primers were directed against the V3 region of the 
25S rDNA, and the intergenic transcribed spacer region (ITS) of rDNA.
Primers  for  PCR were  designed  for two  separate  areas  of the  DNA,  encoding the 
RNA. The first pair of primers, ITS1  (5’-TCC GTA GGT GAA CCT GCG G-3’) and 
ITS4 (5’-TCC TCC GCT TAT TGA TAT GC -3’), has been used in previous studies 
(Williams  et  al,  1995;  Nho  et  al,  1997;  Gilfillan  et  al,  1998;  McCullough  et  al, 
1999b;  McCullough  et al,  1999a).  These  give  an  expected  PCR product  extending 
from the 5’ end of the  18S rDNA to the 3’ end of the 25S rDNA and include both the 
ITS regions (1TS1 and ITS2) as well as the entire 5.8S rDNA.
The second pair of primers, CA25SV3-L (5’-TCT TAA CAG CTT ATC ACC CTG 
GAA  TTG  GTT-3’)  and  CA25SV3-R  (5’-ATT  GTG  TCA  ACA  TCA  CTT  TCT 
GAC  CAT  CAC-3’),  was  designed  from  sequences  submitted  to  Gen  Bank 
(McCullough  et al,  1999b;  McCullough et al,  1999a) and produces a PCR product 
that spans the V3 region of the 25S rDNA (Sullivan et al,  1995).
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The DNA of the isolates was amplified in a reaction volume of 20pl containing  lpM 
from each primer (0.5pl), 0.5 U (0.5pl) of Red Taq polymerase (Sigma-Aldrich) and
103Red Taq buffer (supplied by the same manufacturer as a 10x concentrate and used to 
give a final concentration of 1.1  mM MgCb, 0.2 mM of dATP, 0.2 mM of dCTP, 0.2 
mM of GTP and 0.2mM of dTTP.
The reactions were performed with an automated heated-lid thermal cycler (Techne, 
Genius) by incubation for 3 min at 94°C before 40 cycles at 94°C for 1   min, 60°C for 
1  min and 72°C for 2.5 min prior to a final elongation step of 72°C for 10 min.
The amplicons of the V3-25S and ITS PCR were digested with restriction enzymes 
Hae III  and Dde I, respectively.  Endonuclease digestion was achieved by overnight 
incubation (to allow complete digestion of the PCR amplimers) with  10 U of enzyme 
and  with  the  corresponding  buffer  at  37°C.  It  has  been  shown  that  this  method 
discriminates between all medically important species of Candida (McCullough et al, 
1999b; McCullough et al, 1999a).
Ten microliters of the PCR products, with and without endonuclease digestion, were 
analysed by electrophoresis in a 2% agarose gel in TAE (Sigma-Aldrich) (40 mM of 
Tris acetate, pH  8.3,  containing  1   mM of EDTA) buffer.  Bands were visualised by 
UV transillumination at 302 nm after ethidium bromide staining.
2.S  Defining isolates at sub-species level using genotypic methods
2.5.1  Broad sub-species groups via the presence and size of rDNA intron.
The  primers  used  in  this  assay  for the  PCR were  CA-INT-L  (5’-ATA AGG  GAA 
GTC GGC AAA ATA GAT CCG TAA-3’) and CA-INT-R (5’-CCT TGG CTG TGG 
TTT  CGC  TAG  ATA  GTA  GAT-3’).  These  primers  were  directed  against  the 
transposable  intron  in the 25S  rDNA as previously described (Mercure et al,  1993; 
McCullough et al, 1999b; McCullough et al, 1999a).
104PCR  reaction  mixes  were  used  for  species  identification  as  described  previously 
(Section 2.4.2.1) except that CA-INT-L / CA-INT-R primers were used. The cycling 
parameters were identical to those described for species identification.
Ten microliters of the PCR products were analysed by electrophoresis as described 
previously (Section 2.4.2.1).
Candida albicans isolates were thus divided genotypically into sub-groups A, B, or C 
depending  on  the  presence  or  absence  of this  25S  rDNA  transposable  intron  as 
described previously (Scherer &  Stevens,  1987;  Stevens et al,  1990;  Clemons et al, 
1991; Clemons et al, 1997; McCullough etal, 1999b; McCullough et al, 1999a).
Using the primers described above, it was expected that a single PCR product of -  
450  bp  and  of -   840  bp  would  be  obtained  for  C.  albicans  genotypes  A  and  B, 
respectively.  The  C.  albicans genotype  C  isolates were  expected to yield two  PCR 
products  (C:  -   450  bp  and  -840  bp)  that  were  identical  in  size  to  the  respective 
products  from  C.  albicans  genotype A  and  B.  All  C.  albicans  genotype D  isolates 
would be expected to yield a PCR product identical in size to that of C. dubliniensis 
(-1080 bp) (McCullough et al, 1999b).
2.5.2  Identification of isolates at sub-species level by PCR fingerprinting
PCR fingerprinting was performed on C.  albicans samples isolated from each group
of patients to evaluate the genetic relationship between the groups of isolates.
The DNA from randomly selected C. albicans isolates from DM patients in Parma (n 
= 30),  DM patients  in  London  (n  =  31)  and  London  control  patients  (n  =  30)  was 
assessed  by  PCR  fingerprinting  with  5  different  short  random  primers  (Xu  et  al,
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2000):
M13: 51 - GAC GGT GGC GGT TCT-31
105T3B: 51  - AGG TCG CGG GTT CGA ATC-31  
TELO 5' -  TGG GTG TGT GGG TGT GTG GGT GTG-31  
(GACA)< : 51 - GAC AGA CAG ACA GAC A-31  
OPA-03: 51 - AGT CAG CCA C-31
The DNA of the  isolates and a reaction mix identical to those previously described 
(Section 2.4.2.1) was amplified in a reaction volume of 20pl containing  lpM primer 
(0.5pl),  0.5  U  (0.5pl)  of Red  Taq  polymerase  (Sigma-Aldrich)  in  Red  Taq  buffer 
(Section 2.4.2.1).
PCR  fingerprinting  with  M l3,  T3B,  TELO  and  (GACA)4  was  performed  with  a 
heated-lid thermocycle PCR machine (Techne, Genius) for 1  cycle at 97°C for 3 min, 
40 cycles for 40 s at 93°C, 2 min at 50°C, 40 s at 72°C and a final step of 10 min at 
72°C.
t i
PCR fingerprinting with OPA-03, which requires lower temperatures, was performed 
for 1   cycle at 97°C for 3 min, 45 cycles for  1   min at 93°C, 2 min at 36°C, 2 min at 
72°C and a final step of 10 min at 72°C, as previously reported (Xu et al, 2000).
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Ten microliters of the PCR products were analysed by electrophoresis through a 2% 
w/v  agarose  gel  (SeaKem  Gold,  FMC  BioProducts,  Rockland,  ME,  USA)  in  TAE 
buffer (40mM of Tris-acetate, Sigma-Aldrich and 0.2 mM of EDTA, Sigma-Aldrich; 
pH 8.3) for 2 h at V/cm and visualised by UV transillumination following ethidium 
bromide staining. This resulted in each isolate having 5 distinct PCR fingerprints, one 
for each of the primers, for their identification at sub-species level.
1062.6  Adhesion assay
The  ability  of  individual  isolates  to  adhere  to  paramagnetic  beads  coated  with
fibronectin was assessed in an in vitro assay. A single colony from a 48 h, 37°C SDA
culture was  inoculated  in  5  ml  of Yeast,  Peptone,  and Dextrose (YPD) broth.  This
broth consisted of 20 g of dextrose powder (Sigma-Aldrich), 20 g of peptone powder
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(Sigma-Aldrich)  and  10  g  of yeast  extract  (Sigma-Aldrich)  in  1L  of water.  This- 
inoculum was incubated for  18 h at 37°C, after which 45 ml of YPD was added and 
incubation  continued  for a  further 6  h  at 37°C.  The  cells  were then  centrifuged  at 
3600 rpm (2753 g) (Centrifuge TJ-25 Beckman Coultur, Palo Alto, California, USA) 
for 3  min and washed three times in TE buffer pH  8 (IX:  lOmM Tris HC1 pH  8,  1  
mM EDTA pH 8; Sigma-Aldrich) to remove traces of YPD. The cell pellet was then 
re-suspended in 5 ml of TE buffer pH 7.8. The number of yeasts present was counted
o
with a haemocytometer and adjusted to 10  cells/ml.
In  vitro  adhesion  was  assessed  using  paramagnetic  beads  (Dynabeads®  M-450 
Tosylactivated,  Dynal  Biotech  UK,  Wirral,  UK)  coated  with  fibronectin  (0.1%, 
Sigma-Aldrich). Non-specific  sites were blocked with bovine serum albumin (BSA, 
Sigma-Aldrich) as outlined by the manufacturer (Dynal Biotech UK).
To  coat  the  paramagnetic  beads  (Dynal  Biotech  UK)  with  fibronectin,  they  were 
initially vortexed in a 15 ml tube, which was then placed in the associated magnet for 
2 min. The supernatant was then discarded, the tube removed from the magnet and 
lml of Buffer A (0.019 M NaH2P04 and 0.081  M Na2HP04, at pH 7.4) was added. 
The washing procedure was repeated twice.
Fibronectin 50 pg (Sigma-Aldrich) was added to the suspension which was incubated 
for  10 min at 37°C on slow tilt. Ten pi of Buffer B was added (80 ml of Buffer Bconsisted of 0.88 g of NaCl, 0.1  g of BSA and ten-fold diluted Buffer A diluted in 
distilled water) and the suspension was incubated at slow tilting for a further 24 h at 
37°C. The mixture was put in the magnet for 3 min and the supernatant was carefully 
removed. One millilitre of cold Buffer B was added and the suspension was cooled in 
the fridge for 5 min. This procedure was repeated twice and 1  ml of Buffer C (100 ml 
contained 2.42 g of Tris, Sigma-Aldrich, and 0.1  g of BSA, pH 8.5) was added. The 
suspension was incubated at 37°C for 4-6 h. The mixture was placed in the magnet 
for 3 min and the supernatant was carefully removed. One millilitre of cold buffer B 
was added and the suspension was cooled in the fridge for 5 min.
Dynabeads  coated primarily  with  fibronectin  and  secondarily  with  BSA  were  then
o
suspended in Buffer B and the concentration adjusted to 10  beads/ml (stock solution) 
and finally  stored at 4°C  for subsequent use. A final  100-fold dilution of the  stock 
beads (990 pi of Buffer B with  10 pi of beads stock solution) was prepared and used 
in the assay (106beads/ml).
The Dynabeads coated with fibronectin were incubated with the yeast cells in a 200 
ml final volume in the TE buffer pH 8 (Sigma-Aldrich). The mixture was incubated at
A   ft a ratio of 10  beads/ml dynabeads to  10 cells/ml yeast cells and shaken for 30 min at 
room temperature. The cells bound to the Dynabeads were collected for 3 min using 
the  magnetic  separator  supplied  (Dynal  MPC,  Dynal  Biotech  UK).  Unbound  yeast 
cells were  removed  from the  solution  by  washing three times with  TE  buffer.  The 
adherent yeast cells were finally disassociated from the Dynabeads by re-suspending 
them  in  0.1  N  NaOH  (150  pi).  Free  cells  and  Dynabeads  were  counted  using  a 
haemocytometer and results were  expressed as number of Candida cells bound per
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fibronectin-coated Dynabead.
1082.7 Extracellular proteinase production
The  ability  of  the  individual  isolates  to  produce  extra-cellular  proteinases  was 
assessed in an in vitro assay as previously described (Macdonald & Odds,  1980). A 
culture medium containing 1000 ml of sterile water, 2g of BSA (Sigma-Aldrich), 20 g 
of  dextrose  (Sigma-Aldrich),  lg  of  KH2PO4  (Sigma-Aldrich),  0.5  g  of  MgS0 4  
(Sigma-Aldrich) and a synthetic vitamin solution (20 pg of biotin, 200 pg nicotinic 
acid, 200 pg of riboflavin, 400 pg of thiamine and 400 pg of pyridoxal hydrocloride, 
Sigma-Aldrich) was prepared.  A  single colony  from an  18 h,  37°C  SDA culture of 
each isolate was inoculated in 1   ml of the medium and was shaken for 5 days at room 
temperature. The number of yeasts per ml was enumerated using a haemocytometer 
and then removed by centrifugation at  1500 rpm (Centrifuge TJ-25) for 30 min; 0.5 
ml of the supernatant was incubated in 2 ml of lOg/L BSA solution (Sigma-Aldrich) 
in 0.05  M citric buffer (as protein substrate) (Sigma-Aldrich) pH 3.2, for 30 min at 
37°C. The reaction was stopped by adding 5 ml of trichloracetic acid solution on ice 
(TCA,  50  g/L,  Sigma-Aldrich)  for  15  min  and  the  precipitate  was  removed  by 
centrifugation.  In  negative  control  samples,  incubation  with  BSA  and  citric  buffer 
was  omitted.  The  absorbance  of each  sample  at  280  nm  was  determined  against a 
citrate-buffer  blank  and  representative  fractions  containing  ultraviolet-absorbing 
material  were  assayed  for  proteinase  activity.  Results  were  expressed  as  a  ratio 
between the spectrophotometer reading and numbers of cells/ml.
2.8 In vitro antifungal susceptibility
The  susceptibility  of the  individual  isolates  to  commercially  available  antifungal 
agents was assessed by a broth microdilution assay using alamar blue in the Bio-Rad
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in  vitro  assay,  Fungitest.  A  single  colony  from  a 48  h,  37°C  SDA  culture  of each 
isolate  was  diluted  into  3  ml  of  distilled  water  to  give  a  turbidity  reading  of
109McFarland number  1   (equal to  approximately  3  x  106 cells/ml).  One hundred  pi  of 
this suspension was diluted into  1.9 ml of sterile distilled water and 2 0 pi was added 
to  3  ml  of  a  suspension  medium  (supplied  by  Bio-Rad).  One  hundred  pi 
(approximately  1 x 10  cells/ml) of the yeast suspension were added to each of the 16  X. 
wells of a Fungitest® microplate (Bio-Rad).  This  16-well  microplate contained  six 
different  antifungal  agents  at  two  different  concentrations  (fluconazole  8  and  64 
pg/ml, itraconazole 0.5 and 4  pg/ml, miconazole 0.5  and  8  pg/ml, ketoconazole 0.5 
and 4 pg/ml, amphotericin B 2 and  8  pg/ml and 5-FC 2 and 32  pg/ml), in modified 
RPMI  1640 buffered medium, with the presence of a redox indicator (alamar blue).
Two  growth  control  wells  and  2  negative  control  wells  were  also  present  in  each 
microplate.
After  incubation  at  37°C  for 48  h,  growth  was  assessed  by  colorimetric  means  as 
outlined  by  the  manufacturer.  Results  were  expressed  as  resistant,  intermediately 
resistant or susceptible to each of the antifungal agents tested.
2.9  In  vitro  evaluation  of  the  candidacidal  activity  of  the  monoclonal  anti- 
idiotypic antibody K10
Anti-idiotypic antibodies representing the internal image of PaKT and able to mimic 
its biological activity have been recently obtained (Section 1.7). Such antibodies have 
been produced in monoclonal (KTmAb; K10) and recombinant format (KTscFv) by 
idiotypic vaccination using a PaKT-neutralising monoclonal antibody (mAbKT4) as 
an immunogen (Magliani et al, 1997a; Polonelli et al, 1997) (Section 8.1).
2.9.1  KT-IdAb (K10) purification
Hybridoma  cells  secreting  K10  (Polonelli  et al,  1997)  were  grown  in  RPMI  1640 
(Sigma-Aldrich)  medium  supplemented  with  L-glutamine  (0.3  g/1,  Sigma-Aldrich),
110pyruvic acid (12 mM, Sigma-Aldrich), non-essential amino acids (Mem non-essential
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amino  acid  solution  100X,  Sigma-Aldrich), vitamins  (Mem vitamin  solution  100X,
Sigma),  penicillin-streptomycin  solution  (streptomycin  15  mg/100  ml,  penicillin
15,000  U/100  ml,  Sigma),  and  15%  foetal  bovine  serum  (Sigma-Aldrich).
Supernatant from the culture of these hybridoma cells was collected, precipitated in
saturated ammonium sulphate (38.35 g (NH4)2SC>4 in 50 ml of distilled water at 25°C
overnight  and  re-suspended  in  KH2PO4  0.01M  pH  7.44  )  solution  (1:1,  Sigma-
Aldrich) and then dialyzed against phosphate buffered saline (PBS,  Sigma-Aldrich)
for 48 h. After dialysis, the purified suspension was filtered through a 0.22 pm filter
(Millex-GP,  Millipore,  Bedford,  USA).  Antibody  concentration  was  determined  by
capture ELISA using a pair of mouse monoclonal antibodies against a p heavy chain
of  rat  Ig  (LO-IMEX,  Brussels,  Belgium).  In  brief,  the  wells  of  a  polystyrene
MicroElisa  plate  (Costar,  Coming  Incorporated,  Coming,  New  York,  USA)  were
coated overnight at 4°C with  100  pi  of a purified MAb  (MARM-7,  a mouse  IgGl
against a p heavy chain of rat Ig, Technopharm, Paris, France) at a concentration of 5
pg/ml  in 0.05 M sodium carbonate/bicarbonate buffer (10X:  15.9 g of NaCC>3, 29.3
NaHCC>3 dissolved in sterile water, final volume 1   L) at pH 9.6. The wells were then
washed 5 times with PBS (Sigma-Aldrich), Tween 20 (0.1%) (Sigma-Aldrich) using
Ascent Well-Wash (Lab-Systems Oy, Helsinki, Finland) and saturated for 1  h at 37°C
with 2% skimmed milk (Sigma-Aldrich) dissolved  in  PBS.  After a second cycle of
washing 5 times, as described above,  100 pi of pre-determined scalar dilutions (100,
war
50, 25,  12.5 ng/ml) of a standard rat IgM MAb (LOMA 7, Technopharm) w^pg added 
to a plate  in  four pairs of wells.  One hundred  pi of pre-determined  scalar dilutions 
(1:1000-1:8000) of the rat MAb (K10) for testing was added to second group of four
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well pairs on the same plate.  The  suspensions were  incubated for  1   h at 37°C.  The 
washing procedure described above was repeated again 5 times. One hundred pi of a
111mouse MAb labelled with peroxidase (MARM4-peroxidase, a mouse IgGl  against p 
heavy chain of rat Ig, Technopharm) diluted  1:2000 in PBS was added to each well 
on  the  plate.  The  plate  was  incubated  for  1   h  at  37°C.  The  washing  procedure 
described above was repeated again 5 times. Peroxidase activity was detected using a 
3,3'-5,5' tetramethylbenzidine dihydrochloride tablet as a substrate (Sigma-Aldrich), 
dissolved  in  10  ml  of  0.05M  phosphate-citrate  buffer  (Sigma-Aldrich)  pH  5 
supplemented with 2 pi of fresh 30% hydrogen peroxide (Sigma-Aldrich). Reactions 
were stopped after 15 min at room temperature by adding 50 pi of 2M H2SO4 to each 
well.  Optical  density (OD) of the reaction mixes was recorded at 450 nm  using an 
Ascent Multiskan spectrophotometer (Labsystems Oy, Helsinki, Finland).
A standard curve was constructed (GraphPad, Prism 4, GraphPad Software, Inc., San 
Diego, USA) by plotting the standard scalar concentrations of rat IgM Mab LOMA-7 
(on the X-axis) against the acquired corresponding OD values (on the Y-axis).  The 
unknown value of K10 concentration was obtained by interpolating the values on the 
standard curve (GraphPad Software).
2.9.2  Candidacidal activity of the monoclonal antibody K10
The candidacidal activity of the anti idiotypic antibody K10 was evaluated in vitro by
a cfu assay on randomly selected Candida strains from each patient group (23 strains
from  DM  patients  from  Parma,  24  from  DM  patients  from  London  and  24  strains
from controls) (Chapter 8, Table 8.1). Strains were grown on SDA at 30°C for 24 h.
The  yeast  cells  from  a  single  colony  were  suspended  in  M l99  medium  (Sigma-
Aldrich)  and  incubated  at  37°C  while  shaken  for 2  h.  Candida  cells  were  counted
using  a  haemocytometer  and  10  pi  of yeast  cell  suspension  (2-3  x  10  cells)  was 
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added  to  90  pi  of K10  (final  concentration  20  pg/ml).  Previously  heat-inactivated 
K10, also at the same concentration, was used as a control. A reference strain of C.
112albicans  (10S),  known  to  be  sensitive  to  K10  (Conti  et  al,  1996;  Magliani  et al, 
1997a),  was  used  as  a  positive  control.  Following  18  h  incubation  at  37°C,  the 
suspensions were dispensed onto SDA plates, and incubated at 30°C for 48 h before 
cfu  enumeration.  Each  experiment  was  performed  in  triplicate  and  the  results 
expressed as  a percentage  of inhibition  of each  isolate  against the  heat-inactivated 
K10 control.
2.10  In  vitro  evaluation  of  the  candidacidal  activity  of  a  synthetic  killer 
decapeptide (KP)
Recombinant  single-chain  fragment  variable  (scFvH6)  anti-idiotypic  antibodies
functionally  mimicking  the  activity  of PaKT  (Section  8.1)  have  been  produced  by
idiotypic vaccination with a mouse monoclonal antibody (mAbKT4) that neutralised
PaKT (Magliani et al,  1997a). The sequencing of scFvH6 was performed according
to the conventional Sanger method (Sanger et al,  1977; Sanger et al,  1992). A series
of decapeptides  belonging  to  the  scFvH6  sequence  were  synthesized  with  special
regard  to  CDR  regions.  A  synthetic  decapeptide  (P6,  sequence:  EKVTMTCSAS)
pertaining to CDR-L1  and exerting a remarkable candidacidal activity in vitro, was
selected  for  analysis  by  alanine  scanning  in  order  to  identify  the  functional
contribution of each residue.  In Table 2.1, the in  vitro candidacidal  activities of P6
and peptides obtained by its alanine scanning are compared with those of a scramble
peptide  (SP),  properly  synthesized  as  an  altered  sequence  of  P6  (SP:
MSTAVSKCET), which  showed no  in  vitro candidacidal  activity at all,  and which
was used as a control. All the substituted decapeptides retained some activity, but the
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one  with  alanineN replacing (Ey  named  KP  (Table  2.1,  decapeptide  number  2:
AKVTMTCSAS),  showed  surprisingly  greater  dose-dependant  activity.  The
decapeptide  KP was then  selected  and  synthesized  (Neosystem,  Strasburg,  France)
(Polonelli et al, 2003) to be used in this study.
1132.10.1  Candidacidal activity of KP
The candidacidal activity of KP was evaluated in vitro by a cfu-determining assay on 
randomly selected strains of Candida spp.  isolated and  identified from each patient 
group (23 strains from DM patients from Parma, 24 from DM patients from London 
and 24 strains from controls) (Chapter 8, Table 8.1). Candida strains were re-grown 
in M l99 medium at 37°C for 2 h.
Candida  cells  were  counted  using  a  haemocytometer  and  10  pi  of  yeast  cell 
suspension (2-3  *  102 cells) was added to 90 pi of sterile water containing synthetic 
KP to obtain a final yeast concentration of 20-30 cells/ml. The final concentrations of 
KP  were  100  and  20pg/ml  which  were  incubated  for  6  h  at  37°C.  The  same 
concentrations of the SP, properly synthesized as an altered sequence of the KP, were 
used as controls. After incubation with the respective reagents, the fungal cells were 
dispensed and streaked on the surface of SDA plates, which were then incubated at 
30°C and the resulting cfu enumerated after 48 h. Each experiment was performed in 
triplicate.
In  order to  establish  the  minimal  fungicidal  concentration,  corresponding  to  100% 
killing of C. albicans cells, the above mentioned cfu assay was also performed in the 
presence  of  scalar  concentrations  of  KP  (15  pg/ml,  10  pg/ml,  and  5  pg/ml)  in 
comparison with SP on four of the Candida strains investigated in this study (two C. 
albicans subgroup A,  one  susceptible and  one resistant to  itraconazole;  two  non-C. 
albicans,  one  susceptible  and  one  of intermediate  resistance  to  azoles)  (Chapter  8, 
Table 8.4). The strains selected were previously tested with KP at the above reported 
concentrations (100 and 20 pg/ml) with  100% killing activity. Each experiment was 
performed in triplicate.
The colonies of each Candida strain investigated in this study, which grew on  SDA 
plates  in  each  experiment,  were  cultured  on  SDA  for 24  h,  re-suspended  in  M l99
114medium and re-incubated with 90 pi of KP (final concentration 100 and 20 pg/ml), as 
described above, in order to establish whether the parental Candida cfu were clones 
intrinsically  resistant to the  KP or if they only exhibited transient resistance to  KP 
under the experimental conditions adopted in this study.
115Table  2.1:  In  vitro  activity  against  C.  albicans  of  the  products  obtained  by 
alanine scanning of the decapeptide P6
(Maglianifefah 2004)  ( t.>
Decapeptide 100 pg/ml 25 pg/ml 6.25 pg/ml
l . E K V T M T C S A S 5 . 7 ± 0 . 2 * 2 9 . 8 ± 1 0 . 6 6 7 . 1 ± 1 3 . 8
2 . A K V T M T C S A S 0 * 0 * 0 *
3 . E A V T M T C S A S 9 .9 3 .3 4 2 . 7 ± 2 . 0 5 3 . 4 ± 7 . 0
4 . E K A T M T C S A S 9 . 3 ± 2 . 4 * 1 9 .7 ± 2 .9 6 0 . 1 ± 5 . 2
5 . E K V A M T C S A S 9 . 2 ± 4 . 1 * 2 6 . 6 ± 4 . 2 6 3 . 2 ± 4 . 8
6 . E K V T A T C S A S 0 . 1 ± 0 . 1 * 1 0 .1 ± 3 .0 * 4 0 . 4 ± 1 6 . 0 *
7 . E K V T M A C S A S 5 2 . 9 ± 3 . 9 5 5 . 5 ± 3 . 7 5 8 . 1 ± 8 .2
8 . E K V T M T A S A S 5 5 . 7 ± 1 0 . 2 5 9 . 7 ± 4 . 8 6 4 . 3 ± 6 . 7
9 . E K V T M T C A A S 2 .6 ± 0 . 5 * 2 3 . 1 ± 3 . 6 * 7 2 . 9 ± 7 . 4
1 0 . E K  V T M T C S A A 1 1 .9 ± 0 .6 * 3 2 . 9 ± 0 . 8 * 7 0 .3 ± 9 .1
l l . M S T A V S K C E T 1 0 0 1 0 0 1 0 0
D e c a p e p tid e   1  is P 6 ;  d e c a p e p tid e s  2 - 1 0  a r e  d e tiv e d   fr o m   P 6  b y   a la n in e   sc a n n in g :  d e c a p e p tid e  2   is K P  (h ig h lig h te d  
in  y e llo w );  11  is  th e   sc r a m b le   d e c a p e p tid e   ( S P )  d e r iv e d   fr o m   P 6   a n d   u se d   a s  a   c o n tr o l.  T h e   activity'  o f   e a c h  
d e c a p e p tid e   is  e x p r e s s e d   a s  a   p e r c e n ta g e   o f   g r o w th   in   c o m p a r is o n   w ith   th e   c o n tr o l  in   a   c fu   a s s a y ,  e s s e n tia lly  
ca rried   o u t  a s  p r e v io u s ly   d e s c r ib e d   (S e c tio n   2 .1 0 .1 )  (P o lo n e lli  et al.  2 0 0 3 ) .  a fter  in c u b a tio n   fo r   6   h   at  3 7 ° C   w ith  
th e  r e s p e c tiv e  r e a g e n ts
S ta tistic a lly   s ig n ific a n t d iffe r e n c e s   ( p < 0 .0 0 5 )   in   c fu  c o u n ts  in  c o m p a r is o n   w ith   th e  c o n tr o l  (e a c h   te st  p e r fo r m e d   in 
tr ip lic a te ) a re in d ic a te d  b y  *
S ta tistica l  s ig n ific a n c e  w a s  a s s e s s e d  u s in g  th e  tw o -ta ile d   S tu d e n t's  t test.
116CHAPTER 3 
Patient demographics
3.1 Introduction
A  large  epidemiological  study  (King  et  al,  1998)  of  the  prevalence,  numerical 
estimates and projections of the global distribution of DM between^ 1995 and  2025 
has recently been published (King et al,  1998). Diabetes mellitus is a common multi- 
systemic disorder (Section 1.8) whose global prevalence in adults was estimated to be 
4% in  1995  (135  million  adults affected) and projected to rise to  5.4% by the year 
2025  (300  million  adults  affected)  (King  et al,  1998).  The prevalence  is  higher  in 
developed  than  in  developing  countries  and  is  expected  to  remain  so  until  2025. 
However, proportional increase will be greater in developing countries (48% from 3.3 
to 4.9%), particularly  in China and India, whilst in Europe, the increase will be the 
lower (26%).
In developed countries the majority of persons with DM are currently over 65 years 
of age and this is unlikely to change. Furthermore, on a global scale, there are more 
women with DM than  men (73  vs 62  million as estimated  in  1995).  The excess of 
female patients  is  more  pronounced  in  developed  countries  (31  vs  20  million)  and 
will  probably  decrease  slightly  in  European  countries  by  the  year  2025.  Likely 
explanations for this  female  predominance  are greater longevity of women  and the 
existence of differential distribution of risk factors (especially diet, physical inactivity 
and central obesity) (King et al,  1998).
Other  epidemiological  studies  have  identified  geographical  variations  between
4
different populations (Diamond, 2003) in the incidence of the two types of DM. Type 
2  DM,  the  more  frequent  form  of  disease,  is  reportedly  (Zimmet  et  al,  2001)
117becoming more  common  in the  young and  its  incidence  is  spreading among many 
different  populations  (Asian, Indians,  Chinese,  Japanese,  Aboriginal  Australians, 
Hispanic Americans and Afro-Americans) (Zimmet et al, 2001; Diamond, 2003). The 
epidemiology  of type  1   DM  in  Europe  has  recently  been  studied  by  EURODIAB 
(EURODIAB  ACE  Study  Group,  2000)  in  a  large  number  of European  Diabetic 
Centres  in  order  to  evaluate  geographical  variations  and  environmental  factors 
affecting  this  form  of  DM.  Preliminary  data  from  this  study  confirmed  large 
differences  in type  1   DM  incidence rates within  different  European countries.  It  is 
more likely that these differences are due to environmental factors such as perinatal 
infections or a rapid growth rate in early life than to genetic differences, as Europeans
EURODIAB ACE Study Group, 2000).
Diabetic patients have been regarded by several authors over the years as a group at 
possible risk of developing oral candidal infections (Section 1.8.9.1.1). These studies 
have  focussed  on  a  number  of  variables  that  could  promote  a  switch  from  a
a  fraction  of glycosylated  haemoglobin,  HbAic),  the  duration  of disease  and  the 
presence of long-term diabetic complications have been investigated (Aly et al,  1995; 
Dorocka-Bobkowska  et  al,  1996;  Willis  et  al,  1999;  Manfredi  et  al,  2002).  In 
addition, local factors, such as the presence of dentures or tobacco habits, have been 
assessed for promoting adhesion to the mucosal epithelia.  The relationship between 
the presence of DM and the development of oral  candidal  infections is still  unclear 
(Section  1.8.9.1.1).  One of the possible reasons for the discrepancies between these 
studies is the different sample populations investigated (often type  1   only or type 2 
DM only) or the different measure of glycaemic control used (degree of glycosuria,
(relatively\ genetically are / more homogeneous  (Cavalli-Sforza  &  Piazza,  1993;
C<Xr.  I 6 ‘jC
commensal  state  of Candida  spp. jin  the  oral  cavity  to  a  pathogenic  state  in  DM 
patients. In particular, systemic factors such as diabetic control (usually expressed as
118blood glucose levels, HbAic). Even different sampling techniques have been used to 
quantify  oral  Candida  colonisation  (Section  1.6)  and  have  reported  widespread 
colonisation (Williams & Lewis, 2000).
Therefore, in order to clarify if there are variables that could promote an increase in 
oral  candidal  carriage  or  the  risk  of  developing  oral  candidal  infections  in  DM 
patients,  it is necessary to use the same methodologies to simultaneously evaluate a 
large  number of comparable  DM  patients  affected  by  the  two  types  of DM  and  a 
group  of non-DM  subjects.  An  initial  comparison  between  the  two  DM  groups  is 
required  to  evaluate  the  possible  differences  related  to  gender,  age,  type  of DM, 
glycaemic control and geographical variations that may influence the carriage of oral 
yeasts  (or Candida spp.)  and the  development of oral  candidosis.  Furthermore, the 
presence of dentures could characterise the  dental  management of a particular DM 
(and  elderly) population,  reflecting the  social  behaviour of that particular group  of 
patients,
Local  oral  factors  such  as  the  presence  of dentures  or  smoking  habits  may  also 
directly affect the oral microflora and thus the likelihood of oral Candida infections.
Aim:  The  aim  of  this  chapter  was  to  ascertain  whether  there  were  differences 
between the studied patient cohorts in terms of gender, age, tobacco usage, denture 
presence and diabetic  status.  The  relationship  between  any  observed  differences  in 
these parameters and the occurrence of DM or the patient’s geographical origin was 
ascertained.
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Hypothesis: That there are differences in terms of gender or age, tobacco habits, type 
of DM or glycaemic control and presence of dentures (either partial or full) that may
119attribute  either to the presence  of DM,  or correlate with the patient’s  geographical 
location.
3.2 Methods
A medical history as well as a detailed oral examination for each enrolled patient was 
obtained (Section 2.1).
Analyses  were  made  to  assess  the  possible  differences  between  DM  and  non-DM 
subjects,  irrespective of locality, which may be attributed to patient gender, type of 
DM,  age  of  patients,  smoking  habits,  level  of  haemoglobin  glycosylation  and 
presence of dentures (either partial or full).
Fisher’s exact test and Chi square test were used for statistical analysis of categorical 
data, and the Student T test or Anova were used to analyse numeric data according to 
the  postulates  of each  test.  Differences  among  or  between  groups  were  deemed 
significant when the probability (p) was less than or equal to 0.05.
3.3 Results
3.3.1  Diabetic patients affected by oral candidosis
During  the  course  of this  study,  only  7/242  (2.8%)  patients  attending  these  two 
geographically  different  outpatient  diabetic  clinics  had  clinical  signs  of  oral 
candidosis  (5/242  were  observed  during  London  Diabetic  Clinic  appointments  and 
2/242 during Parma Diabetic Clinic appointments). Five of the affected patients were 
female and two were male. Although all were asymptomatic, 4 patients had clinical 
signs of angular cheilitis (three patients with type 2  DM  and one with type  1   DM) 
associated with Candida, one patient with type 2 DM showed chronic erythematous 
candidosis  of the  palate  and  finally  two  type  2  DM  patients  had  clinical  signs  of 
pseudomembranous candidosis (Table 3.1).
120The six patients with type 2 DM with signs of oral candidosis were all over 60 years 
and  were  wearing  an  oral  prosthesis  (five  had  full  dentures  and  one  had  a partial 
prosthesis).  One  of these type 2  DM patients was a tobacco user.  The only patient 
affected by type  1   DM was younger than 60 years old (30 years old), dentate and a 
tobacco user.
The diagnosis of DM had been made more than  10 years previously to the enrolment 
in  this  study  for  5  of the  7  DM  patients  affected  by  oral  candidosis.  Glycaemic 
control, assessed by HbAic, was used to sub-classify patients into three comparable 
groups  according  to  the  diabetology  guidelines  (Section  2.1.1).  The  HbAic  levels 
were over 8.5% in 2/7 patients (one affected by type  1   DM and one by type 2 DM), 
between 7.5% and 8.5% in 3/7 patients (two affected by type 2 DM and one by type 1  
DM) and under 7.5% in 2/7 patients.
Four out of the seven patients affected by oral candidosis had no long-term diabetic 
complications recorded (1/7 type  1   DM and 3/7 type 2 DM); the others patients (all 
affected  by type  2  DM)  had  neuropathy  and/or retinopathy,  but  none  had  signs  of 
nephropathy.
The oral yeast load (Section 2.3) was greater than 100 cfu/ml in 6/7 (85.7%) patients 
and  lower than  100 cfu/ml only  in  1/7 (14.2%) patients.  All these patients had one 
oral Candida species each: five isolates were further identified (Section 2.4.2, 2.4.2.1) 
as C. albicans genotype A and two as C. parapsilosis (Table 3.1).
Due to their  low number (2.8%,  7/249),  these  patients were  excluded  from  further 
statistical analysis in the present study.
3.3.2  Diabetic patients without oral candidosis
A total of 249 patients affected by DM (77/249 affected by type  1   DM and  172/249 
by type 2 DM) were enrolled in this study. Two hundred and forty-two patients (125
121male,  51.6%;  117 female, 45.8%;  mean age  57.5  years,  SD  15.6) were free of oral
Of the  242  DM  patients  without  oral  candidosis,  DM  type  1   had  been  previously 
diagnosed for 75  (30.9%) patients (56/75  from London and  19/75  from Parma) and 
the  remaining  167/242  (69%)  had  been  diagnosed  with  type  2  DM  (81/167  from 
London and 86/167 from Parma).
Of the  167  DM  patients  with  type  2  DM,  23  (13.7%)  were  being  treated  with  a 
hypoglycaemic diet only,  108  (64.6%) were  being treated with oral  hypoglycaemic 
agents  and  36  (21.5%)  were  using  insulin.  Only  10  out  of these  36  (27.7%)  were 
using a combined therapy of insulin and oral hypoglycaemic agents.
The  diagnosis  of  DM  was  made  more  than  10  years  before  the  present  oral 
examination  for  117/206  (56.7%)  DM  patients  and  less  than  10  years  for  89/206 
(43.2%). For 36 DM patients (all enrolled in London), it was not possible to establish
Glycaemic control from each patient (HbAic) was used to sub-classify patients  into 
three comparable groups according to the diabetology guidelines (Section 2.1.1). The 
HbAic  levels  were  >8.5%  in  105/242  (43.3%)  patients  (64/105  from  London  and 
41/105  from  Parma),  between  7.5%  and  8.5%  for  62/242  (25.6%)  patients  (21/62 
from London and 41/62 from Parma) and <7.5% for 75/242 (30.9%) patients (52/75 
from London and 23/75 from Parma).
Retinopathy  was  the  most  common  long-term  diabetic  complication  recorded  in 
72/242  (29.7%)  patients  (41/72  from  London,  31/72  from  Parma),  followed  by 
neuropathy,  recorded  in  58/242  (23.9%)  patients  (37/58  from  London,  21/58  from 
Parma) and nephropathy  recorded  in  15/242  (6.2%)  of the DM  patients (4/15  from
4
London and 11/15 from Parma).
candidosis and were used for statistical analysis in this study (Tables 3.2-3.3).
oJr
the date bf which DM was first diagnosed.
122At  the  time  of  the  oral  examination,  the  majority  of the  DM  patients  enrolled 
(142/242;  58.6%) were dentate  (or at least had  some teeth  in their oral  cavity) and 
100/242 (41.3%) were wearing partial or full dentures.  Out of the  100 patients who 
were wearing a denture at the time of examination, 50/100 (50%) were wearing a full 
oral  prosthesis  (17/50  from  London  and  33/50  from  Parma)  and  50/100  (50%)  a 
partial one (23/50 from London and 27/50 from Parma). Five patients (2%), out of the 
242 who received oral examination, complained of a dry mouth although no signs of 
dryness or papillary atrophy were detected.
None of the DM patients enrolled in the present study were taking either topical or 
systemic  antifungal  drugs  at  the  time  of oral  examination  or  had  done  so  in  the 
previous 6 months.
The majority of these DM patients were non-smokers  (203/242,  83.8%).  Of the  39 
smokers, 36 patients were tobacco smokers, 2 were betel-nut chewers and one patient 
was  a  pipe  smoker.  These  last  three  patients  were  all  enrolled  from  the  London 
Diabetic Clinic.
3.3.3  Non-DM control subjects from London, UK
A  total  of 130  non-DM  subjects  (63  males,  48.4%;  67  females,  51.5%;  mean  age 
50.74 years,  SD  17.67) (Section 2.1.3) were enrolled as a control group.  It was not 
possible to  establish the  age  of twelve  of these patients.  Of the remaining  118,  84 
(71.1%) were less than 60 years old. None of these patients had oral candidosis, nor 
were  they  immunocompromised  or  taking  any  form  of  systemic  or  topical 
medication.
The majority of the control subjects were dentate 87/130 (66.9%) and 43 out of 130
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(33%) were wearing dentures (either full or partial).  Twenty-one of the 43  (48.8%) 
had a full denture and 22/43 (51.1%) were wearing a partial oral prosthesis.
123One hundred and three of the 130 (79.2%) control patients were non-tobacco smokers 
and only 27/130 (20.7%) tobacco users. Only one of the tobacco users was a betel-nut 
chewer, the other twenty-six were tobacco smokers.
3.4  Results of the comparison between the three groups of patients
The comparison  between the  DM  patients  group  and the  non-DM  subjects  showed 
that there were  no differences  in the  gender distribution  and tobacco  habits among 
these  populations  (Table  3.2).  Although  for  12  of the  non-DM  subjects  it was  not 
possible to establish their date of birth (special needs patients), significant differences 
in age were observed between the two groups (Table 3.2). In particular, DM patients 
were older than non-DM control subjects (p=0.0004).
^J4oweve^>fJiumber of significant differences were observed between the two groups 
of DM patients (Table 3.3). Diabetic patients from Parma were older (p=0.001) than 
those  from  London,  and  more  patients  from  London  than  Parma  had  type  1   DM
Furthermore, although there was no significant difference in the presence of diabetic 
complications  and  duration  of disease  in  DM  patients  (from  London  and  Parma) 
(p=0.72)j|  London  patients  had  a  higher  incidence  of  neuropathy  and  a  lower 
incidence  of  nephropathy  (p<0.0001)  compared  with  those  from  Parma.  More 
specifically, there were fewer DM patients from London who developed nephropathy 
after  10  years of DM  disease  in  comparison to  DM  patients  from  Parma  (p=0.02y  >C
higher levels of HbAlc (>8.5%) were observed in the patients from London (p<0.001) 
and more patients from Parma were denture wearers (p<0.0001) (Table 3.3).
(p=0.001).
1243.5 Discussion
The  aim  of this  study was to  establish  whether there were  differences  in terms  of 
gender,  age,  tobacco  habits,  presence  of dentures  and  diabetic  status  between  the 
patients cohorts assessed in the present study. Although only small differences were 
observed  between  DM  patients  when  compared  with  non-DM  subjects,  the  two 
groups of DM patients evaluated did differ in a number of aspects relating to DM. 
Within the confines of this study, it has not been possible to establish the exact reason 
for these differences. They may simply reflect differences between clinical practices 
in  the  two  regions  or  perhaps  an  unknown  geographic  variation  in  the  frequency 
and/or clinical manifestation of DM.
Diabetic patients from Parma were older (p=0.001) than those from London  (Table
3.3). This age variation may reflect the difference in the type of DM that each group 
had.  Type  1   DM,  which  often  develops  before  30  years  of age  (Section  1.8),  was 
observed mostly in the DM patients from London (p<0.001).
The principal trend observed in the present study was that patients from London were 
more  likely  to  have  the  type  1   disease,  use  insulin,  and  experience  neuropathic 
complications of DM than those from Italy.
Wide  geographical  variations  have  been  described  in  the  incidence  of type  1   DM 
particularly  within  Europe,  with  extremely  high  incidences  observed  in  Finland, 
Sweden, Denmark, Norway and the United Kingdom and much lower incidences in 
France and Italy, with the exception of Sardinia (Bell & Hockaday,  1996; Diamond, 
2003).  The analysis made on the two geographically different DM populations may 
confirm the gradient of disease from North to South of Europe, although of course it
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would be more relevant to evaluate large DM populations from the two countries to 
assess the exact different incidences of the two types of DM.
125It has been hypothesized that patients with DM are prone to fungal infections (Bai et 
al, 1995; Dorocka-Bobkowska et al, 1996; Willis et al, 1999; Willis et al, 2001). 
Although the patients with DM from the UK investigated in the present study were 
different  in  many  aspects  of their  disease  from  the  DM  patients  from  Italy,  both 
groups demonstrated a low incidence of oral Candida infections. During the course of 
this study only 7/249 (2.8%) DM patients that had a detailed oral  examination had 
clinical  signs of oral candidosis.  This  low percentage of oral  candidal  infections  in 
DM patients seems to contrast with data reported elsewhere (Dorocka-Bobkowska et 
al,  1996; Abu-Elteen & Abu-Alteen,  1998;  Willis et al,  1999;  Guggenheimer et al, 
2000b;  Willis et al, 2000b), and cannot simply be attributed to  clinician  awareness 
(all  oral  examinations  in  the  present  study  were  carried  out  by  a  qualified, 
experienced dentist) or diabetic control. Locality may influence the incidence of this 
disease, although the reasons for this are difficult to pinpoint (Manfredi et al, 2002). 
The  development  of oral  infections  by  Candida  spp.  is  a  complex  pathogenetic 
process that involves both the host and the yeast. In the small group of DM patients 
affected by oral candidosis, different factors may have promoted the infection. Local 
factors, such as the presence of a dental prostheses (6/7, 85.7% of the patients were 
wearing a denture at the time of the oral examination), systemic factors, such as poor 
diabetic  control  (5/7,  71.4%  of the  patients  had  a  HbAic  greater  than  7.5%)  or 
impaired  host  immune  defences,  not  investigated  in  this  study,  could  have  all 
promoted Candida spp. pathogenicity in the oral cavity.
These patients may also have had partial disruptions of oral mucosal barriers that had 
provided  sites  for  local  infections  or  a  disruption  of the  ecological  balance  of the 
host’s oral microflora. Significantly, the diabetic status or general conditions of these
4  ~   --------
7 DM patients did not obviously differ from the other 242 DM patients that showed 
no signs of oral candidosis.From the analysis conducted on these groups of patients, it was possible to establish 
that there  were  no  significant differences  in the  demographics  of DM  patients  and 
non-DM subjects evaluated as a control group, but there were interesting variations in 
the diabetic disease of the two geographically different DM populations.
127Table 3.1:  Diabetic patients affected by oral candidosis
V a r i a b l e s   in v e s t i g a t e d L o n d o n   D M   p a t ie n t s P a r m a   D M   p a t i e n t s T o t a l   D M   p a t i e n t s
G e n d e r
M a le 4/5 0/2 4/7 (57.1%)
F e m a le 1/5 2/2 3/7 (42. 9%)
A g e
> 6 0  y e a r s 4/5 2/2 6/7 (85.7%)
< 6 0  y e a r s 1/5 0/2 1/7(14.3%)
D e n tu r e  sta tu s
D e n ta te 4/5 0/2 4/7 (57.1%)
D e n tu r e s 1/5 2/2 3/7 (42.9%)
T o b a c c o   u sa g e
T o b a c c o   u se r s 1/5 1/2 2/7 (28.6%)
N o n - t o b a c c o   u se r s 4/5 1/2 5/7(71.4%)
D M   ty p e
T y p e   1  D M 1/5 0/2 1/7(14.3%)
T y p e  2   D M 4/5 2/2 6/7 (85.7%)
T im e  s in c e  d ia g n o s is  o f  D M
D M  <   1 0  y e a r s 0/5 2/2 2/7 (28.6%)
D M  >   1 0  y e a r s 5/5 0/2 5/7 (71.4%)
G ly c a e m ic  c o n tr o l
H b A l c < 7 .5 % 2/5 0/2 2/7 (28.6%)
7 .5  % <  H b A l c < 8 .5 % 1/5 2/2 3/7 (42.8%)
H b A l c > 8 .5 % 2/5 0/2 2/7 (28.6%)
D M  c o m p lic a tio n s
N e u r o p a t h y 3/5 0/2 3/7 (42.9%)
R e tin o p a th y 2/5 0/2 2/7 (28.6%)
N e p h r o p a t h y 0/5 0/2 0/7 (0%)
O r a l  Candida c a r r ia g e
< 1 0 0  c fu /m l 1/5 2/2 3/7 (42.9%)
> 1 0 0  c fu /m l 4/5 0/2 4/7 (57.1%)
Candida g e n o ty p e
C. albicans A 4/5 1/2 5/7(71.4%)
C. albicans  B 0/5 0/2 0/7 (0%)
C. albiflans C 0/5 0/2 0/7 (0%)
C. parapsilosis 1/5 1/2 2/7 (28.6%)
128Table 3.2:  Demographics of the patients with and w ithout DM
Demographics Total DM  patients Non-DM subjects p value
Male 1 2 5 / 2 4 2   ( 5 1 .7 % ) 6 3 / 1 3 0 ( 4 8 . 5 % )
Female 1 1 7 / 2 4 2   ( 4 8 .3 % ) 6 7 / 1 3 0 ( 5 1 . 5 % ) 0 . 5 8 7
Age (mean, SDA) 5 7 . 5 ( 1 5 . 6 ) 5 0 . 8 ( 1 7 . 5 ) 0.0004
<60 years old 1 1 1 / 2 4 2   ( 4 5 .9 % ) 8 4 / 1 1 8 *   ( 7 1 . 2 % )
>60 Years old 1 3 1 / 2 4 2   ( 5 4 .1 % ) 3 4 / 1 1 8 *   ( 2 8 . 8 % ) <0.0001
Dentate 1 4 2 / 2 4 2   ( 5 8 .7 % ) 8 7 / 1 3 0   ( 6 6 . 9 % )
Dentures 1 0 0 / 2 4 2   ( 4 1 .3 % ) 4 3 / 1 3 0 ( 3 3 . 1 % ) 0 . 1 4 6
Tobacco users 3 9 / 2 4 2 ( 1 6 . 1 % ) 2 7 / 1 3 0 ( 2 0 . 8 % )
Non-tobacco users 2 0 3 / 2 4 2   ( 8 3 .9 % ) 1 0 3 / 1 3 0 ( 7 9 . 2 % ) 0 . 3 1 9
S ta tistica l  a n a ly s is  w a s  p e r fo r m e d  u s in g  F ish e r 's a n d  C h i-sq u a r e  p a r a m e tr ic  tests 
S D A =  sta n d a r d  d e v ia tio n
♦ T w e lv e  o f  th e  n o n - D M  su b je c ts d id  n o t g iv e  th eir d a te  o f  b irth  (s p e c ia l  n e e d s  p a tie n ts)
129Table  3.3:  Comparison  of  patient  gender,  age,  type  and  control  of  DM  and 
denture status between patients with DM from two different geographic locales
V a r i a b l e s   i n v e s t i g a t e d L o n d o n   D M   p a t i e n t s P a r m a   D M   p a t i e n t s p   v a l u e
G e n d e r
M a l e 7 0 / 1 3 7 ( 5 1 . 1 % ) 5 5 / 1 0 5   ( 5 2 . 4 % )
F e m a l e 6 7 / 1 3 7 ( 4 8 . 9 % ) 5 0 / 1 0 5   ( 4 7 . 6 % ) 0 . 8 9
A g e ,   m e a n   ( S D A ) 5 4 . 8 ( 1 6 . 2 ) 6 1 .1   ( 1 4 . 1 ) 0 .0 0 1
D M   t y p e :
T y p e   1 5 6 / 1 3 7 ( 4 0 . 9 % ) 1 9 / 1 0 5   ( 1 8 . 1 % )
T y p e   2 8 1 / 1 3 7   ( 5 9 .1 % ) 8 6 / 1 0 5   ( 8 1 . 9 % ) 0 .0 0 0 1
T i m e  s i n c e   d i a g n o s i s   o f  D M
< 1 0   y e a r s 3 5 / 1 0 1 * *   ( 3 4 .7 % ) 5 4 / 1 0 5   ( 5 1 . 4 % )
> 1 0   y e a r s 6 6 / 1 0 1 * *   ( 6 5 .3 % ) 5 1 / 1 0 5   ( 4 8 . 6 % ) 0 . 0 8
C o m p l i c a t i o n s   o f  D M
N e u r o p a t h y 3 7 / 1 3 7   ( 2 7 % ) 1 1 / 1 0 5 ( 1 0 . 5 % )
R e t i n o p a t h y 4 1 / 1 3 7 ( 2 9 . 9 % ) 3 1 / 1 0 5   ( 2 9 . 5 % )
N e p h r o p a t h y 4 / 1 3 7 ( 2 . 9 % ) 2 1 / 1 0 5   ( 2 0 % ) < 0 . 0 0 0 1
D i a b e t i c   c o n t r o l   ( H b A lc)
H b A )c  < 7 . 5 % 5 2 / 1 3 7   ( 3 8 % ) 2 3 / 1 0 5   ( 2 2 % )
H b A ]c > 7 - 5   -  < 8 . 5 % 2 1 / 1 3 7 ( 1 5 . 3 % ) 4 1 / 1 0 5   ( 3 9 % )
H b A i c  > 8 . 5 % 6 4 / 1 3 7   ( 4 6 .7 % ) 4 1 / 1 0 5   ( 3 9 % ) < 0 . 0 0 0 1
D e n t u r e   s t a t u s
D e n t a t e 9 7 / 1 3 7 ( 7 0 . 8 % ) 4 5 / 1 0 5   ( 4 2 . 9 % )
D e n t u r e s 4 0 / 1 3 7 ( 2 9 . 2 % ) 6 0 / 1 0 5   ( 5 7 . 1 % ) < 0 . 0 0 0 1
Statistical analysis was performed using Fisher's exact and Chi square parametric tests 
SDA  = standard deviation
**  For 36 of the London DM patients it was not possible to establish the date w hen their DM was diagnosed
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Yeast isolation and species identification
4.1  Introduction
Candida spp. have frequently been isolated from the oral cavity of patients affected 
by  DM  (Darwazeh  et al,  1990).  Recently,  it  has  been  reported that  up  to  77%  of 
insulin-treated DM patients harbour Candida spp.  in their oral cavities (Willis et al, 
2000b). A number of factors have been associated with the oral carriage of yeast in 
DM patients,  such as the type and duration of disease and the degree of glycaemic 
control  (Hill  et  al,  1989;  Darwazeh  et  al,  1990).  Oral  factors,  such  as  denture 
wearing,  have  been  postulated  to  contribute  to  yeast  colonization  in  DM  patients 
(Dorocka-Bobkowska et al,  1996). Some controversy therefore remains regarding the 
role of DM in yeast colonisation in the oral cavity.
Candida  dubliniensis,  a  newly  described  species  of Candida  mainly  isolated  from 
immunocompromised  patients  (Sullivan  &  Coleman,  1997;  McCullough  et  al, 
1999a), has recently been isolated from a group of insulin-treated patients with DM in 
Ireland  (Willis  et al,  2000b).  Utilizing  simple  molecular  methodologies,  it  is  now 
possible to delineate C.  dubliniensis from C.  albicans. Furthermore, it is possible to 
separate  C.  albicans  genotypically  into  subgroups which  have  been  shown to  vary 
geographically  and  which  may  be  implicated  in  the  development  of  antifungal 
resistance (McCullough et al, 1999b; McCullough et al, 1999a; Manfredi et al, 2002).
Hence,  there  is  a need to  extend  our understanding  of oral  yeasts  in  DM  patients, 
particularly  with  respect  to  species  of  yeasts  present  and  clinical  parameters
131influencing oral yeast colonisation. Furthermore, the advances in relevant molecular 
biological techniques now allow a more detailed analysis of the relationship between 
DM and oral Candida carriage.
Aim: The aim of this study was to isolate, identify and genotype the Candida isolates 
from two groups of patients affected by DM from London, UK and Parma, Italy, and 
from a healthy non-DM population.
Hypothesis:  That  there  are  differences  in  the  frequency  of  isolation,  degree  of 
colonisation,  species or genotypic distribution of oral yeast that can be attributed to 
either presence of DM or patient geographic location.
4.2 Methods
Oral yeasts isolated from DM patients from London (Section 2.1.1), Parma (Section
2.1.2)  and  from  control  non-DM  London  control  subjects  (Section  2.1.3)  were 
analysed  in  this  part of the  study.  Oral  yeasts  were  isolated  using thejnouth  rinse  X.
technique (Section 2.2), enumerated (Section 2.3), defined at species  level  (Section
2.4)  and genotyped (Section 2.5) as outlined previously.
Fisher’s  exact  test  and  Chi  square  test  were  used  for  the  statistical  analysis  of 
categorical  data,  numeric  data  was  analysed  by  the  Student  T  test  or  ANOVA 
according  to  the  postulates  of each  test,  and  differences  within  or between  groups 
were considered significant when the probability (p) was less than or equal to 0.05.
4.3 Results,
4.3.1  Oral yeast isolation and recovery from all patients
132The present study assessed the oral candidal  load of DM and non-DM subjects. As 
reported (Section 3.3.2), the majority of the patients (242/249, 97%) had no clinical 
evidence  of  oral  candidosis.  Saliva  was  collected  from  the  patients  using  the 
concentrated oral rinse technique (Section 2.2) and the yeast load was expressed as 
cfu  per  ml  of mouth  rinse  (Section  2.3).  This  quantitative  evaluation  showed  that 
whilst there  was  a  general  mean  of approximately  100  cfu/ml,  actual  loads  varied 
extensively  between  patients.  An  oral  carriage  rate  of  100  cfu/ml  was  however 
selected an “internal cut-off’ and used as an  indicator of possible  local or systemic 
factors that could have influenced the oral Candida carriage in these populations.
‘ "I
A total of 372 patients were enrolled in this study.  One hundred and thirty of these 
were  non-DM  control  subjects  (Section  2.1.3)  and the  remaining  242  DM patients 
were individuals attending the clinics in London and Parma (Section 2.1.1-2.1.2). Of 
the 372 patients, 225  (60.4%) were found to carry Candida their oral cavity and the 
oral yeast load was <100 cfu/ml in 117/225 (52%) of these patients. One hundred and 
fifty-two of the  242  DM  patients (62.8%) had  Candida  in their oral  cavity.  For 93 
(61.1%) of these patients, the yeast load was <100 cfu/ml (Table 4.1). Two of the 152 
DM patients (both from Parma) who had Candida in their oral cavity, were found to 
have 2 Candida strains resulting in a total of 154 Candida isolates.
Of the  130  non-DM  subjects,  73  (56.2%)  had  oral  yeast.  Of note,  out of these  73 
patients two had 2 Candida strains isolated, resulting in a total of 75 isolates.
The yeast load was <100 cfu/ml in 24 (32.9%) of these non-DM subjects (Table 4.1).
4.3.1.1  Phenotypic and genotypic identification of Candida isolates
4
4.3.1.1.1  Diabetic patients
133Phenotypic methods  identified  127/154  isolates (82.5%) as either C.  albicans or C. 
dubliniensis.  Genotypic methods further distinguished these  127  isolates  into  99  C. 
albicans genotype A,  17 C. albicans genotype B, 5  C.  albicans genotype C and 6 C. 
dubliniensis. The 27 remaining isolates were identified by genotypic methods as non- 
C.  albicans/dubliniensis  species  and  these  comprised  of  12  C.  glabrata,  2  C. 
lusitaniae,  3  C.  tropicalis,  8  C. parapsilosis,  1   C.  krusei  and  1   C.  guilliermondii. 
Candida dubliniensis was  isolated from the oral cavity of 6 out of 152  (3.9%) DM 
patients who harboured oral yeasts. Four of these six patients were female and all had 
some  natural  teeth  (two  patients  were  partially  dentate  whilst the  other three  were 
fully dentate) (Table 4.1).
As reported in Section 4.3.1, two Italian DM patients had two  Candida  stains each 
(154 isolates in total). One of these patients had two different C. albicans genotypes 
(A  and  B),  whilst  the  other  patient  had  one  C.  albicans  genotype  B  and  one  C. 
glabrata.
4.3.1.1.2  Non-DM subjects 
Sixty-five  out  of 75  isolates  from  the  oral  cavities  of the  non-DM  subjects  were 
identified  as  either  C.  albicans  or  C.  dubliniensis  using  phenotypic  and  genotypic 
methods.  Genotyping identified 46  C.  albicans genotype A,  8  C.  albicans genotype 
B,  2  C.  albicans  genotype  C  and  9  C.  dubliniensis  (Table  4.1).  The  10  remaining 
isolates  were  genotypically  identified  as  non-C.  albicans  spp.:  5  C.  glabrata,  1   C. 
lusitaniae, 1   C. guilliermondii and 3 C. krusei (Table 4.1).
Two non-DM  subjects  harboured two  different isolates  in their oral  cavity.  One  of 
these patients had C. glabrata and C. krusei whilst the other patient had C. lusitaniae
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and  C.  krusei  isolated  simultaneously.  Candida  dubliniensis  was  isolated  from  the 
oral cavities of nine of the 75 (12%) control patients who harboured oral yeast. Six of
134these  patients were  male  and  all  had  some  natural  teeth  (eight patients  were  fully 
dentate and one was partially dentate) at the time of the oral examination. None of 
these patients had mixed yeast species in their oral cavity.
4.3.1.2  Factors influencing oral Candida carriage
4.3.1.2.1  Diabetic patients and non-DM subjects
No significant difference was evident in the isolation of Candida from the oral cavity 
of DM patients with either type  1   or type 2 DM (p=0.15) (Table 4.3). Furthermore, 
the frequency of isolation and oral candidal load (cfu/ml) within the DM patients was 
not  influenced  by patient age,  gender,  duration  or glycosylated haemoglobin  levels 
(p>0.05)  (Tables  4.2-4.3).  Statistically  significant  (p=0.001)  (Table  4.3)  was  the 
finding that  DM  patients  affected  by  nephropathy  had  fewer oral  yeasts  than  DM 
patients affected by other long term diabetes complications. However, no difference 
in  the  occurrence  of diabetic  complications  and  oral  candidal  load  was  observed 
(p>0.05).  Furthermore,  significantly  (p=0.0001) more  denture-wearing DM patients 
had oral Candida (Table 4.2) compared with dentate individuals. There was however 
no  significant difference observed  in the actual candidal  load between these patient 
groups.  No  association  (p>0.05)  was  evident  with  either the  frequency  or  load  of 
yeast carriage and patient smoking habits or DM status (Tables 4.2-4.3).
Neither the frequency nor load of Candida carriage was influenced by age, gender, 
smoking habits or presence or absence of dentures (p>0.05) in non-DM subjects.
4.3.1.2.2 All patients
No significant difference was found in the isolation of Candida from the oral cavity 
of all patients investigated and patient gender, age or tobacco habits (p>0.05) (Table
4.2).  Statistically  significant  (p<0.0001)  was  the  finding  that  a  higher  number  of
135denture  wearers  (105/143;  73.4%)  had  oral  Candida  compared  with  non-dentate 
patients (120/229, 52.4%) (Table 4.2).
There was no significant association (p>0.05) between oral candidal load and patient 
gender, age, presence or absence of dentures and tobacco smoking status (Table 4.2).
4.3.1.3  Factors influencing Candida spp. and C. albicans genotype recovery
4.3.1.3.1  Diabetic patients and non-DM subjects
The species of oral yeast present and genotypic distribution of C.  albicans were not 
influenced by patient age, gender, duration or type of DM, glycosylated haemoglobin 
levels or diabetic complications (p>0.05) (Tables 4.4-4.5).
DM patients with dentures, (either partial or full) had more non-C. albicans (23/78, 
29.5%)  isolated  from  their  mouths  than  dentate  patients  (10/76,  13.1%)  (p=0.01) 
(Table 4.4).
There was no significant correlation between the type of Candida isolated and non- 
DM  subjects’  age,  gender,  smoking  habits,  denture  wearing  status  (p>0.05)  (Table
4.2).
4.3.1.3.2 All patients
The  species  of oral  yeast  present  were  not  influenced  by  patient  gender  (p>0.05). 
However, the frequency of non-C. albicans spp. isolation was significantly higher in 
elderly  patients  (>60  years  old)  (30/107,  28%)  compared  with  younger  patients 
(17/109, 15.6%; p=0.03) (Table 4.4).
No significant association was found between the type of yeast species isolated and 
tobacco  habits  in  any  of  the  patients  investigated  (p>0.05).  Furthermore,  no
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significant association was observed in the genotypic distribution of C.  albicans and 
patient gender or age, presence or absence of dentures or tobacco habits (p>0.05).
1364.3.2 Comparison between DM patients and non-DM subjects
4.3.2.1 Oral yeast growth and degree of colonisation (cfu/ml)
A high yeast load (>100 cfu/ml) was significantly (p=0.001) more frequent in non- 
DM  subjects  (49/73,  67.1%)  compared  with  DM  patients  (59/152,  38.8%)  (Table 
4.1). The oral carriage rate was however significantly greater in elderly DM patients 
(>60  years)  (88/152,  57.8%;  p=0.0002)  compared  with  their  non-DM  equivalents 
(10/64,  15.6%). Interestingly, comparison of oral yeast loads in younger patients (<60 
years)  revealed  that  significantly  more  (p=0.03)  of the  non-DM  subjects  (28/45, 
62.2%) had higher Candida loads (>100 cfu/ml) compared with their DM equivalents 
(19/64, 29.6%).
Comparing  all  DM  patients  and  non-DM  subjects,  revealed  that  there  was  no 
statistical differences in oral yeast carriage rate and there was similarly no statistically 
significant  relationship  between  yeast  load  and  patient  gender,  tobacco  habits  or 
denture wearing status (p>0.05).
4.3.2.2 Species of oral yeasts isolated and genotype of C. albicans
There was a significantly higher number (p=0.04) of non-tobacco-using, DM patients 
(28/124, 22.5%) with non-C. albicans spp. isolated compared with their non tobacco- 
using counterparts (11/57, 19.3%).
No differences were observed in the isolation of C. albicans genotypes between DM 
patients  and  non-DM  subjects;  however,  more  C. parapsilosis  strains  (8/33,  24%) 
were  recovered  from  DM  patients  (p=0.02).  In  addition,  a  higher  incidence  (9/19, 
47%) of C.  dubliniensis isolates (p=0.054) was evident in the oral cavity of non-DM 
individuals (Table 4.1).
1374.3.3. Comparison between the two geographically different DM populations
4.3.3.1 Oral yeast growth and degree of colonisation (cfu/ml)
There was no significant difference  in the frequency of oral yeast carriage between 
the  two  geographical  DM  patient  groups  (p>0.05)  (Table  4.5).  However,  a 
significantly  higher number (p=0.01)  of DM  patients  from  London  (40/83,  48.2%) 
had  oral  candidal  loads  >100  cfu/ml  compared  with  Italian  DM  patients  (19/69, 
27.5%) (Table 4.5). Furthermore, oral Candida carriage and yeast load (cfu/ml) were 
not influenced by patient gender or age, presence or absence of dentures or tobacco 
habits (p>0.05).
All  DM  patients with  complications  attributable to poor  long-term  control  of their 
disease  had  a  higher  incidence  of  yeast  carriage  in  their  oral  cavity,  (Parma 
retinopathy:  23/31;  74%;  Parma  nephropathy:  16/21;  76%;  London  neuropathy: 
24/37,  64.8%;  London  retinopathy:  23/41;  56%;  London  nephropathy:  3/4;  75%) 
compared  with  those  DM  patients  without  complications  irrespective  of  their 
geographic  location.  The  exception  to  this  was  for patients  from  Parma  who  also 
suffered  from  neuropathy,  and  in this  group  oral  yeasts  were  only  isolated  from  a 
small number (7/39; 17.9%).
Interestingly, although patients with diabetic complications had higher oral candidal 
carriage rates, these patients (neuropathy:  15/31, 48.3%;  retinopathy:  16/46;  34.7%; 
nephropathy:  8/19; 42.1%) did not have significantly higher candidal  loads (cfu/ml) 
(p=0.25). No other significant differences were observed in oral Candida carriage or 
yeast load and diabetic status between the two groups of DM patients (p>0.05).
4.3.3.2 Species of oral yeasts isolated and genotype of C. albicans
Overall, there was no significant difference in the species of oral yeasts isolated or in 
the genotype of C.  albicans among the DM patient populations (p>0.05).  Similarly,
138species of Candida or genotypic distribution of C.  albicans were not influenced by 
patient  age  or  gender  (p>0.05)  when  the  two  populations  of DM  patients  were 
compared.
Comparison of C.  albicans genotypes and presence or absence of dentures  showed 
that more C. albicans genotype A (44/49; 89.7%) were isolated from the oral cavities 
of London DM patients who were dentate than Parma dentate DM patients (10/17; 
58.8%) (p=0.0087).
Interestingly, none of the tobacco-smoking DM patients from London had C. albicans 
genotype  B  or  C  isolated  from  the  oral  cavity  (p=0.015).  No  other  statistically 
significant differences  were  observed  in the  genotype  of C.  albicans and  smoking 
habits among the DM populations (p>0.05)
Finally, no significant differences were observed in the species of oral yeasts isolated 
and type of DM, duration of disease, haemoglobin glycosylation  level and diabetes 
complications among the two DM populations.
However,  significantly  more (p=0.002)  C.  albicans genotype A were  isolated  from 
the oral cavity of London DM patients affected by type  1   DM (25/28,  89.2%) than 
Parma DM patients with type 1  DM (3/8, 37.5%) (Table 4.6).
4.4  Discussion
It has been hypothesised that DM patients are prone to developing fungal infections 
(Dorocka-Bobkowska et al,  1996; Willis et al,  1999). The present study assessed, in 
detail,  the  oral  colonisation,  species  and  genotype  of  yeast  in  DM  patients  for 
variations that may be influenced by the type, disease progression, degree of control 
of DM  and  geographic  location.  The  results  of this  investigation  for two  different 
groups of DM patients suggest that all these parameters have little or no influence on 
the oral yeast flora of DM patients (Manfredi et al, 2002).
139In this  study,  Candida  spp.  were  firstly  detected  on  SDA plates  (Section  2.2)  and 
subsequently  identified both by phenotypic  (Section 2.4.1) and genotypic  (Sections 
2.4.2-2.4.2.1-2.5)  techniques.  Although  it  is  well  known  that  SDA  rarely  permits 
differentiation  between  Candida  species  within  the  same  sample  and  other culture 
media  are  now  available  for  a  better  discrimination  of Candida  spp.  (Chapter  1, 
Section  1.6.1-1.6.2), the use of SDA was preferred in this study for the lower cost of 
the material compared with chromogenic media (e.g.  CHROMagar). In addition, the 
differentiation  between  Candida  spp.  provided  by  CHROMagar  (such  as 
discriminating  between  C.  albicans  and  C.  dubliniensis)  appears  to  decline  with 
subculture or when isolates are stored. Moreover, the aim of this study was not to use 
the culture medium as an identification method but as a means of rapidly and easily 
assessing the presence of Candida isolates in the oral cavity of the patients studied. 
More  sophisticated  analyses  were  (Sections  2.4.2-2.4.2.1-2.5)  used  to  identify  the 
yeasts grown on the SDA plates.
The  overall  proportion  of DM  patients  who  had  Candida  isolated  from  their  oral 
cavity in the present study (152/242; 62.8%) was similar to that previously reported 
(Fisher  et  al,  1987;  Aly  et  al,  1992).  However,  contrary  to  previously  published 
reports where oral yeast colonisation was higher in patients with type  1   DM (Aly et 
al,  1992;  Bai  et al,  1995),  there  was no  significant difference  in the present study 
between the number of type  1   and 2  DM patients whose oral  cavity was colonised 
with yeast.
Similarly, it has previously been reported that the duration of DM and the degree of 
glycaemic control may influence the frequency and amount of oral Candida carriage 
(Rayfield et al, 1982; Hill et al, 1989; Willis et al,  1999; Guggenheimer et al, 2000b). 
However,  the  present  results  indicate  that  oral  yeast  carriage  is  not  significantly
140influenced by glycaemic control, duration or complications of DM. Nevertheless, the 
results of the present study indicated that the presence of dentures could affect both 
the amount and species of oral yeast present; therefore local oral factors, such as the 
presence of dentures would appear to be more important in terms of candidal carriage 
rates than any systemic aspects relating to DM.
Inconsistencies in reporting oral yeast prevalence in DM have, at least in part, been 
attributed to the variability of sampling methods (Tapper-Jones et al, 1981; Hill et al, 
1989; Aly et al,  1992; Willis et al, 2000b). Comparisons between this study on two 
different  groups  of DM  patients  and  one  study  on  a  healthy  non-DM  population 
allowed us to compare oral yeast colonisation using identical sampling, storage and 
laboratory methodologies.  From this comparison,  it would appear that DM  patients 
are no more likely to harbour yeast in their oral cavity than healthy controls.
Interestingly, the trend observed in the present study that DM patients have a reduced 
candidal load compared to controls, would indicate that the presence of glucose in the 
saliva of DM patients (Darwazeh et al,  1991a; Dodds & Dodds,  1997) may have an 
inhibitory effect on yeast colonisation. Further studies are required to assess the level 
of salivary  glucose  present  in  these  patients  when  simultaneously  analysing  yeast 
colonisation.
Combining  the  results  for  DM  and  control  patients  revealed  that  48%  of patients 
(108/225) without clinical oral candidosis had over  100 cfu/ml of yeast in their oral 
rinses. Interestingly, as reported by other authors (White et al, 2004), Candida levels 
as high as 3000 cfu/ml were evident in some patients with no signs of oral candidosis, 
while  the  patients  affected  by  oral  candidosis  occasionally  showed  lower candidal 
cfu/ml than those observed of non-infected patients.
141Correlation  between the  quantification  of Candida  in  saliva and  clinical  status has 
long  been  debated  in  literature.  Several  studies  (Samaranayake  et  al,  1986; 
MacFarlane,  1990) have proposed that the presence of elevated candidal numbers (2- 
3 x  103  cfu/ml) in saliva indicates  infection rather than normal commensal carriage 
(600-800 cfu/ml) (McKendrick et al,  1967). However, other studies (Borromeo et al, 
1992;  Al  Karaawi  et  al,  2002;  White  et  al,  2004)  have  shown  that  simple 
quantification of Candida in saliva does not give any indication of health or disease. 
Although the determination of a cut-off limit for cfu between health and disease may 
serve as a useful  clinical  indicator, the results from this  study,  and  from  literature, 
show  that  quantitative  oral  yeast  levels  are  not  useful  in  determining  the  clinical 
status of the patient.
As reported in Chapter 3 (Section 3.3.1), during the course of this study, only 7/242 
DM patients (2.8%) had clinical evidence of oral candidosis. This low incidence rate 
contradicts previous  reports  (Dorocka-Bobkowska et al,  1996;  Abu-Elteen  &  Abu- 
Alteen,  1998;  Guggenheimer  et  al,  2000b;  Willis  et  al,  2000b)  and  cannot  be 
explained simply by clinical awareness or diabetic control.
Candida dubliniensis, first isolated from HIV infected patients (Sullivan et al,  1995), 
has recently been recovered from the oral cavity of 58 out of 318  (18.2%) Candida 
positive, insulin-treated DM patients (Willis et al, 2000b). The prevalence reported in 
the present study (6/154 DM patients; 3.9%) is much lower. This may be due, at least 
in part, to the different culture methods used, as the present study assessed only the 
most prevalent species of yeast present in the oral cavity. A high percentage (14.1%, 
45/318) of the previously  described  isolation of C.  dubliniensis occurred when this 
yeast was found co-colonising the oral cavity with C. albicans or with other Candida 
spp. Whether this co-colonisation has any influence on clinical outcome has yet to be 
determined.  If co-colonisation  of C.  dubliniensis  with  C.  albicans  in  the  previous
142study (Willis et al, 2000b) is excluded, then only 4.1% of patients would be colonised 
solely  with  C.  dubliniensis,  which  is  similar  to  the  findings  in  the  present  study 
(3.9%). Furthermore, 12% (9/75) of isolates from control patients in the present study
were  identified  as  C.  dubliniensis,  statistically  j  (p=0.04)  than  DM  patients
(6/154)  in  the  present  investigation.  Interestingly,  all  DM  patients  and  the  control 
population  investigated  in the  present  study  that  had  C.  dubliniensis  isolated  from 
their oral cavity were dentate (either fully or partially).
Global geographic variability in the genotypes of oral isolates of C. albicans has been 
observed (Clemons et al,  1997; McCullough et al,  1999b). The present study has not, 
however, found any association between a particular genotype of C. albicans and the 
DM type, disease progression and degree of DM control.  It would be interesting to 
assess a larger portion of the genomes of these isolates to confirm this lack of genetic 
variability  and  to  assess  oral  yeast  isolates  from  a  second  group  (geographically 
distant from London, UK) of control subjects. Nevertheless, the results of the present 
study  suggests  that there  is  nothing  unique  in  the  oral  yeast  flora  of DM  patients 
(Manfredi et al, 2002).
143Table  4.1:  Oral  Candida  growth  and  species  isolated  from  patients  with  and
without DIM
Candida  isolates DM  patients Non-DM subjects p value Patients total
Growth 1 5 2 / 2 4 2   ( 6 2 . 8 % ) 7 3 / 1 3 0   ( 5 6 . 2 % ) 2 2 5 / 3 7 2  ( 6 0 .5 % )
No growth 9 0 / 2 4 2   ( 3 7 . 2 % ) 5 7 / 1 3 0   ( 4 3 . 8 % ) 0 .2 2 1 4 7 / 3 7 2   ( 3 9 .5 % )
<100 cfu/ml 9 3 / 1 5 2  ( 6 1 . 2 % ) 2 4 / 7 3   ( 3 2 . 9 % ) 1 1 7 / 2 2 5   ( 5 2 % )
>100 cfu/ml 5 9 / 1 5 2   ( 3 8 . 8 % ) 4 9 / 7 3   ( 6 7 . 1 % ) 0.001 1 0 8 / 2 2 5 ( 4 8 % )   '
C. albicans  total 1 2 1 / 1 5 4 * ( 7 8 . 6 % ) 5 6 / 7 5 * * ( 7 4 . 7 % ) 1 7 7 / 2 2 9 ( 7 7 . 3 % )
Other species total 3 3 / 1 5 4 ^ ( 2 1 . 4 % ) 1 9 / 7 5 * * ( 2 5 . 3 % ) 0 .5 0 5 2 / 2 2 9   ( 2 2 . 7 % )
C. albicans  A 9 9 / 1 2 1   ( 8 1 . 8 % ) 4 6 / 5 6  ( 8 2 . 1 % ) 1 4 5 / 1 7 7   ( 8 1 . 9 % )
C. albicans  B 1 7 /1 2 1   ( 1 4 % ) 8 / 5 6   ( 1 4 . 3 % ) 2 5 / 1 7 7 ( 1 4 . 2 % )
C. albicans C 5 /1 2 1   ( 4 .2 % ) 2 / 5 6  ( 3 .6 % ) 0 .9 8 7 / 1 7 7   ( 3 .9 % )
C. glabrata 1 2 /3 3   ( 3 6 . 4 % ) 5 / 1 9 ( 2 6 . 3 % ) 0 .5 4 1 7 / 5 2   ( 3 2 . 7 % )
C. lusitaniae 2 / 3 3   ( 6 .1 % ) 1 /1 9   ( 5 .3 % ) 1 .0 0 3 / 5 2   ( 5 .8 % )
C. tropicalis 3 / 3 3   ( 9 .1 % ) 0 / 1 9 ( 0 % ) 0 . 2 9 3 / 5 2   ( 5 .8 % )
C. parapsilosis 8 / 3 3   ( 2 4 . 2 % ) 0 / 1 9 ( 0 % ) 0.02 8 / 5 2   ( 1 5 . 4 % )
C. krusei 1 /3 3   ( 3 % ) 3 / 1 9 ( 1 5 . 8 % ) 0 .1 3 4 / 5 2   ( 7 .7 % )
C. guilliermondii 1 /3 3   ( 3 % ) 1 / 1 9 ( 5 . 3 % ) 1.0 0 2 / 5 2   ( 3 .8 % )
C. dubliniensis 6 / 3 3   ( 1 8 . 2 % ) 9 / 1 9  ( 4 7 . 3 % ) 0 . 0 5 4 1 5 / 5 2   ( 2 8 . 8 % )
Statistical analysis was performed using Fisher's exact and Chi-Square parametric tests
* One hundred and fifty-two DM patients from  Parma yielded a single Candida strain; 2 additional patients each 
yielded two strains (154 isolates in total)
**  Seventy-one  non-DM  control  patients  yielded  a  single  Candida  strain;  2  additional  control  patients  each 
yielded 2 strains (75 isolates in total)Table  4.2:  Oral  Candida  isolation  and  load  (cfu/ml)  in  the  different  groups  of 
patients evaluated
Patients Growth
No
growth
p value
<100
cfu/ml
>100
cfu/ml
p value
D/Male 7 8 / 1 2 5 4 7 / 1 2 5 4 8 / 7 8 3 0 / 7 8
D/Female 7 4 / 1 1 7 4 3   1  1 7 0 . 8 9 4 5 / 7 4 2 9 / 7 4 1 .0 0
D/<60 years old 6 4 / 1 1 3 4 9 / 1 1 3 4 5 / 6 4 1 9 /6 4
D/>60 years old 8 8 / 1 2 9 4 1 / 1 2 9 0 . 0 8 4 8 / 8 8 4 0 / 8 8 0 .0 6
D/dentate 7 5 / 1 4 2 6 7 / 1 4 2 4 9 / 7 5 2 6 / 7 5
D/dentures 7 7 / 1 0 0 2 3 / 1 0 0 0.0001 4 4 / 7 7 3 3 / 7 7 0 .3 2
D/tobacco users 2 8 / 3 9 1 1 / 3 9 1 5 /2 8 1 3 /2 8
D/non-tobacco
users
1 2 4 / 2 0 3 7 9 / 2 0 3
0 .2 7
7 8 / 1 2 4 4 6 / 1 2 4 0 . 3 9
C/ Male 3 6 / 6 3 2 7 / 6 3 1 0 /3 6 2 6 / 3 6
C/ Female 3 7 / 6 7 3 0 / 6 7 0 .8 6 1 4 /3 7 2 3 / 3 7 0 .4 5
C/ <60 years old** 4 5 / 8 4 3 9 / 8 4 1 7 /4 5 2 8 / 4 5
C/ >60 years old** 1 8 /3 4 1 6 /3 4 1 .0 0 6 / 1 8 1 2 /1 8 0 . 7 7
C  / dentate 4 5 / 8 7 4 2 / 8 7 1 7 /4 5 2 8 / 4 5
C/ dentures 2 8 / 4 3 1 5 /4 3 0 .1 8 7 /2 8 2 1 / 2 8 0 .3 1
C/ tobacco users 1 7 /2 7 1 0 /2 7 6 / 1 7 1 1 /1 7
C/ non-tobacco 
users
5 6 / 1 0 3 4 7 / 1 0 3 0 .5 1 1 8 /5 6 3 8 / 5 6 1 .0 0
Male total 1 1 4 / 1 8 8 7 4 / 1 8 8 5 8 / 1 1 4 5 6 / 1 1 4
Female total 1 1 1 / 1 8 4 7 3 / 1 8 4 1 .0 0 5 9 /1 1 1 5 2 /1   11 0 . 7 9
<60 years old total 1 0 9 / 1 9 7 8 8 / 1 9 7 6 2 / 1 0 9 4 7 / 1 0 9
>60 years old total 1 0 6 / 1 6 3 5 7 / 1 6 3 0 .0 6 5 4 / 1 0 6 5 2 / 1 0 6 0 .4 1
Dentate total 1 2 0 / 2 2 9 1 0 9 / 2 2 9 6 6 /1 2 0 5 4 / 1 2 0
Dentures total 1 0 5 / 1 4 3 3 8 / 1 4 3 <0.0001 5 1 / 1 0 5 5 4 / 1 0 5 0 .3 5
Tobacco users total 4 5 / 6 6 2 1 /6 6 2 1 / 4 5 2 4 / 4 5
Non-tobacco users 
total
1 8 0 / 3 0 6 1 2 6 / 3 0 6 0 .1 6 9 6 / 1 8 0 8 4 / 1 8 0 0 .5 0
Data was subdivided according to patient age, gender, presence or absence of denture and smoking habits 
Statistical analysis was performed using Fisher’s exact and Chi square parametric tests 
D: DM patients: C: Non-DM control patients
** Of the twelve patients who did not give their date of birth (special needs patients), 10 harboured oral yeasts
145Table 4.3:  Oral Candida isolation and load (cfu/ml) in patients with  DM
DIM  patients Growth No growth p value
<100
cfu/ml
>100
cfu/ml
p value
D/Type  1   DM 4 2 / 7 5 3 3 / 7 5 2 7 / 4 2 1 5 /4 2
D/Type 2 DM 1 1 0 / 1 6 7 5 7 / 1 6 7 0 .1 5 6 6 /1 1 0 4 4 / 1 1 0 0 .7 1
D/DM <10 years* 5 5 / 8 9 3 4 / 8 9 3 6 / 5 5 1 9 /5 5
D/DM >10 years* 7 5 / 1 1 7 4 2 / 1 1 7 0 . 7 7 4 6 / 7 5 2 9 / 7 5 0 .7 1
D/neuropathy 3 1 / 7 6 4 5 / 7 6 1 6 /3 1 1 5 /3 1
D/retinopathy 4 6 / 7 2 2 6 / 7 2 3 0 / 4 6 1 6 / 4 6
D/nephropathv 1 9 /2 5 6 / 2 5 0.001 1 1 /1 9 8 / 1 9 0 .4 8
D/HbAic <7.5% 4 6 / 7 5 2 9 / 7 5 3 0 / 4 6 1 6 / 4 6
D/HbAic >7.5%; <8.5% 4 0 / 6 2 2 2 / 6 2 2 7 / 4 0 1 3 / 4 0
D/HbAIC  >8.5% 6 6 / 1 0 5 3 9 / 1 0 5 0 .9 2 3 6 / 6 6 3 0 / 6 6 0 . 3 4
D/L Type  1   DM 3 3 / 5 6 2 3 / 5 6 2 0 / 3 3 1 3 /3 3
D/L Type 2 DM 5 0 /8 1 3 1 / 8 1 0 .8 5 2 3 / 5 0 2 7 / 5 0 0 . 1 6   !
D/L DM <10 years* 2 2 / 3 5 1 3 /3 5 1 0 /2 2 1 2 /2 2
D/L DM >10 years* 3 9 / 6 6 2 7 / 6 6 1 .0 0 2 2 / 3 9 1 7 / 3 9 0 .4 3
D/L neuropathy 2 4 / 3 7 1 3 / 3 7 1 2 /2 4 1 2 / 2 4
D/L retinopathy 2 3 / 4 1 1 8 /4 1 1 3 /2 3 1 0 /2 3
D/L nephropathy 3 / 4 1 /4 0 .6 1 1 /3 2 / 3 0 . 7 2
D/L HbAic <7.5% 3 4 / 5 2 1 8 /5 2 2 0 / 3 4 1 4 / 3 4
D/L HbAic >7.5%; <8.5% 1 1 /2 1 10/21 6 /1 1 5 /1 1
D/L HbAlc >8.5% 3 8 / 6 4 2 6 / 6 4 0 . 5 6 1 7 /3 8 2 1 / 3 8 0 . 4 8
D/PR Type  1   DM 9 / 1 9 1 0 /1 9 7 / 9 2 / 9
D/PR Type 2 DM 6 0 / 8 6 2 6 / 8 6 0 .1 0 4 3 / 6 0 1 7 / 6 0 1 .0 0
D/PR DM <10 years 3 3 / 5 4 2 1 / 5 4 2 6 / 3 3 7 /3 3
D/PR DM >10 years 3 6 /5 1 1 5 /5 1 0 .4 1 2 4 / 3 6 1 2 / 3 6 0 . 1 9
D/PR neuropathy 7 / 3 9 3 2 / 3 9 4 / 7 3 / 7
D/PR retinopathy 2 3 / 3 1 8 /3 1 1 7 /2 3 6 / 2 3
D/PR nephropathy 1 6 /2 1 5 /2 1 <0.0001 1 0 / 1 6 6 / 1 6 0 . 6 2
D/PR H bAlc <7.5% 1 2 /2 3 1 1 /2 3 1 0 /1 2 2 /1 2
D/PR H bAlc >7.5%;<8.5% 2 9 / 4 1 1 2   4 1 2 1 / 2 9 8 / 2 9
D/PR HbAlc >8.5% 2 8 / 4 1 1 3 /4 1 0 . 2 9 1 9 / 2 8 9 / 2 8 0 . 6 0
D a ta   w a s   s u b d iv id e d   a c c o r d in g   to   p a tie n t  ty p e   a n d   d u r a tio n   o f   D M ,  lo n g -te r m   d ia b e tic   c o m p lic a tio n s   a n d  
g ly c a e m ic  c o n tr o l ( H b A ic)
S ta tistica l a n a ly s is w a s  p e r fo r m e d  u s in g  F is h e r ’s e x a c t a n d  C h i  sq u a r e  p a r a m e tr ic  tests
D :  T o ta l  D M   p a tien ts; D /L :  D M  p a tie n ts fr o m   L o n d o n ,  U K ;  D /P R :  D M  p a tie n ts fr o m   P a r m a .  Italy
*  F o r   3 6   D M   p a tie n ts  fr o m   L o n d o n   it  w a s   n o t  p o s s ib le   to   e sta b lish   th e   d u r a tio n   o f  th eir  d is e a s e .  O f  th e se ,  2 2
h a r b o u r e d  oral  y e a s ts
146Table 4.4:  Candida spp.  and  genotypic  distribution  of C.  albicans  isolates  in  all 
the carriers
Patients C. albicans A B C Other species
D/Male 61/78 50 9 2
*
*
O
O
D/Female 60/74 49 7 4 15**
D/ <60 years old 56/64 46 8 2 10**
D/ >60 years old 65/88 53 9 3 23**
D/dentate 66/75 54 11 1 10**  !
D/dentures 55/77 45 6 4 23**
D/tobacco users 25/28 19 5 1 5**
D/non-tobacco users 96/124 80 12 4 28**
C/Male 26/36 21 4 1 n ***
C/Female 30/37 25 4 1 8***
C/ <60 years old* 38/45 34 3 1 7***
C/ >60 years old* 12/19 9 3 0 7***
C/dentate 35/45 29 5 1 11***
C/dentures 21/28 17 3 1 8***
C/tobacco users 10/17 6 3 1 8***
C/non-tobacco users 46 56 40 5 1 11***
Male total 87/114 71 13 3 29
Female total 90/111 74 11 5 23
<60 years old total 94/109 80 11 3 17
>60 years old total 77/107 62 12 3 30
Dentate total 101/120 83 16 2 21
Dentures total 76/105 62 9 5 31
Tobacco users total 35/45 25 8 2 13
Non-tobacco users total 142/180 120 17 5 39
D a ta  w a s  s u b d iv id e d  a c c o r d in g  to  p a tie n t g e n d e r , a g e .  d e n tu r e  sta tu s a n d  s m o k in g  h a b its 
D :  D M  p a tien ts: C : c o n tr o l n o n - D M   su b je c ts
*  O f  th e  tw e lv e   p a tie n ts w h o   d id   n o t g iv e  th eir d a te  o f  b irth   (s p e c ia l  n e e d s  p a tien ts),  1 0  h a r b o u r e d  o ra l y e a sts.  O f  
th e se  ten ,  9  y ie ld e d  o n e  Candida stra in  e a c h  a n d  o n e  a d d itio n a l  n o n - D M   su b je c t y ie ld e d  t w o  Candida stra in s 
**  O n e  h u n d r e d  a n d  fifty -tw o  D M   p a tie n ts  fr o m   P a r m a  y ie ld e d  a  s in g le   Candida  strain :  2   a d d itio n a l p a tie n ts e a c h  
y ie ld e d  tw o  stra in s ( 1 5 4  is o la te s in  to ta l)
* * *   S e v e n ty -o n e   n o n - D M   c o n tr o l  p a tie n ts  y ie ld e d   a   s in g le   Candida  strain ;  2   a d d itio n a l  c o n tr o l  p a tie n ts  e a c h  
y ie ld e d  2  stra in s (7 5   iso la te s in  to ta l)
147Table  4.5:  Oral  Candida  growth  and  species  isolated  from  the  two  groups  of
patients with  DM
Candida  isolates Parma  DM  patients DM  London patients p value
Growth 6 9 / 1 0 5   ( 6 5 .7 % ) 8 3 / 1 3 7   ( 6 0 .6 % )
No growth 3 6 / 1 0 5   ( 3 4 .2 % ) 5 4 / 1 3 7  ( 3 9 .4 % ) 0 .4 2
<100 cfu/ml 5 0 / 6 9   ( 7 2 .5 % ) 4 3 / 8 3   ( 5 1 .8 % )
>100 cfu/ml 1 9 / 6 9   ( 2 7 .5 % ) 4 0 / 8 3   ( 4 8 .2 % ) 0.01
C. albicans  total 5 2 / 7 1 *   ( 7 3 .2 % ) 6 9 / 8 3   ( 8 3 .1 % )
Other species total 1 9 /7 1 *   ( 2 6 .8 % ) 1 4 / 8 3 ( 1 6 . 9 % ) 0 . 1 6
C. albicans  A 4 0 / 5 2   ( 7 6 .9 % ) 5 9 / 6 9  ( 8 5 .5 % )
C. albicans  B 1 0 / 5 2   ( 1 9 . 2 % ) 7 / 6 9 ( 1 0 . 1 % )
C. albicans C 2 / 5 2   ( 3 .9 % ) 3 / 6 9  ( 4 .4 % ) 0 . 4 7
C. glabrata 7 / 1 9  ( 3 6 . 9 % ) 5 / 1 4   ( 3 5 .8 % ) 1 .0 0
C. lu situ n ine 2 / 1 9 ( 1 0 . 5 % ) 0 / 1 4   ( 0 % ) 0 . 4 9
C. tropicalis 2 / 1 9 ( 1 0 . 5 % ) 1 /1 4   ( 7 .1 % ) 1 .0 0
C. parapsilosis 7 / 1 9  ( 3 6 .9 % ) 1 / 1 4 ( 7 . 1 % ) 0 . 0 9
C. krusei 0 / 1 9  ( 0% ) 1 / 1 4 ( 7 . 1 % ) 0 . 4 2
C. guilliermondii 0 / 1 9  ( 0% ) 1 / 1 4 ( 7 . 1 % ) 0 . 4 2
C. dubliniensis 1 / 1 9 ( 5 . 2 % ) 5 / 1 4  ( 3 5 .8 % ) 0 . 0 7
Statistical analysis was performed using Fisher's exact and Chi square parametric testsTable  4.6:  Candida  spp.  and  genotypic  distribution  of  C.  albicans  isolates  in
patients with DM
DM  patients C. albicans A B C Other species
D/Type 1  DM 3 6 / 4 2 2 8 7 1 6 * *
D/Type 2 DM 8 5 / 1 1 0 7 1 10 4 2 7 * *
D/DM <10 years* 4 5 / 5 5 3 8 3 4 12**
D/DM >10 years* 6 0 / 7 5 4 8 11 1 1 5 * *
D/neuropathy 2 5 / 3 1 21 4 0 6 * *
D/retinopathy 3 2 / 4 6 2 4 7 1 14**
D/nephropathy 1 5 /1 9 12 3 0 5 * *
D/HbAlc <7.5% 3 7 / 4 6 3 0 5 2 1 0* *
D/HbAic >7.5%; <8.5% 3 1 / 4 0 2 4 7 0 1 0* *
D/HbAic >8.5% 5 3 / 6 6 4 5 5 3 1 3 * *
D/L Type 1  DM 2 8 / 3 3 2 5 3 0 5
D/L Type 2 DM 4 1 / 5 0 3 4 4 3 9
D/L DM <10 years* 1 9 /2 2 1 6 0 3 3
D/L DM >10 years* 3 4 / 3 9 3 0 4 0 5
D/L neuropathy 2 0 / 2 4 1 8 2 0 4
D/L retinopathy 1 8 /2 3 1 6 2 0 5
D/L nephropathy 2 /3 2 0 0 1
D/L HbAlc <7.5% 2 7 / 3 4 21 4 2 7
D/L HbAic >7.5%; <8.5% 10 /1 1 9 1 0 1
D/L HbAlc >8.5% 3 2 / 3 8 2 9 2 1 6
D/PR Type  1   DM 8 /9 3 4 1 1* *
D/PR Type 2 DM 4 4 / 6 0 3 7 6 1 1 8 * *
D/PR DM <10 years 2 6 / 3 3 2 2 3 1 9 * *
D/PR DM >10 years 2 6 / 3 6 1 8 7 1 1 0* *
D/PR neuropathy 5 / 7 3 2 0 2 * *
D/PR retinopathy 1 4 /2 3 8 5 1 9 * *
D/PR nephropathy 1 3 /1 6 10 3 0
D/PR H bAlc <7.5% 1 0 /1 2 9 1 0 3 * *
D/PR HbAlc >7.5%; <8.5% 2 1 / 2 9 1 5 6 0 9 * *
D/PR HbAlc >8.5% 2 1 / 2 8 1 6 3 2 7 * *
D a ta   w a s   s u b d iv id e d   a c c o r d in g   to   p a tie n t  ty p e   a n d   d u r a tio n   o f   D M .  lo n g -te r m   d ia b e tic   c o m p lic a tio n s   a n d  
g ly c a e m ic  c o n tr o l  ( H b A l c)
D : T o ta l  D M  p a tien ts;  D /L :  D M  p a tie n ts fr o m   L o n d o n ,  U K ;   D /P R :  D M  p a tie n ts fr o m   P a rm a ,  Italy 
*  F o r 3 6   o f  D M   p a tie n ts  fr o m   L o n d o n   it  w a s   n o t  p o s s ib le  to   e sta b lish   th e   d u ra tio n   o f  th eir d ise a se .  O f  th e s e  2 2 ,
h a r b o u r e d  oral y e a s ts
* *   O f   th e   1 5 2   D M   p a tie n ts  w h o   h a r b o u r e d   oral  y e a sts,  6 9   fr o m   P a r m a   y ie ld e d   a   s in g le   Candida  strain; 2
a d d itio n a l  D M  p a tie n ts fr o m   P a r m a  e a c h  y ie ld e d  tw o  stra in s (1 5 4  iso la te s in to ta l)
149Table 4.7: Oral Candida isolation and load (cfu/ml) in the two different groups of 
patients with DM
Patients Growth No growth p value
<100
cfu/ml
>100
cfu/ml
p value
D/L Male 4 3 / 7 0 2 7 / 7 0 2 2 / 4 3 2 1 / 4 3
D/L Female 4 0 / 6 7 2 7 / 6 7 0 .8 6 2 1 / 4 0 1 9 / 4 0 1.0 0
D/L <60 years old 4 4 / 7 8 3 4 / 7 8 2 7 / 4 4 1 7 / 4 4
D/L >60 years old 3 9 / 5 9 2 0 / 5 9 0 . 2 9 1 6 /3 9 2 3 / 3 9 0 .0 8
D/L dentate 5 4 / 9 7 4 3 / 9 7 3 3 / 5 4 2 1 / 5 4
D/L dentures 2 9 / 4 0 1 1 / 4 0 0 .0 8 1 0 /2 9 1 9 / 2 9 0.02
D/L tobacco users 1 3 / 1 9 6 / 1 9 5 /1 3 8 / 1 3
D/L non-tobacco users 7 0 / 1 1 8 4 8 / 1 1 8 0 .6 1 3 8 / 7 0 3 2 / 7 0 0 .3 7
D/PR Male 3 5 / 5 5 2 0 / 5 5 2 6 / 3 5 9 / 3 5
D/PR Female 3 4 / 5 0 1 6 / 5 0 0 .6 8 2 4 / 3 4 1 0 /3 4 0 .7 9
D/PR <60 years old 2 0 / 3 5 1 5 /3 5 1 8 /2 0 2 / 2 0
D/PR >60 years old 4 9 / 7 0 2 1 / 7 0 0 .1 9 3 2 / 4 9 1 7 / 4 9 0.04
D/PR dentate 2 1 / 4 5 2 4 / 4 5 1 6 /2 1 5 /2 1
D/PR dentures 4 8 / 6 0 1 2 /6 0 0.0008 3 4 / 4 8 1 4 /4 8 0 . 7 7
D/PR tobacco users 1 5 / 2 0 5 / 2 0 1 0 /1 5 5 / 1 5
D/PR non tobacco users 5 4 / 8 5 3 1 / 8 5 0 .4 3 4 0 / 5 4 1 4 /5 4 0 .7 4
Data was subdivided according to patient gender, age, denture status and smoking habits 
Statistical analysis was performed using Fisher's exact and Chi square parametric tests 
D/L: DM patients from London, UK; D/PR: DM patients from Parma, Italy
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Figure 4.1:  Example  of electrophoretic  separation  of PCR  products  of the INT 
region of Candida isolates from patients with and without DM
M: marker; AA: C. albicans A; AB: C. albicans B; AC: C. albicans C; Dub: C. dubliniensis
151M  Gu  Lu  Ps  Pa  Tr  Kr  Gl  AB  AA  AC  Du
Figure 4.2: Dde I undigested and digested PCR products of the ITS region
Dde  I  undigested  products  (upper)  and  digested  products  (lower).  M:  Marker;  Gu:  C.  guilliermondii',  Lu:  C. 
lusitaniae;  Ps:  C.  kefyr  (once  C. pseudotropicalis);  Pa:  C. parapsilosis;  Tr:  C.  tropicalis:  Kr:  C.  krusei;  Gl:  C. 
glabrata\  AB: C. albicans  B: AA: C. albicans A; AC: C. albicans C; Du: C. dubliniensis
152M  Gu  Lu  Ps  Pa  Tr  Kr  Gl  AB  AA  AC  Du
Figure 4.3: Hae III  undigested and digested  PCR products of the V3 25S rDNA 
region
Hae  III  undigested  (upper)  and  digested  (lower)  PCR  products.  M:  Marker:  Gu:  C.  guilliermondii:  Lu:  C. 
lusitaniae:  Ps:  C.  kefyr  (previously  termed  C.  pseudotropicalis)’ ,  Pa:  C.  parapsilosis;  Tr:  C.  tropicalis;  Kr:  C. 
krusei: Gl: C. glabrata: AB: C. albicans B: AA: C. albicans A: AC: C. albicans C: Du; C. dubliniensis
153CHAPTER 5 
Virulence attributes of oral yeasts
5.1  Introduction
Candida  species,  like  all  pathogenic  microorganisms,  have  developed  specific 
virulence mechanisms that confer the ability to colonize host surfaces, invade deeper 
host tissue or evade host defences (Hube & Naglik, 2002).
Adherence to host tissue is the first step in the pathogenic process: once initial contact 
between  host  tissues  and  Candida  has  occurred,  enzymes  facilitate  adherence  by 
damaging  or  degrading  cell  membranes  and  extracellular  proteins  (Cotter  & 
Kavanagh, 2000). The adherence mechanisms of Candida species to many cell types 
or  surfaces  are  complex  and  still  not  elucidated.  Adherence  is  achieved  by  a 
combination  of specific  (ligand-receptor interactions)  and  non-specific  mechanisms 
(electrostatic  forces,  aggregation,  and  cell-surface  hydrophobicity)  (Cotter  & 
Kavanagh, 2000).
Specific adherence is mediated by a number of target proteins located in the epithelial 
cell surface or in the subepithelial extracellular matrix (ECM). Of these, fibronectins 
are  adhesive glycoproteins with  a high  molecular weight involved  in cell  adhesion 
and cell migration, and located in the ECM interstitium (Castellani et al, 1986; Cotter 
&  Kavanagh,  2000).  Other  microorganisms  apart  from  Candida,  such  as 
Staphylococcus aureus and Streptococcus pyogenes, have also been shown to adhere
$ r  y   '  .  1 
to ECM protein‘ fibroftfectins in vitro (Skerl et al, 1984).
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Furthermore,  molecules  (transmembrane  integrins)  present  on  the  surface  of  C. 
albicans  are  thought  to  mediate  adherence  to  ECM  molecules  (Hostetter,  1994). 
These “adhesins” function by recognising ligands that contain amino-acid sequences
154such  as  the  Arg-Gly-Asp  (RGD)  sequence  (Varner  &  Cheresh,  1996).  Candida 
albicans binds RGD-containing proteins, such as fibronectins,  laminin and collagen 
types I and IV, through integrin-related structures (Klotz et al, 1994).
The complex pathogenesis of Candida species is aided by the production of a range 
of extracellular enzymes that facilitate adherence and/or tissue penetration. The three 
most significant hydrolytic enzymes produced by Candida species, and most notably 
by  C.  albicans, are  secreted  aspartic proteinases (Saps),  phospholipases and  lipases 
(Hube & Naglik, 2002).
Many Candida species, including C. albicans, C. dubliniensis (Gilfillan et al,  1998), 
C.  tropicalis  (Togni  et  al,  1991;  Monod  et  al,  1994;  Zaugg  et  al,  2001)  and  C. 
parapsilosis (de Viragh et al,  1993;  Monod et al,  1994) are known to possess SAP 
genes and produce active extracellular proteinases in vitro. However, less pathogenic 
or non-pathogenic Candida species do not produce significant levels of proteinases, 
and this has led to the hypothesis that fungal pathogenicity  is directly  linked to the 
extent of Sap production.
Studies show that the targets of the proteolytic attack of Saps, in vitro and in vivo, are 
very  different.  Extracellular  matrix  and  host  surface  proteins,  such  as  laminin, 
fibronectin, and mucin are efficiently degraded by  Saps,  in particular by  Sap 2, the 
most  active  Sap  in  vitro,  aiding  yeast-cell  adhesion  to  buccal  epithelial  cells. 
Research has shown that Sap 2  also hydrolyses  secretory IgA, normally resistant to 
most bacterial proteinases (Naglik et al, 2003).  Sap 2 activity  is optimal at low pH 
(2.5-5.5) (Naglik et al, 2003; Naglik et al, 2004), but it is also stable at neutral pH 
and  is active under these  conditions (Capobianco et al,  1992;  Wagner et al,  1995). 
Sap 4  and  Sap6  are  extremely  active  at physiological  pH  (Hube  & Naglik,  2002). 
This stability of Saps at different pH ranges (2.0-7.0) may assist Candida species, in
155particular C.  albicans, to colonize and/or infect hosts  in a neutral pH environment,
such as the oral cavity.
Different classes of phospholipases are known and classified according to their mode
of  action  (Hube  &  Naglik,  2002).  In  C.  albicans,  phospholipases  A,  B,  C  and 
lysophospholipases may damage host-cell membranes and facilitate tissue  invasion. 
Recently, it has also been shown that non-C. albicans species secrete phospholipases 
at  lower  levels  (Ghannoum,  2000)  compared  with  C.  albicans.  Furthermore,  a 
correlation  between  phospholipase  activity  in  vitro  and  virulence  has  also  been 
demonstrated (Ghannoum, 2000; Hube & Naglik, 2002).
There are  few  studies which have  investigated the expression of both the  adhesion 
and extracellular proteinase production by oral  Candida isolates from patients with 
DM.  As  reported  in  Chapter  1   (Section  1.8),  DM  is  a  common  disease  found 
worldwide and it has been previously suggested that oral candidal infections may be 
more frequent or severe in patients with DM (Aly et al, 1992; Dorocka-Bobkowska et 
al,  1996; Willis et al,  1999). However, it has been recently reported that only a small 
number of patients affected by DM develop oral candidosis (Section  1.8.9.1.1-3.3.1) 
(Manfredi  et  al,  2002).  Systemic  (e.g.  the  degree  of glycaemic  control)  or  local 
factors  presence of dentures) may  influence the balance between the host and 
yeasts,  and  favour  the  transformation  of  Candida  isolates  from  commensal  to 
pathogenic microorganisms.  It would be interesting to  investigate whether there are
virule  attributes,  such  as adhesion  or  proteinase  expression,  whose  activity  is
enhanced for isolates from DM patients.
Aim:  The  aim  of this  study  was  to  evaluate  the  in  vitro  extracellular  proteinase 
production  and  the  ability  of Candida  isolates  to  adhere  in  vitro to  fibronectin.  Acomparison of these traits was made for isolates from two  geographically different 
groups of DM patients and from a healthy control group of non-DM subjects.
Hypothesis: That there are differences in the ability of Candida recovered from the 
oral  cavities  of  DM  and  non  DM  patients  to  adhere  to  fibronectin  or  produce 
extracellular proteinase.
5.2  Methods
Oral  yeasts  isolated  from  each  group  of  patients  were  evaluated  using  specific 
adhesion (Section 2.6) and proteinase (Section 2.7) assays. Adhesion was assessed by 
quantifying the  attachment  of Candida  to  paramagnetic  beads  (Dynabeads,  Dynal) 
coated primarily with fibronectin and secondarily with BSA. Results were expressed 
as the number of Candida cells bound to a dynabead. Proteinase activity of Candida 
was  assessed  using  a  spectrophotometric  method  (Section  2.7)  and  results  were 
expressed as a ratio between the spectrophotometer reading (280 nm) and numbers of 
cells/ml.
The distribution of the proteinase and adhesion activity for these  isolates failed the 
Kolmogorov  -  Smirnov test for statistical  analysis normality.  Statistical parametric 
tests  assume  that  the  evaluated  data  is  distributed  according  to  an  ideal  Gaussian 
distribution.  Since  the  Gaussian  distribution  is  also  referred  to  as  the  Normal 
distribution, the test is also called a normality test. The Kolmogorov -  Smirnov test 
quantifies  discrepancies  between  the  distribution  of  data  and  an  ideal  Gaussian 
distribution - a larger value denotes larger discrepancies (GraphPad Software Inc. - 
www. graohnad .com).
In this chapter,  data was  not distributed according to the  normality test conditions 
and parametric tests were not applicable.  In addition, the shape distribution of data
157obtained  for  both  adhesion  and  proteinase  of the  Candida  isolates  of the  groups 
studied  was  very  different  and  anomalous  values  (outliers)  were  present  in  each 
group  (DM  and  non-DM).  As  a  consequence,  all  the  isolates  (isolated  from  DM 
patients from London,  UK,  Parma,  Italy and from non-DM  subjects) were divided 
above and below the median for each of these respective tests (median for adhesion: 
116.38;  median  for proteinase:  0.153442),  and  each  isolate  was  thus  classified  as 
having either high or low extra-cellular proteinase activity and high or low adhesive 
properties. The differences among or between groups were evaluated using Fisher’s 
exact test or Chi square test and values were deemed significant when the probability 
(p) was less than or equal to 0.05.
5.3 Isolates
The  229  Candida  strains  isolated  from  the  oral  cavity  of the  two  groups  of DM 
patients  (83  from  the  137  UK  DM  patients  and  71  isolates  from  the  105  Italian 
patients,  154 in total) and the non-DM subjects (75 out of the  130 non-DM subjects) 
were examined in this study.
5.4 Results
5.4.1  Adhesion and proteinase activity of oral Candida isolates of patients with and 
without DM
Analysis of adherence and proteinase production  by the  154  Candida isolates from 
the DM patients demonstrated that there were  no  significant associations with age, 
gender, smoking habits and denture status (Table 5.1).
However,  Candida  from  DM  patients  with  lower  levels  of oral  yeast  colonisation
(<100  cfu/ml)  had  higher adhesion  levels  (p=0.01) than  isolates  from  DM patients
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with a high oral candidal load (>100 cfu/m) (Table 5.1).  \  A . ^ a  O'
J   '«  ... ^No statistical difference was found between Candida spp. or genotypic distribution of 
C.  albicans and adhesion or proteinase expression  (p>0.05).  Furthermore,  although 
the  type  of  DM,  duration  of  disease,  long-term  diabetic  complications  and 
haemoglobin  glycosylation  levels  did  not  influence  the  adhesion  (p>0.05)  of the 
Candida spp. isolated from the DM patients, significantly higher levels of proteinase 
(p=0.02) were detected for isolates recovered from type 2 DM patients compared with 
type 1  DM patients (Table 5.1).
The  in  vitro  ability  of 75  Candida  strains  from  non-DM  subjects  to  adhere  and 
produce  SAPs  was  not  significantly  associated  with  patient  age,  gender,  smoking 
habits,  denture  status,  oral  candidal  load  (cfu/ml),  species  of  Candida  or  the 
genotypic distribution of C. albicans (p>0.05).
*
A  comparison  of the  adhesion  levels  of  Candida  isol^s_from..th£..QM_patjent 
;  population  with those  of the  non-DM  subjects  showed that there was  significantly 
higher levels of adhesion for the yeast from the DM patient groups (p<0.0001) (Table 
5.2).  More  specifically,  the  in  vitro ability to  adhere was  found to  be  significantly 
higher for Candida isolates from patients with DM than those isolated from non-DM 
controls for all the variables evaluated.
No significant differences in  Candida proteinase production were observed between 
DM and non-DM subjects (p=0.48). However, higher levels of proteinase were found 
for isolates from non-DM control subjects with a lower degree of colonisation (<100 
cfu/ml) compared with isolates from the DM patients (p=0.03) (Table 5.2).
5.4.2  Adherence and proteinase activity of all Candida isolates
Analysis  of all  229  Candida  isolates  from  patients  with  DM  and  healthy  subjects 
indicated  that  the  adherence  of isolates  from  individuals  with  levels  of oral  yeast 
colonisation <100 cfu/ml was significantly higher (p=0.0006) than other individuals(Table 5.3). No other differences (p>0.05) were observed in adherence or proteinase 
production of isolates from any of the 229  Candida carriers evaluated in this study 
(Table 5.3).
5.4.3  Influence  of  geographical  locale  on  adhesion  and  proteinase  activity  of 
Candida isolates of patients with DM
Significant differences were observed between the two geographically different DM
populations  in terms  of the  isolates’  ability to  adhere  or produce proteinase  (Table
5.4a and  5.4b).  There was  a tendency (p=0.06)  for oral  isolates  from patients with
\ o ^ '
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DM from Italy to have higher adherence than isolates from UK DM patients and also 
for the latter to produce higher levels of extracellular proteinase (p=0.053).
^   Adherence  of Candida  isolates  from  Italian  DM  patients  who  wore  dentures  was 
significantly  higher  (p=0.03)  than  those  of  isolates  from  UK  DM  patients. 
Furthermore, oral yeasts isolated from Italian DM patients whose diabetic control was 
good (HbAlc<7.5%) exhibited higher adherence (p=0.01) than isolates from London 
patients with the same level of glycaemic control (Table 5.4b).
Higher levels of proteinase activity was found in C.  albicans isolates from UK DM 
patients (p=0.04), particularly with C. albicans genotype A (p=0.04), compared with 
isolates from Italian DM patients (Table 5.4a).
Analyses of proteinase activity of isolates from tobacco users showed that Candida 
from  UK DM patients expressed higher proteinase  levels  (p=0.02) than those from 
patients with DM from Italy (Table 5.4a).
Finally,  higher  levels  of  proteinase  activity  (p=0.02)  was  observed  for  the  oral 
isolates from UK DM patients with good metabolic control (HbAlc<7.5%) compared 
with  isolates  from  Italian  DM  patients  with  the  same  level  of glycaemic  control 
(Table 5.4b).
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This  study  has  investigated the  expression of two  important virulence  attributes  of 
Candida isolates recovered from DM patients and healthy control subjects. There are 
few  studies that have  investigated these two  pathogenic  factors for oral  isolates  of 
DM patients and in general, these have not examined individuals with a spectrum of 
DM.  In  addition,  researchers  have  not  simultaneously  examined  more  than  one 
virulence attribute (Darwazeh et al, 1990; Willis et al, 2000a).
In the present study, comparison of the adherence of the  154 Candida isolates from 
DM  patients  and  non-DM  subjects,  revealed  significant  differences  in  the  in  vitro 
adhesion  between  these  two  populations.  In  particular,  isolates  from  DM  patients 
exhibited a higher capacity to adhere to fibronectin (p<0.0001) compared with non- 
DM controls.
The adherence assay used was based on the binding of yeasts to fibronectin. This is 
one  of the  ECM  glycoproteins  and  it  has  recently  been  identified  as  a  Candida 
adhesin-receptor (Alalp) (Gaur & Klotz,  1997; Gaur et al,  1999; Gaur et al, 2002). 
The  adherence  assay  used  in  this  study  was  based  on  the  interaction  between 
fibronectin  and  Candida  and  therefore  provided  a  general  indicator  to  overall 
adherence potential. Fibronectin was selected as a marker for adherence as the role of 
fibronectin-Candida  interactions  in  the  adherence  process  had  already  been 
established (Yan et al,  1996; Gaur & Klotz,  1997; Cotter et al,  1998; Gozalbo et al, 
1998; Senet,  1998; Yan et al,  1998a; Yan et al,  1998b; Rodier et al,  1999; Pendrak et 
al, 2000;  Singleton et al, 2001; Rauceo et al, 2004). A number of different proteins 
{e.g. keratin, involucrin, salivary mucins) that may be involved in surface interaction 
may also have been used,  but these assays were considered to be more suitable for 
evaluating  the  molecular  adherence  mechanism  of Candida  to  epithelial  surfaces, 
rather than variability of the yeast in adherence.
161The reason for the enhanced adhesion of isolates of patients with DM may reflect the 
presence of a higher concentration of sucrose/glucose in the saliva of patients affected 
by DM compared to healthy non-DM subjects. It has been observed that yeast growth 
and adhesion may be enhanced by high blood and saliva glucose levels (Odds et al, 
1978; Samaranayake et al,  1984a), which can serve as nutrients for Candida cells. It 
could  therefore  be  surmised  that  strains  isolated  from  DM  patients  with  higher 
glucose  salivary  levels,  may have  an  inherently  higher ability to  adhere  due to the 
selection of such strains in the high sugar oral environment associated with DM. 
Although this study  did not show that DM patients with  lower levels  of glycaemic 
control  had  higher  levels  of oral  Candida  carriage  or  yeast  with  higher  adhesion 
levels, the  strains  isolated  from the  oral cavity of patients  suffering from  DM  may 
have, however, increased their ability to adhere in vitro. It is likely that more than one 
factor may promote Candida carriage and enhance the isolates’  adhesion activity in 
DM patients.
Analysis  of  proteinase  production  by  Candida  isolates  from  DM  and  non-DM 
subjects  did  not  reveal  any  significant  differences  (p=0.48).  However,  significant 
association was observed within the DM patient group. Interestingly,  it was evident 
from the present study that yeast isolated from type 2 DM patients had significantly 
higher expression of extracellular proteinases (p=0.02) compared with isolates from 
type  1   DM patients. This finding may well reflect possible variation (related to DM 
type)  in  the  levels  of certain  salivary  constituents  such  as  secretory  IgA,  salivary 
glucose  or  enzyme  levels  e.g.  matrix  metalloproteinase  (MMP-8)  and  gelatinase 
(MMP-9) (Collin et al, 2000b). Indeed it has previously been reported (McCullough 
et al,  1995) that some oral  infections such as periodontitis in type 2 DM patients is 
related to elevated salivary MMP-8 levels.  In addition, salivary lysozyme levels are 
known to be influenced by DM (Stevens et al,  1990), and could theoretically effect
162SAP activity (Rayfield et al,  1982;  Scherer &  Stevens,  1987) and thus extracellular 
proteinase in vitro production, although this remains unproven.
Although many of the pathogenetic  Candida spp. have been shown to possess SAP 
genes and produce active extracellular proteinases in vitro, it has also been reported 
that the most virulent species, such as C.  albicans, C.  tropicalis, C. parapsilosis and 
C.  dubliniensis,  produce  more  proteinases  in  vitro  than  the  less  virulent  species 
(Ruchel,  1992; Naglik et al, 2003; Naglik et al, 2004).  Interestingly, no differences 
were observed in the proteinase production between C. albicans and non-C. albicans 
spp.  in the present study.  This result may be due to the difference in the number of 
such species between the two groups (as there were many more C. albicans than non- 
C. albicans isolates). It has however, been reported that even if C.  albicans exhibits 
higher in vitro Sap activity,  such differences may partly be due, to assay sensitivity 
(Naglik et al, 2003). Thus it would be of interest to evaluate proteinase production of 
the  isolates  studied  with  different relevant assays,  in  order to  confirm  (or not) the 
present result.
Recently,  it  has  been  reported  that  C.  albicans  genotype  B  produces  significantly 
higher proteinase and phospholipase activity compared to genotypes A or C (Sugita et 
al, 2002). In this present study, no differences in extracellular proteinase production 
and C. albicans genotype were observed when the isolates from all the carriers were 
evaluated.  However,  C.  albicans  genotype  A  isolated  from  London  DM  patients 
expressed  higher  levels  of  extracellular  proteinase  than  those  from  Italian  DM 
patients (Table 5.4). Further research is however necessary  in order to elucidate the 
existence of any relationship between Saps and/or phospholipase activity and the C. 
albicans genotype.
Isolates  from  DM  patients  carrying  a  lower  number  of oral  yeasts  (<100  cfu/ml) 
expre^sfed  greater  adhesion  (p=0.01)  than  isolates  from  patients  who  had  a  highernumber of oral yeasts  (Table  5.1).  This was also observed for isolates from all the 
Candida carriers evaluated in this study (Table 5.3).
The inverse relationship between the degree of colonisation and the ability of isolates 
to adhere  is  intriguing.  The assay used to evaluate  adhesiveness directly measured 
the isolates’ ability to adhere to fibronectin. Therefore, it may be assumed that, as the 
number  of yeasts  present  in  the  oral  cavity  increases,  interaction  between  yeasts 
themselves becomes of greater importance than interaction between the yeast and the 
host,  as was analysed  in this  study.  Such a theory  supports the concept of biofilm 
formation  (Baillie  &  Douglas,  1998)  and the  increasing  importance  of interaction 
between  microorganisms  (Sullivan  &  Coleman,  1997;  Willis  et  al,  2000b).  The 
results  of  the  previous  Chapter,  where  it  was  established  that  DM  did  not 
significantly increase the carriage of oral yeasts.  The results of the present Chapter 
show no evidence correlating oral yeasts in vitro virulence and colonisation in DM 
patient.  Thus,  in DM,  neither oral  yeast number nor phenotype are unique, further 
support the notion that patients with DM, at least when treated, are not at increased 
risk of developing oral candidosis.
Further  research  could  be  directed  at  examining  agglutinin-like  sequence  genes 
(ALS),  a  family  of at  least  9  genes that encode  cell  surface  glycoproteins,  mainly 
characterised in C. albicans and related Candida spp. (Hoyer et al, 1995; Hoyer et al, 
1998;  Chandra et al,  2001;  Hoyer,  2001;  Hoyer &  Hecht,  2001) and are known to 
vary in expression depending upon environmental conditions.
The presence of oral prostheses may influence the capability of oral yeasts to adhere. 
In this study, particularly high levels of adhesion were observed in Candida isolates 
from Italian DM patients who wore dentures (Table 5.2 and 5.4a).It is well known that the presence of oral prostheses such as dentures and removable 
(or fixed) orthodontic appliances can  increase oral yeast carriage.  The denture may 
function  as  a  chronic  reservoir  of  infection  and  dissemination  (Davenport,  1970; 
Verran & Maryan,  1997; Maza et al, 2002), and surface irregularities would increase 
the  likelihood  of microorganisms  remaining on the  surface  after the prosthesis has 
been cleaned.
It  may  be  that  DM,  rather  than  the  sole  presence  of a  dental  prosthesis,  affects 
adherence, as the adherence of isolates from the control subgroup was not influenced 
by the presence of dentures. Furthermore, it has been reported (Radford et al,  1999) 
that in vivo, microorganisms never attach directly to prostheses surfaces,  since they 
are always covered with a salivary pellicle of various degrees of maturity. It may be 
that any enhanced interactions between yeasts and local factors such as a low salivary 
content (due to the presence of dentures and hypoglycaemic agents) or poor metabolic 
control may increase the ability of Candida to adhere to oral mucosa, rather than any 
yeast-derived factor.
It  is  known  that  adhesion  is  strongly  related  to  the  presence  of  specific  sugars 
(Samaranayake  &  MacFarlane,  1980;  Samaranayake  et  al,  1980;  McCourtie  & 
Douglas,  1981)  and that the  adherence  of C.  albicans to  acrylic  surfaces  increases 
when  cultured  in  various  carbon  sources,  including  glucose,  maltose  and  galactose 
(McCourtie  &  Douglas,  1984).  This  increase  has  been  attributed  to  enhanced 
formation of a fibrillar-floccular layer, demonstrated by ruthenium red or polycationic 
ferritin staining, which indicates that this layer may be rich in acidic polysaccharides 
(McCourtie & Douglas, 1981).
This  study  has  investigated  the  influence  of DM  upon  the  ability  of oral  Candida 
isolates to enhance the expression of two of the most important virulence attributes of
165Candida spp.: adhesion and production of extracellular proteinase. The assay used in 
this study showed that although  Candida from DM patients had a greater ability to 
adhere  compared  with  those  from  healthy  subjects,  higher  adhesion  levels  were 
shown in Italian patients with DM wearing dentures than in UK patients with DM and 
wearing dentures. In addition, higher levels of adhesion were also recorded in patients 
with a lower oral Candida colonisation (< 100 cfu/ml).
In vitro extracellular proteinase  expression was not significantly higher in  Candida 
isolates of patients with DM compared to those of healthy subjects. However, higher 
extracellular  proteinase  levels  were  observed  in  isolates  from  type  2  DM  patients 
when compared with type 1  DM patients.
As reported,  it would be  interesting to correlate the ALS and SAP gene expression 
obtained by RT-PCR for Candida isolates grown in the culture media previously used 
in the adhesion and extracellular proteinase production assays.
166Table  5.1:  Ability  to  adhere  and  extracellular  proteinase  production  obtained
from Candida isolates of patients with DM
DM patients
Adhesion
above
median
Adhesion
below
median
p value
Proteinase
above
median
Proteinase
below
median
p value
Male 4 5 3 4 0 .1 8 4 1 3 8 0 .3 3
Female 5 1 2 4 3 3 4 2
<60 years 4 1 2 5 1.00 3 3 3 3 0 .7 4
>60 years 5 5 3 3 4 1 4 7
Tobacco users 2 0 10 0 .6 7 1 5 1 5 0 .8 4
Non-tobacco users 7 6 4 8 5 9 6 5
Dentate 4 6 3 0 0 .7 3 3 9 3 7 0 .5 1
Dentures 5 0 2 8 3 5 4 3
<100 cfu/ml 6 7 2 8 0.01 4 0 5 5 0 .0 6
>100 cfu/ml 2 9 3 0 3 4 2 5
G   albicans 7 3 4 8 0 .4 1 6 0 6 1 0 .5 5
Non-C albicans 2 3 10 1 4 1 9
C. albicans A 5 8 4 1 0 .8 4 5 2 4 7 0 .2 7
C, albicans B 12 5 7 10
C. albicans C 3 2 1 4
Type 1  DM 2 6 1 6 1 .00 2 7 1 5 0.02
Type 2 DM 6 9 4 3 4 9 6 3
<10 years DM* 3 4 2 3 0 .8 5 2 4 3 3 0 .1 5
>10 years DM* 4 6 2 9 4 2 3 3
HbAlc <7.5% 3 0 1 7 0 .8 4 2 4 2 3 0 .7 9
HbAlc >7.5%;<8.5% 2 4 1 7 1 8 2 3
HbAlc >8.5% 4 2 2 4 3 2 3 4
Neuropathy 1 9 12 0 .3 6 1 7 1 4 0 .4 4
Retinopathy 2 6 2 0 2 6 2 0
Nephropathy 1 5 5 8 12
Statistical analysis was performed sub-classifying the values above and below the median of each assay (adhesion: 
116.38 and proteinase: 0.153442). then Fisher's exact or Chi square tests were used to analyse data obtained 
*  For 36  DM  patients  from  London  it was  not  possible to establish the duration of their disease.  Of these,  22 
harboured oral yeasts
167Table 5.2:  Ability  to  adhere and extracellular proteinase  production  of Candida
isolates of patients with DM compared with non-DM control subjects
Patients
Adhesion
above
median
Adhesion
below
median
p value
Proteinase
above
median
Proteinase
below
median
p value
Male
D 4 5 3 4 0 .0 0 3 4 1 3 8 0 .4 2
ND 9 2 8 1 6 21
Female
D 5 1 2 4 <0.0001 3 3 4 2 0 .0 7
ND 10 2 8 2 4 1 4
<60 years*
D 4 1 2 5 0.0001 3 3 3 3 0 .4 4
ND 11 3 4 2 6 1 9
>60 vears*
D 5 5 3 3 0.02 4 1 4 7 1 .00
ND 6 1 3 9 10
Tobacco users
D 2 0 10 0.001 1 5 1 5 0 .5 5
ND 3 1 5 11 7
Non-tobacco users
D 7 6 4 8 <0.0001 5 9 6 5 0 .7 4
ND 1 6 4 1 2 9 2 8
<100 cfu/ml
D 6 7 2 8 <0.0001 4 0 5 5 0.03
ND 6 1 8 1 6 8
>100 cfu/ml
D 2 9 3 0 0.01 3 4 2 5 0 .3 3
ND 1 3 3 8 2 4 2 7
Dentate
D 4 6 3 0 0.001 3 9 3 7 0 .7 0
ND 1 4 3 2 2 6 2 0
Dentures
D 5 0 2 8 <0.0001 3 5 4 3 0 .8 2
ND 5 2 4 1 4 1 5
C. albicans
D 7 3 4 8 <0.0001 6 0 6 1 0 .4 1
ND 1 4 4 2 3 2 2 4
Non-C albicans
D 2 3 10 0.03 1 4 1 9 1 .0 0
ND 5 1 4 8 11
C. albicans A
D 5 8 4 1 <0.0001 5 2 4 7 0 .3 7
ND 10 3 6 2 8 1 8
C. albicans B
D 12 5 0 .0 8 7 10 1.00
ND 2 6 3 5
C. albicans C
D 3 2 1.00 1 4 1 .00
ND 1 1 1 1
Statistical analysis was performed sub-classifying the values above and  below the median of each assay (adhesion:  116.38 and 
proteinase: 0.153442), then Fisher’s exact or Chi square tests were used to analyse data obtained 
D: DM patients; ND: non-DM control subjects
* Of the twelve non-DM  control subjects w ho did not give their date of birth (special needs patients),  10 harboured oral yeasts. 
Of these ten, 9 yielded one Candida strain each and one additional non-DM subject yielded two Candida strains
168Table  5.3:  Ability  to  adhere  and  extracellular  proteinase  production  obtained
from all the Candida isolate carriers
All carriers
Adhesion
above
median
Adhesion
below
median
p value
Proteinase
above
median
Proteinase
below
median
p value
Male 5 4 6 2 0 .2 9 5 6 6 0 0 .7 9
Female 6 1 5 2 5 7 5 6
<60 years* 5 2 5 9 0 .1 3 5 9 5 2 0 .4 1   ;
>60 years* 6 1 4 6 5 0 5 7
Tobacco users 2 3 2 5 0 .7 4 2 7 21 0 .4 1
Non-tobacco users 9 2 8 9 88 9 3
Dentate 6 0 6 2 0 .7 9 6 3 5 9 0 .4 2
Dentures 5 5 5 2 4 9 5 8
<100 cfu/ml 7 3 4 6 0.0006 5 6 6 3 0 .4 2
>100 cfu/ml 4 2 6 8 5 8 5 2
C. albicans 8 7 9 0 0 .6 3 9 3 8 4 0 .21
Non-C. albicans 2 8 2 4 2 2 3 0
C. albicans A 68 7 7 0 .6 3 8 0 6 5 0 .1 6
C. albicans B 1 4 11 10 1 5
C. albicans C 4 3 2 5
Statistical analysis was performed sub-classifying the values above and below the median of each assay (adhesion: 
116.8 and proteinase: 0.153442), then Fisher's exact or Chi square tests were used to analyse data obtained 
*  Of the  twelve  non-DM  control  subjects  who  did  not  give  their  date  of  birth  (special  needs  patients),  10 
harboured oral yeasts. Of these ten. 9 yielded one Candida strain each and one additional non-DM subject yielded 
two Candida strains
169Table  5.4  a:  Ability  to  adhere  and  extracellular  proteinase  production  of
Candida isolates of patients with DM from tw o different geographic locales
DM  patients
Adhesion
above
median
Adhesion
below
median
p value
Proteinase
above
median
Proteinase
below
median
p value
Male
D/L 2 0 2 3 0 .1 5 2 6 1 7 0.11
D/PR 2 5 11 1 5 21
Female
D/L 2 6 1 4 0 .6 2 2 0 2 0 0 .3 5
D/PR 2 5 10 1 3 2 2
<60 years
D/L 2 6 1 8 0 .1 3 2 4 2 0 0 .4 3
D/PR 1 5 7 9 1 3
>60 years
D/L 2 0 1 9 0 .0 7 2 2 1 7 0 .1 3
D/PR 3 5 1 4 1 9 3 0
Tobacco users
D/L 6 7 0 .0 5 6 10 3 0.02
D/PR 1 4 3 5 12
Non-tobacco users
D/L 4 0 3 0 0 .3 5 3 6 3 4 0 .3 6
D/PR 3 6 1 8 2 3 3 1
Dentate
D/L 3 2 2 2 0 .7 9 3 1 2 3 0 .1 3
D/PR 1 4 8 8 14
Dentures
D/L 1 4 1 5 0.03 1 5 1 4 0 .4 8
D/PR 3 6 1 3 2 0 2 9
<100 cfu/ml
D/L 2 8 1 5 0 .3 6 2 2 21 0 .1 4
D/PR 3 9 1 3 1 8 3 4
>100 cfu/ml
D/L 1 8 2 2 0 .4 1 2 4 1 6 0 .7 7
D/PR 11 8 10 9
C. albicans
D/L 3 7 3 2 0 .0 9 4 0 2 9 0.04
D/PR 3 6 1 6 2 0 3 2
Non-C albicans
D/L 9 5 0 .7 0 6 8 1.00
D/PR 1 4 5 8 11
C. albicans  A
D/L 3 0 2 9 0 .0 6 3 6 2 3 0.04
D/PR 2 8 12 1 6 2 4
C albicans  B
D/L 6 1 0 .3 3 3 4 1 .00
D/PR 6 4 4 6
C. albicans  C
D/L 1 2 0 .4 1 2 1 .00
D/PR 2 0 0 2
Statistical analysis was performed sub-classifying the values above and below the median of each assay (adhesion: 
116.38 and proteinase: 0.153442). then we used Fisher’s exact or Chi square testsTable  5.4  b:  Ability  to  adhere  and  extracellular  proteinase  production  of
Candida isolates of patients with DM from tw o different geographic locales
DM  patients
Adhesion
above
median
Adhesion
below
median
p value
Proteinase
above
median
Proteinase
below
median
p value
Type 1   DM
D/L 1 9 1 4 0 .4 4 2 2 11 0 .6 9
D/PR 7 2 ;  5 4
Type 2 DM
D/L 2 7 2 3 0 .1 7 2 6 2 4 0 .1 2
D/PR 4 2 2 0 2 3 3 9
DM <10 years*
D/L 10 12 0 .1 0 1 3 9 0 .4 3
D/PR 2 4 11 11 2 4
DM >10 years*
D/L 2 0 1 9 0 .0 9 2 6 1 3 0 .0 6
D/PR 2 6 10 1 6 2 0
HbAlc <7.5%
D/L 1 8 1 6 0.01 21 1 3 0.02
D/PR 12 1 3 1 0
HbAlc >7.5% ;<8.5%
D/L 6 5 1 .00 5 6 1 .00
D/PR 1 8 12 1 3 1 7
HbAlc >8.5%
D/L 2 2 1 6 0 .3 0 2 0 1 8 0 .4 5
D/PR 2 0 8 12 1 6
Neuropathy
D/L 1 3 11 0 .2 0 12 12 0 .4 1
D/PR 6 1 5 2
Retinopathy
D/L 10 1 3 0 .1 3 1 4 9 0 .7 6
D/PR 1 6 7 12 11
Nephropathy
D/L 1 2 0 .1 4 0 3 0 .2 4
D/PR 1 4 3 8 9
Statistical analysis was performed sub-classifying the values above and below the median of each assay (adhesion: 
116.38 and proteinase: 0.153442), then Fisher's exact or Chi square tests were used to analyse data obtained.
D/L: DM patients from London; UK; D/PR: DM patients from Parma, Italy
*  For 36  DM  patients  from  London  it  was  not possible to establish the  duration  of their disease.  Of these,  22 
harboured oral yeasts
171Figure 5.1: Example of aggregation of Candida cells to a dynabead and 
consequent cell-cell aggregation
172CHAPTER 6 
Antifungal susceptibility to six antifungal agents
6.1  Introduction
Several  antifungal  agents,  with  different  modes  of  action,  are  available  for  the 
treatment  of oral  Candida  infections  (Section  1.4,  Table  1.4).  The  most  common 
antifungal drugs  in current clinical use are polyenes (amphotericin B  and nystatin), 
azoles (fluconazole, miconazole, ketoconazole, itraconazole) and 5-fluorocytosine (5- 
FC). Recently, a new second-generation triazole (voriconazole) and an echinocandin 
antifungal agent (capsofungin) have been approved for clinical use by the Food and 
Drug  Association  (FDA)  (Johnson  &  Kauffman,  2003),  although  these  agents  are
s'
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only  recommended  for the treatment of systemic mycoses.  Furthermore,  other new 
triazoles (posaconazole, ravuconazole) are currently being developed for clinical use 
(Espinel-Ingroff, 1998; Espinel-Ingroff et al, 2001; Sanglard & Odds, 2002).
The increasing availability and clinical application of these antifungal agents has led 
to a rise  in the frequency of reports of in  vitro and in vivo antifungal  resistance  of 
Candida spp. (Pfaller et al,  1995; Espinel-Ingroff et al,  1999; Espinel-Ingroff et al, 
2000).  The  emergence  of resistance  amongst pathogenic  fungi  is  a  function  of the 
selective pressure of their exposure to antifungal drugs (White et al,  1998;  Sanglard 
& Odds, 2002). Furthermore, antifungal resistance may depend on the frequency of 
exposure of susceptible fungal strains, the rate of growth of the fungus exposed to the 
drug,  the  number  of mutations  or phenotypic  changes  required  for  resistance,  and 
time (Sanglard & Odds, 2002).
The failure (or success) of the treatment of candidal infection could be the result of 
primary (or intrinsic) and secondary (or acquired) fungal resistance but may also be
173due to  complex  interactions  occurring between the  infecting fungus,  the  antifungal 
agent  and  the  host  environment.  Primary  (or  intrinsic)  resistance  is  that  recorded 
before  in  vivo  or in  vitro  antifungal  drug  exposure,  while  secondary  (or acquired) 
resistance  develops  following  exposure to an antifungal  drug.  Secondary resistance 
can  be  either reversible,  due  to  transient  adaptation,  or  irreversible,  due  to  one  or 
several genetic alterations (Sanglard & Odds, 2002; White et al, 2002).
Several  yeast  species  (C.  glabrata,  C.  krusei,  C.  guilliermondii,  and  C.  lusitaniae) 
have a higher prevalence than others of primary resistance to amphotericin B, and C. 
glabrata and C.  krusei are intrinsically less susceptible to triazoles than C.  albicans 
itself. Furthermore, C. dubliniensis has been shown, in vitro, to rapidly develop stable 
resistance to fluconazole  (Moran et al,  1998;  White et al,  1998;  Sanglard &  Odds, 
2002).  In  addition  to  these  intrinsically  resistant  species,  there  are  intrinsically 
resistant  strains of C.  albicans which may be part of the  commensal  microflora or 
may be acquired from the environment or other individuals (White et al, 1998).
The epidemiological  changes  in the  susceptibility  of pathogenic  fungi  to  antifungal 
drugs  have  led  to  the  standardisation  of antifungal  resistance  assays  in  vitro  and 
resistance  breakpoint  definitions.  Firstly  in  1992  and  then  in  1997  (National 
Committee for Clinical Laboratory Standards,  1997), the US National Committee for 
Clinical  Laboratory  Standards  (NCCLS) proposed  a reference  method,  M27-A,  for 
antifungal  susceptibility  testing,  specifying  the  breakpoints  for  several  antifungal 
agents, such as 5-FC,  itraconazole and fluconazole, thus permitting inter- and intra­
laboratory  reproducibility  and  comparison  of  antifungal  susceptibilities  for  yeast 
pathogens. A second edition of the method, M27-A2, was released in 2002 (National 
Committee  for  Clinical  Laboratory  Standards,  2002).  However,  the  NCCLS 
committee accepts that M27-A/M27-A2 have limitations {i.e. regarding the ability of 
the methods to distinguish between isolates’ susceptible and resistant to amphotericin
174B,  to  newer  azoles  and  echinocandins  and  the  time-consuming  nature  of  the 
methods),  and  many  clinical  laboratories  therefore  prefer  to  use  commercially 
available products that have previously shown correlation with M27-A (White et al, 
1998; Sanglard & Odds, 2002). Several products based on variations of the NCCLS 
microdilution  method  are  now  available  commercially.  These  include  Candifast 
(International  Microbio/Stago  Group,  Diagnostic  International  Distribution,  Milan, 
Italy),  Fungitest  panel  (Sanofi  Diagnostic  Pasteur,  Paris,  France  now  Bio-Rad), 
Integral System Yeasts (Liofilchem Diagnostic, L’Aquila, Italy), and Sensititre Yeast 
One  (Trek  Diagnostic  Systems,  Inc.,  Westlake,  OH/Trek  Diagnostic  System  Ltd., 
East  Grinstead,  England).  Three  recent  studies  compared  one  or  more  of these 
products with the NCCLS methodology (Posteraro et al, 2000; Chryssanthou, 2001; 
Morace et al, 2002). The Sensititre Yeast One product was studied in all evaluations, 
comparing  favourably  with  the  NCCLS  M27-A  methodology  (Hospenthal  et  al, 
2004). Both the Candifast and Integral System Yeast products compared poorly with 
the  reference  method.  Fungitest was  evaluated  in the  largest of these three  studies 
(Morace  et  al,  2002).  This  multicenter  comparative  evaluation  of six  commercial 
systems  and  the  NCCLS  microdilution  method  M27-A  was  conducted  on  the 
fluconazole susceptibility of 800 Candida isolates (Morace et al, 2002). The results 
of the  study  indicated  that  Fungitest  together  with  E-test  (AB  Biodisk,  Slovna, 
Sweden) and Sensititre Yeast One can be considered useful for the in vitro evaluation 
of fluconazole susceptibility among Candida spp. isolates (Morace et al, 2002). 
Although  amphotericin  B  and  5-FC  resistance  has  been  reported,  azole  resistance 
appears to be emerging as the major problem in patients treated for yeast infections 
(Rex et al, 1995), possibly reflecting the relative use of these antifungals (White et al, 
1998).
175The supposed emergence of antifungal resistance, however, may partly reflect the use 
of non-standardised commercial systems for antifungal susceptibility testing and lack 
of agreement on the definition of a resistant fungal isolate. Indeed, large scale surveys 
on  azole  susceptibility  of clinical  yeast  isolates  based  on the NCCLS  method  and 
relative  MIC  breakpoints  do  not  support  the  belief  that  antifungal  resistance 
represents  a  significant  or  increasing  epidemiological  problem  (Sanglard  &  Odds, 
2002).
It has been reported that poor glycaemic control associated with other local factors, 
such  as the presence  of oral  dental  prostheses,  salivary pH,  salivary  flow rate  and 
tobacco  habits,  could  lead  to  the  development  of  oral  candidosis  (Dorocka- 
Bobkowska  et  al,  1996).  The  use  of  topical  antifungal  agents  to  prevent  the 
development  of  candidal  infections  in  patients  with  poor  metabolic  control  is 
frequent, particularly  in  elderly  denture wearing patients.  Elderly people  frequently 
suffer from  an  unpleasant  sensation  in  the  mouth that may  give  rise to  intolerable 
distress (Collin et al, 2000a).  If the elderly are diabetic, typically type 2 DM, with 
poor  glycaemic  control,  diabetologists  and  general  practitioners  tend  to  prescribe 
topical antifungal agents to prevent oral candidosis developing, even if signs of the 
disease  are  not  present.  The  indiscriminate  use  of antifungal  agents,  even  in  DM 
populations, could determine changes in the prevalence of Candida spp. causing the 
disease^and may then result in increased antifungal resistance.
The treatment options of superficial oral  Candida infections (Sections  1.3  and  1.4), 
both  in DM and non-DM  subjects,  are mainly based on the use  of topic/antifungal 
agents, such as azoles (mainly miconazole and fluconazole, but also ketoconazole and 
itraconazole)  or  polyenes  (amphotericin  B  and  nystatin)  (Budtz-Jorgensen  & 
Lombardi,  2000;  Ellepola  &  Samaranayake,  2000b;  Ellepola  &  Samaranayake, 
2000a; Rex et al, 2000; Willis et al, 2001). In this study, we evaluated the antifungalsusceptibility  of Candida  isolates  from  DM  patients  to  the  most  commonly  used 
antifungal agents for the treatment of oral candidosis.
At the  outset of this  study,  the  use  of the NCCLS  microdilution reference  method 
applied  to  different  antifungal  agents  (those  most  commonly  used  as  topical 
treatment) was  considered.  However, the  adoption  of a NCCLS  method for all the
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and the time-consuming nature of this method.  Therefore, a commercially available 
methodology  capable  of rapidly  assessing  a  range  of antifungal  susceptibilities  of 
Candida isolates was used. This method, Fungitest, has proved useful in a multicenter 
comparative  evaluation  of six  commercial  systems  (Morace  et  al,  2002)  and  was 
kindly  provided  by  Prof.  Polonelli’s  team  at the  University  of Parma  (Sezione  di 
Microbiologia,  Dipartimento  di  Patologia e  Medicina  di  Laboratorio,  Universita  di 
Parma, Italy).
Aim:  The  aim  of this  study  was to  assess the  antifungal  susceptibility of Candida 
isolates collected from patients affected by DM and from a group of healthy non-DM 
subjects to six commercially available antifungal agents.
Hypothesis: That there are differences in the antifungal susceptibility to six different 
antifungal agents of oral Candida isolates collected from patients with DM and from 
healthy non-DM subjects.
6.2  Methods
Oral  Candida  yeasts  isolated  from  DM  patients  and  from  a  control  population 
(Section  4.3.1),  were  evaluated  in  vitro  for  their  antifungal  susceptibility  to  six
177different  antifungal  agents  using  the  commercial  Fungitest  kit,  Bio-Rad,  France 
(Section  2.8).  Results  were  expressed  by  classification  of  the  isolates  as  being 
‘resistant’, ‘intermediate resistant’ or susceptible to each antifungal agent.
Fisher’s  exact  test  and  Chi  square  test  were  used  for  the  statistical  analysis  of 
categorical  data,  numeric  data  was  analysed  by  the  Student  T  test  or  ANOVA 
according  to  the postulates  of each test,  and  differences  within  or between  groups 
were considered significant when the probability (p) was less than or equal to 0.05. 
Although there  interesting variations  in the number of isolates fully resistant to 
certain  antifungal  agents,  it  was  not  possible  to  undertake  meaningful  statistical 
analyses with  all  antifungal  agents,  as the number of resistant  isolates  in the  other 
patient populations for the other antifungal agents was either too low or non-existent. 
Furthermore, the intention of this analysis was to determine the changes in antifungal 
sensitivity  over  a  large  number  of geographically  dispersed  isolates  from  specific 
patient populations utilising a rapid screening method. The intention of this study was ^
i
not to report accurate  and clinically  significant antifungal  susceptibility on  specific ( 
strains  to  a  limited  number  of  antifungal  agents.  Therefore,  isolates  with  any 
enhanced  resistance  to  the  antifungal  agents  tested  were  grouped  together  for 
statistical analysis.
6.3  Results
6.3.1 Antifungal susceptibility of Candida isolated from DM and non-DM subjects
6.3.1.1 Antifungal susceptibility of all Candida isolates
The  resistance  rates  of  all  C.  albicans  isolates  (177/229)  tested  were  9% 
(fluconazole),  17%  (itraconazole  and  miconazole),  15%  (ketoconazole),  7% 
(amphotericin B) and 5% (5-FC). Similarly, for non-C. albicans isolates (52/229), the
<1 oY 
Su<X
oocx3  *~
m2 S€ •  < > £
1  * ^
178resistance rates for these antifungals were 29% (fluconazole and itraconazole), 35% 
(miconazole), 23% (ketoconazole), 6% (amphotericin B) and 13% (5-FC).
Interestingly, Candida isolates that expressed resistance or intermediate resistance to 
fluconazole  were  also  found  to  exhibit  resistance  to  at  least  one  other  antifungal 
agent.  This  finding  of fluconazole  cross-resistance  with  other  antifungals  was  not 
encountered with any other combinations of antifungals (Appendix 2).
6.3.1.2  Association  of Candida  load  (cfu/ml),  species  or genotype  with  antifungal 
resistance
There  was  no  relationship  evident  between  oral  candidal  load  and  the  rates  of 
antifungal  resistance  for  the  drugs  tested  (p>0.05)  (Table  6.1a).  It  was,  however, 
found that the  non-C.  albicans  isolates  exhibited  higher resistant or  intermediately 
resistant rates to fluconazole  (p=0.0008)  and miconazole (p=0.01) than  C.  albicans 
isolates  (Table  6.1a).  There  was  no  equivalent  relationship  with  susceptibility  to 
ketoconazole,  itraconazole,  amphotericin B  and  5-FC  (Table  6.1a).  All  C.  albicans 
group B isolates were susceptible to 5-FC.
6.3.1.3 Association of patient age, gender, tobacco habits and dental prostheses with 
antifungal resistance
There  was  no  association  between  patient  age  or  gender  and  the  antifungal 
susceptibility  of Candida  (p>0.05).  There were,  however,  fewer oral yeast  isolated 
from  patients  without  dentures  that  were  resistant  or  intermediately  resistant  to 
miconazole  (p=0.02)  and  5-FC  (p=0.02)  (Table  6.1b).  Furthermore,  isolates  from 
non-tobacco  users  had  higher  resistance  or  intermediate  resistance  to  miconazole 
(p=0.04) or amphotericin B (p=0.04) (Table 6.1b).
1796.3.1.4 Comparison of antifungal susceptibility between Candida from DM and non-
DM subjects
Overall there were no significant differences in the antifungal susceptibility between 
isolates from DM and non-DM subjects (Table 6.2).  In the case of DM isolates the 
antifungal  resistance  rates  were  9%  (itraconazole),  7%  (ketoconazole),  4% 
(fluconazole)  and  1%  (5-FC).  In  comparison,  resistance  rates  for  non-DM  isolates 
were  5%  (itraconazole),  4%  (ketoconazole),  1%  (fluconazole)  and  0%  (5-FC). 
Similarly,  intermediate  resistance  for  DM  recovered  isolates  was  evident  with 
fluconazole  (10%),  miconazole  (21%),  ketoconazole  (13%),  itraconazole  (13%), 
amphotericin B  (5%) and 5-FC (4%).  In the case of non-DM recovered isolates the 
equivalent  incidences  of  intermediate  resistance  were  11%  (fluconazole),  21% 
(miconazole),  7%  (ketoconazole)  and  9%  (itraconazole).  Similarly,  intermediate 
resistance  was  observed with  rates  of 11% for both amphotericin B  and  5-FC.  All 
remaining isolates from both DM and non-DM subjects were susceptible to the tested 
antifungals.
6.3.2  Antifungal susceptibility of isolates from DM patients
6.3.2.1  Effect of geographical location on antifungal resistance 
Significant  differences  were  observed  in  the  antifungal  susceptibility  to  the  six 
different antifungal  agents when the two DM populations  from London and Parma 
were compared.  Specifically, high resistance rates to itraconazole (12/83,  14%) and 
ketoconazole  (11/83,  13%)  were  evident  in  Candida  isolates  from  London  DM 
patients. Interestingly, no resistance to miconazole, ketoconazole and amphotericin B 
were evident for Parma DM isolates (0/71, 0%).
Similarly, intermediate resistance rates of 13% for itraconazole (11/83) and  14% for
ketoconazole  (12/83)  were  encountered  for  London  DM  isolates.  Equivalent
intermediate  resistance  rates  for  Parma  DM  patients  were  6%  for  fluconazole  and
180miconazole (4/71),  13% for itraconazole (9/71),  11% for ketoconazole (8/71),  1% for 
amphotericin B (1/71) and 3% for 5-FC (2/71).
Oral  yeasts  from  London  DM  patients  also  had  higher  resistance  (or  intermediate 
resistance)  to  fluconazole  (p=0.02),  miconazole  (p<0.0001),  and  ketoconazole 
(p=0.01)  than  the  isolates  from  Parma  DM  patients.  There  was  also  a  trend  of 
increased resistance of isolates from London DM patients to  itraconazole and 5-FC 
(p=0.08) (Table 6.3).
6.3.2.2  Effect of specific DM properties on antifungal resistance 
When antifungal susceptibility was compared against type of DM, DM duration and 
haemoglobin  glycosylation  levels,  no  statistically  relevant  associations  could  be 
drawn.  However,  it  was  apparent  that  Candida  isolated  from  DM  patients  with 
neuropathy and retinopathy were more susceptible to miconazole (p=0.04) than those 
strains from patients who had nephropathy (Table 6.4).
No  statistically  significant  (p>0.05)  association  was  found  between  antifungal 
susceptibility and patient age,  gender, tobacco usage or denture wearing among the 
two DM populations.
No significant associations between resistance to any tested antifungal agent and the 
level of oral yeast colonisation (cfu/ml), or C.  albicans genotype were found among 
DM patients from London and from Parma (Table 6.5).
6.4  Discussion
The present study examined the antifungal  susceptibility of oral yeast isolated from 
patients with and without DM.  The objective of the study was to establish whether 
increased  antifungal  resistance  was  evident  for  DM  isolates,  which  may  lead  to 
problems  in  the  management  of  patients  prone  to  oral  candidal  infections.  No
181differences  in  the  antifungal  susceptibility  to  the  six  agents  tested  were  observed 
between  Candida  isolates  from  DM  and  non-DM  subjects.  However,  differences 
were observed between the two geographically different DM populations.
The  higher  incidence  of intermediate  resistance  in  London  DM  isolates  to  certain 
antifungals was probably not related to recent exposure to antifungal treatment, since 
none of these patients had received antifungal drugs in the preceding six months. 
However,  their  exposure  to  antifungal  agents  prior  to  this  time  was  unknown. 
Therefore,  it may  well  be  that  significant variation  in  lifetime  antifungal  exposure 
existed between the two DM populations and that this  lifetime antifungal  exposure 
variation  is  the  reason  for the  elevated  antifungal  resistance  rates  observed  in  the 
London  DM  population.  Interestingly,  one  of the  most  common  antifungal  agents 
used to treat patients with dentures suffering from oral candidosis is miconazole (Dias 
et al,  1997). It could be presumed that, although patients in the present study had not 
taken any antifungal agents in the preceding 6 months, those patients with dentures 
possibly had  increased  exposure to this  antifungal  agent during their lifetime.  This 
may  well  account  for the  increased  level  of resistance  to  miconazole  observed  in 
those  patients  who  wore  dentures  in  the  present  study,  and  indicates  that  lifetime 
antifungal  exposure  may  well  be  more  significant  than  antifungal  exposure  in  the 
preceding 6 month period.
The difference in the antifungal resistance of isolates from the two populations of DM 
patients  may  relate  to  differences  in  the  therapeutic  management  of  candidal 
infections between the two centres in Italy and the UK, since the introduction of these 
antifungal  agents  in the  two  countries.  However,  there was no  available  long-term 
data to support this notion. Although no association could be observed in the diabetic 
status of the patients in London and Parma,  it could be assumed that as the London 
group  had  more  long-standing  DM  with  more  complications  (Chapter  3,  Section
1823.3.2),  they  would  be  more  likely  to  have  received  or taken  the  antifungal  agents 
themselves.
As  has  been  reported  in  literature  (Rex et al,  2000;  Sanglard  &  Odds,  2002),  it  is 
more  likely  that  intermittent  antifungal  therapy  leads  to  the  development  of azole 
resistance rather than  long-term administration, as may be the case with the present 
group of DM patients in London.
The Candida isolated from the oral cavities of the DM patients resident in London, 
demonstrating in vitro resistance to the different antifungal agents tested, may have 
acquired  resistance  as  a  consequence  of the  selective  pressure  of azole  treatment 
(Sanglard & Odds, 2002).
The most  important clinical  consequence  of antifungal resistance usually  manifests 
itself as a failure to successfully treat patients affected by candidosis and in changes 
in the prevalence of Candida spp. causing the disease (Sanglard & Odds, 2002). 
Interestingly,  none  of the  patients  with  resistant  Candida  species  had  signs  and 
symptoms  of  oral  Candida  infections,  reflecting  that  a  patient’s  own  immunity 
system  can  control  the  yeast  pathogenicity.  This  was  observed  for  nearly  all  the 
patients studied in the thesis.
Although some of the yeasts  isolated from the DM population from London  (6/83, 
7.2%)  and  from  the  control  group  (8/75,  10.6%)  showed  an  in  vitro  intermediate 
resistance to amphotericin B, as noted above, none of the Candida isolates from the 
three  groups  of  patients  enrolled  in  the  study  were  completely  resistant  to 
amphotericin  B.  This  antifungal  drug  (Epstein  &  Polsky,  1998;  Lefebvre  & 
Domenge,  2002)  is  the  most  widely  used  in  the  UK  as  a topical  agent  (lozenges, 
suspensions)  for the treatment of oral  candidosis,  and as these topical  formulations 
are not available in Italy,  it is possible that this geographical variation might explain 
the  trends  for  increased  amphotericin  resistance  in  UK  isolates.  In  any  case,
183secondary  resistance  to  amphotericin  B  generally  seems  to  be  an  infrequent 
development  (White  et al,  1998).  However,  the  methodologies  and  results  of the 
present study do not clarify whether the antifungal resistance of examined isolates is 
intrinsic or acquired. In addition, because DM has had little effect on the presence of 
antifungal  resistance  of oral  yeast  isolates,  there  remains  the  possibility  that  any 
resistance  shown has been acquired from family members (or indeed other hospital 
patients)  (Sanglard  &  Bille,  2002;  Sanglard  &  Odds,  2002;  Sullivan  &  Coleman, 
2002).
It is well known that wearing acrylic dentures is an important predisposing factor for 
the development of oral candidosis, as these prostheses, when ill-fitting and not kept 
clean, act as a reservoir for infection (Ellepola et al,  1990; Ellepola & Samaranayake, 
2000a).  Furthermore,  increased  oral  candidal  load  is  much  more  common  in  full- 
denture  wearers  than  in  dentate  individuals  (Parvinen  et al,  1994;  Manfredi  et al, 
2002).  Candida-induced  denture  stomatitis  is  most  commonly  treated  with  the 
polyene  antifungal  agent  nystatin  and,  where  available,  with  an  amphotericin  B 
suspension.  Both  drugs  are  used  topically  and  applied to the  fitting  surface  of the 
denture  before  insertion  (Cawson,  1965).  Topical  miconazole  (oral  gel,  lacquer)  is 
also  a viable treatment option  for patients  affected by this  form of oral  candidosis 
(Konsberg & Axell, 1994; Parvinen et al, 1994; Dias et al, 1997).
Despite  the  availability  of a  range  of antifungal  agents  for  the  treatment  of oral 
Candida infections, therapy frequently fails. In the mouth, the diluent effect of saliva 
and  the  cleansing  action  of the  oral  musculature  may  also  reduce  the  levels  of 
antifungals to below their effective therapeutic concentrations (Ellepola et al,  1990; 
Dorocka-Bobkowska et al, 2003). The formation of Candida biofilms further reduces 
the susceptibility of yeasts to antifungal agents (Douglas, 2002; Douglas, 2003).
184In  this  study,  isolates  from  denture  wearers  were  less  susceptible  in  vitro  to 
miconazole  and  5-FC  than  isolates  collected  from  dentate  patients.  It  can  be 
hypothesised that the in vitro resistance of these Candida isolates is a consequence of 
the past widespread topical use of miconazole for the treatment of Candida-induced 
denture stomatitis.
5-fluorocytosine  is  a DNA  analogue,  mainly  used  for the management of systemic 
Candida  infections,  particularly  in  immunocompromised  patients,  but  not  for  the 
treatment of oral candidosis. However,  it is also well known that Candida spp., and 
C. albicans in particular, rapidly become resistant in vitro to this agent and therefore, 
when  treating  severe  deep  systemic  candidosis,  5-FC  is  usually  combined  with 
another antifungal agent, such as amphotericin B (Ellepola & Samaranayake, 2000a). 
The analysis of the susceptibility of all the oral Candida isolates (collected from the 
three groups of patients enrolled  in the study) to the different antifungal agents has 
shown that C.  albicans strains were more susceptible to fluconazole and miconazole 
than non-C. albicans strains.
It has been demonstrated that C. albicans is usually susceptible to all major antifungal 
agents (Rex et al, 2000), and other Candida spp., such as C. glabrata and C. krusei, 
are  intrinsically  less  susceptible  to triazole  and amphotericin B  (Sanglard &  Odds, 
2002).  However,  C.  albicans  resistance  to  different  antifungal  agents,  such  as 
triazoles,  and  fluconazole  particularly,  has  recently  been  reported  among  different 
groups  of  immunocompromised  patients,  where  this  agent  is  frequently  used  in 
prophylaxis  and  treatment  of fungal  infections  (Rex  et al,  2000;  Rex  et al,  2001; 
Vazquez et al, 2001).
Furthermore, although the  susceptibility of Candida spp. to the available antifungal 
agents can  be predicted  if the  species  of the  infecting  isolate  is known,  individual
185isolates do not necessarily follow the general pattern (Pfaller et al, 1994; Pfaller et al, 
1998c; Rex et al, 2000).
Several  studies  have  reported  that  multiple  genes  are  involved  in  the  process  of 
resistance  to  azoles.  For  example,  CaMDRl,  one  of  the  MF  transporter  genes 
upregulated  in  some  C.  albicans-resistant  strains,  expressed  selectivity  among  the 
azoles, resulting in cells becoming resistant to fluconazole but not to ketoconazole or 
itraconazole (Alarco et al,  1997; Balan et al,  1997; Balkis et al, 2002). Interestingly 
though,  in  the  present  study,  isolates  that  were  resistant  or  showed  intermediate 
resistance  to  fluconazole  were  also  resistant to  at  least one  other antifungal  agent. 
This was not the case for any of the other antifungal agents tested (Appendix 2).
For this reason, susceptibility testing for azole resistance is increasingly important in 
the management of candidosis.
The  findings  in  this  study  confirm  the  results  of  others  who  indicated  that  the 
previously  reported  emergence  of  C.  albicans  fluconazole  and,  more  generally, 
triazole  resistance,  was  probably  mainly  due  to  the  non-standardised  susceptibility 
methods rather than a real increase in the resistance of C. albicans species (Sanglard 
&  Odds,  2002).  However,  the  issue  is  still  controversial.  The  commercial  method 
(Fungitest, Bio-Rad) used in the present study and is considered a useful kit for the in 
vitro  evaluation  of fluconazole  sensitivity  among  Candida  spp.  isolates  in  clinical 
laboratories,  with  a  positive  agreement  among  laboratories  regarding  its 
reproducibility.  Although  this  method  provides  a  limited  number  of  drug 
concentrations and as a commercial kit, has some limitations compared to the NCCLS 
reference methods, it is regarded as one of the easiest and most rapid commercial kits 
available  (Morace  et  al,  2002).  Furthermore,  the  NCCLS  M27-A  antifungal 
concentration breakpoints are only available for three of the most common drugs used 
(fluconazole <  8  -  >64  pg/ml,  itraconazole <0.125  - >1  pg/ml  and  5-FC  <4  -  >32
186pg/ml)  (National  Committee  for  Clinical  Laboratory  Standards,  1997).  Fungitest 
breakpoints  are  specified  by  the  manufacturer  (Bio-Rad)  and  have  been  selected 
following the study of the distribution of the antifungal agents’  Minimal  Inhibitory 
Concentrations  (MIC)  obtained  with  prototype  microplates  used  with  the  same 
procedure  as  Fungitest.  Moreover,  breakpoints  of  Fungitest  for  fluconazole  are 
exactly the same as those in the NCCLS reference method.
The results obtained in this study seem to confirm that the rates of triazole resistance 
in Candida spp. are low and possibly overestimated (Sanglard & Odds, 2002) perhaps 
suggesting  that  the  associated  clinical  problem  could  be  less  serious  than 
hypothesised.  However,  because the present non-C.  albicans spp.  isolates were less 
susceptible to fluconazole and miconazole (Table 6.6b) than C. albicans isolates, the 
increased use of “over the counter” azole formulations could result in increased oral 
carriage of non-C  albicans and thus the possibility of acquisition by, and infection
of, immunocompromised groups (White et al, 1998; Sanglard & Odds, 2002).
Finally, it has been reported (Mercure et al, 1993) that C. albicans genotype B, which 
harbours  a  379  nucleotide  (Group  I  intron)  in  the  25S  rDNA  and  C.  albicans 
genotype C, a mixture of intron-containing and 'intron-less' 25S rDNA, both sho^<d 
a greater susceptibility to 5-FC than the intronless strain C. albicans genotype A. This 
observation was  further confirmed  by other studies (McCullough et al,  1999b)4he 
different  levels  of  susceptibility  to  this  agent  by  these  subgroups  of C.  albicans 
seemed to be  due to the  inhibitory effect of biosynthetic  incorporation of this base 
analogue into the group I intron ribozymes (Mercure etal, 1993).
However, in this study no statistical differences were observed in the susceptibility to 
5-FC  of the  C.  albicans  subgroup  B  isolates  from  all  the patients evaluated  in the 
study, and only one isolate from the C.  albicans subgroup C (Appendix 2, C/M 29) 
expressed intermediate resistance to the same agent. This finding is in agreement with
187others (Tamura et al, 2001) and suggests that the contribution of the group I intron to 
the  susceptibility  of Candida  spp.  to  5-FC  may  only be  one  factor,  and that other 
factors  (von  Ahsen  et  al,  1991;  von  Ahsen  &  Schroeder,  1991)  may  play  more 
important roles in 5-FC susceptibility of Candida spp.
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Figure 6.1: Example of Fungitest (Bio-Rad) commercial kit
This  C.  albicans  isolate  expressed  intermediate  resistance  to  miconazole  and  ketoconazole  (pink-blue).  T+ 
positive control test; 5 FC2: 5-FC at 2 pg/ml; 5FC32: 5-FC at 32 pg/ml; AB 2: amphotericin B at 2 pg/ml; AB 8 
amphotericin  B  at  8  pg/ml;  MCZ  0.5:  miconazole  at  0.5  pg/ml;  MCZ  8:  miconazole  at  8  pg/ml;  KET  0.5 
ketoconazole  at  0.5  pg/ml;  KET  4:  ketoconazole  at  4  pg/ml;  ITR  0.5:  itraconazole  at  0.5  pg/ml;  ITR  4 
itraconazole at 4 pg/ml; FLU 8: fluconazole at 8 pg/ml; FLU 64: fluconazole at 64 pg/ml; T‘: negative control test
189Table  6.1  a:  Analysis  of the  susceptibility  of the  Candida  strains  isolated  from  the  oral  cavity  of all  the  Candida  carriers  to  six  different
antifungal agents
Total patients FS F IR p value IM  S M   I R p value KS K  IR p value 1  S I  IR p value A S A  IR p value 5FCS 5FC IR p value
<100 cfu 1 0 5 14 p = 0 .4 4 4 7 9 8 21 p = 0 .1 9 6 7 9 9 20 p =  1 .0 0 0 0 9 5 2 4 p = 0 .8 3 9 0 1 1 3 6 p = 0 .4 2 6 0 1 1 3 6 p = 0 .3 0 1 4
>100 cfu 9 3 17 8 2 2 8 9 1 1 9 8 9 21 101 9 100 10
C. albicans 1 6 1 1 6 p = 0 .0 0 0 8 1 4 7 3 0 p = 0 .0 1 0 8 1 5 0 2 7 p = 0 .2 0 9 3 1 4 7 3 0 p = 0 .0 7 3 4 1 6 5 12 p =  1 .0 0 0 0 1 6 8 9 p = 0 .0 5 8 0
Non-C. albicans 3 7 1 5 3 4 1 8 4 0 12 3 7 1 5 4 9 3 4 5 7
C. albicans  A 
C. albicans  B  
C. albicans  C
1 3 0 15 p = 0 .4 131 121 2 4 p = 0 .7 0 3 3 122 2 3 p = 0 .5 1 8 9 1 1 9 2 6 p = 0 .7 5 2 2 1 3 5 10 p = 0 .7 5 1 6 1 3 7 8 p = 0 .2 6 9 4
2 4 1 21 4 21 4 22 3 2 3 2 2 5 0
7 0 5 2 7 0 6 1 7 0 6 1
D a ta  w a s  s u b d iv id e d  a c c o r d in g  to  p a tie n t  Candida c o lo n is a tio n  (c fu /m l),  s p e c ie s  a n d   C. albicans g e n o ty p e   su b g r o u p s  
S ta tis tic a l  a n a ly s is  w a s  p e r fo r m e d   u s in g   F is h e r 's  e x a c t a n d   C h i  sq u a r e  p a r a m e tr ic  te sts
F S :  flu c o n a z o le   s u s c e p tib le :  F   1R :  flu c o n a z o le   in te r m e d ia te ly   r e sista n t/r e sista n t;  M S :  m ic o n a z o le   s u s c e p tib le ;  M   1R :  m ic o n a z o le   in te r m e d ia te ly   r e sista n t/r e sista n t:  K S :  k e to c o n a z o le   s u s c e p tib le ;  K   IR : 
k e to c o n a z o le   in te r m e d ia te ly   r e sista n t/r e sista n t:  I  S :  itr a c o n a z o le   s u s c e p tib le :  I  IR :  itr a c o n a z o le   in te r m e d ia te ly   r e sista n t/r e sista n t; A   S :  a m p h o te r ic in   B   s u s c e p tib le ;  A   IR :  a m p h o te r ic in   B   in te r m e d ia te ly  
r e sista n t/r e sista n t:  5 -F C   S :  5 -F C  s u s c e p tib le ;  5 F C   IR :  5 -F C   in te r m e d ia te ly   r e s is ta n t/r e sista n t
190Table  6.1b:  Analysis  of the  susceptibility  of the  Candida  strains  isolated  from  the  oral  cavity  of all  the  Candida  carriers  to  six  different
antifungal agents
Total patients FS F IR p value M S M  IR p value KS K  IR p value 1  S 1   IR p value A S A  IR p value 5-FC S 5-FC IR p value
Male 9 9 17 p = 0 .7 0 0 0 9 5 21 p = 0 .2 6 0 0 9 1 2 5 p = 0 .1 6 9 2 8 9 2 7 p = 0 .1 8 5 1 1 0 9 7 p = 0 .7 9 4 8 1 0 8 8 p =  1 .0 0 0 0
Female 9 9 1 4 8 5 2 8 9 7 1 6 9 5 18 1 0 5 8 1 0 5 8
<60 years old* 9 9 12 p = 0 .4 2 0 6 8 9 22 p = 0 .6 2 1 6 9 3 18 p =  1 .0 0 0 0 9 2 1 9 p = 0 .4 9 2 7 1 0 6 5 p = 0 .7 6 5 0 1 0 8 3 p = 0 .0 7 8 9
>60 years old* 9 1 16 8 2 2 5 8 9 1 8 8 4 2 3 101 6 9 8 9
Dentate 1 0 8 1 4 p = 0 .3 4 1 1 1 0 3 1 9 p = 0 .0 2 4 4 9 8 2 4 p = 0 .2 9 3 0 9 9 2 3 p = 0 .8 6 7 8 1 1 3 9 p = 0 .7 9 0 0 1 1 8 4 p = 0 .0 2 11
Dentures 9 0 17 7 7 3 0 9 2 15 8 5 22 101 6 9 5 12
Tobacco users 4 3 5 p = 0 .6 3 6 3 4 3 5 p = 0 .0 4 6 6 4 1 7 p = 0 .8 2 9 0 3 8 10 p = 0 .8 6 7 4 8 0 p = 0 .0 4 5 1 4 5 3 p =  1 .0 0 0 0
Non-tobacco users 1 5 5 2 6 1 3 7 4 4 1 4 9 3 2 1 4 6 3 5 1 6 6 1 5 1 6 8 1 3
D a ta  w a s  s u b d iv id e d   a c c o r d in g  to   p a tie n t g e n d e r ,  a g e ,  d e n tu r e  sta tu s a n d   s m o k in g  h a b its 
S ta tistic a l  a n a ly s is  w a s  p e r fo r m e d  u s in g  F is h e r ’s  e x a c t a n d  C h i  sq u a r e  p a r a m e tr ic  te s ts
F S :  flu c o n a z o le   s u s c e p tib le :  F   IR :  flu c o n a z o le   in te r m e d ia te ly   r e sista n t/r e sista n t;  M S :  m ic o n a z o le   su s c e p tib le ;  M   IR :  m ic o n a z o le   in te r m e d ia te ly   r e sista n t/r e sista n t;  K S :  k e to c o n a z o le  s u s c e p tib le :  K   IR : 
k e to c o n a z o le   in te r m e d ia te ly   r e sista n t/r e sista n t;  1  S :  itr a c o n a z o le   s u s c e p tib le ;  I  IR :  itr a c o n a z o le   in te r m e d ia te ly   r e sista n t/r e sista n t;  A   S :  a m p h o te r ic in   B   s u s c e p tib le ;  A   IR :  a m p h o te r ic in   B   in te r m e d ia te ly  
r e sista n t/r e sista n t;  5 -F C   S :  5 -F C   su s c e p tib le ;  5 -F C   IR :  5 -F C   in te r m e d ia te ly   r e sista n t/r e sista n t
*  O f  th e  tw e lv e  n o n -D M   c o n tr o l  s u b je c ts w h o   d id   n o t g iv e  th e ir  d a te  o f  b irth   (s p e c ia l  n e e d s   p a tie n ts),  1 0  h a r b o u r e d   o r a l  y e a s ts .  O f  th e s e  te n .  9  y ie ld e d  o n e   Candida  str a in   e a c h  a n d   o n e  a d d itio n a l  n o n - 
D M   su b je c t y ie ld e d  tw o  Candida  str a in s
191Table 6.2: In vitro susceptibility to six different antifungal agents of oral Candida 
isolates from patients with and without DM
Antifungal agents DM  patients Non-DM subjects p value
Fluconazole
S 1 3 2 /1 5 4   ( 8 6 % ) 6 6 /7 5   ( 8 8 % ) p   =   0 .5 7
I 1 6 /1 5 4 ( 1 0 % ) 8 / 7 5 ( 1 1 % )
R 6 / 1 5 4 ( 4 % ) 1 /7 5 ( 1 % )
Miconazole
S 1 2 2 /1 5 4   ( 7 9 % ) 5 9 /7 5   ( 7 9 % )
I 3 2 / 1 5 4   ( 2 1 % ) 1 6 /7 5   ( 2 1 % )
R 0 / 1 5 4 0 /7 5 p =   1 .0 0
Ketoconazole
S 1 2 3 /1 5 4   ( 8 0 % ) 6 7 /7 5   ( 8 9 % )
I 2 0 / 1 5 4 ( 1 3 % ) 5 /7 5   ( 7 % )
R 1 1 /1 5 4   ( 7 % ) 3 /7 5   ( 4 % ) p   =  0 .2 0
Itraconazole
S 1 2 0 /1 5 4   ( 7 8 % ) 6 4 /7 5   ( 8 5 % )
I 2 0 / 1 5 4 ( 1 3 % ) 7 /7 5   ( 9 % )
R 1 4 /1 5 4   ( 9 % ) 4 /7 5   ( 5 % ) p   =   0 .4 0
Amphotericin  B
S 1 4 7 /1 5 4   ( 9 5 % ) 6 7 /7 5   ( 8 9 % )
1 7 /1 5 4   ( 5 % ) 8 / 7 5 ( 1 1 % )
R 0 /1 5 4 0 /7 5 p   =  0 .0 9
5-FC
S 1 4 6 /1 5 4  ( 9 5 % ) 6 7 /7 5   ( 8 9 % )
I 6 / 1 5 4 ( 4 % ) 8 / 7 5 ( 1 1 % )
R 2 / 1 5 4 ( 1 % ) 0 /1 5 4 p   =   0 .0 8
S ta tis tic a l  a n a ly s is  w a s  p e r fo r m e d   u s in g   F is h e r ’s  e x a c t a n d  C h i  sq u a r e  p a r a m e tr ic  te s ts  
S :  s u s c e p tib le ;  I:  in te r m e d ia te ly   r e s is ta n t;  R :  r e s is ta n t
192Table 6.3: Analysis of the antifungal susceptibility of the Candida species isolated 
from the oral cavities of London and Parma patients with DM
Antifungal agents DM  London patients DM  Parma  patients p value
Fluconazole
S 6 6 /8 3   ( 7 9 .5 % ) 6 6 /7 1   ( 9 3 % )
IR 1 7 /8 3   ( 2 0 .5 % ) 5 /7 1   ( 7 % ) p = 0.02
Miconazole
S 5 5 /8 3   ( 6 6 .3 % ) 6 7 /7 1   ( 9 4 .4 % )
IR 2 8 /8 3   ( 3 3 .7 % ) 4 /7 1   ( 5 .6 % ) p <0.0001
Ketoconazole
S 6 0 /8 3   ( 7 2 .3 % ) 6 3 /7 1   ( 8 8 .7 % )
IR 2 3 /8 3   ( 2 7 .7 % ) 8 /7 1   ( 1 1 .3 % ) p = 0.01
Itraconazole
S 6 0 /8 3   ( 7 2 .3 % ) 6 0 /7 1   ( 8 4 .5 % )
IR 2 3 /8 3   ( 2 7 .7 % ) 1 1 /7 1   ( 1 5 .5 % ) p   =   0 .0 8
Amphotericin  B
S 7 7 /8 3   ( 9 2 .8 % ) 7 0 /7 1   ( 9 8 .6 % )
IR 6 /8 3   ( 7 .2 % ) 1 /7 1   ( 1 .4 % ) p   =  0 .0 8
5-FC
S 7 8 /8 3   ( 9 4 % ) 6 8 /7 1   ( 9 5 .8 % )
IR 5 /8 3   ( 6 % ) 3 /7 1   ( 4 .2 % ) p   =   0 .7 2
S ta tis tic a l  a n a ly s is  w a s  p e r fo r m e d   u s in g  F is h e r 's  e x a c t a n d   C h i  sq u a r e   p a r a m e tr ic  te s ts  
S :  s u s c e p tib le ;  IR :  in te r m e d ia te ly   r e s is ta n t/r e s is ta n t
193Table 6.4:  Analysis  of the susceptibility of the Candida  strains  isolated  from  the oral  cavity  of patients with  DM  to  six  different antifungal
agents
DM patients FS F IR p value M S IM   IR p value K S K IR p value 1  S 1   IR p value A S A IR p value 5-FC S 5-FC IR p value
Male 6 7 12 p = 0 .8 1 9 9 6 4 15 p = 0 .5 5 6 2 5 9 2 0 p = 0 .1 1 1 5 5 7 2 2 p = 0 .0 8 3 8 7 5 4 p =  1 .0 0 0 0 7 5 4 p =  1 .0 0 0 0
Female 6 5 10 5 7 18 6 4 11 6 3 12 7 2 3 7 1 4
<60 years old 5 8 9 p = 0 .8 2 1 1 5 3 14 p =  1 .0 0 0 0 5 2 1 4 p = 0 .8 4 0 1 5 2 1 4 p = 0 .8 4 7 2 6 3 3 p =  1 .0 0 0 0 6 5 1 p = 0 .1 3 8 8
>60 years old 7 4 13 6 8 1 9 71 17 6 8 2 0 8 4 4 81 7
Dentate 6 7 10 p = 0 .8 1 8 4 6 2 14 p = 0 .4 3 4 1 5 7 1 9 p = 0 .1 6 1 8 5 9 17 p =  1 .0 0 0 0 7 3 3 p =  1 .0 0 0 0 7 5 1 p = 0 .0 6 3 4
Dentures 6 5 12 5 9 1 9 6 6 12 61 17 7 4 4 7 1 7
Tobacco users 2 7 3 p = 0 .5 7 1 1 2 7 3 p = 0 .1 3 4 8 2 5 5 p = 0 .8 0 0 3 2 3 7 p = 0 .8 1 0 9 3 0 0 p = 0 .3 4 6 6 3 0 0 p = 0 .3 5 5 9
Non-Tobacco users 1 0 5 19 9 4 3 0 9 8 2 6 9 7 2 7 1 1 7 7 1 1 6 8
DM type 1 3 7 5 p = 0 .7 9 6 9 3 4 8 p = 0 .8 2 6 0 31 11 p = 0 .2 6 5 1 3 3 9 p =  1 .0 0 0 0 4 2 0 p = 0 .1 9 0 6 4 1 1 p = 0 .4 4 8 0
DM type 2 9 5 17 8 7 2 5 9 2 2 0 8 7 2 5 1 0 5 7 1 0 5 7
<10 years DM* 4 8 8 p =  1 .0 0 0 0 4 5 11 p =  1 .0 0 0 0 4 6 10 p = 0 .6 6 3 2 41 15 p = 0 .4 0 2 5 5 3 3 p = 0 .6 9 8 2 5 2 4 p = 0 .7 2 1 9
>10 years DM* 6 5 11 6 0 16 5 9 17 61 15 7 3 3 7 2 4
Neuropathy 2 4 7 p = 0 .1 6 3 3 23 8 p=0.0475 2 3 8 p = 0 .7 7 9 9 2 4 7 p = 0 .8 5 3 1 2 8 3 p = 0 .2 9 6 9 2 8 3 p = 0 .9 8 4 6
Nephropathy 16 7 17 9 1 6 4 1 6 4 1 8 2 1 8 2
Retinopathy 3 8 5 36 4 3 3 13 3 4 12 4 5 1 4 1 5
HbAlc <7.5% 3 8 9 p = 0 .5 2 0 3 3 2 15 p = 0 .0 7 2 0 3 5 12 p = 0 .4 4 2 4 3 4 13 p = 0 .4 8 8 2 4 4 3 p = 0 .6 9 5 8 4 3 4 p = 0 .4 1 9 4
HbAlc >7.5%; <8.5% 3 6 5 3 6 5 3 5 6 3 2 9 3 9 2 4 0 1
HbAlc >8.5% 5 8 8 5 3 13 5 3 13 5 4 12 6 4 2 6 3 3
D a ta   w a s   s u b d iv id e d   a c c o r d in g   to   p a tie n t  g e n d e r ,  a g e ,  d e n tu r e   sta tu s,  ty p e   a n d   d u r a tio n   o f  D M ,  lo n g -te r m   d ia b e tic   c o m p lic a tio n s   a n d   g ly c a e m ic   c o n tr o l  ( H b A lc).  S ta tistic a l  a n a ly s is   w a s   p e r fo r m e d  
u s in g   F is h e r 's  e x a c t a n d  C h i  sq u a r e   p a r a m e tr ic  te sts
*  F o r  3 6   D M   p a tie n ts  fr o m   L o n d o n   it w a s  n o t p o s s ib le  to  e s ta b lish  th e  d u r a tio n  o f  th e ir  d is e a s e . O f  th e s e , 2 2  h a r b o u r e d  o r a l y e a s ts
F S :  flu c o n a z o le  su s c e p tib le ;  F   IR :  flu c o n a z o le   in te r m e d ia te ly   r e sista n t/r e sista n t;  M S :  m ic o n a z o le  s u s c e p tib le ;  M   IR :  m ic o n a z o le   in te r m e d ia te ly   r e sista n t/r e sista n t;  K S :  k e to c o n a z o le  su s c e p tib le ;  K   IR : 
k e to c o n a z o le   in te r m e d ia te ly  r e sista n t/r e sista n t:  I  S :  itr a c o n a z o le  su sc e p tib le ;  I  IR :  itr a c o n a z o le  in te r m e d ia te ly  r e sista n t/r e sista n t; A   S :  a m p h o te r ic in   B  s u s c e p tib le ;  A   IR :  a m p h o te r ic in  B   in te r m e d ia te ly  
r e sista n t/r e sista n t;  5 -F C   S :  5 -F C   su s c e p tib le ;  5 -F C   IR :  5 -F C   in te r m e d ia te ly   r e sista n t.
194Table 6.5: Analysis of the susceptibility of the Candida strains isolated from the oral cavity of the two groups of patients with DM to six
different antifungal agents
DM  patients FS F IR p value M S M  IR p value KS K  IR p value IS 1   IR p value A S A  IR p value 5-FC S 5-FC IR p value
<100 cfu 8 4 11 p = 0 .2 4 3 2 7 8 1 7 p = 0 .2 2 5 5 7 7 1 8 p = 0 .6 8 2 2 7 5 2 0 p = 0 .6 9 4 8 9 1 4 p =  1 .0 0 0 0 8 9 6 p = 0 .7 1 1 2
>100 cfu 4 8 11 4 3 1 6 4 6 13 4 5 1 4 5 6 3 5 7 2
C. albicans 1 0 9 12 p = 0 .0 0 8 8 101 2 0 p = 0 .0 2 7 0 9 8 2 3 p = 0 .6 2 4 3 9 7 2 4 p = 0 .2 3 7 0 1 1 6 5 p = 0 .6 4 2 7 1 1 6 5 p = 0 .3 6 9 4
Non-C albicans 2 3 10 21 12 2 5 8 2 3 10 3 1 2 3 0 3
C. albicans  A 8 8 11 p = 0 .6 0 1 0 8 3 1 6 p - 0 .3 1 8 9 7 9 2 0 p = 0 .5 2 5 8 7 8 21 p = 0 .6 6 5 5 9 5 4 p = 0 .8 3 9 8 9 4 5 p = 0 .5 6 0 2
C. albicans  B 16 1 15 2 14 3 15 2 1 6 1 1 7 0
C .  albicans  C 5 0 3 2 5 0 4 1 5 0 5 0
D a ta  w a s  su b d iv id e d   a c c o r d in g  to   p a tie n t  Candida c o lo n is a tio n  (c fu /m l),  s p e c ie s  a n d   C. albicans g e n o ty p e   su b g r o u p s 
S ta tistic a l  a n a ly s is  w a s  p e r fo r m e d  u s in g  F is h e r ’s e x a c t a n d   C h i  sq u a r e  p a r a m e tr ic  te s ts
F S :  flu c o n a z o le  s u s c e p tib le ;  F   IR :  flu c o n a z o le   in te r m e d ia te ly   r e sista n t/r e sista n t;  M S :  m ic o n a z o le   su s c e p tib le ;  M   IR :  m ic o n a z o le   in te r m e d ia te ly   r e sista n t/r e sista n t;  K S :  k e to c o n a z o le   s u s c e p tib le ;  K   IR : 
k e to c o n a z o le   in te r m e d ia te ly   r e sista n t/r e sista n t;  I  S :  itr a c o n a z o le  s u s c e p tib le ;  I  IR :  itr a c o n a z o le   in te r m e d ia te ly   r e sista n t/r e sista n t;  A   S :  a m p h o te r ic in   B   s u s c e p tib le ;  A   IR :  a m p h o te r ic in   B   in te r m e d ia te ly  
r e sista n t/r e sista n t;  5 -F C   S :  5 -F C   su s c e p tib le ;  5 -F C   IR :  5 -F C   in te r m e d ia te ly   r e sista n t/r e sista n t
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CHAPTER 7 
Analysis of the strain relatedness of C. albicans 
isolates utilising multiple PCR fingerprints
7.1  Introduction
The  increasing  incidence  of oral  candidosis,  particularly  in  immunocompromised 
patients, and the emergence of strains resistant to conventional antifungal therapies, 
has  led  to  the  implementation  of  laboratory  techniques  that  allow  the  rapid 
identification  of causative  organisms  and  the  study  of Candida  strains  at  species 
levels.
To increase our understanding of Candida pathogenicity, the  identification of those 
strains most frequently associated with infections is of paramount importance.
Candida  spp.,  and  C.  albicans  in  particular,  are  ubiquitous  organisms  that  can  be 
acquired  endogenously  from  the  host’s  normal  flora  or  exogenously  from  the 
environment,  from  infected  patients  or  from  health  care  workers.  The  ability  to 
identify particularly infective strains allows outbreaks of infections to be monitored 
and cross-infection controls to be assessed (Sullivan & Coleman, 2002).
In addition, strain identification can establish whether relapses of infection are due to 
a  novel  infecting  organism  or  to  persistence/re-infection  by  the  original  strain. 
Furthermore, it is important to remember that more than one strain can be involved in 
an infection (Soil, 2000; Sullivan & Coleman, 2002).
Specific techniques can also determine the dynamics of yeast populations and allow 
the study of association between virulence or drug resistance and specific clones or 
clusters of related strains.
196Traditionally,  the  methods  used  to  characterise  and  speciate  Candida  strains  were 
based on the analysis of phenotypic traits,  such as colony morphology  (and  colour 
indicator  media),  biochemical  and  serological  tests,  characteristic  carbohydrate 
assimilation profiles and chemical resistance patterns (Chapter 1, Section  1.6). These 
methods are  easy  to  perform,  but they  are  not particularly  specific  since  unrelated 
strains  of Candida,  and  sometimes  even  different  species,  often  share  phenotypic 
characteristics (Sullivan & Coleman, 2002).
For this  reason,  strain  differentiation  methods  have  been  developed  based  on  the 
analysis of genotypic differences. Genotypic methods based on nucleic acid analysis 
offer  greater  differentiation  and  reproducibility  for  strain  delineation  than 
phenotyping (McCullough et al, 1996; Bartie et al, 2001).
PCR-based  strategies,  such  as  PCR  fingerprinting  and  Randomly  Amplified 
Polymorphic DNA (RAPD) methods (Sections  1.6.3.1-1.6.3.2; Table  1.7) have been 
used  in  particular  to  investigate  cluster  infections  caused  by  identical  or  similar 
Candida  strains  (Shin  et  al,  2000),  the  emergence  of  resistant  strains  during 
antifungal  therapy  (Metzgar  et  al,  1998),  the  colonisation  pattern  of  strains  in 
different  clinical  situations  and  the  microevolution  of  strains  within  a  particular 
species (Lockhart et al,  1997;  Pujol  et al,  1997; Enger et al, 2001;  Dassanayake & 
Samaranayake, 2003a). These methods are extremely effective in differentiating and 
determining reproducibility; they require minimum starting material and are rapid and 
simple to perform (Lischewski et al,  1995; Barchiesi et al, 1997; Carlotti et al,  1997; 
Clemons et al, 1997; Diaz-Guerra et al, 1997; Meyer et al, 1997).
Different PCR fingerprinting studies have been used to investigate C.  albicans types 
associated with particular disease conditions,  anatomical  sites or geographical areas 
(Soil, 2000; Bartie et al, 2001). Particularly,  it has recently been shown that certain 
related  groups  of  C.  albicans  clones  may  be  endemic  in  specific  hospitals  and
197geographic areas (Clemons et al, 1997; Pfaller et al, 1998b; McCullough et al, 1999b; 
Schmid et al,  1999).  Furthermore, a discrete genetic cluster of fluconazole-resistant 
C.  albicans strains recovered from separate HIV-infected patients has recently been 
observed  (Xu  et  al,  2000;  Sullivan  &  Coleman,  2002).  This  finding  supports  the 
hypothesis that resistance occurred independently or that a resistant strain was spread 
by horizontal transmission among patients and highlights the potential value of strain 
characterisation in elucidating pathogenic and epidemiological traits.
In this  study,  C.  albicans  genetic  relatedness  was  assessed  for two  geographically 
different patient groups (London, UK and Parma, Italy) affected by DM. In this way, 
it would  be  possible  to  establish  a  geographic  variation  amongst  oral  C.  albicans 
strains that may  be  indicative  of local  diabetic treatment,  including antifungal use. 
Furthermore, C. albicans samples from oral cavities of non-DM healthy subjects were 
also  analysed  by  PCR  fingerprinting  to  evaluate  the  possible  genetic  differences 
among diabetic endogenous strains and non-DM ones. To the best of my knowledge, 
this  is  the  first  study  to  evaluate  the  genetic  variability  of the  C.  albicans  strains 
among DM patients and non-DM subjects using PCR fingerprinting methods.
Aim:  The  aim  of this  study  was  to  assess  the  genetic  variability  of the  oral  C. 
albicans  strain  among  DM  patients  from  different  localities,  and  amongst  DM 
patients and a group of non-DM subjects.
Hypothesis:  That there  are  genetic  differences between  Candida  isolates from DM 
patients and non-DM subjects as a result of differing and distinct oral environments. 
Furthermore,  it  is  hypothesised  that  London  and  Parma  DM  patients  will  carry 
genetically  distinct  Candida  strains  arising  from  the  respective  different  treatment 
regimens.
1987.2 Material and methods
Candida albicans isolates were collected as previously described (Sections 2.2). All 
isolates were well characterised and had been defined at species level as C. albicans 
(Sections 2.4-2.5).  The  analysis attempted to  evaluate the genetic  differences of C. 
albicans isolates from the 3  different groups of patients evaluated in this study. The 
analysis  did  not  include  other  Candida  spp.,  which  may  present  a  greater  genetic 
variability. The sample size of 30 C.  albicans isolates within each group was based 
on similar earlier comparative trials (Xu et al, 2000) and analyses showed that this 
number  was  needed  to  achieve  80%  power  for  revealing  genetic  differences,  if 
present.
Genomic  DNA  was  extracted  from  all  isolates  (Section  2.4.2).  Five  separate  PCR 
fingerprinting  techniques  were  performed  to  genotypically  assess  strain  similarity. 
Each  of these  techniques  used  a  specific  single  primer  (Table  7.1)  and  controlled 
thermocycler  parameters  as  outlined  in  Section  2.5.2.  All  PCR  amplicons  were 
separated  in  2%  agarose  gel  in  TAE  buffer  for  2  h  at  2  V/cm,  and  visualised  by 
ultraviolet transillumination following ethidium-bromide staining.
The results of the 5 PCR fingerprinting methods were combined by selecting 3 to 5 
polymorphic  bands  for  each  method,  resulting  in  17  polymorphic  bands  that were 
shown  to  be  widely  spread  through  the  genome.  Each  band  was  scored  as  either 
present or absent.  These results were phylogenetically analysed using the computer 
program PAUP 4.08. Simple analyses were carried out using the optimal criterion as 
distance  and  pair-wise  distances  between  each  of the  isolates  measured.  To  aid 
visualization of the relationship between isolates based on this analysis, a phenogram 
was generated by the unweighted pair-group method with arithmetic mean (UPGMA) 
(Nei,  1987).  Ties  (if  encountered)  were  broken  systematically  and  the  distance
199measure was set to mean character difference. The statistical analysis of the present 
chapter was performed by Dr M. J. McCullough,
7.3  Results
7.3.1  Comparison of genetic variability between DM patients and non-DM subjects 
Two C. albicans isolates (1  from UK non-DM control patients and 1  from Italian DM 
patients) previously identified and studied did not re-grow. Twenty-nine C.  albicans 
isolates from the non-DM control UK patients, 30 from the DM UK patients and 30 
from the DM Italian patients were selected (total of 89 C. albicans isolates) at random 
and  analysed  using the  results  from  all  5  fingerprinting methods.  Each  isolate was 
given a designation consisting of 17 digits. All  17 of the polymorphic bands chosen 
were parsimony-informative. These digits were either 0 or  1, depending on whether 
the polymorphic band was either absent or present respectively. For example, Table
7.2  shows the genotypic designation of 8 randomly chosen C.  albicans isolates. The 
number of differences in the bands between strains was measured.
Figures  7.1-7.5  show  examples  of electrophoretic  separation of PCR fingerprinting 
using the 5 different primers.
Statistical analyses of these PCR fingerprint banding pattern differences (Table 7.3) 
showed  that  there  was  an  average  of  3.24  differences  between  all  isolates  and 
genotype B; the  C  isolate  group was  significantly more  genetically coherent (mean 
difference  of 2.23  bands)  than  the  genotype  A  C.  albicans  isolate  group  (mean 
difference  of 3.72  bands,  p  <  0.0001).  Moreover,  the  isolates  from the  Italian  DM 
patients  were the  most  genetically  cohesive  group,  with  a mean  difference  of only 
2.93 bands; the isolates from the control patients had 3.09 mean differences and the 
isolates  from  the  UK  DM  patients  had  significantly  more  genetic  diversity  with  a 
mean number of differences between isolates of 3.65 (p < 0.0001; Table 7.3).
200Phylogenetic  analysis  of these  isolates  was  graphically  depicted  by  a  phylogram, 
shown in Figure 7.6. The distance shown at the bottom of this phylogram of 0.1  is the 
distance within which strains are 90% similar. The 89 C. albicans isolates studied can 
thus  be  grouped  and  sub-grouped  based  on  this  phylogenetic  analysis.  Table  7.4 
shows that these isolates can be divided into 4 large genotypic groups (A to D) that 
are co-located on the phylogram  (Figure 7.6) and are more than 90% genotypically 
similar, while the other  17 genotypic sub-groups (A1-A17) are co-located and more 
than 95% similar (Table 7.4)
201Table  7.1:  Designation  and  sequence  of the  5  primers  used  in  each  of  the  5 
distinct PCR fingerprinting techniques for phlyogenetic analysis
Designation Sequence 5’ - 3 ’
TELO T G G   G T G   T G T  G G G   T G T   G T G   G G T  G T G
GACA G A C   A G A   C A G   A C A   G A C   A
M 13 G A C   G G T   G G C   G G T  T C T
O PA-03 A G T   C A G   C C A   C
T3B A G G   T C G   C G G   G T T  C G A   A T C
202Table 7.2: Genetic strain designation of 8 randomly selected isolates based on the 
17 polymorphic PCR fingerprinting methods
Strain designation TELO GACA M13 OPA-03 T3B
A 0100 010 Oil 11 10100
B 0100 110 Oil 11 11101
C 0010 110 Oil 10 00001
D 0010 110 Oil 01 00011
E 0101 110 Oil 11 11101
F 0100 110 Oil 11 11101
G 0100 010 Oil 11 11101
H 0101 110 111 11 11101Figure 7.1:  Examples of electrophoretic separation of PCR fingerprinting using 
(GACA)4 sequence
T h r e e   b a n d s  w e r e   s e le c te d   fo r  e v a lu a tio n   in  th is  s tu d y :  A :  - 3 1 0 b p ,  B :  - 2 8 1   b p ;  C :~  2 3 4   b p
3 B
Figure 7.2:  Examples of electrophoretic separation  of PCR fingerprinting using 
OPA-03 sequence
T w o  b a n d s   w e r e   s e le c te d   fo r  e v a lu a tio n   in  th is  s tu d y :  A :  - 1 0 5 3   b p :  B :  a b o v e  6 0 3   b p
204Figure 7.3:  Examples of electrophoretic separation of PCR fingerprinting using
T3 B sequence
F iv e  b a n d s w e r e  s e le c te d  fo r  e v a lu a tio n   in  th is  stu d y :  A :  - 1 0 5 3   b p :  B :  - 1 0 7 8  b p ; C :  - 8 7 2   b p :  D :  b e lo w   8 7 2   b p ;  E :
a b o v e  3 1 0  b p
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Figure 7.4:  Examples of electrophoretic separation of PCR fingerprinting using 
M13 phage core sequence
T h r e e  b a n d s  w e r e  s e le c te d   fo r  e v a lu a tio n   in   th is  s tu d y :  A :  b e lo w  8 7 2   b p :  B :  a b o v e  3 1 0  b p ;  C :  - 3 1 0  b p
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Figure  7.5:  Examples  of eletrophoretic  separation  of PCR  fingerprinting  using 
TELO 1
F o u r  b a n d s w e r e  s e le c te d   fo r e v a lu a tio n   in  th is  stu d y :  A :  a b o v e  6 0 3   b p ;  B :  a b o v e   3 1 0  b p ;  C :  - 2 7 1   b p ;  D :  ~ 2 3 4 b p
206Table 7.3: Statistical analysis of the PCR fingerprint banding pattern
Variable Isolates N Mean p value
All isolates 8 9 3 9 1 6 3 .2 4   ( 2 .0 6 )
Genotype A 6 0 1 6 5 3 3 .7 2   ( 2 .2 5 )
Genotypes B and C 2 9 4 6 5 2 .2 3 ( 1 .1 7 ) <0.0001#
Non-DM control subjects 2 9 4 0 6 3 .0 9 ( 1 .7 9 )
UK DM  patients 3 0 4 3 5 3 .6 5   ( 2 .2 8 )
Italian  DM  patients 3 0 4 3 5 2 .9 3 ( 1 .9 2 ) <0.0001*
S ta tis tic a l  a n a ly s is  w a s  p e r fo r m e d   u s in g  T  te s t ( # ) a n d   A N O V A  (* ) te s t
N   is  th e   n u m b e r  o f  c o m p a r is o n s  m a d e  b e tw e e n  th e   is o la te s  w ith in  th e  c o h o r t o f  p a tie n ts r e s u ltin g   in  th e  g iv e n  
m e a n  (S D  =   sta n d a r d  d e v ia tio n ) g e n o t y p ic   d iv e r s ity   fo r  e a c h  o f  th e  g r o u p s
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Figure 7.6-A:  First part (of two) of the phylogram  of the 89 C.  albicans isolates 
based on the analysis of the PCR fingerprinting results
H o r iz o n ta l  lin e s   a r e   s h o w n ,  s tr a in s  to   th e   r ig h t  o f  th e s e   a r e   9 0 %   a n d   9 5 %   s im ila r ,  v e r tic a l  lin e s   a n d   d e s ig n a tio n s  
s h o w n   o n   th e   r ig h t  m a r g in   a r e   b a s e d   o n   th e s e   le v e ls   o f  s im ila r ity   a n d   a r e   lis te d   in   T a b le   7 .4
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Figure 7.6-B: Second part (of two) of the phylogram of the 89 C. albicans isolates 
based on the analysis of the PCR fingerprinting results
H o r iz o n ta l  lin e s   a r e   s h o w n ,  s tr a in s  to   th e   r ig h t  o f  th e s e   a r e   9 0 %   a n d   9 5 %   s im ila r ,  v e r tic a l  lin e s   a n d   d e s ig n a tio n s  
sh o w  n   o n   th e   r ig h t  m a r g in   a r e   b a s e d   o n   th e s e   le v e ls  o f  s im ila r ity   a n d   a r e   lis te d   in   T a b le   7 .4
209Table  7.4:  Genotypic  distribution  of  the  89  C.  albicans  isolates  based  on 
phylogenetic analysis of the PCR fingerprinting results
G e n o t y p e   g r o u p I s o la t e   d e s ig n a t io n
A l D P R 9 5
A 2
C M 7 1 ,  C M  1 9 ,  C M  1 0 4 ,  C 2 4 ,  D L  1 1 4 ,  D L 8 4 ,  D L 4 2 ,  D P R  1 1 1 ,  D P R 9 0 ,  D P R 4 0 , 
D P R 1 ,  D P R 9 ,  C Z 4 1 ,  C Z 4 3 ,  C Z 4 4 ,  C Z 2 2 ,  D L 1 2 4 ,  D L 1 1 5 ,  D P R 9 4 ,  D P R 8 6 , 
D P R 2 ,  D P R 3 0 ,  C M 2 9 ,  C M 2 3
A 3 D L 1 3 ,  D L 1 5 ,  D P R 1 5 ,  D P R 1 0 5
A 4 D L 6 6 ,  D P R 2 5 ,  D L 9 ,  C M  1 8 ,  D L 7 7 ,  D L  1 1 ,  D L 8 ,  D L 2 ,  D P R 4 1 ,  D P R 8 4
A 5 D L 1 0 ,  D P R 7 2 a ,  D P R 8 9 ,  D L 7
A 6 C Z 5 7 .  C Z 6 3
A 7 D L 5 4
A 8 D P R 4 ,  C Z 6 1 ,  D P R 3 ,  C Z 2 1 ,  C Z 3 7 ,  D P R 8 ,  C Z 2 8
A 9 C Z 1 6 ,  C Z 1 0 4
A 1 0 D P R  1 7 ,  D P R 9 3 ,  C Z 1 5 ,  D L 1 1 3 ,  C Z 3 6
A l l D L 4 4 ,  D L 8 1
A 1 2 D L 1 1 6
A 1 3 D L 1 1 0 ,C M 7 7
A 1 4 C Z 5 0 ,D L 1 2 1 ,D L 1 1 2 ,C M 8 4
A 1 5 C M 7 5
A 1 6 D P R  1 2 ,  D P R 3 2 ,D P R 4 4 ,D L  1
A 1 7 D P R 3 8 b ,D P R 7 4 ,D L 6 7
B D L 1 1 1 ,   D L 1 2 2
C D L 6 ,D P R 9 6 ,D L 4
D C M 8 5 ,  D P R  1 8 ,  C Z 1 0 5 ,  D L 1 2 6 , C Z 3 8 ,  C Z 1 0 2 ,  D P R 2 7
T h e   th r e e   la r g e   g e n o ty p ic   g r o u p s   (A   to   C )  a r e   is o la te s   th a t  a r e   c o -lo c a te d   o n   th e   p h y lo g r a m   (F ig u r e   7 .6 )  a n d   a re 
m o r e   th a n   9 0 %  g e n o ty p ic a lly   s im ila r ,  w h ile   th e   o th e r   1 7   g e n o ty p ic   su b g r o u p s  ( A 1 -A 1 7 )  a r e   c o -lo c a te d   a n d   m o r e  
th a n   9 5 %   s im ila r   (s e e   p h y lo g r a m   F ig u r e   7 .6 ).  T h e   fin a l  g e n o ty p ic   g r o u p .  G r o u p   D .  c o n s is ts   o f  th e   m o s t  d iv e r s e  
is o la te s :  n o n e   o f  th e s e   is o la te s   a r e   m o r e   th a n   9 0 %   s im ila r  to   o n e   a n o th e r  o r   to   a n y   o th e r   is o la te .  T h e   le tte r   in   th e  
is o la te  d e s ig n a tio n   in d ic a te s  th e  p a tie n t c o h o r t  fr o m   w h ic h  th e   is o la te  w a s  iso la te d :  C M   a n d  C Z  =  n o n -D M  c o n tr o l 
p a tie n ts:  D L   =   D M   p a tie n ts fr o m   L o n d o n   U K ;  D P R   =  D M   p a tie n ts fr o m   P a r m a .  Ita ly
2107.4 Discussion
The observed variation in genotypic diversity of the C. albicans isolates in the present 
study may be indicative of the distinct ecological niches that occur in the oral cavities 
of these  patient  cohorts.  The  statistical  correlation  of this  genotypic  diversity,  as 
assessed in the present study, shows that the group of isolates isolated from the DM 
patients  in the  UK were the  most diverse  (mean  diversity  =  3.65,  Table  7.3).  This 
diversity was statistically higher than both control patient isolates (mean diversity =
3.09,  Table 7.3) and isolates from DM patients in Italy (mean diversity = 2.93, Table 
7.3). This result may reflect the patient cohort from which these strains were isolated, 
with DM patients  in the UK affected by  long-standing DM and with more diabetic 
complications (neuropathies and retinopathies) than patients from Italy. Alternatively, 
it may reflect the antifungal treatment that these patients received. As reported in the 
previous  Chapter  (Section  6.3.4),  more  Candida  isolates  from  UK  patients  had 
increased  resistance  to  azole  agents  and  a  trend  of  increased  resistance  to 
amphotericin B than those from DM patients from Parma.
Further research  is  necessary to  elucidate the true cause  of the  observed  genotypic 
diversity, with the  inclusion of isolates from patient cohorts with systemic diseases 
different to DM, and from more diverse geographic localities.
The  broad  genotypic  subgroups  of  isolates  designated  as  subgroup  A,  B  and  C 
(Section 2.5.1) are based on the presence or absence of a transposable intron within 
the  25  S  rDNA  (Mercure  et al,  1993).  Genotypic  subgroup  A  does  not  have  this 
intron,  while  in  subgroup  B  it  is  present  in  all  copies  of the  25  S  rDNA  and  in 
subgroup C it is partially present (Mercure et al,  1993). The analysis of the genotypic 
diversity in the present study showed that subgroup A isolates without the intron are 
less genotypically cohesive than  sub-group B  or C  isolates.  It may well  be that the 
ability  to  acquire  this  intron  within  the  25  S  rDNA  is  confined  to  a  particularly
211genetically  cohesive  sub-group  of  C.  albicans  that  possess  currently  unknown 
phenotypic traits. Interestingly, the present study did not find any association between 
a particular genotype of C.  albicans and the type, disease progression and degree of 
control  of DM  (Chapter 4,  Section 4.3.1.3),  although previous  studies  have  shown 
that these strains exhibit enhanced antifungal susceptibility (Mercure et al, 1993).  ^  
Phylogenetic analysis of these isolates, as presented in the phylogram (Fig. 7.6, A and 
B)  and  the  table  of clustered  isolates  (Table  7.4)  shows  a  different  aspect  of the 
genotypic  diversity  of these  isolates  from that expressed by the  statistical  analysis. 
The  statistical  analysis  describes  the  similarity  that  each  isolate  had  with  other 
isolates from patients within the same cohort. The phylogenetic analysis assesses the 
uniqueness of each isolate and parsimoniously compares this with all isolates studied. 
Phylogenetic  analysis  has  revealed  several  interesting  findings.  Firstly,  this  PCR 
fingerprinting method found genetic identity in eight pairs of isolates (subgroups A2, 
A5, A10 twice, A14, A16 twice and A17), four triplets (subgroups A3, A4 and A8 
twice), a group of 7 isolates (subgroup A4), a group of 10 isolates (subgroup A2) and 
a group of 12 isolates (also in subgroup A2) (Fig. 7.6). This would indicate that the 
PCR fingerprinting method is not so overtly sensitive that it discriminates all isolates 
to the  individual  level,  yet  is  able to  cluster genetically  similar isolates  into  useful 
epidemiological  subgroups.  Furthermore,  the  fact  that  all  17  PCR  fingerprinting 
bands  chosen  for  inclusion  in  the  analysis  were  parsimony-informative reflects  the 
genetic diversity of these codominant markers.
Secondly,  out of the  15  groups  of isolates outlined  in the preceding paragraph that 
showed  genotypic  identity  with  this  method,  in  only  two  of these  groups  did  all 
isolates come from the same patient cohort. This occurred with two pairs of isolates 
in the  subgroups A2  and A16.  The  fact that this  PCR fingerprinting  method  found 
isolate  identities between  isolates from  all  three patient cohorts reflects the  genetic
212similarity that exists within this fungal species. A more interesting observation is the 
extreme genetic diversity seen in isolates within subgroup D (Fig. 7.6 and Table 7.4). 
These  isolates  had  very  little  genetic  relationship  with  either the  other  C.  albicans 
isolates or other members of the same  subgroup.  The presence of these  isolates did 
not skew the statistical analysis (Table 7.4) as only one of these 7 isolates (DL126) 
came from the most genotypically diverse patient cohort (the strains isolated from the 
DM  patients  in  London,  UK).  Therefore,  as  indicated  above  there  must  be  other 
reasons  for  the  genotypic  diversity  observed  in  the  DM  London  patient  isolates. 
Nevertheless, these extremely genetically diverse isolates that make up this subgroup 
D (Fig.  7.6 and Table  7.4) warrant further study.  It could be hypothesised that this 
subgroup represents  a unique  non-clonal  expansion  of C.  albicans  strains that may 
indicate either sexual or some other method of rapid transfer of genetic information. 
Finally, and as indicated above, the present analysis was only conducted with patients 
from two localities, who were either deemed suitable to represent a “normal” control 
population, or who had DM.
Further studies that include isolates from patient cohorts with systemic diseases other 
than DM, and from more diverse geographic localities are needed in order to compare 
the results obtained in these population groups.
213CHAPTER 8 
In vitro activity of a rat monoclonal IgM antibody (K10) 
and of a synthetic anti-idiotype peptide (KP) against 
different strains of Candida spp.
8.1  Introduction
Yeast killer toxins (KTs) are exotoxins (generally proteins or glycoproteins) secreted 
by a number of yeast species that are capable of killing susceptible cells belonging to 
the  same  or  different  species  (Somers  &  Bevan,  1969;  Young  &  Yagiu,  1978; 
Wickner, 1985; Polonelli et al, 1991b; Magliani et al, 1997b). Killer cells are immune 
to  their  own  toxins,  and  much  remains  to  be  elucidated  over  the  mechanisms  of 
killing and immunity associated with killer systems (Magliani et al, 1997b).
Interest in the yeast killer phenomenon has recently increased, particularly because of 
the  surprising  susceptibility  of  microorganisms  of  clinical  interest,  such  as  C. 
albicans, Pneumocystis carinii and Mycobacterium tuberculosis, to killer toxins from 
species of the genera Pichia and Williopsis (Polonelli & Morace, 1986a; Morace et al, 
1989; Aliouat et al, 1993; Magliani et al, 1997b).
A toxin produced by the killer yeast Pichia anomala ATCC 96603 (PaKT) has been 
identified  as  a  large  glycopeptide  molecule  and  exhibits  activity  against organisms 
possessing  target  cell-wall  receptors.  Candida  species  are  among  the  organisms 
susceptible to PaKT and to this effect the p-glucans of the cell wall are believed to act 
as toxin receptors (Polonelli & Morace,  1986b; Polonelli et al,  1990). However, even 
if  the  candidacidal  activity  of  PaKT  is  mediated  in  part,  or  as  a  whole  by  its
214interaction with 0-glucans, the exact mechanism through which PaKT works is still 
unknown.
A  wide  spectrum  of activity  has  led to the  consideration  of a potential  therapeutic 
effect  of  PaKT  (Polonelli  et  al,  1986)  in  the  treatment  of  fungal  infections. 
Regretfully, the value of PaKT as an antibiotic therapeutic is hampered due to its high 
level  of  toxicity,  antigenicity  and  its  instability  at  physiological  pH  (Pettoello- 
Mantovani et al,  1995; Conti et al,  1996). Anaphylactic reactions may be provoked, 
or  neutralizing  antibodies  may  be  produced  by  the  immune  system  after 
administration  of yeast killer toxins.  Only  small  biologically  active  killer peptides, 
devoid of immunogenicity, have the potential to be applied therapeutically (Magliani 
etal, 1997b).
In order to exploit the antimicrobial activity of PaKT without undesired side-effects, a 
KT-neutralizing monoclonal antibody (mAbKT4) has been generated according to the 
idiotypic network theory (Jeme, 1974), for the production of anti-idiotypic antibodies, 
and this antibody mimics the killer toxin, PaKT.
The  idiotypic  network  is  based  on  the  dual  character of the  antibody  molecule,  in 
which any antibody is able to interact with an antigen through the antigen-binding site 
(paratope) and at the same time,  its variable region (idiotope) can be matched by a 
complementary three-dimensional  surface of another antibody variable region (anti­
idiotype).  An  idiotype  produced  in  the  course  of an  immune  response  against  a 
particular  antigen  can  stimulate  the  production  of  complementary  anti-idiotypes, 
according to an idiotypic cascade (Figure 8.1) (Magliani et al,  1997b). Production of 
anti-idiotypes  may  be  self-limiting  because  of their  similarity  to  the  idiotypes.  An 
important implication of the network theory is that the combining site of some anti­
idiotypes,  which  are  complementary  to  the  antigen-complementary  idiotype,  may 
resemble the immunogenic determinant of the external antigen (Figure 8.1, Ab2(3). In
215this  case,  the  anti-idiotype  variable  region  represents  the  internal  image  of  the 
external  antigen  and,  in  certain  circumstances,  may  mimic  its  biological  activity 
(Georgatos, 1993; Fields et al, 1995).
According to the theory of the idiotypic network, mAbKT4 was used as immunogen 
(idiotypic  vaccination)  to  elicit  anti-idiotypic  antibodies  representing  the  internal 
image of PaKT. Immunisation of animals of different species (rabbits, rats and mice) 
by  intravenous  or  intravaginal  route  with  mAb  KT4  resulted  in  the  production  of 
serum  or  secretory  immunoprotective  KT-like  anti-idiotypic  antibodies  (KT-IdAb) 
(Polonelli & Morace,  1988; Polonelli et al,  1991a; Polonelli et al,  1993; Polonelli et 
al, 1994).
KT-IdAb,  as  an  internal  image  of PaKT,  has been  shown  to  interact with putative 
killer toxin cell-wall receptors (KTR) of sensitive C.  albicans cells (Polonelli et al, 
1990;  Magliani  et al,  1997b).  KTR has recently been  identified as having  p-glucan 
moieties  (Guyard  et al,  2002a;  Guyard  et al,  2002c) thus  indirectly  supporting the 
concept that KT-IdAb could indeed recognize the p-glucan cell-wall polysaccharide 
components through which it could exert its cytocidal action (Cassone et al, 1997).
The  KT-IdAb,  which  contains  the  internal  image  of KT  and  thus  mimics  PaKT’s 
fungicidal  effect,  has  demonstrated  killer  activity  against  KT-sensitive  yeasts 
(Magliani et al,  1997a).  To obtain  standardizable reagents in sufficient amounts for 
therapeutic  assays,  KT-IdAb  were  produced  in  the  monoclonal  (KtmAb-KlO)  and 
recombinant  single-chain  fragment variable  (KTscFvH6)  format  by  hybridoma  and 
phage  display  molecular  technologies  from  animals  vaccinated  with  mAbKT4 
(Magliani  et  al,  1997a;  Polonelli  et  al,  1997).  All  these  novel  KT-mimicking 
antibodies  displayed  in  vitro  and  in  vivo  antimicrobial  activity  against  KTR 
possessing,  pathogenic  microorganisms  (Magliani  et al,  1997a;  Seguy  et al,  1997;In an attempt to  identify biologically  active  fragments for possible therapeutic  use, 
the  entire  sequence  of KTscFvH6  was  sequenced  and  synthesised  in  a  number  of 
overlapping decapeptides, each displaced of two residues, and with special focus on 
those pertaining to complementary-determining region (CDR) domains.  A  synthetic 
decapeptide  fragment  (P6),  which  was  derived  from  the  sequence  of the  variable 
region of KTscFvH6 and contained part of the CDR1  of the VL chain, was analysed 
by alanine  scanning  in order to  identify the  functional  contribution of each  residue 
(Section 2.10). The decapeptide with the highest candidacidal activity (KP) was then 
selected for  large  scale  synthesis based  on  its  high  candidacidal  reactivity  in  vitro. 
Figure  8.2  shows the  interaction of PaKT with  KTR and  also that of natural,  anti- 
idiotypic  polyclonal,  monoclonal  and  recombinant  antibodies,  representing  its 
internal image, and synthetic peptides (mimotopes) (Magliani et al, 2004).
Aim: The aim of this study was to evaluate the killer activity of a monoclonal anti- 
idiotypic antibody (K10) and of the synthetic decapeptide (KP) on selected Candida 
spp. isolated from the oral cavity of DM patients and a non-DM control population.
Hypothesis: Differences occur in Candida isolates susceptibility to mAbKlO and KP 
depending  on  their  patient  origin  and  that  these  differences  correlate  with  the 
susceptibility profiles observed using conventional antifungal agents.
8.2  Methods
8.2.1  mAbKlO
Hybridoma cells secreting mAbKlO were grown in a specific medium (Section 2.9.1) 
and  the  supernatant  from  the  culture  was  collected,  precipitated  in  ammonium
217sulphate  saturated  solution  and then  dialysed  against PBS  for 48  h  (Section  2.9.1) 
(Polonelli et al, 1997).
Antibody  concentration  was  achieved  by  capture  ELISA  using  a  pair  of  mouse 
monoclonal antibodies against p heavy chain of rat immunoglobulin (Section 2.9.1). 
The  candidacidal  activity  of  mAbKlO  was  evaluated  in  vitro  by  a  cfu  assay  on 
selected isolates of Candida spp. from each of the patient group’s investigated in this 
study (DM patients from London and Parma and a control non DM group,  Sections
2.1.1,  2.1.2,  2.1.3).  Due  to  the  limited  availability  of K10  and  KP,  analysis  was 
undertaken with a reduced but still representative number of Candida isolates.
Twelve Candida isolates (C.  albicans and non-C.  albicans spp.) that had previously 
been shown to be sensitive to six antifungal agents (Section 2.8 and 6.3) and a further 
12  resistant  isolates  were  initially  selected  from  each  patient  group  for this  study. 
However, during the course of investigation one of the isolates (from a DM patient 
from  Parma)  did  not  re-culture  and  was  excluded.  Time  constraints  precluded  its 
replacement (Tables 8.1-8.2).
Statistical analysis of data was performed using the Mann-Whitney (when two groups 
of data were analysed) or Kruskall-Wallis (when more than two groups of data were 
analysed)  non  parametric  tests  and  differences  within  or  between  groups  were 
considered significant when the probability (p) was less than or equal to 0.05.
8.2.2  Killer Peptide (KP)
Soluble  powder  of  synthesised  KP  was  kindly  provided  by  Professor  Polonelli 
(Sezione  di  Microbiologia,  Dipartimento  di  Patologia  e  Medicina  di  Laboratorio, 
Parma University, Italy). The candidacidal activity of KP was evaluated in vitro by a 
cfu assay on selected isolates of Candida spp. as detailed earlier (Section 2.10).
2188.3 Results
8.3.1  Candidacidal activity of mAbKlO
The  rat  monoclonal  mAbKlO  was  found  to  have  a  significant  antifungal  activity 
against all the Candida strains evaluated in this study (Tables 8.1-8.2-8.3).
To confirm that the colonies of Candida spp. that initially survived the killer activity 
of mAbKlO were not resistant mutants of Candida  strains, a second cfu assay was 
performed  on  these  colonies  under  the  same  experimental  conditions.  All  isolates
remained sensitive with a 100% killing rate upon repeat testing.  ^  Soi' 1
cr ‘.> '«■’<
No  significant  differences  (p=0.45)  were  observed  in  the  candidacidal  activity  of 
mAbKlO  between  C.  albicans  (50-99% killing  rate,  mean =  76.9,  SD  =  13.1)  and 
non-C.  albicans  isolates  (30 -99.5% killing  rate,  mean =  73.2,  SD  =  17.8)  (Table 
8.1). In addition, no significant differences (p=0.76) were evident in the candidacidal 
activity of mAbKlO against oral yeast isolates that had previously found to be either 
resistant  or  intermediately  resistant  to  conventional  antifungals  (30-99.5%  killing 
rate,  mean =  74,  SD  =  17)  and those  isolates that were previously  susceptible  (50- 
97% killing rate, mean = 76.1,  SD =  13.8) (Table 8.2). Furthermore, no statistically 
significant differences  (p=0.71) were  again apparent  in the  candidacidal  activity  of 
mAbKlO for the isolates from the different patient populations (London DM patients, 
45-99% killing rate, mean = 77.5, SD =  12.8; Parma DM patients, 30-99.5% killing 
rate,  mean =  72.7,  SD  =  18.4;  and  non-DM  controls (45-99% killing  rate,  mean  =
74.9,  SD= 15) (Table 8.3).
8.3.2.  Candidacidal activity of KP  v/
Synthetic  peptide  KP  had  a  significant  candidacidal  activity  upon  all  the  Candida 
isolates examined in this study. There was a  100% killing rate when a concentration
219of lOOpg/ml KP was used. Although the killing rate decreased when a concentration 
of 20pg/ml was used, although for most isolates the killing rate still exceeded 90% 
(Tables 8.1-8.2-8.3).
To confirm that the colonies of Candida spp. that initially survived the killer activity 
of KP were not resistant mutants of Candida strains, a second cfu assay was again 
performed  under  the  same  experimental  conditions  and  as  previously  noted  with 
mAbKlO, all the isolates were sensitive.
No  significant differences (p=0.14) were evident in the candidacidal activity of KP 
for C.  albicans (58-100% killing rate, mean = 92.8, SD =  10.1) and non-C. albicans 
isolates  (68.7-100%  killing  rate,  mean  =  92.2,  SD  =  7.1)  (Table  8.1).  In  addition, 
there  were  no  differences  (p=0.47)  in  the  candidacidal  activity  of KP  against  oral 
yeast isolates that had previously been shown to be either resistant or intermediately 
resistant to conventional antifungals (61-100% killing rate, mean = 93, SD = 8.5) and 
those  isolates that were previously  susceptible  (58-100% killing rate,  mean =  92.1, 
SD = 8.7) (Table 8.2).
Statistically significant differences (p<0.01) were observed in the antifungal activity 
of KP  against the  isolates  from  London DM  patients  (58-100%  inhibition,  mean  =
89.9,  SD = 11.4) and those from Parma (84-100% inhibition, mean = 96.2, SD = 5.3) 
(Table  8.3).  Statistically  significant  differences  (p<0.01)  were  also  observed  in  the 
antifungal  activity  of  KP  against  isolates  from  Parma  DM  patients  (84-100% 
inhibition, mean = 96.2, SD = 5.3) and non DM controls (75-100% inhibition, mean = 
91.7, SD = 6.7) (Table 8.3).
The fungicidal action of KP was dose-dependant, as determined by testing the peptide 
at different concentrations against small  groups of C.  albicans and non-C.  albicans 
isolates of differing antifungal susceptibilities. Almost  100% fungicidal activity was
220obtained  at  20pg/ml  of  KP,  but  good  candidacidal  activity  was  also  evident  at 
15pg/ml  (90-99%  Candida  killing  rate)  and  at  lOpg/ml  (48-96%  Candida  killing 
rate)  of KP.  At  a  concentration  of 5|jg/ml,  the  candidacidal  action  of KP  showed 
considerable  variation  and  with  one  C.  albicans  isolate  expressing  resistance  to 
itraconazole, 5pg/ml of KP had no candidacidal action (Table 8.4).
8.4  Discussion
Recently,  rat  IgM  monoclonal  (mAbKlO)  and  recombinant  single-chain  fragment 
variable  (scFvH6)  anti-idiotypic  antibodies,  functionally  mimicking  the  activity  of 
PaKT,  have  been  produced  by  idiotypic  vaccination  with  a  mouse  monoclonal 
antibody  (mAbKT4)  that neutralised  PaKT  (Magliani  et al,  1997a;  Polonelli  et al, 
1997). Monoclonal antibody K10 and scFvH6 displayed microbicidal activity in vitro 
and  a  therapeutic  effect  in  vivo  against  KTR-bearing  eukaryotic  and  prokaryotic 
pathogenic  microorganisms  (Magliani  et al,  1997a;  Seguy  et al,  1997;  Conti  et al, 
1998; Conti et al, 2000; Cenci et al, 2002; Conti et al, 2002; Savoia et al, 2002). The 
most active among the synthesised decapeptides of scFvH6 (P6), containing part of 
the  CDR-L1  region,  was  selected  for  large  scale  synthesis  and  analysed  through 
alanine  scanning  to  evaluate  the  critical  relevance  of each  residue.  A  decapeptide 
(KP) proved,  in comparison with  its own  scramble peptide (SP), to  exert enhanced 
candidacidal activity in vitro. This activity was found to be inhibited by laminarin (a 
soluble  p-1,3  glucan  preparation)  but  not  by  pustulan  (a  soluble  p— 1,6  glucan 
preparation).  Furthermore,  KP  also  showed  a  potent  therapeutic  effect  in  vivo  in 
immunocompetent  and  immunosuppressed  mice  against  vaginal  and  systemic
candidiasis  caused  by  fluconazole  sensitive  and  resistant  strains  (Polonelli  et  al,
/
2003).  ^
221In the present study, mAbKlO and KP have been shown to have significant antifungal 
activity on a wide spectrum of oral isolates of different Candida spp., irrespective of 
the  species  or  previous  susceptibility  to  conventional  antifungals.  However,  KP 
activity  on  the  Candida  isolates  from  Parma  DM  patients  was  higher than  that  of 
isolates  from  the  London  DM  patients  (p=0.006)  and  that  of the  non-DM  control 
subjects  (p=0.02).  This observed  variation  is not readily  explained,  but may reflect 
the  natural  variability  of expression  of the  KTR  throughout  all  fungi.  It  has  been 
reported (Chapter 6, Section 6.3.4) that the isolates from the London DM population 
were more resistant to several conventional antifungal agents than  Candida  isolates 
from  Parma  and  from  the  control  group.  Furthermore,  although  the  range  of KP 
activity  on  the  isolates  of the  three  groups  was  varied,  the  inhibition  of candidal 
growth by KP on the  isolates of the London DM group was over 58% (Table  8.3), 
even  for  the  isolates  that  were  completely  resistant  to  the  conventional  antifungal 
agents  tested.  The  wide  spectrum  of candidacidal  activity  most  likely  reflects  the 
ability  of  mAbKlO  and  KP  to  interact  with  all  tested  P-glucan-KTR-possessing 
pathogenic microorganisms, including Candida spp. (Magliani et al,  1997a; Polonelli 
et al,  1997; Conti et al,  1998).  It has recently been described (Polonelli et al, 2003) 
that the candidacidal  activity of mAbKlO and KP against the reference  C.  albicans 
strain was  inhibited dose-dependently by laminarin (a p-1,3  glucan soluble product 
representing the main target of PaKT). Furthermore, it has recently been reported that 
the KTR is a p-glucan component of the cell wall (Guyard et al, 2002b; Guyard et al, 
2002c). As glucan and glucan-like molecules are widely present in microbes, where 
they exert critical structural and/or virulence properties, their targeting may provide a 
novel  and  extensive  therapeutic  approach  to  microbial  infections  (Bromuro  et  al,
2002).  Therefore,  mAbKlO  and  KP  can  display  a  wide  spectrum  of antimicrobial 
activity,  including  yeasts  and  filamentous  fungi,  other than  Candida  spp.,  and  this
222activity has been shown in diverse species such as Aspergillus fumigatus (Cenci et al,
2002),  Cryptococcus neoformans (Cenci et al, 2004), Paracoccidioides brasiliensis, 
Pneumocystis carinii (Seguy  et al,  1997),  as well  as protozoa,  such  as Leishmania 
spp. (Savoia et al, 2002) and bacteria (Conti et al, 1998; Conti et al, 2000; Conti et al, 
2002).
The previously described variation in the susceptibility of the different yeast isolates 
to  mAbKlO  and  KP  may  reflect  the  expression  of  specific  cell-wall  receptors. 
Candida colonies that initially survived exposure to mAbKlO and KP during the cfu 
assay were subsequently shown to be equally susceptible in a second cfu experiment 
{i.e.  they  were  not  resistant  mutants  of Candida  strains).  Changes  in  the  time  of 
interaction of the  Candida  cells with mAbKlO and KP or in the different phase of 
growth  of Candida  cells  were  shown  to  influence  the  killing  activity  on  the  same 
Candida isolates, presumably in terms of expression of number of cell-wall receptors 
that could  interact with the  sufficient amount of mAbKlO  and KP  (Polonelli  et al,
2003).  -
The  marked  susceptibility  of  strains  of  Candida  spp.  (resistant  to  conventional 
antifungal  agents) to mAbKlO and KP  is of particular interest in view of increased 
clinical  concern  regarding  antimicrobial  resistance  in  these  and  allied  fungi 
(Alexander  &  Perfect,  1997).  The  mechanisms  of  resistance  to  conventional 
antifungal agents found in the Candida spp. isolates investigated in the present study 
do not affect the susceptibility of these isolates to mAbKlO and KP. Even though the 
active  mechanism  of these  antibody  derivates  is  still  undetermined,  their  evident 
interaction  with  a  presumptive  KTR  localized  in  the  cell  wall,  such  as  p-glucan, 
suggests the presence of a fungal target that has therapeutic potential.  This may  be 
similar to a p-1,3 glucan synthesis inhibitor, such as pneumocandin or echinocandin, 
which displays fungicidal activity on different species of yeast and mould (Onishi et
223al, 2000; Denning, 2003). Resistance to these antifungal agents has been reported in 
spontaneous mutants of S.  cerevisiae and C.  albicans. However, this resistance may 
not  be  of clinical  relevance  as  the  mutants  exhibit  attenuated  virulence  in  animal 
models of experimental infections (Douglas et al, 1994; Kurtz et al, 1996).
KP  exerted  greater  candidacidal  activity  on  all  the  isolates  tested  in  the  study 
(percentage  of Candida  killing  rate,  total  mean  =  92.5)  than  mAbKlO.  This  may 
reflect the  different  structure  of the two  tested  molecules  compared  with  the  same 
concentration (20pg/ml) but characterised by different molecular weights (KP = -1 
Kda, K10 = -900 Kda) where K10 is a rat monoclonal Ig M antibody (Polonelli et al, 
1997),  and KP a synthetic decapeptide containing the first three amino acids of the 
light chain CDR1, which represents an active fragment of the KTscFv. Interestingly, 
the  deletion  of the  COOH-terminal  serine  alone  caused  a  remarkable  drop  (about 
three logs)  in KP activity, as recently reported (Polonelli et al, 2003). Nevertheless, 
the engineered synthetic anti-idiotype fragment KP represents the evolution of KT- 
IdAbs, through the monoclonal (K10) and recombinant format (Magliani et al, 1997a; 
Magliani et al, 1997b).
The impressive candidacidal activity of KP in vitro at low concentrations (5-10pg/ml) 
on  four  different  selected  Candida  strains,  indicates  that  KP  may  be  capable  of 
exerting  antifungal  action  in  vivo  with  therapeutic  administration.  An  in  vivo 
experimental  model  of  rat  vaginal  candidosis  showed  that  KP  was  capable  of 
significantly accelerating the clearance of Candida from the vagina of rats, similar to 
a therapeutic course of fluconazole (De Bemardis et al,  1999a).  KP also eradicated 
the vaginal infection in rats caused by a fluconazole-resistant strain of C. albicans, a 
finding of special interest in view of increased clinical concern regarding fluconazole 
resistance in this and allied fungi (Edwards, 1991; Alexander & Perfect, 1997).
224The potent therapeutic effect of KP was also observed in a mouse model of systemic 
candidosis (Mencacci et al,  1994) where the curative effect was similarly exerted in 
normal,  immunocompetent Balb/c  as well as  in  SCID  mice,  demonstrating that the 
therapeutic  benefit  of  KP  did  not  require  the  participation  of  an  adaptive  host 
immunity (Polonelli et al, 2003).
Although both mAbKlO and KP expressed good candidacidal activity in this in vitro 
study,  KP in particular, as a synthetic peptide, may represent the compound for the 
generation  of  a  new  class  of  broad-spectrum  antimicrobial  molecules  for  the 
prevention and treatment of superficial and systemic infection caused by KT-sensitive 
microorganisms.  The  mechanism  of  action  of  this  new  class  of  drug  reflects  a 
naturally  occurring  phenomenon,  that of killer yeasts,  and  as  such  may  be  able to 
overcome  currently  recognised  mechanisms  of  resistance  to  conventional 
antimicrobial  drugs  in  epidemiologically  relevant  prokaryotic  and  eukaryotic 
pathogenic microorganisms.
225Table 8.1:  Susceptibility  of C.  albicans and  non-C.  albicans isolates  to  mAbKlO 
and KP
C. albicans isolates
K10a
(% )
KPa
(% )
Candida isolates
K I0a
(% )
KPa
(% )
C. albicans A DL 2 99 1 0 0 C. dubliniensis DL 63 9 0 9 1 .7
C. albicans A DL 4 9 7 .1 9 7 .7 C. dubliniensis DL 41 9 7 8 9 .7
C. albicans A DL 7 7 7 .4 9 8 .6 C. dubliniensis DL 92 7 5 .1 9 2
C. albicans A DL  1 8 3 .4 9 7 .9 C. dubliniensis DL 72 7 0 6 8 .7
C. albicans A DL  18 7 1 9 3 .1 C. dubliniensis DPR 47 7 3 .4 9 9
C. albicans A DL 24 7 0 .5 8 9 .8 C. dubliniensis CZ 69 6 5 .2 7 5 .3
C. albicans A DL 66 8 4 .1 9 2 .2 C. dubliniensis CM 24 9 3 .1 8 8 .2
C. albicans A DL  121 7 8 .2 5 8 .2 C. dubliniensis CM 31 9 6 .1 9 5 .6
C. albicans A DPR 59 6 5 9 9 .7 C. dubliniensis CM 35 7 0 9 8 .1
C. albicans A DPR 67 5 0 .1 1 0 0 C. dubliniensis CM 72 6 0 .3 9 2 .5
C. albicans A DPR 96 7 4 .3 9 7 .4   | C. glabrata DL 48 7 3 .4 9 6 .3
C. albicans A DPR 98 6 5 .9 9 8 .4 C .  glabrata DL 102 6 5 8 3 .3
C. albicans A DPR 100 9 0 .4 1 0 0 C. glabrata DL 107 5 1 .6 9 9 .5
C. albicans A  DPR 38a 5 2 .7 8 2 .9 C. glabrata DL 125 9 3 9 5 .9
C. albicans A DPR 39 6 2 .4 9 8 C . glabrata DPR 28 9 9 .5 8 4 .4
C. albicans A DPR 95 8 0 9 7 .1 C. glabrata DPR 33 8 2 9 6 .9
C. albicans A DPR  107 9 7 1 0 0 C. glabrata DPR 24 6 2 .1 9 0 .5
C. albicans A CZ 58 9 9 9 2 .4 C. glabrata CZ 96a 4 5 .4 9 5 .4
C. albicans A CM 75 7 0 .5 7 6 .9 C. glabrata CZ 20 8 0 8 7 .2
C. albicans A CZ 22 7 4 .4 9 7 .1 C. glabrata CZ 98 5 4 .1 9 6 .3
C. albicans A CM 76 9 2 .2 9 3 .4 C. guilliermondii DL 73 7 8 .4 9 5 .2
C. albicans A CM 95 6 0 1 0 0 C. guilliermondii CZ 29 9 4 .4 9 2 .2
C. albicans B DL 67 7 8 .3 6 1 C. krusei DL 70 4 5 9 4 .2
C. albicans B DL  13 7 7 9 2 .9 C. krusei CM 30b 5 6 .1 9 5 .1
C. albicans B DPR 89 7 6 .2 9 8 C. krusei CZ 96b 8 7 7 9 .4
C. albicans B DPR  111 5 5 .3 9 9 C. krusei CM 20 6 0 9 4
C. albicans B CM  104 8 0 .2 9 9 .3 C. parapsilosis DL 98 7 2 .1 9 3
C. albicans B CM 23 8 5 .3 8 4 .7 C. parapsilosis DPR 66 3 0 9 9 .3
C. albicans C DL 54 8 0 .2 9 0 .5 C. parapsilosis DPR 23 9 3 .4 9 4 .1
C. albicans C DL 84 7 5 8 7 .2 C. parapsilosis DPR 68 8 8 9 9 .2
C   albicans C DPR74 8 7 .4 9 7 .8 C. tropicalis DL 86 7 8 .4 1 0 0
C.  albicans C DPR 9 9 1 .4 9 9 .8 C. tropicalis DPR 51 5 0 8 4
C. albicans C CM 29 7 7 9 0 .1 C. lusitaniae DPR 31 9 1 .1 9 8 .8
C. albicans C CM  110 6 0 9 6 .7 C. lusitaniae DPR 65 5 6 .4 9 8 .7
C. lusitaniae CM 30a 8 6 .2 9 3 .7
* m A b K 1 0  a n d   K P  w e r e   u s e d  a t  a  c o n c e n tr a tio n   o f  2 0   p g /m l;  th e ir  a c tiv ity   is e x p r e s s e d   a s a  p e r c e n ta g e   k illin g  ra te
e v a lu a te d   b y   th e  c fu  a s s a y   in   c o m p a r is o n   w ith  th e  p r o p e r  c o n tr o ls
S ta tis tic a l  a n a ly s is  w a s  p e r fo r m e d  u s in g  th e   M a n n -W h itn e y   n o n   p a r a m e tr ic  te st
D P R :  D M   p a tie n ts  fr o m   P a r m a .  Ita ly ;  D L :  D M  p a tie n ts   fr o m   L o n d o n .  U K ;  C M   a n d  C Z :  n o n -D M   s u b je c ts
226Table  8.2:  mAbKlO  and  KP  candidacidal  activity  on  Candida  isolates  with
different antifungal susceptibilities
Candida isolates
K10*
(%)
KPa
(%)
ASb Candida isolates
K10a
(%)
KPa
(%)
ASb
C. albicans A DL 2 99 100
.  R  
itr G albicans A DL  1 83.4 97.9 S
C. albicans A DL 4 97.1 97.7
i
mcz G. albicans A DL  18 71 93.1 S
C. albicans A DL 7 77.4 98.6 itrR  ketR 5-FCR G. albicans A DL 24 70.5 89.8 S
C. albicans B DL 67 78.3 61
.  1   1   „  R  .  R   ket  mcz  flu  itr G. albicans A DL 66 84.1 92.2 S
C. albicans C DL 54 80.2 90.5
i
mcz G albicans A DL  121 78.2 58.2 S
C. dubliniensis DL 63 90.0 91.7
„  i  i
flu mcz G. albicans B DL  13 77 92.9 s
C. glabrata DL 48 73.4 96.3 J r ,  1 ■   1   1 ab flu  itr  mcz G albicans C DL 84 75 87.2 s
C. glabrata DL  102 65.0 83.3 mcz'fluR ketR  itrR G dubliniensis DL 41 97.0 89.7 s
C. glabrata DL  107 51.6 99.5 ^  1 ,  1 •  1   1   flu  ket  itr  mcz G dubliniensis DL 92 75.1 92.0 s
C. guilliermondii DL 73 78.4 95.2 i .  i  i 
ket  itr mcz G dubliniensis DL 72 70.0 68.7 s
C. krusei DL 70 45.0 94.2
~  I   I .  R  
flu  mcz  itr G glabrata DL 125 93.0 95.9 s
C. parapsilosis DL 98 72.1 93 flu1  mcz15-FC1 G tropicalis DL 86 78.4 100 s
C. albicans A DPR 59 65 99.7 itr* G. albicans A DPR 38a 52.7 82.9 s
C. albicans A DPR 67 50.1 100 5-FCR G albicans A DPR 39 62.4 98 s
C. albicans A DPR 96 74.3 97.4
.  i
itr G. albicans A DPR 95 80 97.1 s
C. albicans A DPR 98 65.9 98.4 .  1«   R  •   R  ket  flu  itr G. albicans A DPR  107 97 100 s
C. albicans A DPR 100 90.4 100
.  i
itr C. albicans B DPR  111 55.3 99 s
C. albicans B DPR 89 76.2 98 ket‘ G albicans C DPR 9 91.4 99.8 s
C. albicans C DPR74 87.4 97.8
.  i 
itr G dubliniensis DPR 47 73.4 99.0 s
C. glabrata DPR 28 99.5 84.4
„   i .  i  i 
flu  itr  mcz G. glabrata DPR 24 62.1 90.5 s
C. glabrata DPR 33 82.0 96.9
.  i
itr G parapsilosis DPR 23 93.4 94.1 s
C. lusitaniae DPR 31 91.1 98.8 flu  ket* itr' mcz'5-FC1 G . parapsilosis DPR 68 88.0 99.2 s
C. lusitaniae DPR 65 56.4 98.7 flu' ket' itr'mcz' 5-FC* G tropicalis  DPR 51 50.0 84.0 s
C. parapsilosis DPR 66 30.0 99.3 ket1   I - - - -
C. albicans A CZ 58 99 92.4
.   R  
itr G. albicans A CZ 22 74.4 97.1 s
C. albicans A CM 75 70.5 76.9
, 1   I  _   R  .   R   R
abmcz  flu  itr  ket G albicans A CM 76 92.2 93.4 s
G albicans B CM 71 70.2 94.4
.   1  •   R   ket  itr G albicans A CM 95 60 100 s
G albicans B CM  104 80.2 99.3
i
mcz C. albicans B CM 23 85.3 84.7 s
G albicans C CM 29 77 90.1 5-FC1 G. albicans A CZ 11 81.4 94.4 s
G dubliniensis CZ 69 65.2 75.3
i
mcz G albicans C CM  110 60 96.7 s
G. glabrata CZ 96a 45.4 95.4
i
mcz C. dubliniensis CM 24 93.1 88.2 s
C. guilliermondii CZ 29 94.4 92.2
.  i
itr G dubliniensis CM 31 96.1 95.6 s
C. krusei CM 30b 56.1 95.1 flu' ket' mcz  5-FC* C. dubliniensis CM 35 70.0 98.1 s
C. krusei CZ 96b 87.0 79.4 flu* ket' itr1  mczS-FC1 C. dubliniensis CM 72 60.3 92.5 s
G krusei CM 20 60.0 94.0 ab'flu' ket' itr* mcz1  5-FC* G glabrata CZ 20 80.0 87.2 s
C. lusitaniae CM 30a 86.2 93.7 5-FC* G glabrata CZ 98 54.1 96.3 s
D a ta   w a s   a n a ly s e d   c o m p a r in g   m A b K lO   a n d   K P   a c tiv itie s   o f   Candida  is o la te s   w ith   s o m e   a n tifu n g a l  r e s is ta n c e  
v e r s u s   Candida  is o la te s  s u s c e p tib le  to  th e  a n tifu n g a l  a g e n ts  p r e v io u s ly  te s te d
am A b K 1 0  a n d   K P  w e r e   u s e d   a t  a  c o n c e n tr a tio n   o f  2 0   p g /m l;  th e ir  a c tiv ity   is  e x p r e s s e d  a s a  p e r c e n ta g e   k illin g   ra te 
e v a lu a te d  b y   th e  c fu  a s s a y   in  c o m p a r is o n   w ith  th e  p r o p e r  c o n tr o ls
bA S ,  a n tifu n g a l  s u s c e p tib ility :  flu .  flu c o n a z o le ;  k e ,  k e to c o n a z o le ;  itra ,  itr a c o n a z o le ;  m ic ,  m ic o n a z o le ;  a m , 
a m p h o te r ic in   B ;  5 -F C ,  5   flu o r o c y to s in e ;  I.  in te r m e d ia te ly   r e sista n t;  R .  r e sista n t;  S ,  s e n s itiv e   to   a ll  th e   a n tifu n g a ls  
te s te d
S ta tis tic a l  a n a ly s is  w a s  p e r fo r m e d   u s in g  th e   M a n n -W h itn e y  n o n   p a r a m e tr ic  te st
D P R :  D M   p a tie n ts   fr o m   P a r m a ,  Ita ly :  D L :  D M   p a tie n ts fr o m   L o n d o n ,  U K ;  C M   a n d  C Z :  n o n -D M   s u b je c ts
227Table  8.3:  mAbKlO  and  KP  candidacidal  activity  on  Candida  isolates  from
patients with  DM and from non-DM control subjects
D/L Candida  isolates
K10 1
(%)
KPa
(%)
D/PR Candida  isolates
K10a
(%)
KPa
<%)
ND Candida  isolates
K10a
(%)
KPa
<%)
C. albicans  A DL 2 99 100 C albicans  A DPR 59 65 99.7 G albicans  A CZ 58 99 92.4
C. albicans  A DL 4 97.1 97.7 C. albicans  A DPR 67 50.1 100 G. albicans  A CM 75 70.5 76.9
C. albicans  A DL 7 77.4 98.6 C. albicans  A DPR 96 74.3 97.4 G albicans  B CM 71 70.2 94.4
C. albicans  B DL 67 78.3 61 C. albicans A DPR 98 65.9 98.4 G albicans  B CM  104 80.2 99.3
C. albicans C  DL 54 80.2 90.5 C. albicans  A  DPR  100 90.4 100 G albicans C  CM 29 77 90.1
C. dubliniensis  DL 63 90.0 91.7 C. albicans  B DPR 89 76.2 98 G. dubliniensis  CZ 69 65.2 75.3
C. glabrata  DL 48 73.4 96.3 C. albicans C  DPR74 87.4 97.8 C. glabrata  CZ 96a 45.4 95.4
C. glabrata  DL 102 65.0 83.3 C. glabrata  DPR 28 99.5 84.4 G guilliermondii  CZ 29 94.4 92.2
C. glabrata  DL 107 51.6 99.5 C. glabrata  DPR 33 82.0 96.9 G krusei CM 30b 56.1 95.1
C. guilliermondii  DL 73 78.4 95.2 C. lusitaniae  DPR 31 91.1 98.8 G krusei CZ 96b 87.0 79.4
C. krusei  DL 70 45.0 94.2 C. lusitaniae  DPR 65 56.4 98.7 C. krusei CM 20 60.0 94.0
C. parapsilosis  DL 98 72.1 93 C. parapsilosis  DPR 66 30.0 99.3 C. lusitaniae  CM 30a 86.2 93.7
C. albicans  A DL 1 83.4 97.9 G albicans  A DPR 38a 52.7 82.9 G albicans  A CZ 22 74.4 97.1
C. albicans  A DL 18 71 93.1 G albicans  A DPR 39 62.4 98 G. albicans  A CM 76 92.2 93.4
C. albicans  A DL 24 70.5 89.8 G albicans  A DPR 95 80 97.1 G. albicans  A CM 95 60 100
C. albicans A DL 66 84.1 92.2 G albicans  A DPR 107 97 100 G albicans  B CM 23 85.3 84.7
C. albicans  A DL  121 78.2 58.2 G albicans  B DPR  111 55.3 99 G. albicans  A CZ 11 81.4 94.4
C. albicans  B DL 13 77 92.9 C. albicans C  DPR 9 91.4 99.8 C. albicans  C CM  110 60 96.7
C albicans C  DL 84 75 87.2 G. dubliniensis  DPR 47 73.4 99.0 G. dubliniensis  CM 24 93.1 88.2
C. dubliniensis  DL 41 97.0 89.7 C. glabrata  DPR 24 62.1 90.5 G. dubliniensis  CM 31 96.1 95.6
C. dubliniensis  DL 92 75.1 92.0 G parapsilosis  DPR 23 93.4 94.1 G dubliniensis  CM 35 70.0 98.1
C. dubliniensis  DL 72 70.0 68.7 G parapsilosis  DPR 68 88.0 99.2 G dubliniensis  CM 72 60.3 92.5
C  glabrata  DL 125 93.0 95.9 G tropicalis  DPR 51 50.0 84.0 C. glabrata  CZ 20 80.0 87.2
C. tropicalis  DL 86 78.4 100 G glabrata  CZ 98 54.1 96.3
“mAbKlO and KP were used at a concentration of 20 pg/ml; their activity is expressed as a percentage killing rate
evaluated by the cfu assay in comparison with the proper controls
Statistical analysis was performed using the Kruskal-Wallis non parametric test
DL: DM patients from London. UK; DPR: DM patients from Parma. Italy; ND: non-DM subjects
CM and CZ: non-DM subjects
228Table 8.4:  KP activity at different concentrations on  four selected  Candida spp. 
isolates
Candida  isolates ASa
KP 20b
( % )
KP  15b
( % )
KP  10b
( % )
KP 5b
< % )
C. tropicalis  DL86 S 1 0 0 9 9 .8 9 8 .2 6 8 .4
C. albicans  A  DPR 107 S 1 0 0 91.1 4 7 .7 2 5 .5
C. albicans  A  DL2 itr R 1 0 0 9 0 .4 8 0 0
C. glabrata  DLI07 flu   *  k e t^   itr   1  m c z ^ 9 9 .5 9 8 .5 9 5 .9 7 2 .8
*AS, antifungal  susceptibility:  S, susceptible to all  the antifungals tested:  flu,  fluconazole:  ket,  ketoconazole:  itr, 
itraconazole: mcz, miconazole: ab, amphotericin B: 5-FC. 5 fluorocytosine; I, intermediately resistant: R. resistant 
bKP was tested at 20,  15.  10 and 5 pg/ml: its activity' is expressed as a percentage killing rate evaluated by the cfu 
assay in comparison with the proper control
DL: DM patients from London, UK; DPR: DM patients from Parma. Italy
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Figure  8.2:  Schematic  view  of  KT  interactions  produced  by  the  yeast  Pichia 
anomala (PaKT)
R e c e p to r   (K T R )-m e d ia te d   in te r a c tio n s   o f  Pichia anomala  k ille r   to x in   (P a K T )  a n d   P a K T -lik e   n a tu r a l  (a n ti-K T R  
P a K T A b s ),  a n ti-id io ty p ic   p o ly c lo n a l  (a n ti-id   P a K T A b s),  m o n o c lo n a l  (P a K T m A b ),  r e c o m b in a n t  (P a K T s c F v ) 
a n tib o d ie s  a n d  m im o to p e s  (P 6 .  K P )  in   th e   id io ty p ic   v a c c in a tio n  a n d  a n ti-id io ty p ic  th e r a p y   (M a g lia n i et al,  2 0 0 4 )
231Figure 8.3:  Typical  effect of mAbKlO  on  a  susceptible  Candida  strains  used  in 
the study
L e ft:  Y e a s t c e lls  tr e a te d   w ith   h e a t-in a c tiv a te d  m A b K lO ;  R ig h t:  Y e a s t c e lls  tr e a te d  w ith   m A b K lO
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Figure  8.4:  Typical  effect  of the  KP  on  one  of the  Candida  strains  used  in  the 
study
L e ft:  Y e a s t c e lls  tr e a te d  w ith  s c r a m b le   p e p tid e  (S P );  R ig h t:  Y e a s t c e lls  tr e a te d   w  ith   K P
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Summary and conclusions
9.1 Summary
Diabetes  mellitus  is  a  common  multi-systemic  disorder  that  may  result  in  oral 
alterations and diseases in affected patients. In particular, oral  Candida carriage and 
infections may be more frequent and severe in patients with DM.
This research has  investigated the molecular characterisation of oral  yeasts  isolated 
from  British  and  Italian  patients  with  DM  and  from  healthy  individuals  within 
different dental clinical settings in the United Kingdom.
From  this  study,  a  lower  than  expected  incidence  (7/249,  2.8%)  of oral  Candida
V'
infections among patients affected by DM was observed. This low percentage of oral 
candidal  infection  in  DM  patients  seems  to  contrast  with  data  reported  elsewhere 
(Dorocka-Bobkowska  et  al,  1996;  Abu-Elteen  &  Abu-Alteen,  1998;  Willis  et  al, 
1999; Guggenheimer et al, 2000b; Willis et al, 2000b) and cannot be explained solely 
by clinical awareness or diabetic control. Locality may have influenced the incidence 
of this disease, although the reasons for this are difficult to ascertain (Manfredi et al, 
2002).  In  addition,  the  results  of this  investigation  on two  different groups  of DM 
patients  suggest that DM  and  its  parameters  of glycaemic  control  have  little  or no 
influence on the oral candidal carriage of patients (Manfredi et al, 2002). The overall 
proportion  of DM  patients  who  had  Candida  isolated  from their oral  cavity  in the 
present study (152/242; 62.8%) was similar to that reported previously (Fisher et al, 
1987; Aly et al,  1992). However, contrary to other published studies where oral yeast 
colonisation was higher in patients with type 1   DM (Aly et al,  1992; Bai et al,  1995), 
there was no significant difference in the present study between the number of type  1
233and 2 DM patients whose oral cavity was colonised with yeasts (Rayfield et al,  1982; 
Willis  et  al,  1999).  In  addition,  it  would  appear  that  from  the  comparison  of the 
population of DM patients with a group of healthy non-DM subjects, the former are 
no more likely to harbour yeast in their oral cavity than healthy control individuals. 
There was no notable association between the presence of oral yeasts and genotypic 
diversity  of C.  albicans of isolates from  individuals within different clinical  dental 
settings, and there was no significant difference in the presence of oral yeasts between 
Italian and UK DM patients. However, a greater (p=0.04) number of C.  dubliniensis 
isolates  were  found  in  the  healthy  non-DM  individuals,  and  interestingly  in  the 
present study both DM patients and control  subjects that harboured  C.  dubliniensis 
were dentate (either fully or partially).
Virulence  attributes  of Candida  isolates were  studied  in  vitro  using  adherence  and 
proteinase assays (Section 2.6-2.7). In this study, isolates from patients affected with 
DM showed a greater ability to adhere (pO.OOOl) in vitro to fibronectin than those 
isolated  from  healthy  subjects.  This  observation  could  indicate  that  a  higher 
concentration  of glucose  in  the  saliva  of DM  patients  may  enhance  the  ability  of 
Candida to adhere in vitro, as reported previously (Odds et al, 1978; Samaranayake et
v
al,  1984b).  Although  no  differences were  observed between  isolates  from  DM  and 
non-DM  subjects  in  the  in  vitro  production  of extracellular  proteinase,  oral  yeast 
isolates  from  patients  with  type  2  DM  produced  more  extracellular  proteinase 
(p=0.02) than those from patients with type 1  DM. The difference in the expression of 
this virulence attribute may reflect variations of certain constituents in saliva of type 2 
DM  patients,  such  as  higher  salivary  IgA  levels  and  certain  salivary  enzymes  e.g. 
metalloproteinases (Collin et al, 2000b).
In the  present  study,  an  intriguing  relationship  between  lower candidal  load  (<100 
cfu/ml)  and  a  higher  in  vitro  ability  to  adhere  was  observed  for  all  the  Candida
234carriers  evaluated.  The  assay  used to  assess  in vitro adhesion  directly  measured the
ability  of  isolates  to  adhere  to  fibronectin  coated  with  dynabeads  (Dynal,  UK).
Therefore, it can be assumed that, as the number of yeasts present in the oral cavity
increases, interactions between yeasts become more important than those between the
yeast and the host, as was found in this study. Such a theory supports the concept of
biofilm  formation  (Baillie  &  Douglas,  1998)  where  interactions  between
microorganisms appear to be of greater significance than those with the host surfaces
?  o ro)  dk
themselves (Sullivan & Coleman, 1997; Willis et al, 2000a).  w   C
,vv
The  most  notable  observation  of this  research  study  was  that  oral  prostheses  may 
influence  not  only  the  oral  carriage  and  the  species  of oral  Candida  but  also  the 
capability of oral yeasts to adhere in DM patients. Dentures may function as a chronic 
reservoir  of  yeasts  inoculation  and  dissemination  (Davenport,  1970;  Verran  & 
Maryan,  1997;  Maza  et  al,  2002),  and  surface  irregularities  would  increase  the 
likelihood of microorganisms remaining on the surface after the prosthesis has been 
cleaned. Increased oral candidal load is much more common in full-denture wearers 
than in dentate individuals (Parvinen et al, 1994; Manfredi et al, 2002). It may also be 
the case that DM, rather than the presence of a dental prosthesis, affects adherence, as 
the ability of isolates from the control subgroup to adhere was not influenced by the 
presence of dentures. In addition, any enhanced interactions between yeasts and local 
factors such as a low salivary medium (^g^due to the presence of dentures) or poor 
metabolic  control  may  increase  the  ability  of Candida  to  adhere  to  oral  mucosa, 
rather than any yeast-derived factor.
As well as dentures,  locality may  influence different aspects of oral yeasts. In vitro 
antifungal  susceptibility testing established that isolates from UK DM patients were 
much more resistant to azole antifungal agents than those from Italian patients. The 
difference  in  the  antifungal  resistance  of isolates  from the  two populations  of DM
235patients may reflect differences in the therapeutic management of candidal infections 
between  the  two  centres  in  Italy  and  UK;  however,  there  was  no  long-term  data 
available to  support this  notion.  Although  no  association  could be  observed  in the 
DM  status  of the  patients  in  London  and  Parma,  it  could  be  assumed  that  as  the 
London group had more  long-standing DM  patients with  more  complications, they 
would be more likely to have received or taken the antifungal agents themselves. In 
this study,  C.  albicans strains were more susceptible to fluconazole and miconazole 
than non-C.  albicans strains when evaluated using a commercial kit, Fungitest (Bio- 
Rad).  This  could  be  considered  a  useful  kit  for  in  vitro  evaluation  of fluconazole 
sensitivity  among  Candida  spp.  isolates  in  clinical  laboratories,  with  positive 
agreement  among  laboratories  regarding  its  reproducibility,  according  to  recent 
reports (Morace et al, 2002).  The results obtained  in the present study confirm that 
previously  reported  emergence  of  C.  albicans  fluconazole  and,  more  generally, 
triazole resistance was probably  due to the non-standardised susceptibility methods 
rather than a real shift towards more resistant Candida species.
It has  been  reported that  C.  albicans  genotype  B  and  C  (both  characterised by the 
presence of Group I intron in the 25S rDNA) showed a greater susceptibility to 5-FC 
than intronless strain C. albicans genotype A (Mercure et al, 1993; McCullough et al, 
1999b).  In  this  study,  no  statistical  differences  were  observed  in  the  5-FC 
susceptibility of C.  albicans genotype B  isolates from all the carriers evaluated and 
only one  isolate from  subgroup C  (Appendix 2, C/M 29) expressed an intermediate 
resistance to this antifungal agent. Probably the contribution of the Group I intron of 
the 25S rDNA to the susceptibility of C. albicans genotypes to the 5-FC susceptibility 
is  not  the  only  one  factor  implicated  in  the  complex  process  of yeast  antifungal 
resistance.
236PCR  fingerprinting,  with  subsequent phylogenetic  analysis  on  C.  albicans  isolates 
from all subjects, revealed that there were significant differences between C. albicans 
isolates,  indicative of the distinct ecological niches that occur in the oral cavities of 
these patient cohorts.  The most diverse group was isolates from the DM patients in 
the UK, probably reflecting the antifungal treatment that these patients have received. 
Finally, the activity of a rat IgM monoclonal anti-idiotypic antibody (mAbKlO) and a 
synthetic decapeptide (KP) derived from the sequence of a single-chain, recombinant, 
anti-idiotypic antibody, was evaluated for the first time on different selected Candida 
spp.  isolates from the two DM populations and from the non-DM control group.  In 
the present study, both mAbKlO and KP were found to be extremely active against 
wide spectra of oral isolates of different Candida spp., and both C. albicans and non- 
C. albicans spp. were susceptible to mAbKlO and KP. Likewise, strains resistant to 
conventional antifungal agents were also susceptible to the antifungal activity of these 
two  new  agents,  suggesting  new  perspectives  in  the  design  and  production  of 
candidacidal  compounds  whose  mechanism  reflects that exerted  in nature  by  killer 
yeasts.
9.2 Conclusions
The  evaluation  of  the  molecular  characteristics  of  Candida  isolates  from  two 
geographically  different  groups  of DM  patients  and  from  healthy  non-DM  control 
subjects has  led to the conclusion that  local  factors,  such as the presence of dental 
prostheses,  associated  with  DM,  may  influence  the  carriage,  species  and  virulence 
attributes of oral Candida yeasts more than systemic factors alone.
Geographical  locality  may  also  influence  different properties  of Candida  spp.,  but 
further studies including the study of patients from more diverse geographic  locales 
are necessary to establish this association. In particular, the results obtained from the
237study  of a  group  of non-DM  healthy  subjects  enrolled  in  Italy  should  be  analysed 
together  with  those  evaluated  in  this  thesis  to  better  establish  the  correlations 
reported.
Research  could  include  the  evaluation  of the  expressionjdifferent  virulence  genes  A  
(e.g.  SAP and ALS) using ^JRT-PCR for the  Candida  isolates grown  in the same  ^  
media used for the adhesion and proteinase activity assays in the present study.
Interesting differences were observed from the PCR fingerprinting analysis of the C. 
albicans isolates of DM and non-DM subjects, indicative of the occurrence of distinct 
ecological niches  in the oral cavities of these patient cohorts.  It may be of value to 
extend the analysis to a larger grcup of C. albicans isolates of patients with DM and 
without  DM  from  different  geographic  localities  in  order  to  evaluate  C.  albicans 
genetic relatedness in a particular group of carriers.
The  significant  in  vitro  candidacidal  activity  of both  K10  and KP  on  the  Candida 
isolates evaluated in this study suggests that the activity of the two molecules could 
be further evaluated  in an in  vivo experimental model of animal oral candidosis,  in 
order to confirm (or not) the results already obtained in a previous study (Polonelli et 
al,  2003)  which  successfully  reported  KP  activity  on  a  mice  vaginal  candidosis 
model.
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278Appendix 1: Diagnostic Criteria for DM
(The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus,
1998)
Diabetes mellitus may be diagnosed by any one of 3 methods. Whatever method
is used it must be repeated on a subsequent day.
1.  Symptoms of diabetes plus random (not fasting) plasma glucose >200 mg/dl. The 
blood for examination of glucose may be drawn at any time of day and without 
regard  to  time  since  the  last  meal.  The  relevant  symptoms  of diabetes  include 
polyuria, polydypsia and unexplained weight loss.
or
2.  Fasting plasma glucose >126 mg/dl. Fasting is defined as no caloric intake for at 
least 8 h.
or
3.  Two-hour post-prandial glucose >200 mg/dl during an oral glucose tolerance test 
(OGTT).  The  test  should  be  performed  using  a  glucose  load  containing  the 
equivalent of 75  g of anhydrous glucose dissolved in water. This method is not 
recommended for routine clinical use
Categories of 2-hour post-prandial glucose (2hPG) include:
1.  2hPG< 140 mg/dl = normal glucose tolerance
2.  2hPG > 140 mg/dl and <200 mg/dl = impaired glucose tolerance
3.  2hPG >200 mg/dl = provisional diagnosis of diabetes (this must be confirmed on 
subsequent day)
Categories of fasting plasma glucose (FPG) include:
FPG<110 mg/dl =normal fasting glucose
FPG >110 mg/dl and <126 mg/dl = Impaired fasting glucose
FPG  >  126  mg/dl  = provisional  diagnosis  of diabetes  (this  must  be  confirmed  on 
subsequent day)
279Appendix  2:  Candida  isolates  evaluated  in  the  study  with  the  antifungal 
susceptibilities of each isolate
Candida isolate Species F M I K AB 5-FC
D/L1 C. albicans A S S S S S S
D/L2 C. albicans A S S R S S s
D/L4 C. albicans A s IR S s S s
D/L6 C. albicans A s IR S s S s
D/L7 C. albicans A s S R R s R
D/L8 C. albicans A s S S R s S
D/L9 C. albicans A s S IR S s 1   s
D/L10 C. albicans A s S S R s s
D/L11 C. albicans A s S S S s s
D/L13 C. albicans B s S S S s s
D/L15 C. albicans A s S S S s s
D/L16 C. albicans A s S IR IR s s
D/L17 C. albicans A s S R R s s
D/L18 C. albicans A s S S S s s
D/L19 C. albicans A s S S R s s
D/L20 C. albicans A s S S S s s
D/L21 C. albicans A s S S S s s
D/L24 C. albicans A s S S S s s
D/L25 C. albicans A s S S S s s
D/L26 C. albicans A s S R R s s
D/L27 C. albicans A s S R R IR IR
D/L30 C. albicans A IR IR IR IR IR s
D/L31 C. albicans A s S S S S s
D/L32 C. albicans A s S S S S s
D/L34 C. albicans A IR IR IR IR s s
D/L35 C. albicans A s S S S s s
D/L36 C. albicans A s S S S s s
D/L39 C. albicans A s IR S S s s
D/L40 C. albicans A s S S S s s
D/L41 C. dubliniensis s S S s s s
D/L42 C. albicans B s S S s s s
D/L43 C. albicans A s IR S s IR s
D/L44 C. albicans B s S S s IR s
D/L46 C. albicans A IR IR IR IR S s
D/L48 C. qlabrata IR IR IR S IR s
D/L50 C. albicans A S IR IR S S s
D/L54 C. albicans C S IR S S S s
D/L61 C. albicans A S IR S S s s
D/L62 C. albicans A IR IR S S IR IR
D/L63 C. dubliniensis IR IR S s s  ! s
D/L64 C. albicans A IR IR R IR s s
D/L65 C. dubliniensis S IR S s s s
D/L66 C. albicans A S S S s s s
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D/L67 C. albicans B R IR R IR S s
D/L69 C. albicans A S IR S S s s
D/L70 C. krusei IR IR R S s s
D/L72 C. dubliniensis s S S S s s
D/L73 C. guilliermondii f   s IR IR IR s s
D/L77 C. albicans B s IR S S s s
D/L78 C. albicans A s S S S s s
D/L81 C. albicans C s IR S S s s
D/L84 C. albicans C s S S S s s
D/L86 C. tropicalis s S S S s s
D/L87 C. albicans A s S S S s s
D/L91 C. albicans A R IR IR IR s IR
D/L92 C. dubliniensis S S S S s s
D/L94 C. albicans A IR IR R R s s
D/L95 C. albicans A S S S S s s
D/L96 C. albicans A S S S S s s
D/L98 C. parapsilosis IR IR S S s IR
D/L100 C. albicans A IR S IR IR s s
D/L101 C. albicans A S S S S s s
D/L102 C. qlabrata R IR R R s s
D/L103 C. albicans A S S S S s s
D/L107 C. qlabrata IR IR IR IR s s
D/L108 C. albicans A S S S S s s
D/L109 C. qlabrata S S S IR s s
D/L110 C. albicans A S s s S s s
D/L111 C. albicans A R IR R IR s s
D/L112 C. albicans A R IR R R s s
D/L113 C. albicans A S S S S s s
D/L114 C. albicans A S S S S s s
D/L115 C. albicans A s S S S s s
D/L116 C. albicans A s S S S s s
D/L118 C. albicans B s S S S s s
D/L121 C. albicans A s S S S s s
D/L122 C. albicans A s S S S s s
D/L124 C. albicans A s S s  i S s s
D/L125 C. qlabrata s S S S s s
D/L126 C. albicans A s S S S s s
D/L135 C. albicans A s S S S s s
D/L137 C. albicans B s S S S s s
D/L139 C. albicans A s S S R s s
D/PR1 C. albicans A s s S S s s
D/PR2 C. albicans A s s S S s s
D/PR3 C. albicans A s s S S s s
D/PR4 C. albicans A s s s S s s
D/PR6 C. qlabrata s s s S s s
D/PR8 C. albicans A s s s S s sCandida isolate Species F M I K AB 5-FC
D/PR9 C. albicans C S s s s s s
D/PR12 C. albicans A S s s s s s
D/PR15 C. albicans A s s s s s s
D/PR17 C. albicans A s s s s s s
D/PR18 C. albicans A s s s s s s
D/PR23 C. parapsilosis s s s s !   s s
D/PR24 C. qlabrata s s s s s s
D/PR25 C. albicans A s s s s s s
D/PR27 C. albicans A s s s s s s
D/PR28 C. qlabrata IR IR IR s s s
D/PR30 C. albicans A S s s s s s
D/PR31 C. lusitaniae IR IR IR IR s IR
D/PR32 C. albicans A S S s s s s
D/PR33 C. qlabrata S s IR s s s
D/PR 34 C. albicans A S s s s s s
D/PR35 C. albicans A S s s s s s
D/PR38a C. albicans A S s s s s s
D/PR38b C. albicans B S s s s s s
D/PR39 C. albicans A S s s s s s
D/PR40 C. albicans B S s s s s s
D/PR41 C. albicans B S s s s s s
D/PR44 C. albicans B s s s s s s
D/PR45 C. albicans A s s s s s s
D/PR46 C. albicans A s s s s s s
D/PR47 C. dubliniensis s s s s s s
D/PR51 C. tropicalis s s s s s s
D/PR54 C. parapsilosis s s s s s s
D/PR55 C. qlabrata s s s s s s
D/PR56 C. albicans A s s s s s s
D/PR57 C. albicans A s s s s s s
D/PR58 C. albicans A s s s s s s
D/PR59 C. albicans A s s IR s s s
D/PR65 C. lusitaniae IR IR IR IR s IR
D/PR66 C. parapsilosis s s s IR s s
D/PR67 C. albicans A s s s s s R
D/PR68 C. parapsilosis s s s s s s
D/PR71 C. albicans A s s s s s s
D/PR72a C. albicans B s s s s s s
D/PR72b C. qlabrata s s s s s s
D/PR73 C. albicans A s s s s  I s s
D/PR74 C. albicans C s s IR s s s
D/PR75 C. albicans A s s S s s s
D/PR76 C. albicans A s s S s s s
D/PR79 C. albicans A s s s s s s
D/PR81 C. parapsilosis s s s s s s
D/PR82 C. qlabrata s s s s s s
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D/PR84 C. albicans B S S s s S s
D/PR86 C. albicans A S S s s S s
D/PR89 C. albicans B s s s IR S s
D/PR90 C. albicans A s s s S S s
D/PR93 C. albicans B s s s S S s
D/PR94 C. albicans A s s s S s s
D/PR95 C. albicans A s s s S s s
D/PR96 C. albicans A s s IR S s s
D/PR97 C. albicans A s s S s s s
D/PR98 C. albicans A R s R IR s s
D/PR100 C. albicans A S s IR S s s
D/PR101 C. parapsilosis S s S S s s
D/PR102 C. parapsilosis S s S S s s
D/PR105 C. albicans B s s R IR s s
D/PR106 C. tropicalis IR IR IR IR IR s
D/PR107 C. albicans A S s S S S s
D/PR109 C. albicans A S s S IR s s
D/PR110 C. albicans A S s S S s s
D/PR111 C. albicans B S s S S s s
C/Z24 C. albicans A S s S S s s
C/Z 16 C. albicans A S s S S s s
C/Z15 C. albicans A s s S S s s
C/Z 21 C. albicans A s s S S s s
C/Z 28 C. albicans B s IR S S s s
C/Z 22 C. albicans A s s S S s s
C/Z 38 C. albicans A s s S S s s
C/Z 36 C. albicans A IR s S S s s
C/Z 44 C. albicans B S s S S s s
C/Z 43 C. albicans A S s s S s s
C/Z 37 C. albicans A S s s S s s
C/Z 57 C. albicans A s s s S s s
C/Z 105 C. albicans A s s s s s s
C/Z 102 C. albicans A s s s S s s
C/Z 104 C. albicans A s IR s S IR s  '
C/Z 19 C. qlabrata IR s IR S s s
C/Z 41 C. albicans A S s S s s s
C/Z 49 C. qlabrata IR IR IR IR s s
C/Z 50 C. albicans A S S S R s s
C/Z 61 C. albicans B S S S S s s
C/Z 63 C. albicans B S S S S IR s
C/Z 98 C. qlabrata S S S S s s
C/M 96 C. albicans A S S S S s s
C/Z 100 C. albicans A S S S S s s
C/Z 69 C. dubliniensis S IR S S s s
C/Z 20 C. qlabrata s S S S s s
C/M 55 C. albicans A s S S S s IR
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C/Z 17 C. albicans A S S s S S s
C/M  104 C. albicans B S IR s s s s
C/Z 90 C. albicans A s IR s s s s
C/Z 96a C. glabrata s IR s s s s
C/Z 96b C. krusei IR IR IR IR s IR
C/Z 99 C. albicans A S IR S S s S
C/Z 97 C. albicans A S IR s S s S
C/Z 103 C. albicans A S IR s s s S
C/M 18 C. albicans A S S s s IR S
C/M 19 C. albicans A S S s s IR S
C/M 20 C. krusei IR IR IR IR IR IR
C/M 21 C. albicans A IR S IR S IR S
C/M 23 C. albicans B S S S S S S
C/M 24 C. dubliniensis S S S S S S
C/M 29 C. albicans C S S S s S IR
C/M 30a C. lusitaniae S S S s S IR
C/M 30b C. krusei IR IR S IR S IR
C/M 31 C. dubliniensis S S S s S S
C/M 71 C. albicans B S S R IR S S
C/M 72 C. dubliniensis S S S S S S
C/M 73 C. dubliniensis S S S S S S
C/M 74 C. dubliniensis s S S S S S
C/M 75 C. albicans A R IR R R IR S
C/M 76 C. albicans A S S S S S S
C/M 77 C. albicans A S S S S S S
C/M 78 C. dubliniensis S S S S S S
C/M 80 C. dubliniensis S S S S S S
C/M 81 C. albicans A S S IR S S S
C/M 84 C. albicans B S S S S S S
C/M 85 C. albicans A S s S s S S
C/M 94 C. albicans A S s R R S S
C/M 95 C. albicans A S s S S s S
C/Z 11 C. albicans A s s S S s S
C/Z 13 C. albicans A s s S S s s
C/Z 29 C. guilliermondii s s IR S s s
C/Z 48 C. albicans A s s S S s s
C/Z 54 C. albicans A s s S S s s
C/Z 58 C. albicans A s s R S s s
C/Z 56 C. albicans A s s S S s s
C/Z 32 C. albicans A IR IR S s s IR
C/Z 78 C. albicans A S IR S s s s
C/Z 25 C. albicans A s S S s s s
C/M 88 C. albicans A s S s s s s
C/Z 30 C. albicans A s S s  ! s s s
C/M  110 C. albicans C s S s s s s
C/M 46 C. albicans A s S s S  |  IR IR
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C/M 35 C. dubliniensis S S s s S s
C/M 27 C. albicans A S S s s s s
D /L :  D M   fr o m   L o n d o n ,  U K ;  D /P R :  D M   fr o m  P a r m a .  Ita ly ; C /M  a n d  C /Z  n o n -D M   s u b je c ts
F :  flu c o n a z o le :  M :  m ic o n a z o le ;  I:  itr a c o n a z o le ;  K : k e to c o n a z o le : A B :  a m p h o te r ic in e  B :  5 -F C :  5 -flu o r o c y to s in e
S :  S u s c e p tib le :  IR :  in te r m e d ia te ly   r e sista n t;  R :  r e sista n t
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